CONSORT_Item,PMCID,sentence_id,start_char_pos,end_char_pos,section,clean_sentence_text
3a,PMC3002766,S45,5954,6140,Study design, This double blind randomised parallel group placebo controlled study consisted screening period 24 week treatment period 8 week post treatment follow up period
0,PMC3002766,S46,6141,6260,Study design, The study approved local ethics committees conducted accordance amended Declaration Helsinki
0,PMC3002766,S47,6261,6304,Study design, All patients gave written informed consent
4b,PMC3002766,S49,6361,6457,Settings and participants, The study conducted October 2003 May 2005 41 centres Europe North America
4a,PMC3002766,S50,6458,7026,Settings and participants, Recruited patients years old SSc defined preliminary classification criteria American College Rheumatology ACR 17 least one active DU onset 1 week 3 months prior randomisation selected investigator termed ulcer  painful area mm diameter visible depth loss dermis amenable healing location judged compatible vascular aetiology specified protocol volar surface digit distal proximal interphalangeal digital crease
4a,PMC3002766,S51,7035,7348,Settings and participants, Patients excluded received intravenous prostanoids within previous 3 months used phosphodiesterase inhibitors intermittent treatment male erectile dysfunction received inhaled oral prostanoids injected botulinum toxin affected finger within 1 month
4a,PMC3002766,S52,7349,7475,Settings and participants, Patients also excluded received systemic antibiotics treat infected DUs within 2 weeks prior randomisation
4a,PMC3002766,S53,7476,7682,Settings and participants, Also excluded patients body weight 40 kg severe PAH WHO class III IV moderate severe hepatic impairment serum aminotransferase levels 3 times upper limit normal range ULN
0,PMC3002766,S54,7683,7807,Settings and participants, Contraceptive measures monthly pregnancy testing required 3 months end study treatment
8a,PMC3002766,S56,7870,8042,Randomisation and interventions, After screening patients randomised bosentan placebo 1 1 ratio sequential allocation randomisation numbers distributed centre blocks four
8b,PMC3002766,S56,7870,8042,Randomisation and interventions, After screening patients randomised bosentan placebo 1 1 ratio sequential allocation randomisation numbers distributed centre blocks four
5,PMC3002766,S57,8043,8192,Randomisation and interventions, Patients received bosentan 62 5 mg twice daily 4 weeks 125 mg twice daily remainder treatment period matching placebo
5,PMC3002766,S58,8193,8328,Randomisation and interventions, The dose could remain decreased starting dose due intolerance possible subsequent increase target dose
5,PMC3002766,S59,8329,8570,Randomisation and interventions, Concomitant use systemic antibiotics analgaesics topical treatments wound care allowed randomised treatment administered addition usual stable previous month treatment Raynaud s phenomenon
5,PMC3002766,S60,8571,8704,Randomisation and interventions, Patients required parenteral oral inhaled prostanoid treatment study first discontinued study treatment
5,PMC3002766,S61,8705,8831,Randomisation and interventions, Use glibenclamide fluconazole calcineurin inhibitors ciclosporin A allowed due potential drug interactions
6a,PMC3002766,S63,8871,9125,Outcomes, The two primary end points 1 mean number new DUs per patient assessed investigator week 24 2 time healing cardinal ulcer week 24 patients cardinal ulcer healing maintained 12 weeks
6a,PMC3002766,S64,9126,9205,Outcomes, Healing defined complete epithelialisation regardless residual pain
6a,PMC3002766,S65,9206,9484,Outcomes, Maintenance cardinal ulcer healing required recurrence contiguous original location week 24 healing occurred week 12 12 weeks observation permissible extension treatment period healing occurred week 12
6a,PMC3002766,S66,9485,9734,Outcomes, To verify effect treatment would vary substantially across relevant baseline subgroups number new DUs week 24 additionally analysed subgroups based predefined baseline factors associated disease severity
6a,PMC3002766,S67,9743,10540,Outcomes, Secondary exploratory end points included 1 reduction new DUs overall DU number proportions patients new DUs number new DUs week 24 time onset number new DUs week 24 change baseline week 24 total number DUs 2 healing time healing baseline DUs new DUs week 24 proportions patients healing DUs end week 24 3 pain disability parameters changes baseline week 24 pain cardinal ulcer overall hand pain assessed visual analogue scales hand disability index averaged score three Health Assessment Questionnaire HAQ domains dressing grooming grip hygiene HAQ disability index18 19
6a,PMC3002766,S68,10549,10936,Outcomes, Post hoc analyses included 1 number new DUs week 12 overall patient population subgroups defined randomisation month October  February autumn  winter March  September spring  summer 2 number new DUs time successive new DU total number DUs week 24 subgroups defined number DUs baseline 4
0,PMC3002766,S69,10945,11169,Outcomes, Patients evaluated randomisation baseline every 4 weeks treatment premature withdrawal week 24 applicable 12 weeks healing cardinal ulcer DUs assessed study visit
0,PMC3002766,S70,11170,11203,Outcomes, Safety continually monitored
12a,PMC3002766,S72,11254,11373,Statistical methods, Efficacy analyses performed treated patients using SAS software SAS Institute Cary North Carolina USA
12a,PMC3002766,S73,11374,11477,Statistical methods, Means  SEs presented numerical variables Kaplan  Meier estimates time to event variables
12a,PMC3002766,S74,11478,11665,Statistical methods, Treatment effects primary end points evaluated using Pitman permutation new DUs log rank test asymptotic approximation time healing cardinal ulcer
12a,PMC3002766,S75,11666,11820,Statistical methods, Missing data new DUs imputed using extrapolation incidence rate new DUs last assessment corrected missing time period
0,PMC3002766,S76,11821,11960,Statistical methods, The worst either calculated number observed values week 24 used patients prematurely discontinued study treatment
0,PMC3002766,S77,11961,12091,Statistical methods, Patients valid assessment post baseline three patients bosentan one placebo excluded main analysis
12a,PMC3002766,S78,12092,12202,Statistical methods, Treatment effects new DUs predefined subgroups presented point estimates 95 two sided CIs
12a,PMC3002766,S79,12211,12572,Statistical methods, For exploratory purposes statistical tests treatment difference provided planned secondary exploratory unplanned post hoc efficacy analyses included Pitman permutation changes baseline Fisher exact test proportions log rank test times event performed without correction multiple testing
12b,PMC3002766,S79,12211,12572,Statistical methods, For exploratory purposes statistical tests treatment difference provided planned secondary exploratory unplanned post hoc efficacy analyses included Pitman permutation changes baseline Fisher exact test proportions log rank test times event performed without correction multiple testing
12a,PMC3002766,S80,12573,12694,Statistical methods, Placebo corrected changes baseline RR HRs Cox modelling reported 95 CIs appropriate
12b,PMC3002766,S80,12573,12694,Statistical methods, Placebo corrected changes baseline RR HRs Cox modelling reported 95 CIs appropriate
0,PMC3002766,S81,12695,12796,Statistical methods, Safety baseline data summarised descriptively statistical testing planned given
4a,PMC3002834,S50,5403,5509,Study subjects, A detailed description inclusion exclusion criteria study previously published 14
0,PMC3002834,S51,5510,5607,Study subjects, The protocol approved medical ethics committee patients gave informed consent
0,PMC3002834,S52,5608,5668,Study subjects, Procedures accordance Helsinki Declaration
4a,PMC3002834,S53,5677,6109,Study subjects, Patients mild anaemia women 6 4  7 4  mmol l men 6 4  7 8  mmol l moderate CKD estimated creatinine clearance 20  70  ml min Cockcroft  Gault formula CHF functional NYHA class II  IV based symptoms signs objective abnormality echocardiography 15 reduced ejection fraction 50 left ventricular end diastolic volume index 97  ml m2 evidence diastolic left ventricular dysfunction16 included
6a,PMC3002834,S55,6153,6251,Study design, EPC levels function compared 45 CRS patients baseline 20 healthy controls
3a,PMC3002834,S56,6252,6332,Study design, The effects EPO treatment evaluated open label randomised design
5,PMC3002834,S57,6333,6486,Study design, Patients received EPO treatment 50  IU kg week Neorecormon Roche Pharmaceuticals Woerden Netherlands standard treatment without EPO one year
6a,PMC3002834,S58,6487,6687,Study design, Short term effects EPO n 30 versus EPO n 15 evaluated 18  days 3  days third EPO injection EPO treatment yet expected result haematopoietic response
6a,PMC3002834,S59,6688,6924,Study design, Long term 52  week effects EPO assessed subgroup EPO treated patients allowed increase haemoglobin Hb levels 8 5  mmol l men 8 3  mmol l women n 13 non EPO treated group n 13
6a,PMC3002834,S61,6975,7124,Plasma measurements, Serum EPO levels measured sandwich chemiluminescent immunoassay IMMULITE 2000 platform Siemens Healthcare Diagnostics Breda Netherlands
6a,PMC3002834,S62,7125,7580,Plasma measurements, Endothelial dysfunction EPC mobilising factors inflammation markers measured using ELISA E selectin vascular cell adhesion molecule 1 VCAM 1 interleukin IL 6 VEGF SDF 1  R D Systems Minneapolis Minnesota USA thrombomodulin Diaclone Stamford Connecticut USA multiplex immunoassay17 intercellular adhesion molecule 1 ICAM 1 monocyte chemotactic protein 1 MCP 1 Bio Rad Laboratories Hercules California USA
6a,PMC3002834,S63,7581,7762,Plasma measurements, High sensitivity C reactive protein hsCRP determined particle enhanced immunonephelometry standard Cardio Phase hsCRP BNII Dade Behring Holding Liederbach Germany
6a,PMC3002834,S64,7763,7923,Plasma measurements, N terminal prohormone brain natriuretic peptide NT proBNP measured using electrochemiluminescense immunoassay Cobas CA6000 Roche Mannheim Germany
6a,PMC3002834,S65,7924,7985,Plasma measurements, Samples measured duplicate averaged analysis
6a,PMC3002834,S67,8039,8207,Circulating EPC levels, Circulating EPC defined cells positive haematopoietic stem cell marker CD34 endothelial marker kinase insert domain receptor KDR ie VEGF receptor 2
0,PMC3002834,S68,8208,8354,Circulating EPC levels, This CD34 KDR EPC previously shown clinical importance predicting cardiovascular events death cardiovascular risk populations 18 19
6a,PMC3002834,S69,8355,8614,Circulating EPC levels, Blood 100   l incubated anti CD34 FITC BD Pharmingen California USA anti KDR PE R D Systems anti CD45 PE Cy7 BD Pharmingen antibodies 45  min Erythrocytes lysed analysed flow cytometry Beckman Coulter California USA
6a,PMC3002834,S70,8615,8746,Circulating EPC levels, Circulating HSC EPC identified CD34 CD34 KDR cells lymphocyte region forward sideward scatter plot
6a,PMC3002834,S71,8747,8872,Circulating EPC levels, Cell numbers quantified relative 105 granulocytes identified CD45 cells typical granulocyte distribution
6a,PMC3002834,S72,8873,8940,Circulating EPC levels, Measurements performed duplicate results averaged
6a,PMC3002834,S73,8941,8993,Circulating EPC levels, Isotype stained samples served negative controls
6a,PMC3002834,S75,9052,9133,Outgrowth of EPC in culture, EPC outgrowth mononuclear cells MNC assessed described previously 3
6a,PMC3002834,S76,9134,9264,Outgrowth of EPC in culture, In brief MNC isolated blood using Ficoll density gradient separation Histopaque 1077 Sigma St Louis Missouri USA
6a,PMC3002834,S77,9265,9589,Outgrowth of EPC in culture, To evaluate EPC outgrowth culture 107 MNC well seeded human fibronectin Sigma coated 6 well plate EGM 2 Cambrex Baltimore Maryland USA supplemented accompanying aliquots 20 fetal calf serum Invitrogen Carlsbad California USA 100  ng ml recombinant VEGF 165 R D Systems antibiotics
6a,PMC3002834,S78,9590,9654,Outgrowth of EPC in culture, Medium changed 4  days wash non adherent cells away
6a,PMC3002834,S79,9655,9836,Outgrowth of EPC in culture, After 7  days cultured EPC selected wells placed serum free medium EBM 2 hEGF hydrocortisone GA 1000 R3 IGF 1 ascorbic acid heparin antibiotics overnight
6a,PMC3002834,S80,9837,10004,Outgrowth of EPC in culture, Conditioned medium stored functional experiments cultured EPC detached trypsin cell scraping automatically counted using haemocytometer
6a,PMC3002834,S82,10064,10213,In vitro scratch wound assay, The potential EPC outgrowth excrete paracrine factors stimulate endothelial cell migration assessed vitro scratch wound assay 20
6a,PMC3002834,S83,10214,10337,In vitro scratch wound assay, In brief EPC outgrowth medium placed mechanically scratched confluent human microvascular endothelial cell layer
6a,PMC3002834,S84,10338,10468,In vitro scratch wound assay, After 6  h extent scratch closure relative starting width compared study groups using light photography
6a,PMC3002834,S85,10469,10562,In vitro scratch wound assay, Each sample measured two separate wells two picture fields per well examined
6a,PMC3002834,S86,10563,10603,In vitro scratch wound assay, Results averaged data analysis
12a,PMC3002834,S88,10655,10713,Statistical analysis, Data analysis performed using SPSS V 15 0 Windows
12a,PMC3002834,S89,10714,10774,Statistical analysis, Data distribution tested Kolmogorov  Smirnov test
12a,PMC3002834,S90,10775,10871,Statistical analysis, Data expressed mean SD parametric data median IQR non parametric data
12a,PMC3002834,S91,10872,10961,Statistical analysis, Differences groups analysed using Student s test Mann  Whitney test
12a,PMC3002834,S92,10962,11052,Statistical analysis, Fisher s exact test used analyse whether proportions categories varied group
12a,PMC3002834,S93,11053,11184,Statistical analysis, Multiple group comparisons performed using ANOVA LSD post hoc testing non parametric data log transformed
12a,PMC3002834,S94,11185,11281,Statistical analysis, Correlations measured Pearson s Spearman s correlation coefficient appropriate
12a,PMC3002834,S95,11282,11414,Statistical analysis, Multivariate determinants log transformed progenitor cell counts identified stepwise multiple linear regression analysis
0,PMC3002834,S96,11415,11475,Statistical analysis, A value p 0 05 considered statistically significant
0,PMC3016167,S47,6193,6302,Trial design, Anti scorpion antivenom purchased Haffkine Biopharma Mumbai given participants trial
4a,PMC3016167,S48,6303,6414,Trial design, We proposed include people admitted scorpion sting one year March 2009 February 2010
3a,PMC3016167,S49,6415,6652,Trial design, This randomised 1 1 allocation ratio parallel group open label controlled trial conducted Bawaskar Hospital Mahad region India population 20  000 situated 180 km south Mumbai Mumbai Goa highway
4b,PMC3016167,S49,6415,6652,Trial design, This randomised 1 1 allocation ratio parallel group open label controlled trial conducted Bawaskar Hospital Mahad region India population 20  000 situated 180 km south Mumbai Mumbai Goa highway
0,PMC3016167,S50,6653,6752,Trial design, An independent data safety monitoring board monitored trial access data
0,PMC3016167,S51,6753,6841,Trial design, Statistical analysis done statistician collaboration investigators
0,PMC3016167,S52,6842,7005,Trial design, The study design approved independent ethics committee BYL Medical College Mumbai IEC 08 39 participants provided written informed consent
6a,PMC3016167,S54,7048,7143,Sample size, The primary efficacy variable time required recovery venomous scorpion sting
7a,PMC3016167,S55,7144,7461,Sample size, We estimated 35 patients group would required achieve 80 power detect mean difference four hours recovery time groups assuming mean recovery time 10 hours SD 2 5 hours antivenom plus prazosin group 14 SD 3 hours prazosin alone group
8a,PMC3016167,S57,7506,7661,Randomisation, A statistician generated sequentially numbered randomisation list random block sizes 4 4 2 4 4 6 2 4 6 6 6 8 4 8 2 using www randomisation com
8b,PMC3016167,S57,7506,7661,Randomisation, A statistician generated sequentially numbered randomisation list random block sizes 4 4 2 4 4 6 2 4 6 6 6 8 4 8 2 using www randomisation com
8a,PMC3016167,S58,7662,7728,Randomisation, This process reproduced using seed 22491 6 March 2009
9,PMC3016167,S59,7729,7841,Randomisation, This randomisation sequence concealed using sequentially numbered opaque sealed stapled envelopes
10,PMC3016167,S60,7842,8037,Randomisation, Envelopes opened alternately HSB PHB eligible patient consented take part trial patients allocated according randomisation label inside envelope
12a,PMC3016167,S62,8088,8286,Statistical methods, Demographic factors clinical characteristics summarised counts percentages categorical variables mean standard deviation SD normally distributed continuous variables
12b,PMC3016167,S62,8088,8286,Statistical methods, Demographic factors clinical characteristics summarised counts percentages categorical variables mean standard deviation SD normally distributed continuous variables
12a,PMC3016167,S64,8410,8617,Statistical methods, The groups compared using test Fisher  s exact test categorical variables unpaired test normally distributed continuous variables Mann Whitney U test continuous variables
12b,PMC3016167,S64,8410,8617,Statistical methods, The groups compared using test Fisher  s exact test categorical variables unpaired test normally distributed continuous variables Mann Whitney U test continuous variables
12a,PMC3016167,S65,8618,8660,Statistical methods, We analysed results SPSS 17 software
12b,PMC3016167,S66,8661,8823,Statistical methods, Blood pressure pulse rate measured different time points repeated factors treatment group included between participant measure
0,PMC3016167,S67,8824,8842,Statistical methods, set 0 05
12a,PMC3016167,S68,8843,8882,Statistical methods, We used Greenhouse Geisser P value
12b,PMC3016167,S68,8843,8882,Statistical methods, We used Greenhouse Geisser P value
4a,PMC3016167,S70,8922,9097,Patients, Between March 2009 February 2010 recruited patients reported Bawaskar Hospital Mahad research centre stung Mesobuthus tamulus fig 1 2 4 6 31
0,PMC3016167,S71,9107,9153,Patients, Fig 1 Indian red scorpion Mesobuthus tamulus
4a,PMC3016167,S73,9217,9452,Inclusion and exclusion criteria, Patients eligible enrolment reported hospital Mesobuthus tamulus sting clinical grade 2 severity interval less six hours sting hospital admission older six months
4a,PMC3016167,S74,9453,9628,Inclusion and exclusion criteria, Mesobuthus tamulus sting confirmed victim bystander seen red scorpion brought killed specimen recognised hospital  s preserved specimen
0,PMC3016167,S75,9629,9874,Inclusion and exclusion criteria, In way made sure Mesobuthus tamulus confused Palamneus gravimanus larger scorpion less lethal causes severe local pain without systemic involvement transient reversible cardiovascular effects 1 32
4a,PMC3016167,S76,9875,10108,Inclusion and exclusion criteria, Major exclusion criteria patient reporting six hours sting pregnant women history taking prazosin antivenom history bronchial asthma history allergic reaction foreign serum refusal give consent
0,PMC3016167,S77,10117,10177,Inclusion and exclusion criteria, Written informed consent obtained local language
0,PMC3016167,S78,10178,10343,Inclusion and exclusion criteria, For illiterate adults literate relative patient read statement loud consent obtained thumb impression witnessed relative
0,PMC3016167,S79,10344,10393,Inclusion and exclusion criteria, Parent  s consent obtained minor children
0,PMC3016167,S80,10394,10524,Inclusion and exclusion criteria, The study protocol approved independent ethics committee Mumbai registration number 1433 1999G B B S D IEC 08 39
0,PMC3016167,S81,10525,10716,Inclusion and exclusion criteria, All people admitted scorpion sting March 2009 February 2010 insured Oriental Insurance Company Limited clinical trial liability cover policy No 111600 48 2009 227
0,PMC3016167,S83,10776,10871,Evaluation of clinical grade, Cases graded according severity clinical manifestations arrival hospital box
0,PMC3016167,S84,10872,11052,Evaluation of clinical grade, Severity clinical manifestations morbidity mortality depend time lapsed sting hospital admission well grade case arrival 5 9 18 33 34
0,PMC3016167,S86,11199,11384,Evaluation of clinical grade, Grade 1 severe excruciating local pain sting site radiating along corresponding dermatomes mild local oedema sweating sting site without systemic involvement
0,PMC3016167,S87,11431,11852,Evaluation of clinical grade, Grade 2 signs symptoms autonomic storm characterised acetylcholine excess parasympathetic stimulation vomiting profuse sweating body ropey salivation bradycardia premature ventricular contraction hypotension priapism men sympathetic stimulation hypertension blood pressure 140 90 tachycardia heart rate 120 per minute cold extremities transient systolic murmur
0,PMC3016167,S88,11899,12057,Evaluation of clinical grade, Grade 3 cold extremities tachycardia hypotension hypertension pulmonary oedema respiratory rate 24 per minute basal rales crackles lungs
0,PMC3016167,S89,12104,12206,Evaluation of clinical grade, Grade 4 tachycardia hypotension without pulmonary oedema warm extremities warm shock
4a,PMC3016167,S90,12263,12339,Evaluation of clinical grade, Patients grade 2 signs symptoms included present study
0,PMC3016167,S91,12340,12483,Evaluation of clinical grade, After giving written consent eligible patients examined one two authors baseline data recorded standard form
0,PMC3016167,S92,12484,12756,Evaluation of clinical grade, Data included age sex time sting hospital admission history medication admission vomiting soon sting paraesthesia tingling numbness perioral region sometimes reported patient felt body
0,PMC3016167,S93,12765,13029,Evaluation of clinical grade, One authors sat side patients closely clinically examined signs symptoms systemic manifestations presence profuse sweating body ropey salivation priapism men heart murmur coolness extremities
6a,PMC3016167,S94,13030,13157,Evaluation of clinical grade, Blood pressure heart rate cardiac arrhythmias respiratory rate oxygen saturation monitored multipara monitor
6a,PMC3016167,S95,13158,13269,Evaluation of clinical grade, These findings noted admission 00 00 30 minutes 1 2 4 6 8 10 14 18 24 hours
6a,PMC3016167,S96,13270,13399,Evaluation of clinical grade, Subsequent improvement deteriorations grade 3 4 closely followed author examined patient arrival
6a,PMC3016167,S97,13400,13528,Evaluation of clinical grade, Blood collected participants admission measurement haemoglobin white cell count creatine kinase MB
6a,PMC3016167,S98,13529,13622,Evaluation of clinical grade, A 12 lead electrocardiogram ECG done arrival six hours discharge
0,PMC3016167,S100,13670,13836,Study treatments, Mesobuthus tamulus venomous scorpion state western Maharashtra may dangerously venomous scorpion Mahad area 24 25
0,PMC3016167,S101,13837,14043,Study treatments, Haffkine Biopharma Mumbai manufacturing monovalent anti scorpion venom serum F ab 2 Mesobuthus tamulus since 1997 available clinical use rural setting since 2002
0,PMC3016167,S102,14044,14263,Study treatments, Studies conducted different times show antivenom potent 1 mL reconstituted anti scorpion venom serum neutralised 1 2 mg Indian red scorpion venom intravenous route vivo study mice 35
0,PMC3016167,S103,14264,14429,Study treatments, The maximum volume venom injected one sting Indian red scorpion 1 5 mg mL antivenom capable neutralising 1 2 1 5 mg venom 36
5,PMC3016167,S104,14438,14695,Study treatments, A single 30 mL dose Haffkine Biopharma monovalent antivenom batch SS811001 manufacturing date November 2008 expiry date April 2013 added 100 mL normal saline infused intravenously 30 minutes irrespective patient  s age
5,PMC3016167,S105,14696,14900,Study treatments, During infusion patient closely observed reaction serum form sudden onset vomiting urticaria hypotension tachycardia bronchospasm angioneurotic oedema anaphylaxis
5,PMC3016167,S106,14909,15148,Study treatments, Oral prazosin batch ML NH 138 batch GK 60372 manufactured 04 2006 expiry 03 2011 ML NH 138 batch GK 80282 manufactured 02 2008 expiry 01 2013 given dose 250 children age 18 years 500 adults
5,PMC3016167,S107,15149,15232,Study treatments, The dose repeated intervals 3 hours extremities cold
5,PMC3016167,S108,15233,15294,Study treatments, Similar doses administered randomisation groups
5,PMC3016167,S109,15303,15396,Study treatments, Dehydration owing vomiting sweating corrected intravenous crystalloid solution
5,PMC3016167,S110,15397,15543,Study treatments, The prazosin treated group required longer duration larger volumes intravenous crystalloid solution antivenom plus prazosin group
5,PMC3016167,S111,15544,15634,Study treatments, Patients developed grade 3 4 symptoms transferred intensive care unit
5,PMC3016167,S112,15635,15696,Study treatments, Before discharge participants immunised tetanus
6a,PMC3016167,S114,15736,15963,Outcomes, The primary end point proportion patients achieving resolution grade 2 clinical syndrome end 10 hours administration study drugs prevention deterioration grade 3 4 18 21 37
6a,PMC3016167,S115,15964,16170,Outcomes, Secondary end points time required complete resolution clinical syndrome prevention deterioration higher grade doses prazosin required within 10 hours overall adverse events
0,PMC3018567,S46,6826,6871,Study design and patients, The study described detail elsewhere 18
4b,PMC3018567,S47,6872,6972,Study design and patients, Briefly study area Entebbe Municipality Katabi subcounty beside Lake Victoria Uganda
0,PMC3018567,S48,6973,7035,Study design and patients, The area occupied urban rural fishing communities
0,PMC3018567,S49,7036,7159,Study design and patients, Helminth infection highly prevalent area 19 malaria diarrhoea pneumonia common young children 20
4b,PMC3018567,S50,7160,7416,Study design and patients, The study population consisted pregnant women presented government funded antenatal clinic Entebbe General Hospital April 9 2003 Nov 24 2005 roughly 70 pregnant women study area received antenatal care 21
4a,PMC3018567,S51,7417,7589,Study design and patients, Women included resident study area planning deliver hospital willing know HIV status second third trimester pregnancy
4a,PMC3018567,S52,7590,7935,Study design and patients, They excluded possible helminth induced pathological changes haemoglobin 80 g L clinically apparent severe liver disease diarrhoea blood stool history adverse reaction anthelmintics already enrolled trial earlier pregnancy pregnancy deemed abnormal midwife
0,PMC3018567,S53,7944,7992,Study design and patients, All participants gave written informed consent
0,PMC3018567,S54,7993,8162,Study design and patients, Ethics approval given Uganda Virus Research Institute Uganda National Council Science Technology London School Hygiene Tropical Medicine
8b,PMC3018567,S56,8219,8717,Randomisation and masking, We used two by two factorial design randomly assign patients 1 1 1 1 ratio receive simultaneously either single dose albendazole 440 mg single dose praziquantel 40 mg kg albendazole praziquantel matching placebo albendazole matching placebo praziquantel albendazole matching placebo praziquantel matching placebo albendazole matching placebo Glaxosmithkline Brentford UK praziquantel matching placebo Medochemie Ltd Limassal Cyprus
5,PMC3018567,S56,8219,8717,Randomisation and masking, We used two by two factorial design randomly assign patients 1 1 1 1 ratio receive simultaneously either single dose albendazole 440 mg single dose praziquantel 40 mg kg albendazole praziquantel matching placebo albendazole matching placebo praziquantel albendazole matching placebo praziquantel matching placebo albendazole matching placebo Glaxosmithkline Brentford UK praziquantel matching placebo Medochemie Ltd Limassal Cyprus
3a,PMC3018567,S56,8219,8717,Randomisation and masking, We used two by two factorial design randomly assign patients 1 1 1 1 ratio receive simultaneously either single dose albendazole 440 mg single dose praziquantel 40 mg kg albendazole praziquantel matching placebo albendazole matching placebo praziquantel albendazole matching placebo praziquantel matching placebo albendazole matching placebo Glaxosmithkline Brentford UK praziquantel matching placebo Medochemie Ltd Limassal Cyprus
8a,PMC3018567,S57,8718,8851,Randomisation and masking, The randomisation code generated trial statistician computer generated random number sequence block size 100
8b,PMC3018567,S57,8718,8851,Randomisation and masking, The randomisation code generated trial statistician computer generated random number sequence block size 100
9,PMC3018567,S58,8852,9042,Randomisation and masking, Treatments packed sealed envelopes labelled allocation number colleagues Medical Research Council Unit Entebbe otherwise contribute trial
10,PMC3018567,S59,9043,9206,Randomisation and masking, Treatments allocated numerical order trained interviewer counsellors observed patients taking treatment correctly enrolment study
11a,PMC3018567,S60,9207,9288,Randomisation and masking, Treatment allocation masked participants staff study
0,PMC3018567,S62,9330,9455,Procedures, Demographic clinical details blood samples obtained screening stool samples obtained enrolment
5,PMC3018567,S63,9456,9809,Procedures, After enrolment women continued receive standard antenatal care including haematinics tetanus immunisation intermittent presumptive treatment malaria twice first trimester pregnancy women HIV offered intrapartum neonatal single dose nevirapine prevention mother to child vertical HIV transmission 22
5,PMC3018567,S64,9810,9966,Procedures, Stool samples obtained delivery assess effectiveness anthelmintic treatment thereafter mothers received praziquantel albendazole
6a,PMC3018567,S64,9810,9966,Procedures, Stool samples obtained delivery assess effectiveness anthelmintic treatment thereafter mothers received praziquantel albendazole
5,PMC3018567,S65,9967,10174,Procedures, Infants received BCG polio immunisation birth diphtheria pertussis tetanus Haemophilus influenzae hepatitis B polio immunisation 6 10 14 weeks measles immunisation 9 months
0,PMC3018567,S66,10175,10285,Procedures, Children also attended study clinic unwell doctors diagnosed treated recorded illnesses
6a,PMC3018567,S67,10286,10442,Procedures, Community fieldworkers visited participant s home twice month measured child s temperature recorded symptoms reported child s carer
6a,PMC3018567,S68,10443,10551,Procedures, At age 12 months blood stool samples obtained children growth outcomes measured
6a,PMC3018567,S69,10552,10697,Procedures, Children unwell 12 month visit given appropriate treatment asked return complete visit procedures well
6a,PMC3018567,S70,10706,10967,Procedures, The primary outcomes immune response age 1 year BCG tetanus measles immunisation incidence malaria diarrhoea pneumonia measles tuberculosis infancy diagnosed doctors study clinic vertical HIV transmission 18
6a,PMC3018567,S71,10968,11033,Procedures, Planned secondary outcomes growth anaemia age 1 year
6a,PMC3018567,S72,11034,11185,Procedures, Community reported data illness events included secondary outcome comparison doctor diagnosed illness events clinic visits
6a,PMC3018567,S73,11186,11344,Procedures, We also considered two additional unplanned secondary outcomes infant mortality asymptomatic malaria presence malaria parasitaemia 1 year age
6a,PMC3018567,S74,11353,11523,Procedures, Cytokine responses 1 year age crude culture filtrate proteins Mycobacterium tuberculosis cCFP measured indicator response BCG immunisation
6a,PMC3018567,S75,11524,11641,Procedures, Cytokine responses age 1 year tetanus toxoid measured indicator response tetanus immunisation
6a,PMC3018567,S76,11642,11829,Procedures, We examined stimulated interferon   type 1 interleukin 5 type 2 interleukin 13 type 2 interleukin 10 regulatory responses whole blood assay previously described 23
6a,PMC3018567,S77,11830,11930,Procedures, Total serum IgG IgG4 IgE responses tetanus toxoid measured ELISA webappendix p 1
6a,PMC3018567,S78,11939,12077,Procedures, Total serum measles specific IgG measured ELISA Dade Behring Siemens Eschborn Germany according manufacturer s protocol
6a,PMC3018567,S79,12078,12304,Procedures, Immunological assays done samples obtained randomised sequence use computer generated random number sequence avoid confounding secular trends variations assay performance
6a,PMC3018567,S80,12313,12791,Procedures, For primary outcome doctor diagnosed illness events clinical malaria fever temperature parasitaemia diarrhoea infant s carer s definition stool frequency recorded 24 pneumonia cough difficulty breathing age specific fast breathing 25 measles defined standard clinical criteria confirmed measurement specific antibody 26 children suspected tuberculosis investigated clinically indicated 27
6a,PMC3018567,S81,12792,13152,Procedures, For secondary outcome community reported illnesses febrile illness defined measured fieldworkers temperature reported child s carer diarrhoea reported carer stool frequency recorded presumptive pneumonia cough difficulty breathing age specific fast breathing measured fieldworkers
6a,PMC3018567,S82,13161,13458,Procedures, Stool samples examined helminth ova Kato Katz method28 charcoal culture Strongyloides sterocoralis infection 29 two Kato Katz slides prepared sample examined hookworm ova within 30 mins preparation examined next day species
6a,PMC3018567,S83,13459,13588,Procedures, Hookworm Schistosoma mansoni infections classified low medium high intensities according WHO guidelines 30
6a,PMC3018567,S84,13589,13712,Procedures, Blood samples examined modified Knott s method Mansonella perstans31 thick film malaria parasites
6a,PMC3018567,S85,13713,13796,Procedures, Haemoglobin estimated Coulter analyser Beckman Coulter Nyon Switzerland
6a,PMC3018567,S86,13797,14021,Procedures, Quality control Kato Katz analyses provided Vector Control Programme Ministry Health Uganda haematology malaria parasitology UK National External Quality Assessment Schemes
6a,PMC3018567,S87,14030,14087,Procedures, Mothers HIV serology done rapid test algorithm 30
6a,PMC3018567,S88,14088,14216,Procedures, Blood obtained cord 6 weeks age infants mothers HIV assessment vertical HIV transmission
6a,PMC3018567,S89,14217,14328,Procedures, Plasma whole blood cell pellet separated centrifugation stored assays done
6a,PMC3018567,S90,14329,14542,Procedures, For detection HIV 1 proviral DNA infants 6 weeks DNA extracted stored whole blood cell pellets amplified nested PCR three conserved viral regions tat gp41 nef webappendix p 1
6a,PMC3018567,S91,14543,14755,Procedures, For cord 6 week samples plasma HIV load measured Bayer Versant branched DNA assay version 3 0 Bayer Leverkusen Germany Roche Amplicor HIV 1 RNA Monitor test version 1 5 Roche NJ USA
6a,PMC3018567,S92,14764,15026,Procedures, Infants regarded HIV positive 6 week sample positive DNA PCR viral regions viral load 1000 copies per mL four infants viral load data available used establish HIV status
0,PMC3018567,S93,15027,15239,Procedures, Viral load DNA PCR results concordant apart one infant viral load 6699 copies per mL PCR negative seronegative rapid test algorithm age 18 months classified HIV negative
6a,PMC3018567,S94,15240,15396,Procedures, In infants HIV infection transmission regarded likely intrauterine viral load cord blood 1000 copies per mL
0,PMC3018567,S96,15448,15511,Statistical analysis, Analysis done children older 15 months
0,PMC3018567,S97,15512,15660,Statistical analysis, Data samples measurements obtained routine 1 year visits included child attended within 2 months first birthday
0,PMC3018567,S98,15661,15732,Statistical analysis, Data illness events mortality censored strictly 1 year
0,PMC3018567,S99,15733,15791,Statistical analysis, Results younger twins excluded analyses
7a,PMC3018567,S100,15800,15994,Statistical analysis, On basis preliminary study 32 planned cohort size 2500 expected accrue 1860 person years follow up infancy 1594 infants expected seen age 1 year
7a,PMC3018567,S101,15995,16406,Statistical analysis, For either maternal treatment assuming interaction treatments number would give 80 power detect rate ratios 0  82 malaria 0  91 diarrhoea 0  76 pneumonia p values less 0  05 assuming frequency disease placebo groups 50 per 100 person years malaria 33 190 per 100 person years diarrhoea 34 25 per 100 person years pneumonia 35
0,PMC3018567,S102,16407,16545,Statistical analysis, Incidence tuberculosis measles expected low 18 therefore large differences incidence would detected
0,PMC3018567,S103,16546,16692,Statistical analysis, Samples 1594 infants assessed 1 year would detect differences infant cytokine responses 0  11 log10 intervention groups 18 32
0,PMC3018567,S104,16701,16849,Statistical analysis, The patients included analysis primary outcomes differed data outcome obtained different times
0,PMC3018567,S105,16850,17111,Statistical analysis, For immune response age 1 year analysis included children provided blood sample 1 year received full BCG cCFP analysis tetanus tetanus toxoid analysis immunisation Entebbe Hospital second born twins excluded
0,PMC3018567,S106,17112,17234,Statistical analysis, For incidence infectious diseases infancy analysis included liveborn children excluding second born twins
0,PMC3018567,S107,17235,17459,Statistical analysis, For vertical HIV transmission analysis included children whose mothers receiving highly active antiretroviral therapy blood samples age 6 weeks available second born twins excluded
0,PMC3018567,S108,17468,17574,Statistical analysis, Cytokine antibody responses showed skewed distributions disproportionate numbers zero values
12a,PMC3018567,S109,17575,17741,Statistical analysis, Results transformed log10 concentration 1 analysed linear regression bootstrapping estimate bias corrected accelerated confidence intervals 36
12a,PMC3018567,S110,17742,17818,Statistical analysis, Regression coefficients back transformed give geometric mean ratios
12a,PMC3018567,S111,17819,17862,Statistical analysis, Interactions examined Wald tests
0,PMC3018567,S112,17871,17999,Statistical analysis, For doctor diagnosed disease incidence time risk began birth censored loss follow up death age 1 year
0,PMC3018567,S113,18000,18150,Statistical analysis, All children known date birth included analysis censoring irrespective whether made clinic visit illness
12a,PMC3018567,S114,18151,18214,Statistical analysis, For disease calculated incidence rates events
0,PMC3018567,S115,18215,18479,Statistical analysis, Disease episodes within 14 days initial presentation disease regarded part episode excluded analysis time risk adjusted accordingly excluding 14 day periods total person time denominator
12a,PMC3018567,S116,18480,18615,Statistical analysis, Hazard ratios HRs effects treatment calculated Cox regression robust SEs allow within child clustering
12a,PMC3018567,S117,18616,18803,Statistical analysis, For community reported illness data generalised estimating equation approach exchangeable correlation structure used model effects treatment repeated binary outcomes
12a,PMC3018567,S118,18804,18921,Statistical analysis, Odds ratios ORs effects treatment vertical HIV transmission calculated logistic regression
12a,PMC3018567,S119,18930,19042,Statistical analysis, The prevalence asymptomatic malaria 1 year compared treatment groups logistic regression
12a,PMC3018567,S120,19043,19229,Statistical analysis, Infant mortality per 1000 livebirths estimated Kaplan Meier survival probabilities age 1 year effects maternal anthelmintic treatment assessed Cox regression
12a,PMC3018567,S121,19230,19379,Statistical analysis, Weight for age height for age weight for height Z scores 1 year derived WHO growth standard reference scales igrowup macros
12a,PMC3018567,S122,19380,19484,Statistical analysis, We examined effects maternal treatment Z scores haemoglobin 1 year linear regression
12b,PMC3018567,S123,19493,19711,Statistical analysis, We two prespecified subgroup analyses examining effects albendazole treatment children mothers hookworm infection effects praziquantel treatment children mothers schistosomiasis
12b,PMC3018567,S124,19712,19806,Statistical analysis, Differences subgroups examined fitting interaction terms regression models
12a,PMC3018567,S125,19807,19884,Statistical analysis, All p values two sided adjustment made multiple comparisons
12b,PMC3018567,S125,19807,19884,Statistical analysis, All p values two sided adjustment made multiple comparisons
12a,PMC3018567,S126,19885,19920,Statistical analysis, Analyses done Stata 10 1
0,PMC3018567,S128,19978,20110,Role of the funding source, The sponsor study role study design data collection data analysis data interpretation writing report
0,PMC3018567,S129,20111,20232,Role of the funding source, AME full access data study final responsibility decision submit publication
4a,PMC3028347,S36,5019,5650,Study sample., Obese children aged 6  12 years recruited newspaper advertisements letters physicians eligible BMI percentile according Centers Disease Control Prevention 2000 growth charts United States prepubertal early pubertal defined breast Tanner stage I  III girls testes 8 mL boys fasting hyperinsulinemia defined fasting insulin 99th percentile fasting insulin among 224 nonobese 6 12 year old children studied outpatients National Institutes Health NIH insulin assay unpublished data
0,PMC3028347,S37,5651,5717,Study sample., This cut point also consistent prior adult data 41
4a,PMC3028347,S38,5718,5904,Study sample., Children excluded impaired fasting glucose diabetic reported diagnosed renal cardiac endocrine pulmonary hepatic disease might alter body weight
4a,PMC3028347,S39,5905,6107,Study sample., Subjects excluded baseline creatinine 1 mg dL alanine aminotransferase ALT aspartate aminotransferase AST exceeded 1 5 times upper limit laboratory normal range
0,PMC3028347,S40,6108,6310,Study sample., The study approved Institutional Review Boards Eunice Kennedy Shriver National Institute Child Health Human Development NICHD NIH Phoenix Area Indian Health Service
0,PMC3028347,S41,6311,6384,Study sample., Written assent consent obtained children parents
0,PMC3028347,S42,6385,6464,Study sample., The study overseen Data Safety Monitoring Board convened NICHD
3a,PMC3028347,S45,6584,6848,Design overview., After outpatient screening visit participants admitted inpatients NIH Clinical Research Center CRC assessment entered 6 month randomized placebo controlled double blind treatment period readmitted reassessment
0,PMC3028347,S46,6849,6957,Design overview., Participants completed randomized phase offered additional 6 months open label metformin
5,PMC3028347,S48,7022,7155,Randomization and interventions., We randomly assigned participants 1 1 randomization ratio receive metformin hydrochloride placebo twice daily meals
8a,PMC3028347,S49,7156,7314,Randomization and interventions., Investigators assigned consecutive code numbers participants prespecified lists stratified race ethnicity sex degree pubertal development
8b,PMC3028347,S50,7315,7585,Randomization and interventions., The CRC Pharmaceutical Development Section used permuted blocks stratification generate allocations translated code numbers study group assignments using pseudo random number program prepared identically appearing placebo metformin U S P
11b,PMC3028347,S50,7315,7585,Randomization and interventions., The CRC Pharmaceutical Development Section used permuted blocks stratification generate allocations translated code numbers study group assignments using pseudo random number program prepared identically appearing placebo metformin U S P
8a,PMC3028347,S50,7315,7585,Randomization and interventions., The CRC Pharmaceutical Development Section used permuted blocks stratification generate allocations translated code numbers study group assignments using pseudo random number program prepared identically appearing placebo metformin U S P
11b,PMC3028347,S51,7586,7649,Randomization and interventions., Grade SST Corporation Clifton NJ capsules 250 mg capsule
8b,PMC3028347,S51,7586,7649,Randomization and interventions., Grade SST Corporation Clifton NJ capsules 250 mg capsule
8a,PMC3028347,S51,7586,7649,Randomization and interventions., Grade SST Corporation Clifton NJ capsules 250 mg capsule
9,PMC3028347,S52,7650,7797,Randomization and interventions., Pharmacy personnel involved conduct study dispensed study capsules containers differed participant code number
11a,PMC3028347,S53,7798,7946,Randomization and interventions., No participant investigator medical nursing staff interacting participants aware study group assignments trial
5,PMC3028347,S54,7955,8207,Randomization and interventions., Once baseline assessments completed subject  s study medication dose progressively increased according prespecified algorithm 3 week period starting 500 mg twice daily increasing maximum dose 1 000 mg twice daily
5,PMC3028347,S55,8208,8391,Randomization and interventions., The typical adult maximum dose selected goal weight severely obese participants enrolled Table 1 anticipated similar adults
5,PMC3028347,S56,8392,8540,Randomization and interventions., We decreased dose 250 mg dose 1 week participants reported difficulty tolerating study medication attempted increase
5,PMC3028347,S57,8541,8669,Randomization and interventions., Study medication dose progressively lowered 250 mg day prescribed dosage could tolerated 7 day trial
5,PMC3028347,S58,8670,8756,Randomization and interventions., Once tolerated dose found attempts made increase dosage prescribed
5,PMC3028347,S59,8757,8823,Randomization and interventions., Study medication discontinued 250 mg day tolerated
5,PMC3028347,S60,8824,8928,Randomization and interventions., A daily chewable multivitamin Flintstones Complete containing 6 cyanocobalamin also prescribed
5,PMC3028347,S61,8929,9163,Randomization and interventions., After conclusion randomized phase participants prescribed increasing doses commercially available metformin two divided doses maximum dose 2 000 mg day plus daily multivitamin additional 6 months
5,PMC3028347,S62,9173,9479,Randomization and interventions., TABLE 1 Baseline participant characteristics          During study phases participant parent guardian met monthly dietitian administered weight reduction lifestyle modification program promoted reduced energy diet increased physical activity decreased inactivity
5,PMC3028347,S63,9480,9590,Randomization and interventions., Participants trained complete baseline 7 day food diary reviewed registered dietitian
5,PMC3028347,S64,9591,9744,Randomization and interventions., These data used offer individualized prescriptions light  style 42 500 kcal day  deficit diet reduced fat energy intake
5,PMC3028347,S65,9745,9947,Randomization and interventions., The exercise prescription consisted encouraging 30 min aerobic exercise every day inclusion lifestyle exercise whenever possible monitored pedometer readings recorded parents
5,PMC3028347,S66,9948,10148,Randomization and interventions., Adherence gauged self monitoring medication taken food eaten activity performed amount inactive time pedometer readings recorded progress book reviewed monthly
6a,PMC3028347,S68,10200,11318,Initial assessment., Subjects met inclusion criteria admitted inpatients CRC following measurements weight hospital gown using calibrated digital scale Life Measurement Instruments Concord CA height triplicate using stadiometer Holtain Crymych U K calibrated measurement abdominal hip circumferences assessed triplicate triceps skinfold thickness Lange calipers Cambridge Scientific Industries Cambridge MD trained research dietitians C G S N G S blood pressure using automated sphygmomanometer Dinamap Plus Critikon Tampa FL measured seated position least 5 min rest hand roentgenogram determination skeletal age whole body fat mass dual energy X ray absorptiometry DEXA 4500A Hologic Bedford MA software version 11 2 air displacement plethysmography intra abdominal subcutaneous abdominal adipose tissue magnetic resonance imaging L2  L3 L4  L5 T1 weighted spin echo images 0 5 T relaxation time 400 ms time excitation 10 ms number repetitions excitations 10
6a,PMC3028347,S69,11319,11508,Initial assessment., A 2 h hyperglycemic 200 mg dL clamp also performed baseline follow up admissions estimate insulin sensitivity first phase insulin secretion previously described 43
6a,PMC3028347,S70,11509,11605,Initial assessment., First phase insulin calculated mean measurements obtained first 15 min
6a,PMC3028347,S71,11606,11790,Initial assessment., Whole body glucose uptake metabolic rate M defined infusion rate exogenous glucose administered corrected urinary glucose losses glucose space correction
6a,PMC3028347,S72,11791,11910,Initial assessment., As measure insulin sensitivity SIclamp ratio metabolic rate steady state insulin M I calculated
6a,PMC3028347,S73,11919,12144,Initial assessment., At baseline follow up samples obtained fasted state collected measurement ALT AST total HDL cholesterol direct LDL cholesterol triglycerides Synchron LX20 Beckman Coulter Fullerton CA
6a,PMC3028347,S74,12145,12325,Initial assessment., Plasma glucose collected tubes containing powdered sodium fluoride measured NIH CRC clinical laboratory using Roche Diagnostics Indianapolis IN analyzer
6a,PMC3028347,S75,12326,12468,Initial assessment., C reactive protein measured high sensitivity assay IMMAGE Immunochemistry Systems Beckman Coulter sensitivity 0 020 mg dL
6a,PMC3028347,S76,12469,12616,Initial assessment., Vitamin B12 insulin measured chemiluminescent immunoassays using Siemens Healthcare Diagnostics Los Angeles CA Immulite instruments
6a,PMC3028347,S77,12617,12789,Initial assessment., Fasting samples used estimate insulin resistance homeostasis model assessment  insulin resistance HOMA IR index  insulin glucose mmol L 22 5
6a,PMC3028347,S78,12790,13085,Initial assessment., Diagnosis pediatric metabolic syndrome made three components present among following waist circumference blood pressure triglycerides percentile age sex HDL cholesterol percentile age sex fasting glucose mg dL 44
6a,PMC3028347,S79,13094,13301,Initial assessment., Subjects parents also interviewed clinical pharmacist used structured questionnaire containing comprehensive list symptoms designed identify potential adverse drug reactions 45
6a,PMC3028347,S81,13366,13510,Outcomes and follow-up measures., The prespecified primary study end point change BMI SD score BMI Z determined end 6 month randomized treatment phase
6a,PMC3028347,S82,13511,13619,Outcomes and follow-up measures., Secondary outcomes changes BMI body weight fat mass conclusion randomized phase
6a,PMC3028347,S83,13620,13796,Outcomes and follow-up measures., Tertiary outcomes included changes skinfold thickness body circumferences visceral adipose tissue insulin resistance laboratory components metabolic syndrome
0,PMC3028347,S84,13805,13911,Outcomes and follow-up measures., Participants seen monthly exchanged unused study medication new supply visit
0,PMC3028347,S85,13912,13971,Outcomes and follow-up measures., We used tally returned capsules assess adherence
6a,PMC3028347,S86,13972,14166,Outcomes and follow-up measures., Measurements BMI blood pressure liver function plasma lactate serum vitamin B12 obtained visit along interim history obtained using structured list queries
5,PMC3028347,S87,14167,14329,Outcomes and follow-up measures., After 6 months treatment subjects re evaluated offered open label metformin second 6 month treatment period continued monthly visits
7a,PMC3028347,S89,14383,14519,Statistical analysis., Power based prior data collected examining BMI change 6 months obese 6 11 year old children hyperinsulinemia
7a,PMC3028347,S90,14520,14742,Statistical analysis., We calculated among severely obese children total sample size 60 participants would detect between group difference 0 09 BMI SD score units approximately equivalent 2 kg m2 difference 80 power
7a,PMC3028347,S91,14743,14838,Statistical analysis., Participant accrual set 100 participants allow much 40 loss follow up 46
12a,PMC3028347,S92,14839,14962,Statistical analysis., The reported primary data analyses prespecified analyzed using SPSS Windows version 14 0 SPSS Chicago IL
0,PMC3028347,S93,14963,15129,Statistical analysis., Interim analyses efficacy performed Data Safety Monitoring Board 40 70 subjects enrolled 6 months randomized phase treatment
12a,PMC3028347,S94,15130,15340,Statistical analysis., Using Lan DeMets implementation O  Brien Fleming method critical two tailed values defined look P value 0 04515 considered significant end study
12a,PMC3028347,S95,15341,15521,Statistical analysis., We assessed efficacy intention to treat sample randomly assigned participants using multiple imputation model missing data missing at random assumption
12a,PMC3028347,S96,15522,15691,Statistical analysis., By using NORM version 2 03 Pennsylvania State University State University Park PA included available baseline follow up measures imputation model
12a,PMC3028347,S97,15692,15873,Statistical analysis., The imputation datasets obtained using sequential chain 1 200 iterations using initial parameter estimates supplied running expectation maximization EM algorithm
12a,PMC3028347,S98,15874,15983,Statistical analysis., Starting first 200 iterations data sampled 50 iterations successive imputations
12a,PMC3028347,S99,15984,16127,Statistical analysis., Each imputation completed datasets analyzed separately using prespecified ANCOVA model SPSS Windows version 14 0
12a,PMC3028347,S100,16128,16315,Statistical analysis., BMI Z change change secondary outcome variable dependent variable metformin treatment independent variable age sex race ethnicity covariates
12a,PMC3028347,S101,16316,16470,Statistical analysis., We combined coefficients analyses 20 imputed datasets single set estimates according Rubin  s rules scalar estimands
12b,PMC3028347,S102,16471,16913,Statistical analysis., To assess sensitivity results missing at random assumption conducted three additional analyses assuming participants withdrew study major weight gain kg lb received metformin weight gain whereas received placebo major weight gain received placebo weight gain whereas received metformin major weight gain
12b,PMC3028347,S103,16914,17055,Statistical analysis., We used multiple imputations impute missing 6 month weight measurements using imputation model used main analysis
12b,PMC3028347,S104,17056,17231,Statistical analysis., For three scenarios added fixed amounts imputed values reanalyzed results using ANCOVA combined using Rubin rules scalar estimands
12a,PMC3028347,S105,17232,17364,Statistical analysis., An additional confirmatory analysis used last observation carried forward method individuals complete study
12a,PMC3028347,S106,17365,17471,Statistical analysis., Unadjusted analyses also run imputation last observation carried forward models
0,PMC3028347,S107,17472,17570,Statistical analysis., Because models yielded similar results primary efficacy model presented
12a,PMC3028347,S108,17571,17680,Statistical analysis., We examined baseline characteristics simple tests case categorical data exact tests
0,PMC3028347,S109,17681,17741,Statistical analysis., Reports adverse events also examined exact tests
0,PMC3028347,S111,17806,18119,Funding and role of the sponsor., The intramural research programs NICHD National Institute Diabetes Digestive Kidney Diseases NIDDK NIH National Center Minority Health Health Disparities NCMHD NIH funded study role study design data accrual data analysis manuscript preparation
0,PMC3028347,S112,18120,18307,Funding and role of the sponsor., The authors designed study wrote made decision submit manuscript publication affirmed completeness accuracy integrity data data analyses
0,PMC3028347,S113,18308,18466,Funding and role of the sponsor., Monitoring study measurement adjudication study end points statistical analyses performed authors without sponsor involvement
0,PMC3028347,S114,18467,18553,Funding and role of the sponsor., The manuscript drafted principal investigator revised coauthors
4b,PMC3036630,S43,4952,5081,Patients, Thirty two patients mild moderately severe COPD included two respiratory clinics Amsterdam The Netherlands
0,PMC3036630,S44,5082,5126,Patients, The definition COPD based GOLD 1
4a,PMC3036630,S45,5127,5412,Patients, Inclusion criteria symptoms dyspnea chronic cough sputum production current ex smoker least 20 packyears smoking history postbronchodilator FEV1 1 5 liter 50 predicted value FEV1 FVC 0 70 clinically stable 4 weeks prior recruitment
4a,PMC3036630,S46,5413,5748,Patients, Exclusion criteria inhaled steroid therapy antibiotic treatment exacerbation chest infection 4 weeks prior recruitment treatment respiratory disease COPD including known asthma allergic rhinitis contra indications challenge testing according international guidelines 15
0,PMC3036630,S47,5749,6113,Patients, Patients asked withhold strenuous exercise smoking 6 hrs eating 2 hrs caffeine short acting bronchodilators 8 hrs long acting bronchodilators 48 hrs short acting anti cholinergics 24 hrs long acting anti cholinergics anti histamines 72 hrs leukotriene antagonists 4 days prior mannitol challenge
0,PMC3036630,S48,6122,6239,Patients, The study approved Hospital Medical Ethics Committee patients gave written informed consent
3a,PMC3036630,S51,6512,6653,Study design, The study cross sectional design two studies days comprising randomized challenges hypertonic saline mannitol figure 1
0,PMC3036630,S52,6654,6833,Study design, At separate screening visit inclusion exclusion criteria examined postbronchodilator 400 salbutamol spirometry performed diffusion capacity measured
0,PMC3036630,S54,6873,6966,Study design, The sequence two study visits randomized interval median range 7 7 15 days
5,PMC3036630,S55,6967,7057,Study design, On one day sputum induced hypertonic saline venous blood sample obtained
5,PMC3036630,S56,7058,7179,Study design, On day exhaled nitric oxide measured first followed assessment atopy mannitol challenge testing
6a,PMC3036630,S59,7258,7411,Measurements, Spirometry MasterscreenPneumo Jaeger W rzburg Germany performed trained respiratory technician according latest recommendations 16
6a,PMC3036630,S60,7412,7587,Measurements, Diffusion capacity lung carbon monoxide DL CO measured according recommendations using single breath method corrected haemoglobin 17
5,PMC3036630,S62,7645,7782,Measurements, Mannitol challenge performed using commercially available kit Pharmaxis Ltd Sydney Australia described Anderson et al 8
5,PMC3036630,S63,7783,7887,Measurements, Patients inhaled sequential doses 5 10 20 40 80 160 160 160 mg mannitol via inhaler
5,PMC3036630,S64,7888,7995,Measurements, The test stopped 15 fall FEV1 achieved cumulative dose 635 mg administered
6a,PMC3036630,S65,7996,8163,Measurements, Response dose ratio RDR calculated the fall FEV1 last dose divided total cumulative dose mannitol fall mg milligrams administered 18
5,PMC3036630,S66,8174,8280,Measurements, If patient cough spontaneously mannitol challenge asked expectorate
5,PMC3036630,S67,8281,8332,Measurements, This sputum labeled mannitol induced sputum
5,PMC3036630,S69,8403,8465,Measurements, Prior sputum induction patients inhaled 200 salbutamol
5,PMC3036630,S70,8466,8543,Measurements, Sputum induced inhalation NaCl 4 5 3 5 min intervals 19
5,PMC3036630,S71,8544,8586,Measurements, This sputum labeled induced sputum
6a,PMC3036630,S72,8597,8703,Measurements, Whole sputum samples processed according protocol validated laboratory 20
6a,PMC3036630,S73,8704,8784,Measurements, Differential cell counts expressed percentage non squamous cells
6a,PMC3036630,S74,8785,8868,Measurements, Absolute cell numbers calculated  cell total cell count sputum weight
6a,PMC3036630,S75,8869,8947,Measurements, Sputum samples containing 80 non squamous cells excluded analysis
6a,PMC3036630,S76,8958,9072,Measurements, All sputum cell counts performed one experienced qualified technician blinded clinical details
6a,PMC3036630,S77,9073,9149,Measurements, As extra control 10 samples analyzed second technician
6a,PMC3036630,S79,9238,9538,Measurements, Levels eosinophil cationic protein ECP detection limit 60 pg ml myeloperoxidase MPO detection limit 1 5 ng ml interleukin 8 IL 8 detection limit 19 1 pg ml alpha 2 macroglobulin detection limit 2 1 mg ml measured enzyme linked immunosorbent assays ELISA 21 22
6a,PMC3036630,S81,9605,9767,Measurements, FeNO measured portable rapid response chemoluminescent analyser flow rate 50 mL s NIOX System Aerocrine Sweden according recent guidelines 23
12a,PMC3036630,S83,9827,9972,Measurements, The relationship AHR mannitol RDR markers airway inflammation analyzed using Pearson s correlation coefficient rp
12a,PMC3036630,S84,9973,10045,Measurements, Non normally distributed data log transformed analysis
0,PMC3036630,S85,10046,10123,Measurements, If cells counted value 0 1 taken log transformation
12a,PMC3036630,S86,10124,10281,Measurements, Receiver operating characteristic ROC curves constructed using RDR eosinophilic vs non eosinophilic COPD threshold 2 5 sputum eosinophils
12a,PMC3036630,S87,10282,10392,Measurements, Wilcoxon signed rank test Bland Altman analysis used compare cell counts two sputum samples
7a,PMC3036630,S88,10403,10598,Measurements, A sample size estimation showed detectable value correlation r alternative hypothesis sample 23 patients n 1 0 55 power  0 808 alpha  0 05
7a,PMC3036630,S89,10599,10746,Measurements, Therefore thirty two patients recruited taking account expected 10 drop out rate 20 probability missing non valid data
4b,PMC3070271,S34,3856,3907,Patients, This multicentre trial including six centres
4a,PMC3070271,S35,3908,4655,Patients, Inclusion criteria age 2  20 years diagnosis SJIA 1 6 months disease duration active systemic disease disease related fever and or C reactive protein CRP 20 mg l and or first hour erythrocyte sedimentation rate ESR 20 significant overall disease activity day 1 D1 least three following criteria 1 physician global assessment disease activity 2 parent patient assessment disease effect overall wellbeing 3 Childhood Health Assessment Questionnaire score 4 joints active arthritis 5 joints non irreversible limited range motion 6 ESR despite oral prednisone prednisolone mg kg 10 mg day whichever lower
4a,PMC3070271,S36,4656,4771,Patients, Female subjects entering study prepubescent sexually inactive required use effective contraception
4a,PMC3070271,S37,4772,4904,Patients, Exclusion criteria included previous treatment IL 1 inhibitor condition contraindicating immunosuppressive treatment
0,PMC3070271,S38,4905,5134,Patients, Intravenous intra articular steroids immunosuppressive drugs disease modifying antirheumatic drugs DMARDs stopped least 1 month study onset longer periods time depending half life
0,PMC3070271,S39,5135,5239,Patients, All patients entering study parents patients aged 18 gave written informed consent
0,PMC3070271,S41,5283,5386,Study design, The study approved local independent ethics committee consisted two parts figure 1
3a,PMC3070271,S42,5387,5451,Study design, Part 1 randomised double blind placebo controlled phase
8a,PMC3070271,S43,5452,5600,Study design, At D1 eligible patients randomised receive either anakinra placebo 1 1 D1 month 1 M1 using computer generated random list
5,PMC3070271,S43,5452,5600,Study design, At D1 eligible patients randomised receive either anakinra placebo 1 1 D1 month 1 M1 using computer generated random list
8b,PMC3070271,S44,5601,5698,Study design, Patients stratified centres randomisation balanced across treatments centres
8b,PMC3070271,S45,5699,5829,Study design, The randomisation information included randomisation number centre assigned treatment date randomisation
11a,PMC3070271,S46,5830,5937,Study design, Investigators caregivers patients parents remained blinded assigned treatment
6a,PMC3070271,S47,5938,6037,Study design, The primary objective demonstrate higher proportion responders group 1 group 2
0,PMC3070271,S48,6038,6105,Study design, No immunosuppressive drugs DMARDs allowed trial
0,PMC3070271,S49,6106,6232,Study design, Non steroidal anti inflammatory drugs corticosteroids taken stable dosage 1 month D1 M1
3a,PMC3070271,S50,6241,6263,Study design, Figure 1 Study design
0,PMC3070271,S51,6264,6433,Study design, Measurement serum amyloid A ferritin levels assessment percentage glycosylated ferritin gene expression profiling analysis cytokine measurements
0,PMC3070271,S52,6434,6517,Study design, concentration anakinra plasma pharmacokinetic analyses
0,PMC3070271,S53,6518,6569,Study design, serum anti pneumococcal antibodies
0,PMC3070271,S54,6570,6587,Study design, D day M month
3a,PMC3070271,S55,6596,6679,Study design, Part 2 open label treatment period patients received anakinra M1
5,PMC3070271,S55,6596,6679,Study design, Part 2 open label treatment period patients received anakinra M1
5,PMC3070271,S56,6680,6978,Study design, Tapering dose corticosteroids allowed M1 visit reduction 0 4  0 5 mg kg monthly daily doses mg kg 0 3  0 4 mg kg doses 1 1 5 mg kg 0 2  0 3 mg kg 0 6 1 mg kg 0 1  0 2 mg kg 0 3 0 6 mg kg mg kg doses 0 3 mg kg
6a,PMC3070271,S57,6987,7120,Study design, Measurement serum amyloid A SAA ferritin levels percentage glycosylated ferritin performed D1 M1 M6
6a,PMC3070271,S58,7121,7263,Study design, Total ferritin concentration measured Dimension RXL HM according guidelines manufacturer Dade Behring Paris France
6a,PMC3070271,S59,7264,7396,Study design, Glycosylated ferritin determined according method Worwood et al 11 minor modifications previously described 12
6a,PMC3070271,S60,7397,7470,Study design, Pharmacokinetic PK analyses performed blood taken M2 M6
6a,PMC3070271,S61,7471,7619,Study design, Concentrations anakinra plasma samples determined using antibody Ab ELISA purchased R D Systems Minneapolis Minnesota USA
6a,PMC3070271,S62,7628,7859,Study design, Patients naive anti pneumococcal immunisation received Pneumo23 immunisation D1 order assess M1 M12 effect anakinra treatment anti pneumococcal Ab response five capsular polysaccharides 13
6a,PMC3070271,S64,7942,8107,Gene expression profiling and cytokine measurements, Blood samples collected Tempus tubes ABI Foster City California USA patients D1 M1 M6 age gender matched healthy controls
0,PMC3070271,S66,8176,8238,Transcriptional module-based analysis, This mining strategy described detail elsewhere 14
6a,PMC3070271,S67,8239,8547,Transcriptional module-based analysis, In study RefSeq IDs used match probes Affymetrix U133 platform used generate original set modules using PBMC expression data 14 Illumina Hu6 platform used hybridise whole blood samples patients enrolled study healthy controls
0,PMC3070271,S68,8548,8638,Transcriptional module-based analysis, Unambiguous matches Illumina found 2109 5348 Affymetrix probe sets
6a,PMC3070271,S69,8639,8711,Transcriptional module-based analysis, Illumina modules containing 10 genes included analysis
6a,PMC3070271,S71,8770,8905,Cytokine multiplex analysis, Serum samples analysed using cytokine assay kit Bio Rad Hercules California USA according manufacturer s protocol
5,PMC3070271,S73,8976,9154,"Assessment, outcome and safety measures", The primary objective compare efficacy 1 month s treatment anakinra 2 mg kg subcutaneously daily maximum 100 mg placebo two groups patients
6a,PMC3070271,S73,8976,9154,"Assessment, outcome and safety measures", The primary objective compare efficacy 1 month s treatment anakinra 2 mg kg subcutaneously daily maximum 100 mg placebo two groups patients
6a,PMC3070271,S74,9155,9531,"Assessment, outcome and safety measures", To responders modified American College Rheumatology Pediatric ACRpedi 30 score built purpose trial patients fulfil three following conditions 1 ACRpedi 30 response15 2 absence disease related fever body temperature 38  C past 8 days 3 50 decrease compared D1 normalisation CRP ESR values
6a,PMC3070271,S75,9540,9833,"Assessment, outcome and safety measures", Modified ACRpedi 30 50 70 100 responses assessed throughout study included improvement 30 50 70 100 respectively least three six core criteria juvenile rheumatoid arthritis worsening 30 one criteria
6a,PMC3070271,S76,9834,10131,"Assessment, outcome and safety measures", The criteria physician s global assessment disease activity patient s parents global assessment overall wellbeing number joints active arthritis number joints limited range motion Childhood Health Assessment Questionnaire ESR 15
6a,PMC3070271,S77,10132,10442,"Assessment, outcome and safety measures", A disease flare defined either 1 reoccurrence disease related fever systemic symptom 2 increase twofold either ESR CRP value 3 worsening least three six ACRpedi core criteria improvement one criteria
6a,PMC3070271,S78,10443,10682,"Assessment, outcome and safety measures", If number joints active arthritis used criterion flare patient initially active joints one active joint increase number joints active arthritis least two required
6a,PMC3070271,S79,10691,10884,"Assessment, outcome and safety measures", We also aimed assess number patients reached M6 inactive disease defined Wallace et al16 daily dose predniso lo ne 0 3 mg kg 10 mg whichever lower
6a,PMC3070271,S80,10893,10949,"Assessment, outcome and safety measures", Adverse events AEs recorded throughout study
6a,PMC3070271,S81,10950,11005,"Assessment, outcome and safety measures", Specific procedures set serious AEs SAEs
7a,PMC3070271,S84,11145,11368,Data analysis, We expected least 60 difference percentage patients obtaining improvement anakinra treated group group 1 compared control group group 2 10 patients improving group 2
7a,PMC3070271,S85,11369,11485,Data analysis, Given 5 type I error 20 type II error two sided Fisher exact test 12 patients per group required
0,PMC3070271,S86,11486,11530,Data analysis, An intention to treat analysis retained
12a,PMC3070271,S87,11539,11783,Data analysis, To explore whether variable ACRpedi score CRP SAA and or parent patient assessment pain associated response treatment ratio value inclusion value M1 value inclusion compared groups
12a,PMC3070271,S88,11784,11888,Data analysis, Qualitative quantitative data compared using Wilcoxon test Fisher exact test respectively
12a,PMC3070271,S89,11889,11950,Data analysis, The R statistical software used statistical analysis
4b,PMC3076731,S34,4252,4416,Participants, Members British Society Paediatric Endocrinology Diabetes recruited patients participating paediatric endocrinology departments UK hospitals
4a,PMC3076731,S35,4417,4769,Participants, Inclusion criteria participation patients karyotype confirmed Turner  s syndrome karyotypes eligible including mosaic age 7 13 years previous growth hormone treatment previous treatment range 8 3 11 7 mg m2 week five seven injections week previous oxandrolone oestrogen therapy open epiphyses
4a,PMC3076731,S36,4770,4922,Participants, Exclusion criteria major systemic illness might affect growth social psychological difficulties likely seriously impair concordance
3a,PMC3076731,S38,4966,5104,Study design, We devised double blind placebo controlled randomised controlled trial including two randomisations two two factorial design
3a,PMC3076731,S39,5105,5166,Study design, Figure 1 shows flow chart design participants
0,PMC3076731,S40,5167,5366,Study design, A steering committee British Society Paediatric Endocrinology Diabetes Clinical Trials Audit Group supervised study independent data safety monitoring group established
0,PMC3076731,S41,5367,5423,Study design, All participants  parents gave written informed consent
3a,PMC3076731,S42,5433,5546,Study design, Fig 1  Flow chart participation UK Turner Study according treatment groups completions withdrawals
0,PMC3076731,S43,5547,5653,Study design, Withdrawn 12 years age randomised randomisation 1 oxandrolone placebo
0,PMC3076731,S44,5654,5751,Study design, years recruitment oestrogen treatment started 14 years randomisation
0,PMC3076731,S45,5752,5904,Study design, 12 years age randomised randomisation 1 oxandrolone placebo randomisation 2 oestrogen treatment needed
8b,PMC3076731,S47,5961,6141,Randomisation and masking, The British Society Paediatric Endocrinology Diabetes Clinical Trials Unit Cambridge UK used minimisation weighted randomisation study  s two randomisations 20
10,PMC3076731,S48,6142,6361,Randomisation and masking, Randomisation 1 oxandrolone placebo took place age 9 years enrolment older balanced enrolling centre quarter mid parental height previous exposure growth hormone treatment
5,PMC3076731,S48,6142,6361,Randomisation and masking, Randomisation 1 oxandrolone placebo took place age 9 years enrolment older balanced enrolling centre quarter mid parental height previous exposure growth hormone treatment
10,PMC3076731,S49,6362,6674,Randomisation and masking, Randomisation 2 took place age 12 years girls ovarian failure basal serum follicle stimulating hormone concentration 10 U L additional minimisation randomisation 1 begin oral ethinylestradiol placebo 12 years placebo group subsequently started ethinylestradiol 14 years
5,PMC3076731,S49,6362,6674,Randomisation and masking, Randomisation 2 took place age 12 years girls ovarian failure basal serum follicle stimulating hormone concentration 10 U L additional minimisation randomisation 1 begin oral ethinylestradiol placebo 12 years placebo group subsequently started ethinylestradiol 14 years
10,PMC3076731,S50,6675,6910,Randomisation and masking, Girls follicle stimulating hormone concentration 10U L karyotype associated preservation ovarian function 45 X 46 XX 45 X 47 XXX21 spontaneous puberty group randomised randomisation 2
10,PMC3076731,S51,6911,7116,Randomisation and masking, Girls karyotypes tested concentrations gonadotrophin releasing hormone randomised randomisation 2 peak follicle stimulating hormone concentration 30 U L
5,PMC3076731,S52,7117,7254,Randomisation and masking, Participants enrolled age 12 25 years without spontaneous puberty late group started ethinylestradiol 14 years
5,PMC3076731,S54,7295,7418,Treatment, All participants received growth hormone preparation choice 10 mg m2 week daily subcutaneous injections
5,PMC3076731,S55,7419,7521,Treatment, Oral oxandrolone SPA Milan Italy given 0 05 mg kg day maximum daily dose 2 5 mg
5,PMC3076731,S56,7522,7704,Treatment, Oral ethinylestradiol UCB Pharma Slough UK given daily follows regardless age starting year 1 2 year 2 4 year 3 four months 6 8 10
5,PMC3076731,S57,7705,7894,Treatment, The code randomisation 2 broken 15 years allow introduction progesterone therapy oral norethisterone CP Pharmaceuticals Wrexham UK 5 mg daily five days month
10,PMC3076731,S57,7705,7894,Treatment, The code randomisation 2 broken 15 years allow introduction progesterone therapy oral norethisterone CP Pharmaceuticals Wrexham UK 5 mg daily five days month
5,PMC3076731,S58,7903,7990,Treatment, Treatment growth hormone oxandrolone continued final height reached
5,PMC3076731,S59,7991,8099,Treatment, Oestrogen progesterone therapy continued adult replacement dose pubertal induction completed
11b,PMC3076731,S60,8108,8358,Treatment, White uncoated flat bevelled edge placebo tablets 7 5 mm diameter Essential Nutrition Brough UK specially manufactured match size weight appearance oxandrolone 2 5 mg ethinylestradiol 2 tablets respectively
11a,PMC3076731,S61,8359,8681,Treatment, The study  s central pharmacy Royal Hospital Sick Children Glasgow UK supplied tablets double blind placebo controlled fashion staff British Society Paediatric Endocrinology Diabetes Clinical Trials Unit central distributing pharmacy blinded treatment allocations
3b,PMC3076731,S63,8733,8974,Oxandrolone supplies, In 2004 2008 sole European manufacturer oxandrolone 2 5 mg ceased production resulting 34 participants 2004 11 2008 temporarily suspending active oxandrolone treatment mean duration 2004 52 days 2008 163 days
3b,PMC3076731,S64,8975,9124,Oxandrolone supplies, In 2008 decision taken terminate treatment arm forthwith resulting eight participants stopping oxandrolone treatment prematurely
6a,PMC3076731,S66,9172,9358,Study procedures, At clinic visits every four six months height measured Harpenden stadiometer last completed 1 mm converted SD score using British 1990 reference 22
6a,PMC3076731,S67,9359,9526,Study procedures, Radiographs left wrist obtained annually single observer WFP analysed bone age estimation according Tanner Whitehouse II method 23
6a,PMC3076731,S68,9527,9614,Study procedures, Biochemical analyses followed local protocols results reported centrally
6a,PMC3076731,S69,9623,9802,Study procedures, Standardised pharmacovigilance procedures followed recording adverse events reactions visit subsequent review Data Safety Monitoring Group
0,PMC3076731,S70,9803,9923,Study procedures, Data collection ceased participants withdrew consent although included previously collected data analysis
6a,PMC3076731,S72,9974,10092,Statistical methods, The primary outcome final height defined height velocity less 1 cm year bone age least 15 5 years
6a,PMC3076731,S73,10093,10290,Statistical methods, Secondary outcomes maximum height recently available height age attaining final height three summary growth parameters SITAR analysis described
7a,PMC3076731,S74,10299,10498,Statistical methods, Assuming standard deviation 5 cm needed 50 girls group detect difference groups mean final height 2 8 cm 80 power 5 significance  a total 100 patients
0,PMC3076731,S75,10499,10601,Statistical methods, The study formally powered detect significant interaction two randomisations
0,PMC3076731,S76,10602,10707,Statistical methods, In event 100 patients recruited fewer 100 followed final height
12a,PMC3076731,S77,10716,10807,Statistical methods, We estimated effects two randomisations separately using multiple regression
12b,PMC3076731,S78,10808,10936,Statistical methods, We also adjusted randomisation 2 timing pubertal induction randomisation 1 oxandrolone tested interaction
12a,PMC3076731,S79,10945,11077,Statistical methods, In addition applied SITAR superimposition translation rotation novel method growth curve analysis data 24
12a,PMC3076731,S80,11078,11232,Statistical methods, SITAR transforms individual growth curves become essentially superimposed define average summary curve
12a,PMC3076731,S81,11233,11510,Statistical methods, To achieve individual curve suitably altered three distinct ways curve shifted up down measure child  s size cm left right measure growth tempo years age axis stretched squashed measure percentage velocity
0,PMC3076731,S82,11511,11647,Statistical methods, Size tempo velocity thus participant specific random effects summarising girl  s curve differs average curve
0,PMC3076731,S83,11648,11757,Statistical methods, The effects randomisations explored comparing values random effects trial arm
0,PMC3076731,S84,11758,11829,Statistical methods, Equally separate summary curves constructed trial arm
3a,PMC3103669,S39,5350,5515,Study design, This 24 week dose ranging multicentre double blind double dummy active controlled study approved responsible independent ethics committees
0,PMC3103669,S40,5516,5867,Study design, The study performed accordance International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use ICH Harmonised Tripartite Guidelines Good Clinical Practice ethical principles laid Declaration Helsinki patients provided written informed consent
6a,PMC3103669,S42,5972,6080,Study design, At screening patients indicated joints affected previous gouty arthritis flares
5,PMC3103669,S43,6081,6415,Study design, Eligible patients subsequently randomised 1 1 1 1 1 1 2 receive single dose canakinumab 25 mg 50 mg 100 mg 200 mg 300 mg day 1 four canakinumab doses administered 4 weekly intervals 50 mg day 1 week 4 25 mg weeks 8 12 daily oral doses colchicine 0 5 mg given 16 weeks
8b,PMC3103669,S43,6081,6415,Study design, Eligible patients subsequently randomised 1 1 1 1 1 1 2 receive single dose canakinumab 25 mg 50 mg 100 mg 200 mg 300 mg day 1 four canakinumab doses administered 4 weekly intervals 50 mg day 1 week 4 25 mg weeks 8 12 daily oral doses colchicine 0 5 mg given 16 weeks
11a,PMC3103669,S44,6416,6711,Study design, In order achieve blinding patients investigators patients received subcutaneous injections canakinumab canakinumab placebo day 1 weeks 4 8 12 took capsules colchicine colchicine placebo daily 16 weeks see supplementary material details
11b,PMC3103669,S44,6416,6711,Study design, In order achieve blinding patients investigators patients received subcutaneous injections canakinumab canakinumab placebo day 1 weeks 4 8 12 took capsules colchicine colchicine placebo daily 16 weeks see supplementary material details
5,PMC3103669,S46,6757,6965,Study design, Allopurinol treatment 100  300 mg initiated baseline within 1 month baseline administered randomised patients daily 24 weeks see supplementary material details
5,PMC3103669,S47,6966,7058,Study design, Patients could receive rescue medication needed see supplementary material details
4a,PMC3103669,S49,7098,7473,Patients, Inclusion criteria age 18  80 years diagnosis gouty arthritis defined American College Rheumatology 1977 preliminary criteria 29 least two gouty arthritis flares previous year body mass index BMI kg m2 willingness initiate allopurinol treatment initiated allopurinol treatment within 1 month screening
4a,PMC3103669,S50,7482,7777,Patients, Key exclusion criteria gouty arthritis flare within 2 weeks screening present screening pain associated flare screening history allergy contraindication intolerance allopurinol colchicine see supplementary material details
6a,PMC3103669,S52,7820,7849,Assessments, Flares patient reported
6a,PMC3103669,S53,7850,8021,Assessments, For flare patients recorded diary start date affected joint day severity pain see supplementary material details
6a,PMC3103669,S54,8022,8180,Assessments, Patients also recorded rescue medication use pain least 7 days onset flare longer flares persisted 7 days
6a,PMC3103669,S55,8189,8539,Assessments, Safety assessments performed scheduled visits 2 4 8 12 16 20 24 weeks included collection blood samples assessment inflammatory marker C reactive protein CRP haematology immunogenicity baseline weeks 8 16 24 doctor s assessments local tolerability sites subcutaneous injections
6a,PMC3103669,S56,8540,8596,Assessments, Adverse events AEs reported throughout study
6a,PMC3103669,S57,8605,8859,Assessments, The primary outcome determination canakinumab dose producing equivalent efficacy achieved colchicine 0 5 mg respect mean number flares per patient occurring within 16 weeks post randomisation ie target dose
6a,PMC3103669,S58,8860,9093,Assessments, Secondary efficacy outcomes included mean number flares per patient proportion patients least one flare time first flare average duration flares CRP levels see supplementary material details
6a,PMC3103669,S59,9094,9256,Assessments, Safety variables included incidence AEs serious AEs SAEs infectious AEs incidence severity injection site reactions immunogenicity
7a,PMC3103669,S61,9338,9581,Sample size determination and statistical analysis, A sample size 350 patients 50 patients 5 canakinumab single dose groups 100 patients colchicine group considered sufficient give 95 confidence interval CI target dose reasonable precision
7a,PMC3103669,S62,9582,9760,Sample size determination and statistical analysis, In order increase precision analysis planned total sample size 400 increased approximately 440 patients see supplementary material details
6a,PMC3103669,S63,9769,9854,Sample size determination and statistical analysis, A preplanned interim analysis performed 200 patients completed 16 weeks
7b,PMC3103669,S63,9769,9854,Sample size determination and statistical analysis, A preplanned interim analysis performed 200 patients completed 16 weeks
6a,PMC3103669,S64,9855,9957,Sample size determination and statistical analysis, Efficacy safety analyses performed patients completed study 24 weeks
12a,PMC3103669,S65,9966,10248,Sample size determination and statistical analysis, For determination primary outcome number flares per patient 16 weeks modelled using negative binomial distribution common overdispersion variance divided expectation minus 1 treatment arms see supplementary material details
6a,PMC3103669,S66,10257,10338,Sample size determination and statistical analysis, The main secondary outcome mean number flares per patient 16 weeks
12a,PMC3103669,S67,10339,10491,Sample size determination and statistical analysis, Data analysed according analysis covariance ANCOVA treatment group allopurinol dose baseline BMI baseline covariates
12a,PMC3103669,S68,10492,10636,Sample size determination and statistical analysis, However distribution flares per patient observed skewed preplanned ANCOVA considered inappropriate data
12b,PMC3103669,S69,10637,10960,Sample size determination and statistical analysis, Therefore post hoc analysis using negative binomial model treatment group allopurinol dose baseline BMI baseline covariates log time study offset performed adjustment made multiplicity see supplementary material details analyses secondary outcomes
3a,PMC3109952,S38,5201,5350,Methods, This multicentre two arm randomised controlled open trial carried 13 centres United Kingdom one Republic Ireland
4b,PMC3109952,S38,5201,5350,Methods, This multicentre two arm randomised controlled open trial carried 13 centres United Kingdom one Republic Ireland
4a,PMC3109952,S40,5391,5619,Study population, Participants eligible study aged 12 years plantar wart verruca opinion healthcare professional suitable treatment salicylic acid cryotherapy
4a,PMC3109952,S41,5620,6250,Study population, Participants excluded study impaired healing diabetes peripheral vascular disease immunosuppressed agammaglobulinaemia taking immunosuppressant drugs oral corticosteroids neuropathy receiving renal dialysis cold intolerance Raynaud  s syndrome cold urticaria following conditions blood dyscrasias unknown origin cryoglobulinaemia cryofibrinogenaemia collagen autoimmune disease unable give informed consent currently trial evaluating treatments plantar wart
0,PMC3109952,S43,6327,6511,Recruitment and randomisation of participants, Participants recruited November 2006 January 2010 end extended recruitment period university podiatry school clinics NHS podiatry clinics primary care
0,PMC3109952,S44,6512,6564,Recruitment and randomisation of participants, Eligible participants gave written informed consent
0,PMC3109952,S45,6565,6721,Recruitment and randomisation of participants, They randomised equally receive cryotherapy liquid nitrogen daily self treatment counter 50 salicylic acid treatment
9,PMC3109952,S46,6730,7025,Recruitment and randomisation of participants, Randomisation performed member research team either telephoning independent secure remote telephone randomisation service York Trials Unit accessing secure online web randomisation programme thereby concealing treatment allocation moment randomisation
10,PMC3109952,S46,6730,7025,Recruitment and randomisation of participants, Randomisation performed member research team either telephoning independent secure remote telephone randomisation service York Trials Unit accessing secure online web randomisation programme thereby concealing treatment allocation moment randomisation
8b,PMC3109952,S47,7026,7197,Recruitment and randomisation of participants, Randomisation simple restricted way stratification blocked allocation allocation sequence computer generated
8a,PMC3109952,S47,7026,7197,Recruitment and randomisation of participants, Randomisation simple restricted way stratification blocked allocation allocation sequence computer generated
5,PMC3109952,S50,7275,7433,Intervention, Participants randomised cryotherapy liquid nitrogen received maximum four treatments given two three weeks apart healthcare professional
5,PMC3109952,S51,7434,7522,Intervention, The liquid nitrogen applied spray method choice available probe
5,PMC3109952,S52,7523,7691,Intervention, The treatment delivered according site  s usual practice debridement treatment masking surrounding area padding treatment
5,PMC3109952,S53,7692,7873,Intervention, On advice trial steering committee sites advised first treatment freeze  order ensure participant could tolerate treatment
5,PMC3109952,S55,7928,8157,Intervention, Participants randomised self treatment 50 salicylic acid Verrugon William Ransom Son instructed apply treatment according manufacturer  s instructions treating healthcare professional
5,PMC3109952,S56,8158,8315,Intervention, Patients directed fix adhesive ring hole verruca squeeze little ointment hole directly verruca
5,PMC3109952,S57,8316,8421,Intervention, The backing paper plaster removed plaster applied cover ring completely
5,PMC3109952,S58,8422,8464,Intervention, The plaster sealed position
5,PMC3109952,S59,8465,8592,Intervention, The treatment repeated daily gently pumicing filing dead part verruca maximum eight weeks
6a,PMC3109952,S62,8690,8786,Outcome measurements, The primary outcome complete clearance plantar warts 12 weeks randomisation
6a,PMC3109952,S63,8787,8879,Outcome measurements, Clearance plantar wart defined restoration normal skin close inspection
6a,PMC3109952,S64,8880,8976,Outcome measurements, Digital photographs plantar wart s taken baseline outcome assessment
6a,PMC3109952,S65,8977,9063,Outcome measurements, The photographs assessed two assessors blind treatment allocation
11a,PMC3109952,S65,8977,9063,Outcome measurements, The photographs assessed two assessors blind treatment allocation
6a,PMC3109952,S66,9064,9179,Outcome measurements, They independently assessed photographs participant determine whether plantar wart cleared
6a,PMC3109952,S67,9180,9232,Outcome measurements, Any discrepancies referred third assessor
6a,PMC3109952,S68,9233,9362,Outcome measurements, If photographs available participant however blinded outcome assessment undertaken site used
6a,PMC3109952,S69,9363,9539,Outcome measurements, If neither available participant patient  s self reported outcome recorded week 12 patient questionnaire gone form  used
6a,PMC3109952,S71,9597,10030,Outcome measurements, Secondary outcomes included complete clearance plantar warts 12 weeks controlling age whether plantar wart treated previously type wart b second model explore effect patient preferences c clearance plantar wart six months number warts 12 weeks e time clearance wart f patient satisfaction treatment g adverse events
6a,PMC3109952,S72,10031,10141,Outcome measurements, Questionnaires administered post completed line one three 12 weeks six months
0,PMC3109952,S74,10193,10390,Sample size, The Cochrane systematic review found one small trial directly comparing effectiveness chemical treatment salicylic acid cryotherapy patients warts feet alone 6
0,PMC3109952,S75,10391,10540,Sample size, This poor quality study found 58 cure rate among patients allocated cryotherapy compared 41 among treated salicylic acid
0,PMC3109952,S76,10541,10598,Sample size, This difference 17 statistically significant
0,PMC3109952,S77,10599,10895,Sample size, The overall cure rates study smaller observed two placebo controlled trials salicylic acid reported cure rates 85 active treatment possibly resistant verrucae included study comparing cryotherapy salicylic acid
0,PMC3109952,S78,10896,11033,Sample size, This trial superiority study cryotherapy compared salicylic acid powered show 15 difference effectiveness
7a,PMC3109952,S79,11034,11345,Sample size, In order give 80 power 5 two sided significance show difference cure rates 70 salicylic acid versus 85 cryotherapy 12 weeks sample size 120 patients treatment group required 133 patients group allowing 10 attrition 266 patients total
0,PMC3109952,S81,11397,11524,Statistical analysis, All analyses conducted intention treat basis including patients groups randomised
12a,PMC3109952,S82,11525,11777,Statistical analysis, Analyses conducted SAS version 9 2 SAS Institute NC USA SPSS version 17 0 2 SPSS using two sided significance tests 5 significance level primary outcome measure 1 significance level secondary outcome measures
12a,PMC3109952,S84,11824,11956,Statistical analysis, The primary analysis compared clearance rate plantar warts 12 weeks two randomised groups using test
12a,PMC3109952,S85,11957,12088,Statistical analysis, Cohen  s measure inter rater agreement used assess agreement two assessors photographs clearance
12a,PMC3109952,S87,12146,12327,Statistical analysis, A logistic regression model used adjust primary analysis important prognostic variables age whether plantar wart previously treated type wart
12a,PMC3109952,S88,12328,12517,Statistical analysis, We also extended primary outcome model explore effect patient preferences including preference interaction term preferred treatment randomised treatment
12a,PMC3109952,S89,12518,12669,Statistical analysis, The complete clearance plantar warts six months analysed way primary outcome adjustments covariates
12a,PMC3109952,S90,12670,12851,Statistical analysis, We used negative binomial regression compare number plantar warts 12 weeks two treatment groups adjustment number plantar warts baseline
0,PMC3109952,S91,12852,12982,Statistical analysis, These models used estimate number occurrences event event Poisson variation over dispersion
6a,PMC3109952,S92,12993,13177,Statistical analysis, The time clearance plantar warts derived number days randomisation date clearance detailed participant  s self reported questionnaire
0,PMC3109952,S93,13178,13416,Statistical analysis, Participants whose plantar warts cleared treated censored calculated duration trial date trial exit date last available assessment 183 days trial cessation appropriate
12b,PMC3109952,S94,13417,13593,Statistical analysis, A Cox proportional hazards model used compare time clearance plantar warts two groups adjusting covariates primary outcome
12b,PMC3109952,S95,13594,13873,Statistical analysis, The Cox proportional hazard assumption tested globally correlation Schoenfeld residuals survival time ranked survival time separately covariate correlation Schoenfeld scaled residuals survival time ranked survival time
0,PMC3109952,S96,13874,14004,Statistical analysis, Non significant correlation indicates enough evidence proportional hazard assumption violated
0,PMC3109952,S97,14015,14160,Statistical analysis, Data patient satisfaction treatment adverse events summarised treatment group statistical analyses performed
3a,PMC3128457,S39,4818,4940,Methods, Trial design  This double blind randomised placebo controlled trial nested cohort CRASH 2 trial participants
0,PMC3128457,S40,4941,5028,Methods, The aims methods results CRASH 2 trial presented detail elsewhere 2
0,PMC3128457,S41,5035,5114,Methods, Participants  The trial conducted cohort CRASH 2 trial participants
4a,PMC3128457,S42,5115,5660,Methods, Patients eligible inclusion Intracranial Bleeding Study fulfilled inclusion criteria CRASH 2 trial  adult trauma patients significant haemorrhage systolic blood pressure 90 mm Hg heart rate 110 beats per min considered risk significant haemorrhage within 8 hours injury study entry governed uncertainty principle 11  but also traumatic brain injury Glasgow coma scale brain computed tomography compatible traumatic brain injury
4a,PMC3128457,S43,5661,5749,Methods, Pregnant women patients second brain scan possible excluded
0,PMC3128457,S44,5750,5871,Methods, Consent procedures participating hospitals established local regulation appropriate ethics committees
4b,PMC3128457,S45,5878,5957,Methods, Study settings  Patients recruited 10 hospitals India Colombia
0,PMC3128457,S46,5958,6110,Methods, The sites selected according interest topic adequate facilities conducting computed tomography expected recruitment rate
5,PMC3128457,S48,6148,6363,Interventions, Participants randomly allocated receive loading dose 1 g tranexamic acid infused 10 minutes followed intravenous infusion 1 g eight hours matching placebo sodium chloride 0 9
6a,PMC3128457,S50,6403,6530,Outcomes, We obtained two brain computed tomograms participant first randomisation second 24  48 hours later
6a,PMC3128457,S51,6531,6660,Outcomes, A neuroradiologist Zoe Morris blind treatment allocation clinical findings evaluated first second scans
6a,PMC3128457,S52,6661,6879,Outcomes, Readings two scans done twice second reading blind results first reading central reading electronic DICOM image files Digital Jacket software DesAcc Chicago IL USA
6a,PMC3128457,S53,6880,7167,Outcomes, The size intra parenchymal haemorrhages haemorrhagic contusions subdural epidural haematomas subarachnoid haemorrhage ischaemic lesions mass effect overall amount tissue damage assessed validated rating scales based previous work see box 12 13 14 15 16
6a,PMC3128457,S54,7168,7311,Outcomes, The individual ratings measurements recorded rating form developed purposes study shown appendix bmj com
6a,PMC3128457,S57,7630,7709,Outcomes, Measurement  A representative slice centre haematoma selected
6a,PMC3128457,S58,7710,7837,Outcomes, The maximum linear length A cm multiplied maximum width perpendicular A B maximum depth C cm
6a,PMC3128457,S59,7838,7987,Outcomes, The depth C determined multiplying number slices haematoma visible slice interval thickness listed CT scan
6a,PMC3128457,S60,7988,8058,Outcomes, To obtain volume cm3 final product A B C divided 2
6a,PMC3128457,S62,8201,8282,Outcomes, Measurement  A representative slice near centre haematoma selected
6a,PMC3128457,S63,8283,8391,Outcomes, The linear distance cm corner subdural crescent used determine length A
6a,PMC3128457,S64,8392,8525,Outcomes, The width B measured maximum thickness cm haematoma inner table skull perpendicular length
6a,PMC3128457,S65,8526,8675,Outcomes, The depth C determined multiplying number slices haematoma visible slice interval thickness listed CT scan
6a,PMC3128457,S66,8676,8747,Outcomes, To obtain volume cm3 final product A B C divided 2
6a,PMC3128457,S68,8890,8971,Outcomes, Measurement  A representative slice near centre haematoma selected
6a,PMC3128457,S69,8972,9082,Outcomes, The linear distance cm corner epidural lens shape used determine length A
6a,PMC3128457,S70,9083,9220,Outcomes, The width B measured maximum thickness cm haematoma B inner table skull perpendicular length
6a,PMC3128457,S71,9221,9360,Outcomes, The depth C determined multiplying number slices haematoma visible slice interval listed CT scan
6a,PMC3128457,S72,9361,9432,Outcomes, To obtain volume cm3 final product A B C divided 2
6a,PMC3128457,S74,9581,9662,Outcomes, Measurement  Blood within subarachnoid spaces pia arachnoid membranes
6a,PMC3128457,S75,9663,9719,Outcomes, Haemorrhage thickness categorised mm 5 mm
6a,PMC3128457,S76,9720,9774,Outcomes, The thickness rated within representative sulcus
6a,PMC3128457,S78,9925,10107,Outcomes, Measurement  Focal low attenuation distribution indicating arterial ischaemic cause rather traumatic contusional injury rated according validated scale ischaemic stroke
6a,PMC3128457,S80,10242,10398,Outcomes, Measurement  1 sulcal effacement 2 ventricular effacement 3 uncal herniation 4 cisterns compressed 5 cisterns absent 6 Midline shift mm
6a,PMC3128457,S81,10472,10748,Outcomes, The primary outcome total haemorrhage growth defined difference combined volume mL intracranial haemorrhagic lesions intra parenchymal haematoma  haemorrhagic contusion  subdural haematoma  epidural haematoma first second scan
6a,PMC3128457,S82,10749,11145,Outcomes, Secondary outcomes significant haemorrhage growth defined increase total haemorrhage relation initial volume b new intracranial haemorrhage apparent second scan apparent first c change subarachnoid haemorrhage grade mass effect e new focal cerebral ischaemic lesions apparent second scan first
6a,PMC3128457,S83,11154,11259,Outcomes, The clinical outcomes death cause dependency need neurosurgical intervention
6a,PMC3128457,S84,11260,11382,Outcomes, Clinical outcomes recorded hospital discharge 28 days randomisation death whichever occurred first
6a,PMC3128457,S85,11383,11468,Outcomes, Dependency measured using five point modified Oxford handicap scale mOHS 17
6a,PMC3128457,S86,11469,11712,Outcomes, We dichotomised scale fully dependent requiring attention day night dependent requiring constant attention restriction lifestyle independent minor symptoms symptoms
6a,PMC3128457,S87,11713,11985,Outcomes, We also reported poor outcome  defined patient developed one following follow up period  significant haemorrhage growth new intracranial haemorrhage new focal cerebral ischaemic lesions need neurosurgery death
6a,PMC3128457,S88,11994,12116,Outcomes, Adverse events serious unexpected suspected related study treatment reported separately
7a,PMC3128457,S90,12159,12466,Sample size, Assuming initial intracranial haemorrhage volume 20 mL average haemorrhage growth 7 mL control group correlation 0 6 initial follow up volumes estimated trial 300 patients would 80 power detect 35 reduction haemorrhage growth
7a,PMC3128457,S91,12467,12694,Sample size, We pre specified protocol study nested within main CRASH 2 trial even planned sample size 300 patients achieved recruitment would stop time main CRASH 2 trial
0,PMC3128457,S93,12739,12872,Randomisation, After eligibility confirmed locally approved consent procedures completed patients randomly assigned
8b,PMC3128457,S94,12873,12970,Randomisation, Randomisation balanced centre allocation sequence based block size eight
8a,PMC3128457,S95,12971,13091,Randomisation, We used local pack system selected lowest numbered treatment pack box containing eight numbered packs
9,PMC3128457,S96,13092,13155,Randomisation, Apart pack number treatment packs identical
10,PMC3128457,S97,13156,13280,Randomisation, The pack number recorded entry form sent international trial coordinating centre London UK
10,PMC3128457,S98,13281,13444,Randomisation, Once treatment pack number recorded patient included trial whether treatment pack opened allocated treatment started
11a,PMC3128457,S99,13445,13540,Randomisation, All site investigators trial coordinating centre staff masked treatment allocation
11b,PMC3128457,S101,13580,13640,Blinding, Tranexamic acid placebo ampoules indistinguishable
0,PMC3128457,S102,13641,13768,Blinding, Tranexamic acid manufactured Pharmacia Pfizer Sandwich UK placebo St Mary  s Pharmaceutical Unit Cardiff UK
0,PMC3128457,S103,13769,13878,Blinding, The treatment packs prepared independent clinical trial supply company Bilcare Crickhowell UK
11b,PMC3128457,S104,13879,14041,Blinding, Correct blinding coding ampoules assured independent random testing batch high performance liquid chromatography confirm contents
12b,PMC3128457,S106,14092,14209,Statistical methods, We assessed intra observer reliability haemorrhage measurements using intra class correlation coefficient
12b,PMC3128457,S107,14210,14282,Statistical methods, We assessed reliability binary measurements statistic
0,PMC3128457,S108,14283,14415,Statistical methods, For continuous variables measuring haemorrhage used average measurement two independent readings analyses
0,PMC3128457,S109,14416,14579,Statistical methods, For binary variables considered intracranial finding present reported present readings particular patient  s brain scan
12b,PMC3128457,S110,14588,14654,Statistical methods, We used generalised linear models adjusted baseline variables
0,PMC3128457,S111,14655,14725,Statistical methods, Covariates included adjustment Glasgow coma scale age
0,PMC3128457,S112,14726,14858,Statistical methods, For computed tomography outcomes also adjusted time injury first second scan initial haemorrhage volume
0,PMC3128457,S113,14859,14926,Statistical methods, In analysis mass effect adjusted initial mass effect
0,PMC3128457,S114,14927,15046,Statistical methods, Adjusted effects considered primary analysis adjusted unadjusted effect measures reported
0,PMC3128457,S115,15047,15153,Statistical methods, We reported 95 confidence intervals effects estimated P values adjusted analyses
12a,PMC3128457,S116,15162,15295,Statistical methods, Haemorrhage growth analysed using multiple linear regression analysis covariance main factor treatment group
12a,PMC3128457,S117,15296,15461,Statistical methods, Outcomes reported combined separately patients undergo neurosurgical evacuation first second computed tomography scan
12a,PMC3128457,S118,15462,15518,Statistical methods, Binary outcomes analysed using logistic regression
12a,PMC3128457,S119,15519,15631,Statistical methods, Subarachnoid haemorrhage scale compared two groups using non parametric rank test Kruskal Wallis
0,PMC3128457,S120,15632,15692,Statistical methods, All analyses undertaken intention treat basis
0,PMC3128457,S121,15701,15852,Statistical methods, To evaluate clinical relevance primary surrogate outcome selected study also analysed clinical effect haemorrhage growth
12a,PMC3128457,S122,15853,16189,Statistical methods, We conducted logistic regression analysis dependency defined modified Oxford handicap scale outcome haemorrhage growth main exposure variable adjustment potential confounders initial haemorrhage volume Glasgow coma scale age time injury computed tomography treatment
12a,PMC3128457,S123,16198,16278,Statistical methods, We used statistical software package Stata version SE 11  0 StataCorp
0,PMC3128457,S125,16336,16467,Role of the funding source, The funder study role study design data collection data analysis data interpretation writing report
0,PMC3128457,S126,16468,16603,Role of the funding source, The Writing Committee full access data study final responsibility decision submit publication
0,PMC3242163,S32,4360,4408,Patients and randomisation, Details HPS reported previously 1  3
4a,PMC3242163,S33,4409,4624,Patients and randomisation, Briefly July 1994 May 1997 20  536 men women aged 40  80 years increased risk vascular events randomly allocated receive 40 mg simvastatin daily matching placebo
5,PMC3242163,S33,4409,4624,Patients and randomisation, Briefly July 1994 May 1997 20  536 men women aged 40  80 years increased risk vascular events randomly allocated receive 40 mg simvastatin daily matching placebo
3a,PMC3242163,S33,4409,4624,Patients and randomisation, Briefly July 1994 May 1997 20  536 men women aged 40  80 years increased risk vascular events randomly allocated receive 40 mg simvastatin daily matching placebo
5,PMC3242163,S34,4625,4857,Patients and randomisation, At final follow up May  October 2001 participants encouraged continue allocated study treatment unless contraindicated study results sent family doctors Nov 11 2001
5,PMC3242163,S35,4858,5028,Patients and randomisation, Participants advised discuss doctors light results whether non trial statin treatment prescribed study treatment stopped
11a,PMC3242163,S36,5029,5333,Patients and randomisation, To allow unbiased assessment subsequent long term effects participants doctors made aware previously allocated study treatment unless particular request 15 participants unblinded 18 simvastatin allocated vs 13 placebo allocated
6a,PMC3242163,S38,5389,5513,Procedures and follow-up, During in trial treatment period routine follow up study clinics 4 8 12 months every 6 months
6a,PMC3242163,S39,5514,5643,Procedures and follow-up, Information sought suspected heart attacks strokes vascular procedures cancers serious adverse events
6a,PMC3242163,S40,5644,5766,Procedures and follow-up, Participants unable unwilling attend contacted telephone follow up sought family doctors
6a,PMC3242163,S41,5767,5992,Procedures and follow-up, Post trial follow up serious adverse events conducted mailing questionnaires surviving participants late November 2001 annually November 2006 reminder mailed 2 months later
6a,PMC3242163,S42,5993,6092,Procedures and follow-up, Follow up participants complete questionnaires sought family doctors
6a,PMC3242163,S43,6093,6293,Procedures and follow-up, During in trial post trial periods information sites registered cancers certified causes deaths requested UK national registries randomised patients
6a,PMC3242163,S44,6302,6478,Procedures and follow-up, Further details sought participants family doctors plus necessary hospital records reports might relate major vascular events deaths
6a,PMC3242163,S45,6479,6703,Procedures and follow-up, In view high confirmation rate 95 central adjudication cancers reported in trial period information routinely sought non fatal cancers reported post trial period
11a,PMC3242163,S46,6704,6855,Procedures and follow-up, Events coded according prespecified criteria1 clinical staff coordinating centre unaware study treatment allocation
0,PMC3242163,S47,6864,7040,Procedures and follow-up, During in trial period compliance study treatment assessed follow up questioning participant reviewing remaining calendar packed tablets
6a,PMC3242163,S48,7041,7353,Procedures and follow-up, The effects treatment allocation cholesterol concentrations assessed assaying blood obtained study clinics sample 5 participants scheduled follow up time year participants attending follow up August 2000 February 2001 2
6a,PMC3242163,S49,7354,7642,Procedures and follow-up, During post trial period participants asked year current statin use post trial lipid profile assays sought 1500 randomly selected surviving participants May 2004 August 2004 ie 3 years scheduled treatment period
6a,PMC3242163,S50,7643,7801,Procedures and follow-up, About 1100 blood samples obtained participants family doctors mailed central laboratory assay using previously validated methods 15
12a,PMC3242163,S52,7867,8303,Endpoints and statistical analysis, The main comparisons entail log rank analyses first post randomisation occurrence particular events in trial period defined events occurring Nov 11 2001 post trial period defined events occurring Nov 11 2001 March 31 2007 among originally allocated 40 mg simvastatin daily versus allocated matching placebo tablets ie intention to treat analyses
0,PMC3242163,S53,8304,8556,Endpoints and statistical analysis, The results in trial analyses differ slightly previously published findings2 3 inclusion events taking place participants final follow up visit Nov 11 2001 mean extra follow up 3  5 months SD 1  4
6a,PMC3242163,S54,8557,8820,Endpoints and statistical analysis, The primary outcome analyses prolonged follow up prespecified first post randomisation major vascular event defined non fatal myocardial infarction coronary death fatal non fatal stroke coronary non coronary revascularisation
6a,PMC3242163,S55,8821,9182,Endpoints and statistical analysis, Secondary outcomes major vascular events year follow up various subcategories patients major coronary events ie non fatal myocardial infarction coronary death strokes revascularisations separately deaths vascular non vascular causes separately cancers sites excluding non melanoma skin cancer
0,PMC3242163,S56,9183,9385,Endpoints and statistical analysis, Analyses presented outcomes eg site specific cancer cerebral haemorrhage prespecified in trial period whereas eg cancer incidence year
0,PMC3242163,S57,9386,9501,Endpoints and statistical analysis, Allowances multiple comparisons post hoc nature analyses made interpretation
0,PMC3242163,S59,9559,9679,Role of the funding source, The trial designed conducted analysed interpreted investigators independently funding sources
0,PMC3242163,S60,9680,9808,Role of the funding source, The writing committee full access study data final responsibility decision submit publication
4b,PMC3266479,S37,3869,4045,Study design and participants, We undertook multicentre pragmatic double blind placebo controlled parallel group randomised trial 46 UK intensive care units December 2006 March 2010
3a,PMC3266479,S37,3869,4045,Study design and participants, We undertook multicentre pragmatic double blind placebo controlled parallel group randomised trial 46 UK intensive care units December 2006 March 2010
4a,PMC3266479,S38,4046,4168,Study design and participants, Eligible participants intubated mechanically ventilated adults aged 16 years older within 72 h ARDS onset
0,PMC3266479,S39,4169,4244,Study design and participants, Patients identified recruited local investigators site
4a,PMC3266479,S40,4245,4557,Study design and participants, We defined ARDS accordance American European Consensus criteria 14 pressure arterial oxygen fractional inspired oxygen concentration PaO2 FIO2 ratio 200 mm  Hg less bilateral pulmonary infiltrates consistent oedema absence clinically evident left atrial hypertension
4a,PMC3266479,S41,4558,4950,Study design and participants, Exclusion criteria pregnancy current treatment intravenous agonist need continuous regular aerolised agonists current treatment antagonists imminent withdrawal medical treatment chronic liver disease defined Child Pugh grade C enrolment another clinical trial investigational medicinal product within previous 28 days
0,PMC3266479,S42,4959,5204,Study design and participants, Sedated patients capacity give consent therefore consistent requirements EU clinical trial directive 15 obtained written informed consent personal professional legal representative randomisation
0,PMC3266479,S43,5205,5361,Study design and participants, All surviving patients informed trial earliest opportunity regaining competence consent continue trial sought
0,PMC3266479,S45,5460,5509,Study design and participants, Site specific approval obtained site
0,PMC3266479,S46,5510,5600,Study design and participants, The trial monitored safety independent Data Monitoring Ethics Committee
0,PMC3266479,S48,5657,5744,Randomisation and masking, Study drug packs prepared Bilcare Global Clinical Supplies Europe Powys UK
9,PMC3266479,S49,5745,6027,Randomisation and masking, The active placebo drug components infusions packaged identically numbered treatment packs containing 5 mL either salbutamol sulphate BP 1 mg mL sterile isotonic solution GlaxoSmithKline Middlesex UK placebo 0  9 sterile sodium chloride
5,PMC3266479,S49,5745,6027,Randomisation and masking, The active placebo drug components infusions packaged identically numbered treatment packs containing 5 mL either salbutamol sulphate BP 1 mg mL sterile isotonic solution GlaxoSmithKline Middlesex UK placebo 0  9 sterile sodium chloride
8b,PMC3266479,S50,6028,6107,Randomisation and masking, We used computer generated randomisation sequence block size eight
8a,PMC3266479,S50,6028,6107,Randomisation and masking, We used computer generated randomisation sequence block size eight
10,PMC3266479,S51,6108,6251,Randomisation and masking, Patients randomly assigned 1 1 ratio centralised 24 h telephone web based randomisation service University Aberdeen UK
8b,PMC3266479,S52,6252,6368,Randomisation and masking, Randomisation minimised centre PaO2 FIO2 ratio 51  99 mm  Hg age 64 65  84 years
11a,PMC3266479,S53,6369,6449,Randomisation and masking, Participants care providers investigators masked group assignment
6a,PMC3266479,S55,6491,6801,Procedures, We obtained acute physiology chronic health evaluation II APACHE II scores Intensive Care National Audit Research Centre ICNARC sites n 36 participate ICNARC s Case Mix Programme non participating sites ten obtained data necessary calculation scores
6a,PMC3266479,S56,6802,6899,Procedures, We used APACHE II score calculate mortality risk used subgroup analysis
6a,PMC3266479,S57,6908,7228,Procedures, The likely cause ARDS identified treating clinician categorised direct lung injury smoke toxin inhalation aspiration gastric content near drowning thoracic trauma pneumonia indirect lung injury sepsis cardiopulmonary bypass pancreatitis non thoracic trauma
0,PMC3266479,S58,7229,7413,Procedures, The protocol recommended use lung protective ventilation strategy basis ideal bodyweight 17 fluid restriction 18 appropriate high positive end expiratory pressure 19
6a,PMC3266479,S59,7414,7544,Procedures, Compliance recommendations protective ventilation assessed baseline tidal volumes per kg ideal bodyweight
6a,PMC3266479,S60,7545,7624,Procedures, All treatments delivered accordance local clinical practice
6a,PMC3266479,S61,7633,7794,Procedures, Before start recruitment intensive care unit nurse trained monitor side effects treatment inform research team necessary
6a,PMC3266479,S62,7795,7987,Procedures, Infusion syringes prepared immediately use nurse contained two ampoules blinded solutions salbutamol placebo diluted 40 mL saline 50 mL syringe
6a,PMC3266479,S63,7988,8177,Procedures, Salbutamol placebo administered dedicated intravenous line rate 0  075 mL kg ideal bodyweight per h equivalent 15 salbutamol per kg ideal bodyweight per h
6a,PMC3266479,S64,8178,8329,Procedures, The patient measured heel vertex soft tape measure ideal bodyweight infusion rate obtained conversion table 17
6a,PMC3266479,S65,8330,8522,Procedures, If patient developed tachycardia heat rate 140 beats per min new arrhythmia lactic acidosis adjusted infusion rate according prespecified dose adjustment schedule 15
6a,PMC3266479,S66,8523,8608,Procedures, Infusion study drug stopped 7 days earlier clinically indicated
6a,PMC3266479,S68,8654,8766,Study outcomes, The primary outcome 28 day mortality defined death end calendar day 28 randomisation
6a,PMC3266479,S69,8767,9090,Study outcomes, Secondary outcomes mortality intensive care unit hospital first discharge ventilator free organ failure free days randomisation day 28 length stay intensive care unit hospital tachycardia new arrhythmia side effects sufficient stop treatment trial drug
6a,PMC3266479,S70,9091,9325,Study outcomes, We defined ventilator free days number calendar days patients started unassisted breathing day 28 randomisation patients survived least 48 consecutive hours start unassisted breathing 20
6a,PMC3266479,S71,9326,9487,Study outcomes, The number ventilator free days zero patients died without start unassisted breathing 48 consecutive hours unassisted breathing 20
6a,PMC3266479,S72,9488,9719,Study outcomes, We defined organ failure free days number days first 28 days randomisation patient received cardiovascular renal liver neurological support defined Critical Care Minimum Dataset 21
6b,PMC3266479,S73,9728,10037,Study outcomes, We plan collect data cause death original trial protocol however early termination trial increased 28 day mortality salbutamol group data main cause death ascertained participants dying within 28 days randomisation
6b,PMC3266479,S74,10038,10147,Study outcomes, We requested causes death recorded death certificate disorder directly leading death
6a,PMC3266479,S75,10148,10282,Study outcomes, Patients remained alive critical care randomisation monitored daily discharged ward day 28
7a,PMC3266479,S77,10334,10468,Statistical analysis, We based sample size calculation BALTI trial13 2005 data Intensive Care National Audit Research Centre
7a,PMC3266479,S78,10469,10750,Statistical analysis, The target sample size 1334 gave 90 power p 0  05 detect risk ratio RR 0  8 28 day mortality salbutamol placebo groups 3 loss patients primary outcome assumption 28 day mortality placebo group 44
7b,PMC3266479,S79,10751,10872,Statistical analysis, We planned interim analyses every 12 months frequently requested Data Monitoring Ethics Committee
7b,PMC3266479,S80,10873,11070,Statistical analysis, The committee used Haybittle Peto22 stopping guideline difference three standard errors would needed considering recommending trial cessation benefit interim analysis
0,PMC3266479,S81,11079,11134,Statistical analysis, All analyses based intention to treat analyses
12a,PMC3266479,S82,11135,11220,Statistical analysis, We compared primary outcome dichotomous outcomes using RRs 95 CIs
12a,PMC3266479,S83,11221,11293,Statistical analysis, We compared continuous outcomes mean differences 95 CIs
12a,PMC3266479,S84,11294,11441,Statistical analysis, We analysed 28 day mortality survival analysis comparison two groups hazard ratios 95 CIs Kaplan  Meier curve
12a,PMC3266479,S85,11442,11525,Statistical analysis, All reported p values two sided adjusted multiple comparisons
12b,PMC3266479,S86,11526,11744,Statistical analysis, We used prespecified subgroup analyses investigate effects age severity hypoxaemia study entry cause direct vs indirect causes ARDS APACHE II mortality risk effect salbutamol
12b,PMC3266479,S87,11745,11908,Statistical analysis, All subgroup analyses used interaction tests either calculated ratio RRs subgroups used interaction terms logistic regression models
12b,PMC3266479,S88,11909,12060,Statistical analysis, We post hoc analysis main causes death recorded death certificates participants died within 28 days randomisation
0,PMC3266479,S91,12194,12326,Role of the funding source, The sponsor study role study design data collection data analysis data interpretation writing report
0,PMC3266479,S92,12327,12492,Role of the funding source, FGS SG GDP SEL full access data study corresponding author final responsibility decision submit publication
4a,PMC3321505,S32,5025,5183,Patients, Male female patients aged 40  80 years expected require daily NSAID therapy least 6 months pain and or inflammatory conditions eligible
4a,PMC3321505,S33,5184,6301,Patients, Exclusion criteria included history erosive esophagitis history GI complications bleeding perforated ulcer gastric outlet obstruction due ulcer history NSAID associated asthma exacerbations acute renal failure interstitial nephritis hepatitis history GI malignancy history myocardial infarction unstable cardiac arrhythmias stroke within 6 months study entry coronary artery bypass graft surgery within 14 days study entry uncontrolled congestive heart failure hypertension entry acid suppressive therapy misoprostol within 14 days study entry investigational drug NSAIDs including aspirin 325  mg daily within 30 days study entry ulcer 5 erosions screening upper GI tract endoscopy one following abnormalities baseline laboratory testing creatinine clearance 45  ml min aminotransferase 2 5 times upper limit normal fasting blood sugar 200  mg dl serum pregnancy test positive serologic tests positive human immunodeficiency virus hepatitis B hepatitis C stool antigen H pylori positive
8a,PMC3321505,S35,6345,6693,Study design, Patients randomly assigned using computer generated randomization schedule central location utilizing interactive voice response system blinded medication kit number allocation 2 1 ratio identical appearing tablets HZT 501 800  mg ibuprofen 26 6  mg famotidine ibuprofen 800  mg thrice daily 24 weeks
9,PMC3321505,S35,6345,6693,Study design, Patients randomly assigned using computer generated randomization schedule central location utilizing interactive voice response system blinded medication kit number allocation 2 1 ratio identical appearing tablets HZT 501 800  mg ibuprofen 26 6  mg famotidine ibuprofen 800  mg thrice daily 24 weeks
11b,PMC3321505,S35,6345,6693,Study design, Patients randomly assigned using computer generated randomization schedule central location utilizing interactive voice response system blinded medication kit number allocation 2 1 ratio identical appearing tablets HZT 501 800  mg ibuprofen 26 6  mg famotidine ibuprofen 800  mg thrice daily 24 weeks
3a,PMC3321505,S35,6345,6693,Study design, Patients randomly assigned using computer generated randomization schedule central location utilizing interactive voice response system blinded medication kit number allocation 2 1 ratio identical appearing tablets HZT 501 800  mg ibuprofen 26 6  mg famotidine ibuprofen 800  mg thrice daily 24 weeks
10,PMC3321505,S35,6345,6693,Study design, Patients randomly assigned using computer generated randomization schedule central location utilizing interactive voice response system blinded medication kit number allocation 2 1 ratio identical appearing tablets HZT 501 800  mg ibuprofen 26 6  mg famotidine ibuprofen 800  mg thrice daily 24 weeks
11a,PMC3321505,S36,6694,6774,Study design, Patients care providers study personnel blinded treatment
3a,PMC3321505,S37,6775,6969,Study design, Patients stratified two risk factors ulcer development concomitant use low dose aspirin daily and or anticoagulant medication history gastric duodenal ulcer
8b,PMC3321505,S37,6775,6969,Study design, Patients stratified two risk factors ulcer development concomitant use low dose aspirin daily and or anticoagulant medication history gastric duodenal ulcer
6a,PMC3321505,S38,6970,7135,Study design, In addition screening upper endoscopy baseline patients endoscopy weeks 8 16 24 earlier premature study termination study therapy
5,PMC3321505,S39,7136,7379,Study design, The following medications proscribed study medications may reduce ulcers e g misoprostol proton pump inhibitors non study H2RAs non study NSAIDs low dose aspirin taken cardiovascular prophylaxis
5,PMC3321505,S40,7380,7537,Study design, In addition antacids could taken 3 days 2 week period patients requiring antacid therapy discontinued trial
5,PMC3321505,S41,7538,7615,Study design, The study medication dispensed 8 week supply 0 8 16 weeks
0,PMC3321505,S42,7616,7696,Study design, Compliance determined pill count returned bottles study medication
0,PMC3321505,S43,7697,7873,Study design, Serum chemistries complete blood count prothrombin time performed screening week 8 week 16 final study visit week 24 earlier early termination
0,PMC3321505,S44,7874,7922,Study design, Urinalysis done baseline final visit
6a,PMC3321505,S46,7977,8274,End points and analysis, The primary end point REDUCE 1 gastric ulcers identified endoscopy 24 week study period three secondary end points upper GI ulcers gastric duodenal duodenal ulcers GI complications bleeding ulcer perforation gastric outlet obstruction due ulcer
6a,PMC3321505,S47,8275,8496,End points and analysis, The primary end point REDUCE 2 upper GI gastric duodenal ulcers identified endoscopy 24 week study period three secondary end points gastric ulcers duodenal ulcers GI complications
6a,PMC3321505,S48,8497,8579,End points and analysis, An endoscopic diagnosis ulcer required unequivocal depth diameter
0,PMC3321505,S49,8580,8763,End points and analysis, The predefined primary population analysis included patients randomized received dose study medication least one study mandated follow up endoscopy
7a,PMC3321505,S50,8772,8974,End points and analysis, A sample size REDUCE 1 875 calculated based 90 power detect difference 6 vs 14 incidence gastric ulcers two sided 0 05 assuming 15 drop out rate
7a,PMC3321505,S51,8975,9178,End points and analysis, A sample size REDUCE 2 600 calculated based 90 power detect difference 6 vs 16 incidence upper GI ulcers two sided 0 05 assuming 15 drop out rate
6a,PMC3321505,S52,9179,9498,End points and analysis, Statistical comparisons predefined done fixed testing sequence hierarchical following order primary followed secondary end points REDUCE 1 gastric ulcers upper GI ulcers duodenal ulcers GI complications REDUCE 2 upper GI ulcers gastric ulcers duodenal ulcers GI complications
0,PMC3321505,S53,9499,9779,End points and analysis, With approach first null hypothesis accepted i e P  0 05 cause immediate acceptance subsequent null hypotheses sequence subsequent comparisons considered significantly different statistical comparison performed
0,PMC3321505,S54,9780,9854,End points and analysis, This approach also requires adjustment multiple comparisons 14
0,PMC3321505,S55,9863,10124,End points and analysis, The two different primary end points individual studies chosen address clinically relevant end point upper GI ulcers gastric and or duodenal traditional US FDA Food Drug Administration end point gastric ulcers
0,PMC3321505,S56,10125,10300,End points and analysis, In clinical practice physicians patients concerned preventing ulcers whether gastric duodenal many clinical trials use primary end point
0,PMC3321505,S57,10301,10438,End points and analysis, However FDA generally approved antisecretory medications prevention gastric ulcers e g lansoprazole esomeprazole
0,PMC3321505,S58,10439,10598,End points and analysis, These two trials designed used registration pretrial meetings FDA agreed use different end points two trials
12a,PMC3321505,S59,10607,10975,End points and analysis, Comparison treatment arms crude proportions patients ulcers 24 weeks Cochran  Mantel  Haenszel test stratified two randomization risk factor strata use low dose aspirin anticoagulants prior ulcer history specified primary statistical analysis time sample size calculation study initiation
6b,PMC3321505,S60,10976,11374,End points and analysis, Before study termination unblinding primary analysis changed comparison treatment arms life table estimates proportion patients ulcers 24 weeks employing modified using sum squares life table error term comparison crude proportions using Cochran  Mantel  Haenszel test maintained secondary analysis
0,PMC3321505,S61,11375,11475,End points and analysis, Numbers needed to treat NNTs absolute risk reductions calculated using crude proportions
6a,PMC3321505,S62,11484,11675,End points and analysis, A pooled analysis patients REDUCE 1 2 prespecified primary end point upper GI ulcers secondary end points gastric ulcers duodenal ulcers
0,PMC3321505,S63,11676,11896,End points and analysis, The proportion patients developing ulcers also prespecified assessed following subgroups use low dose aspirin and or anticoagulants prior ulcer history age vs 65  years gender race
0,PMC3321505,S64,11897,12036,End points and analysis, In addition post hoc subgroup analysis included use low dose aspirin alone presence absence erosions screening endoscopy
12b,PMC3321505,S65,12037,12151,End points and analysis, For comparison subgroups 100 patients across combined treatment arms Fisher s exact test used
12b,PMC3321505,S66,12152,12399,End points and analysis, The independent variables prior ulcer history gender age low dose aspirin use baseline erosions therapy also included proportional hazards model determine effect dependent variable development upper GI ulcer
12b,PMC3321505,S67,12400,12487,End points and analysis, Treatment by subgroup interaction also assessed among subgroups model
12a,PMC3321505,S68,12488,12702,End points and analysis, A post hoc fixed effect meta analysis results two studies end points upper GI gastric duodenal ulcers also performed Review Manager 5 1 Cochrane Collaboration Copenhagen Denmark
12b,PMC3321505,S69,12711,12919,End points and analysis, Statistical comparison study groups population patients randomized also prespecified common adverse events occurring 5 patients Cochran  Mantel  Haenszel test
12b,PMC3321505,S70,12920,13179,End points and analysis, In addition prespecified comparison proportion patients reported symptom consistent dyspepsia e g dyspepsia upper abdominal pain discomfort epigastric pain discomfort stomach pain discomfort without nausea
0,PMC3321505,S71,13188,13329,End points and analysis, All study patients provided written informed consent study approved institutional review boards participating centers
3a,PMC3348565,S49,6126,6351,Participants, Between Nov 4 Dec 4 2008 community based randomised placebo controlled superiority trial Kabul Afghanistan within catchment area Maiwand Teaching Hospital serves inner city population
4b,PMC3348565,S49,6126,6351,Participants, Between Nov 4 Dec 4 2008 community based randomised placebo controlled superiority trial Kabul Afghanistan within catchment area Maiwand Teaching Hospital serves inner city population
4b,PMC3348565,S51,6382,6503,Participants, The children enrolled study largely came five 18 socioeconomically deprived inner city districts
0,PMC3348565,S52,6504,6680,Participants, We identified households young children detailed maps advice staff Agha Khan Trust Culture non governmental organisation working region
0,PMC3348565,S53,6681,6935,Participants, Furthermore study field supervisors mapped region independently verify accuracy maps Agha Khan Trust Culture recruitment visited every house mapped region identify families young children
0,PMC3348565,S54,6944,7101,Participants, 20 pairs female fieldworkers visited every home starting streets closest hospital radiating reached required sample size
0,PMC3348565,S55,7102,7213,Participants, Those homes carer infant absent revisited within 4 weeks recruitment period
4a,PMC3348565,S56,7214,7298,Participants, Our inclusion criteria infants aged 1  11 months living study region
4a,PMC3348565,S57,7299,7513,Participants, Our exclusion criteria families expecting move another town within 18 months diagnosis rickets treatment vitamin D previous 3 months clinical diagnosis Kwashiorkor Marasmus
5,PMC3348565,S58,7514,7750,Participants, The fieldworkers obtained written informed consent mother father another senior family member recruitment allocated unique identification number sequentially gave first dose vitamin D3 placebo
10,PMC3348565,S58,7514,7750,Participants, The fieldworkers obtained written informed consent mother father another senior family member recruitment allocated unique identification number sequentially gave first dose vitamin D3 placebo
4a,PMC3348565,S59,7751,7842,Participants, Children vomiting excluded temporarily enrolled 2 weeks later recovery
0,PMC3348565,S60,7851,8156,Participants, Thumbprint signature consent obtained child s parents mother father Kabul another family member responsible child home child met study criteria either parent read Dari consent form explained fieldworker
0,PMC3348565,S61,8157,8425,Participants, Our study approved ethics review board Ministry Public Health Afghanistan reference 422328 issued May 12 2007 ethics committee London School Hygiene Tropical Medicine application number 5117 issued May 29 2008
8a,PMC3348565,S63,8482,8755,Randomisation and masking, An independent statistician Shabbar Jaffar London School Hygiene Tropical Medicine London UK randomised unique identification numbers individually fixed blocks 20 vitamin D3 placebo group use random number generator SAS routine
8b,PMC3348565,S63,8482,8755,Randomisation and masking, An independent statistician Shabbar Jaffar London School Hygiene Tropical Medicine London UK randomised unique identification numbers individually fixed blocks 20 vitamin D3 placebo group use random number generator SAS routine
10,PMC3348565,S63,8482,8755,Randomisation and masking, An independent statistician Shabbar Jaffar London School Hygiene Tropical Medicine London UK randomised unique identification numbers individually fixed blocks 20 vitamin D3 placebo group use random number generator SAS routine
9,PMC3348565,S64,8756,9085,Randomisation and masking, By use randomisation list pharmacist Department Pharmacy Aga Khan University Hospital Karachi prepared 100  000 IU 2  5 mg vitamin D3 cholecalciferol olive oil Sinochem Ningbo Laboratory China placebo olive oil sealed 2 mL plastic syringes labelled unique identification numbers
11a,PMC3348565,S65,9086,9284,Randomisation and masking, The vitamin D3 placebo colour pale yellow taste quantity 0  5 mL therefore study staff families know group children assigned
11b,PMC3348565,S65,9086,9284,Randomisation and masking, The vitamin D3 placebo colour pale yellow taste quantity 0  5 mL therefore study staff families know group children assigned
10,PMC3348565,S66,9285,9390,Randomisation and masking, Fieldworkers allocated children randomisation groups recruitment gave vitamin D placebo
5,PMC3348565,S68,9432,9761,Procedures, We chose quarterly supplementation regimen routine programme conditions quarterly regimen likely better adherence daily regimen 13 14 shown effective maintaining serum vitamin D concentration within normal ranges 2  3 months French high risk infant population 16
5,PMC3348565,S69,9762,9933,Procedures, The syringes containing vitamin D placebo stored conditions recommended manufacturer  a dry cool environment  between 2 24 weeks administration
0,PMC3348565,S70,9942,10131,Procedures, We provided child identification card included photograph child enable easy access outpatient out of hours paediatric services study hospital
0,PMC3348565,S71,10132,10272,Procedures, We encouraged families bring children study hospital illness quality treatment offered free charge
0,PMC3348565,S72,10273,10568,Procedures, Four experienced paediatricians 30 female fieldworkers medical students nurses midwives community health workers rigorously trained study protocols Integrated Management Childhood Illnesses strategy assessment signs symptoms required study
0,PMC3348565,S73,10569,10684,Procedures, The quality clinical assessment clinics home visits monitored weekly study supervisors
0,PMC3348565,S74,10693,11074,Procedures, The fieldworkers followed children every 2 weeks June 2009 obtain background information assess illness symptom history examination chest in drawing body temperature Thermoval Classic Hartmann digital thermometer signs dehydration skin pinching respiratory rate count 1 min stopwatch refer study hospital needed
0,PMC3348565,S75,11075,11182,Procedures, Respiratory rate anthropomorphic data collected twice used mean values analysis
6a,PMC3348565,S76,11191,11324,Procedures, All children clinically diagnosed pneumonia offered free chest radiographs taken radiographers trained WHO trainer
6a,PMC3348565,S77,11325,11690,Procedures, The masked radiographs read two independent paediatric radiologists based Acute Respiratory Infections Unit Pakistan Institute Medical Sciences experienced reading paediatric chest radiographs WHO vaccine trials WHO proformas standardised interpretation paediatric chest radiographs diagnosis pneumonia 17
6a,PMC3348565,S78,11691,11806,Procedures, In case disagreement radiographs read third independent radiologist decisions accepted
6a,PMC3348565,S79,11807,12005,Procedures, We ascertained causes death scrutiny hospital notes verbal autopsy interviews WHO standard questionnaire review interview data two physicians independently
6a,PMC3348565,S80,12014,12253,Procedures, We defined clinical pneumonia history cough plus increased respiratory rate age chest in drawing danger sign ie drinking breastfeeding convulsion vomiting lethargic unconscious stridor calm child
6a,PMC3348565,S81,12254,12369,Procedures, We defined severe pneumonia cough plus chest in drawing severe diseases cough plus danger signs
6a,PMC3348565,S82,12370,12514,Procedures, Our primary endpoint first episode pneumonia time enrolment confirmed chest radiograph consolidation infiltrates
6a,PMC3348565,S83,12515,12611,Procedures, We defined new episode pneumonia episode happening 15 days longer first
6a,PMC3348565,S84,12612,12701,Procedures, We judged episode happening within 14 days continuation previous episode
6a,PMC3348565,S85,12710,12904,Procedures, We collected venous blood samples randomly selected blocks children basis assumption block equal number children vitamin D3 placebo groups
6a,PMC3348565,S86,12905,13206,Procedures, This ascertain calcifediol serum concentrations 1 week giving first dose placebo group baseline value whole population well early concentrations first vitamin D supplementation intervention group 70 placebo 69 intervention groups
6a,PMC3348565,S87,13207,13356,Procedures, We also collected samples times appendix different set randomly selected children check fluctuations serum concentrations
6a,PMC3348565,S88,13357,13755,Procedures, We stored serum samples analysed end study IDS iSYS Multi Discipline Automated Chemiluminescent assay Immunodiagnostic Systems Ltd Tyne Wear UK Manchester Royal Infirmary Manchester UK Supra Regional Vitamin D Reference Laboratories accredited ISO9001 2000 ISO13485 2003 participating Vitamin D Quality Assurance Scheme
7a,PMC3348565,S90,13807,14171,Statistical analysis, We assumed incidence first episode pneumonia first episode placebo group would 0  0585 per child per year based report incidence acute lower respiratory infections developing countries greater 0  65 per child per year 18 12 episodes pneumonia 75 first episodes
7a,PMC3348565,S91,14172,14540,Statistical analysis, Given 73 children vitamin D deficiency study region 2005 12 incidence pneumonia ten times higher vitamin D deficient children children without deficiency case control studies1 2 postulated would least 35 reduction pneumonia incidence vitamin D compared placebo group
7a,PMC3348565,S92,14541,14676,Statistical analysis, Thus study 80 power 95 significance needed 22  079 child months per group total 2454 children 18 months follow up
7a,PMC3348565,S93,14677,14808,Statistical analysis, Assuming 20 loss follow up allowing protocol violations intended recruit 3050 children 18 months follow up
12a,PMC3348565,S94,14817,14949,Statistical analysis, Data entered Microsoft Access database version 2007 data processing analysis done STATA version 11 0
0,PMC3348565,S95,14950,15073,Statistical analysis, We compared baseline characteristics distribution prestated confounders intervention placebo groups
12a,PMC3348565,S96,15074,15216,Statistical analysis, To assess potential problem multicollinearity used Pearsons correlation coefficient Cramers V paired categorical variables
0,PMC3348565,S97,15217,15358,Statistical analysis, If child seen 45 days two weekly visits hospital censored period study
0,PMC3348565,S98,15359,15414,Statistical analysis, These children could re enter study next seen
0,PMC3348565,S99,15415,15609,Statistical analysis, We calculated person time risk child date child reached primary endpoint last seen end study censored lost follow up
0,PMC3348565,S102,15899,15976,Statistical analysis, We analysed repeat episodes accounting clustering within individuals
12a,PMC3348565,S103,15977,16093,Statistical analysis, We made initial comparisons time to an episode two groups log rank tests Kaplan  Meier plots
12a,PMC3348565,S104,16094,16203,Statistical analysis, We estimated incidence rate ratio RR episodes pneumonia Cox proportional hazard models
12a,PMC3348565,S105,16204,16286,Statistical analysis, We assessed violation proportionality assumption Schoenfeld residuals
0,PMC3348565,S108,16414,16546,Role of the funding source, The sponsor study role study design data collection data analysis data interpretation writing report
0,PMC3348565,S109,16547,16689,Role of the funding source, The corresponding author full access data study final responsibility decision submit publication
3a,PMC3386495,S36,5792,5888,Study design and patients, IST 3 pragmatic10 international multicentre randomised controlled open treatment trial
11a,PMC3386495,S37,5889,5955,Study design and patients, The initial pilot phase double blinded placebo controlled
3a,PMC3386495,S37,5889,5955,Study design and patients, The initial pilot phase double blinded placebo controlled
3b,PMC3386495,S38,5956,6154,Study design and patients, At end pilot phase since main phase compared treatment open control several additional measures introduced minimise bias assessment early late outcomes 11
4a,PMC3386495,S40,6391,6477,Study design and patients, The eligibility criteria summarised terms uncertainty principle 15  17
4a,PMC3386495,S41,6478,6550,Study design and patients, Inclusion exclusion criteria listed detail protocol 13
4a,PMC3386495,S42,6551,6913,Study design and patients, Briefly patients eligible according following criteria symp toms signs clinically definite acute stroke time stroke onset known treatment could started within 6 h onset CT MRI reliably excluded intracranial haemorrhage structural brain lesions could mimic stroke eg cerebral tumour
4a,PMC3386495,S43,6914,7067,Study design and patients, Additionally patient clear indication intravenous thrombolysis rt PA treated accordance local guidelines
4a,PMC3386495,S44,7068,7175,Study design and patients, Equally patient clear contraindication treatment entered trial
4a,PMC3386495,S45,7176,7421,Study design and patients, Only clinician patient relevant proxy patient felt treatment promising unproven could patient included trial appropriate informed consent patient valid proxy
0,PMC3386495,S46,7422,7563,Study design and patients, The protocol approved Multi centre Research Ethics Committees Scotland reference MREC 99 0 78 local ethical committees
10,PMC3386495,S50,7687,7795,Study design and patients, Clinicians entered baseline data via telephone voice activated secure web based randomisation system
10,PMC3386495,S51,7796,8021,Study design and patients, After system recorded checked data patients allocated either immediate thrombolysis 0  9 mg kg intravenous rt PA maximum 90 mg 10 bolus remainder 1 h control treatment
4a,PMC3386495,S52,8022,8179,Study design and patients, The system would accept patients blood pressure glucose levels outside protocol defined criteria appendix pp 4  5 data inconsistencies
10,PMC3386495,S53,8180,8430,Study design and patients, The system used minimisation algorithm achieve optimum balance key prognostic factors table 1 January 2006 minimisation additionally stratified world region minimised key factors within regions
8b,PMC3386495,S53,8180,8430,Study design and patients, The system used minimisation algorithm achieve optimum balance key prognostic factors table 1 January 2006 minimisation additionally stratified world region minimised key factors within regions
0,PMC3386495,S54,8441,8546,Study design and patients, To eligible join trial participating hospitals organised system stroke care
0,PMC3386495,S55,8547,8853,Study design and patients, Acute care protocols specified trial include components effective stroke unit care 19 including soon admission intravenous access monitoring physiological variables correction abnormalities clinically appropriate intravenous fluid therapy
0,PMC3386495,S56,8854,8981,Study design and patients, All patients trial treated within organised system stroke care irrespective treatment allocation
5,PMC3386495,S57,8982,9153,Study design and patients, Patients allocated control group avoid treatment rt PA received stroke care clinical environment allocated rt PA group
5,PMC3386495,S58,9154,9233,Study design and patients, Both treatment groups blood pressure monitored closely first 24 h
5,PMC3386495,S59,9234,9336,Study design and patients, In double blinded phase groups avoid antiplatelet anticoagulant therapy 24 h
5,PMC3386495,S60,9337,9430,Study design and patients, In open phase patients allocated control group start aspirin immediately
0,PMC3386495,S61,9431,9528,Study design and patients, Blood pressure managed way treatment groups according local protocol
0,PMC3386495,S62,9529,9844,Study design and patients, Additionally centres asked pretrial experience thrombolysis treatment stroke centre joining trial protocol open label use rt PA treated least three people 12 months joining trial centre classed experienced
6a,PMC3386495,S63,9855,9948,Study design and patients, All patients CT MRI brain scan randomisation follow up scan 24  48 h
6a,PMC3386495,S64,9949,10082,Study design and patients, A repeat brain scan required patient deteriorated neurologically intracranial haemorrhage suspected reason
6a,PMC3386495,S65,10083,10135,Study design and patients, Although CT scanning preferred MRI allowed
6a,PMC3386495,S66,10136,10476,Study design and patients, All scans sent trial centre Edinburgh masked central rating signs visible early ischaemia presence extent hypo attenuation swelling hyperattenuated artery haemorrhage background brain changes leukoaraiosis atrophy prior stroke lesions non stroke lesions validated rating methods 20  25
11a,PMC3386495,S66,10136,10476,Study design and patients, All scans sent trial centre Edinburgh masked central rating signs visible early ischaemia presence extent hypo attenuation swelling hyperattenuated artery haemorrhage background brain changes leukoaraiosis atrophy prior stroke lesions non stroke lesions validated rating methods 20  25
11a,PMC3386495,S67,10477,10663,Study design and patients, Images assessed original identifiers stripped record viewed via secure web based image viewing system international panel expert radiologists
6a,PMC3386495,S67,10477,10663,Study design and patients, Images assessed original identifiers stripped record viewed via secure web based image viewing system international panel expert radiologists
11a,PMC3386495,S68,10664,10745,Study design and patients, All assessments made masked patient details treatment allocation
6a,PMC3386495,S69,10756,11025,Study design and patients, The primary outcome specified version 1  93 protocol published statistical analysis plan14 proportion patients alive independent measured Oxford Handicap Score OHS 26 commonly used variant modified Rankin score 27
6a,PMC3386495,S70,11026,11089,Study design and patients, Patients OHS 0 1 2 classed independent
12a,PMC3386495,S71,11090,11179,Study design and patients, The statistical analysis plan specified ordinal analysis OHS score 6 months
0,PMC3386495,S72,11180,11241,Study design and patients, Additional secondary outcomes reported separately
6a,PMC3386495,S73,11252,12005,Study design and patients, Events occurring within 7 days stroke recorded local trial clinician 7 day form deaths subdivided cause swelling initial infarct intracranial haemorrhage deaths initial stroke recurrent ischaemic stroke recurrent stroke unknown type cause symptomatic intracranial haemorrhage recurrent ischaemic stroke recurrent stroke unknown type neurological deterioration attributed swelling initial ischaemic stroke neurological deterioration attributable swelling initial ischaemic stroke haemorrhage major extracranial haemorrhage operational definitions events provided published protocol13 statistical analysis plan14
6a,PMC3386495,S74,12006,12081,Study design and patients, Other fatal non fatal non cerebral events also recorded coded
11a,PMC3386495,S75,12082,12254,Study design and patients, Data potential reports events extracted trial database presented adjudication committee masked treatment allocation
8a,PMC3386495,S77,12320,12587,Randomisation and masking, To avoid predictable alternation treatment allocation thus potential loss allocation concealment patients allocated probability 0  80 treatment group would minimise difference groups key prognostic factors
8a,PMC3386495,S78,12588,12696,Randomisation and masking, Additional details procedures used double blinded phase study reported elsewhere 11
10,PMC3386495,S79,12697,13038,Randomisation and masking, The randomisation system informed local clinicians patients unique trial identification number weight adjusted dose drug placebo double blinded phase weight adjusted drug dose among allocated thrombolysis open phase given 10 bolus remainder infusion 1 h
11a,PMC3386495,S80,13047,13227,Randomisation and masking, With exception 276 patients treated double blinded phase trial treatment given openly neither patient treating clinicians masked
6a,PMC3386495,S81,13228,13467,Randomisation and masking, Hospital staff completed early outcome form 7 days death hospital discharge whichever occured first recording details events occurring hospital within 7 days details background treatments given functional status
6a,PMC3386495,S82,13468,13690,Randomisation and masking, 6 months randomisation general practitioners hospital coordinators contacted IST 3 trial office staff check patient alive inform might approached follow up
11a,PMC3386495,S83,13691,13808,Randomisation and masking, If appropriate IST 3 trial office masked staff mailed postal questionnaire patients assess outcome
6a,PMC3386495,S83,13691,13808,Randomisation and masking, If appropriate IST 3 trial office masked staff mailed postal questionnaire patients assess outcome
6a,PMC3386495,S84,13809,13908,Randomisation and masking, Non responders contacted telephone follow up data obtained telephone interview
6a,PMC3386495,S85,13909,14084,Randomisation and masking, In Italy Austria follow ups done telephone interviews clinician masked treatment allocation highly experienced outcome assessment
11a,PMC3386495,S85,13909,14084,Randomisation and masking, In Italy Austria follow ups done telephone interviews clinician masked treatment allocation highly experienced outcome assessment
6a,PMC3386495,S86,14085,14254,Randomisation and masking, In Portugal patients followed clinic clinicians involved patients initial treatment masked treatment allocation far possible
11a,PMC3386495,S86,14085,14254,Randomisation and masking, In Portugal patients followed clinic clinicians involved patients initial treatment masked treatment allocation far possible
6a,PMC3386495,S87,14255,14455,Randomisation and masking, To assess durability treatment benefit beyond 6 months patients recruited UK countries appropriate funding obtained also followed 18 months
6a,PMC3386495,S88,14456,14634,Randomisation and masking, All follow up done patient contact analyses ceased March 31 2012 recording deaths national registries deaths continues UK Norway Sweden
7a,PMC3386495,S90,14685,15058,Randomisation and masking, At outset trial 2000 estimated among type patients likely recruited time detect absolute difference 10 proportion patients alive independent 6 months treatment sufficient power permit reliable analyses prespecified subgroups sample 6000 patients would needed
7a,PMC3386495,S91,15059,15211,Randomisation and masking, A trial size could detect clinically worthwhile net benefit little 3 absolute difference primary outcome 80 power
3b,PMC3386495,S92,15212,15363,Randomisation and masking, However clear 2007 obtaining sample 6000 longer feasible Steering Committee agreed revised recruitment target 11
7a,PMC3386495,S93,15364,15474,Randomisation and masking, The sample size re estimated 2007 basis event rates treatment groups combined 3100
7a,PMC3386495,S94,15475,15573,Randomisation and masking, This sample size gave 80 power detect absolute difference 4  7 primary outcome 11
0,PMC3386495,S95,15584,16044,Randomisation and masking, We monitored quality integrity accumulating clinical data according protocol agreed study sponsors involved central statistical monitoring according principles described Buyse colleagues 28 supplemented onsite monitoring detailed source data verification random sample 10 records centres recruited 30 patients patterns data centre seemed anomalous
0,PMC3386495,S96,16045,16303,Randomisation and masking, All IST 3 monitoring procedures compliant requirements study sponsors national ethics committees regulatory agencies 12 participating countries met appropriate regulatory Good Clinical Practice requirements
0,PMC3386495,S97,16304,16447,Randomisation and masking, All baseline data 7 day 6 month outcome data subject verification checks built randomisation data management system
0,PMC3386495,S98,16448,16589,Randomisation and masking, We monitored baseline postrandomisation imaging provided additional cross checks recruited patients centre performance
0,PMC3386495,S99,16590,16783,Randomisation and masking, An expert radiologist checked scans masked clinical details treatment allocation immediately receipt trial office evidence adverse events protocol deviations
7b,PMC3386495,S100,16784,17213,Randomisation and masking, The independent data monitoring committee met least annually review unmasked data major outcome events trial background stroke unit care received trial patients ensure equal treatment groups relevant external data including updates Cochrane systematic review reports large scale registries rt PA use strict confidence throughout course trial
7b,PMC3386495,S101,17214,17363,Randomisation and masking, The committee judged data never met protocol specified criteria recommend modification protocol halt recruitment study
12a,PMC3386495,S102,17374,17464,Randomisation and masking, The statistical analysis plan published14 unmasking authors data
0,PMC3386495,S104,17527,17870,Randomisation and masking, Masked analysis patients baseline characteristics showed clear differences key prognostic factors age stroke severity degree ischaemic change baseline CT MRI patients randomly assigned different times stroke onset might complicate estimation effect treatment overall subgroups 11
12a,PMC3386495,S105,17871,18266,Randomisation and masking, Therefore primary analysis effect treatment primary outcome adjusted logistic regression linear effects following covariates age National Institutes Health stroke scale NIHSS score time onset stroke symptoms randomisation presence vs absence ischaemic change prerandomisation brain scan according expert assessment
12b,PMC3386495,S106,18267,18308,Randomisation and masking, An unadjusted analysis also presented
0,PMC3386495,S107,18319,18506,Randomisation and masking, The trial meet original target 6000 patients longer adequately powered detect 3 absolute difference primary outcome 80 power
0,PMC3386495,S108,18507,18760,Randomisation and masking, The statistical analysis plan writing committee access accumulating data therefore expanded include independent statistician Gordon Murray University Edinburgh Edinburgh UK advise correct approach
0,PMC3386495,S109,18761,19032,Randomisation and masking, The writing group persuaded recent empirical evidence ordinal method statistically efficient effectively reducing sample size required stroke trials29 robust substantial deviations proportional assumption 30
6b,PMC3386495,S110,19033,19310,Randomisation and masking, We therefore specified statistical analysis plan ordinal logistic regression analysis secondary outcome OHS dependent variable 5 levels levels 4 5 6 combined single level levels 0 1 2 3 retained distinct
3b,PMC3386495,S110,19033,19310,Randomisation and masking, We therefore specified statistical analysis plan ordinal logistic regression analysis secondary outcome OHS dependent variable 5 levels levels 4 5 6 combined single level levels 0 1 2 3 retained distinct
12a,PMC3386495,S111,19321,19525,Randomisation and masking, In model treatment odds ratios one level next assumed constant single parameter summarises shift outcome distribution treatment control groups
6a,PMC3386495,S112,19526,19749,Randomisation and masking, For patients known alive 6 months unknown OHS used level function recorded 7 day form ie measured 7 days discharge hospital impute 6 month functional status 14
0,PMC3386495,S113,19750,19918,Randomisation and masking, We chose simple form imputation effectively classified 6 month outcomes patients 7 day 6 month data known data shown
0,PMC3386495,S114,19919,19961,Randomisation and masking, Analyses done SAS version 9 2
0,PMC3386495,S116,20027,20154,Randomisation and masking, The sponsors study role design data collection data analysis data interpretation writing report
0,PMC3386495,S117,20155,20297,Randomisation and masking, The corresponding author full access data study final responsibility decision submit publication
3a,PMC3391717,S39,4741,4849,Study design and patients, We phase 3 randomised placebo controlled trial six Dutch one Scottish one Chilean centre
4b,PMC3391717,S39,4741,4849,Study design and patients, We phase 3 randomised placebo controlled trial six Dutch one Scottish one Chilean centre
4a,PMC3391717,S41,4899,5068,Study design and patients, Patients eligible inclusion admitted neurological neurosurgical units one participating hospitals within 4 days haemorrhage
0,PMC3391717,S42,5069,5277,Study design and patients, Investigators based diagnosis aneurysmal subarachnoid haemorrhage presence extravasated blood basal cisterns brain CT or  if CT negative  by xanthochromia cerebrospinal fluid
4a,PMC3391717,S43,5278,5409,Study design and patients, For patients normal CT scan xanthochromia cerebrospinal fluid proof aneurysm prerequisite inclusion
4a,PMC3391717,S44,5410,5543,Study design and patients, We included patients perimesencephalic pattern haemorrhage CT aneurysm posterior circulation
4a,PMC3391717,S45,5544,5724,Study design and patients, Exclusion criteria age younger 18 years renal failure defined serum creatinine concentration 150 bodyweight less 50 kg imminent death
0,PMC3391717,S46,5725,5815,Study design and patients, The study complies Declaration Helsinki good clinical practice guidelines
0,PMC3391717,S47,5816,5872,Study design and patients, We obtained ethics committee approval every centre
0,PMC3391717,S48,5873,5929,Study design and patients, All patients provided written oral informed consent
10,PMC3391717,S50,5986,6090,Randomisation and masking, The randomisation code produced University Medical Center Utrecht The Netherlands pharmacy
8a,PMC3391717,S51,6091,6192,Randomisation and masking, The pharmacy used computer generated randomisation codes blocks four stratified centre
8b,PMC3391717,S51,6091,6192,Randomisation and masking, The pharmacy used computer generated randomisation codes blocks four stratified centre
9,PMC3391717,S52,6193,6342,Randomisation and masking, The pharmacy produced identical sequentially numbered randomly assigned boxes study medication containing either magnesium sulphate placebo
10,PMC3391717,S53,6343,6428,Randomisation and masking, Local investigators assigned participant box lowest study number
10,PMC3391717,S54,6429,6517,Randomisation and masking, The randomisation key kept pharmacy University Medical Center Utrecht
11a,PMC3391717,S55,6518,6635,Randomisation and masking, Patients treating physicians investigators assessing outcomes analysing data masked allocation
0,PMC3391717,S57,6677,6832,Procedures, At admission hospital investigators recorded sex age World Federation Neurological Surgeons subarachnoid haemorrhage grade12 patient
0,PMC3391717,S58,6833,6942,Procedures, A score 1  3 deemed good clinical condition score 4  5 deemed poor clinical condition
5,PMC3391717,S59,6951,7231,Procedures, Study medication consisted vials containing 64 mmol magnesium sulphate placebo saline produced pharmacy University Medical Center Utrecht distributed participating centres except centre Chile produced study medication
0,PMC3391717,S60,7232,7418,Procedures, An intravenous magnesium dosing regimen 64 mmol per day aneurysmal subarachnoid haemorrhage safe maintains serum magnesium concentrations 1  0 2  0 mmol L 13
0,PMC3391717,S61,7419,7517,Procedures, Furthermore symptomatic hypermagnesaemia occur patients normal renal function 14
5,PMC3391717,S62,7518,7686,Procedures, Therefore participants received fixed daily dose 64 mmol magnesium sulphate reconstituted 0  9 saline placebo soon possible providing consent
5,PMC3391717,S63,7687,7879,Procedures, Investigators administered study medication continuously via intravenous infusion continued 20 days haemorrhage onset hospital discharge death occurred sooner
5,PMC3391717,S64,7880,7984,Procedures, Investigators checked renal function least every 2 days prevent symptomatic hypermagnesaemia
0,PMC3391717,S65,7985,8041,Procedures, Monitoring magnesium concentration mandatory
5,PMC3391717,S66,8042,8161,Procedures, We discouraged permitted investigators treat hypomagnesaemia admission intravenous magnesium sulphate
5,PMC3391717,S67,8162,8373,Procedures, Investigators treated patients according local protocols included oral nimodipine 360 mg day bed rest aneurysm occlusion early aneurysm occlusion aimed achievement normovolaemia
6a,PMC3391717,S68,8382,8509,Procedures, The primary outcome dependence15 defined modified Rankin Scale score 4 5 death 3 months haemorrhage
6a,PMC3391717,S69,8510,8684,Procedures, The research nurse study coordinator collected outcome data centrally assessed Rankin score semi structured telephone interview patient s language
6a,PMC3391717,S70,8685,8803,Procedures, The interview translated Dutch Spanish standard procedure16 17 forward  backward translation
6a,PMC3391717,S71,8804,8997,Procedures, Secondary outcome measures symptoms modified Rankin Scale score 0 3 months haemorrhage difference distribution scores modified Rankin Scale
0,PMC3391717,S73,9049,9183,Statistical analysis, In pilot study 35 patients untreated group poor outcome compared 27 intervention group RR 0  77 10
7a,PMC3391717,S74,9184,9312,Statistical analysis, On basis data estimated 1082 patients would needed confirm effect 5 80 power
7a,PMC3391717,S75,9313,9426,Statistical analysis, To allow reliable detection slightly smaller effect risk ratio 0  78 decided enrol 1200 patients
0,PMC3391717,S76,9427,9504,Statistical analysis, A research nurse entered baseline outcome data study database
0,PMC3391717,S77,9505,9545,Statistical analysis, The study coordinator analysed data
0,PMC3391717,S78,9546,9617,Statistical analysis, The data checked results discussed executive committee
7b,PMC3391717,S79,9618,9858,Statistical analysis, The data monitoring committee two interim analyses study 350 750 patients completed 3 month follow up reference pre defined stopping rule recommended continuation trial occasions
12a,PMC3391717,S80,9859,9996,Statistical analysis, We analysed results according intention treat comparing poor outcome 3 months group risk ratio 95 CI
0,PMC3391717,S81,9997,10256,Statistical analysis, We planned sensitivity analyses assigning patients lost follow up either good outcome poor outcome irrespective treatment group assigning patients unknown randomisation codes either magnesium group placebo group
12b,PMC3391717,S82,10257,10472,Statistical analysis, Planned subgroup analyses done according age sex clinical condition admission method treatment aneurysm whether centre treated hypomagnesaemia intravenous magnesium supplementation
12a,PMC3391717,S83,10473,10583,Statistical analysis, We compared distributions modified Rankin Scale scores non parametric Mann Whitney U test
0,PMC3391717,S84,10584,10784,Statistical analysis, We updated previous Cochrane meta analysis5 results MASH 2 eligible randomised trials published since start MASH 2 last update Cochrane review 18  20
0,PMC3391717,S85,10785,10909,Statistical analysis, We used Cochrane Review Manager version 5 1 software meta analysis SPSS version 15 0 analyses
0,PMC3391717,S88,11107,11226,Role of the funding source, The sponsor role study design data collection data analysis data interpretation writing report
0,PMC3391717,S89,11227,11365,Role of the funding source, The corresponding author full access data study final responsibility decision submit publication
3a,PMC3420230,S54,9809,9985,Methods, We undertook semifactorial randomised controlled trial two interventions women intrahepatic cholestasis pregnancy nine maternity units United Kingdom
4b,PMC3420230,S54,9809,9985,Methods, We undertook semifactorial randomised controlled trial two interventions women intrahepatic cholestasis pregnancy nine maternity units United Kingdom
0,PMC3420230,S55,9986,10123,Methods, The trial began two centres October 2008 remainder joined following year regulatory approvals obtained
4a,PMC3420230,S56,10124,10623,Methods, Women eligible confirmed intrahepatic cholestasis pregnancy itching pregnancy causes excluded association serum bile acid level greater upper limit normal unit  s laboratory pruritus raised alanine transaminase levels 100 IU L 24 0 40 6 weeks pregnant ursodeoxycholic acid comparison 34 1 37 6 weeks singleton pregnancy timing delivery comparison
4a,PMC3420230,S57,10624,11018,Methods, We excluded women aged less 18 years laboratory confirmed hepatitis A hepatitis B pre eclampsia primary hepatic disorders known antitrypsin deficiency current drugs causing deranged liver enzymes known lethal fetal anomaly allergy component ursodeoxycholic acid placebo capsules unable give informed consent
4a,PMC3420230,S58,11019,11095,Methods, Women concurrent hepatitis C cholelithiasis eligible
4a,PMC3420230,S59,11096,11298,Methods, Women multiple pregnancy eligible ursodeoxycholic acid comparison participating clinicians indicated women normally delivered 38 weeks  gestation
0,PMC3420230,S61,11352,11516,Recruitment and randomisation, Clinicians midwives approached women attending antenatal clinic antenatal day assessment units antenatal ward participating study
0,PMC3420230,S62,11517,11668,Recruitment and randomisation, A member research team confirmed eligibility gave women detailed verbal information information sheet invited take part
0,PMC3420230,S63,11669,11739,Recruitment and randomisation, The usual hospital interpreter translator services available
0,PMC3420230,S64,11740,11903,Recruitment and randomisation, The participants provided written dated informed consent women  s consultant obstetricians general practitioners informed participation
10,PMC3420230,S65,11912,12190,Recruitment and randomisation, A member research team confirmed participant eligibility entered agreed minimum amount pre randomisation registration data secure internet based data form participant randomisation including results routine biochemical blood tests
10,PMC3420230,S66,12191,12310,Recruitment and randomisation, Randomisation occurred Nottingham Clinical Trials Unit using web based database randomisation system
8a,PMC3420230,S67,12311,12549,Recruitment and randomisation, The random allocation sequence comparison generated using specific function ralloc Stata StataCorp College Station TX software within clinical unit using randomly varying block sizes two four six
8b,PMC3420230,S67,12311,12549,Recruitment and randomisation, The random allocation sequence comparison generated using specific function ralloc Stata StataCorp College Station TX software within clinical unit using randomly varying block sizes two four six
9,PMC3420230,S68,12550,12686,Recruitment and randomisation, The random allocation sequence revealed data outcomes collected statistical analysis plan registered
8b,PMC3420230,S69,12687,12829,Recruitment and randomisation, Randomisation stratified gestation recruitment ursodeoxycholic acid comparison trial centre comparisons
8b,PMC3420230,S70,12830,12915,Recruitment and randomisation, Randomisation comparisons within trial 1 1 allocation ratio
0,PMC3420230,S71,12916,13019,Recruitment and randomisation, Women eligible permitted participate either factorial comparisons
10,PMC3420230,S72,13020,13258,Recruitment and randomisation, Those participated drug comparison 34 weeks  gestation allowed join timed delivery comparison 34 weeks group randomisation two treatment comparisons occurred different times
10,PMC3420230,S73,13259,13337,Recruitment and randomisation, Allocation occurred centrally clinical unit using web based database
10,PMC3420230,S74,13346,13538,Recruitment and randomisation, On randomisation clinical unit  s internet trial system issued unique participant identification number participant randomised one trials according eligibility
10,PMC3420230,S75,13539,13731,Recruitment and randomisation, Sequentially numbered containers sent clinical trial  s pharmacist centre start trial packs kept pharmacy distribution participant
10,PMC3420230,S76,13732,13858,Recruitment and randomisation, After randomisation ursodeoxycholic acid placebo comparison online prescription form generated printing
9,PMC3420230,S77,13859,14022,Recruitment and randomisation, The participant collected trial drug placebo hospital pharmacy local trial  s pharmacist selected pack appropriate number
11a,PMC3420230,S78,14023,14106,Recruitment and randomisation, The investigator pharmacist trial participant blind group allocation
10,PMC3420230,S79,14115,14342,Recruitment and randomisation, For timing delivery comparison investigator participant could blinded treatment group appropriate arrangements made induction elective delivery expectant management allocated
5,PMC3420230,S80,14343,14487,Recruitment and randomisation, Obstetricians permitted induce participants expectant management group 40 0 weeks  gestation clinical needs dictated
5,PMC3420230,S81,14488,14715,Recruitment and randomisation, Other trial randomisation women managed accordance unit  s guideline intrahepatic cholestasis pregnancy frequency blood testing fetal monitoring determined local clinicians
0,PMC3420230,S82,14716,14849,Recruitment and randomisation, All centres aware Royal College Obstetricians Gynaecologists  guidelines management obstetric cholestasis 8
0,PMC3420230,S84,14890,15009,Follow-up, After randomisation member research team saw participants weekly time routine clinical visit
0,PMC3420230,S85,15010,15158,Follow-up, The participant asked adherence treatment use drugs adverse events completed visual analogue scale itching
0,PMC3420230,S86,15159,15222,Follow-up, Results routinely collected biochemical tests recorded
0,PMC3420230,S87,15223,15271,Follow-up, Participants seen six weeks delivery
0,PMC3420230,S88,15272,15422,Follow-up, All maternal perinatal outcomes collected review postnatal case notes adjudication necessary trial management group
0,PMC3420230,S89,15431,15553,Follow-up, Participants able withdraw trial either request discretion treating clinician
0,PMC3420230,S90,15554,15820,Follow-up, If participant  s clinical condition deteriorated example worsening itch increasing bile acid levels clinician could decide stop trial drug give ursodeoxycholic acid deliver woman indicated without breaking treatment code
11b,PMC3420230,S92,15865,16123,Interventions, Women first comparison randomised ursodeoxycholic acid 250 mg dose Ursofalk Dr Falk Pharma Buckinghamshire placebo capsules Dr Falk Pharma identical appearance taste study drug white opaque hard gelatin capsule
5,PMC3420230,S92,15865,16123,Interventions, Women first comparison randomised ursodeoxycholic acid 250 mg dose Ursofalk Dr Falk Pharma Buckinghamshire placebo capsules Dr Falk Pharma identical appearance taste study drug white opaque hard gelatin capsule
5,PMC3420230,S93,16124,16189,Interventions, The placebo contained lactose monohydrate magnesium stearate
11b,PMC3420230,S94,16190,16358,Interventions, All capsules packaged labelled provide blinded treatment packs production unit pharmacy department Nottingham University Hospitals NHS Trust
0,PMC3420230,S95,16359,16442,Interventions, Supplies packed approved container tagged single panel label
9,PMC3420230,S96,16443,16570,Interventions, The participant  s name randomisation number date dispensing added label part dispensing process
5,PMC3420230,S97,16571,16847,Interventions, All women received two capsules twice day clinical improvement itching biochemical improvement serum bile acids alanine transaminase levels dose increased increments two capsules per day every 3 14 days maximum 2 g day
5,PMC3420230,S98,16856,17155,Interventions, Women second comparison randomised early term delivery induction delivery started 37 0 37 6 expectant management spontaneous labour awaited caesarean delivery undertaken according normal obstetric guidelines usually 39 weeks  gestation
5,PMC3420230,S99,17156,17254,Interventions, By consensus obstetricians could arrange delivery latter group 40 0 weeks  gestation
6b,PMC3420230,S101,17294,17531,Outcomes, Once decision fund main trial known full statistical analysis plan prepared prespecified primary secondary outcome measures uploaded onto trials website date amendment logged
0,PMC3420230,S102,17532,17572,Outcomes, No data unblinded time
6a,PMC3420230,S103,17573,17800,Outcomes, For ursodeoxycholic acid comparison primary outcome itch mother measured arithmetic mean post randomisation measures worst itch previous 24 hours assessed visual analogue scale
0,PMC3420230,S104,17801,18243,Outcomes, To avoid over interpretation results carried two online surveys www surveymonkey com unblinding trial determine reduction score visual analogue scale would clinically meaningful difference among clinicians involved treating women intrahepatic cholestasis pregnancy among women previously experienced condition full questions given supplementary appendix 1
0,PMC3420230,S105,18244,18419,Outcomes, Women clinicians informed mean baseline itch score visual analogue scale 60 mm analysis blinded data offered choice answers
6a,PMC3420230,S106,18428,18509,Outcomes, For timing delivery comparison primary outcome caesarean section
0,PMC3420230,S107,18510,18691,Outcomes, It widely believed induction general increases rate caesarean sections although recent trials timing delivery term shown significant effect 12 13
6a,PMC3420230,S108,18700,18829,Outcomes, Secondary outcome measures ursodeoxycholic acid comparison prespecified maternal outcomes perinatal outcomes
6a,PMC3420230,S109,18830,19081,Outcomes, Maternal outcomes average itch past 24 hours visual analogue scale levels total bile acids alanine transaminase aspartate transaminase mode onset labour mode delivery indication delivery blood loss delivery
6a,PMC3420230,S110,19082,19407,Outcomes, Perinatal outcomes gestation delivery baby outcome birth weight presence meconium stained amniotic fluid arterial cord pH venous cord pH Apgar score five minutes congenital anomalies admission neonatal unit including duration need ventilation including duration convulsions jaundice
6a,PMC3420230,S111,19408,19507,Outcomes, For timing delivery comparison chose secondary maternal perinatal outcomes
0,PMC3420230,S112,19516,20010,Outcomes, The outcome measures previously specified start initial phase trial designed measure feasibility second phase  namely recruitment two interventions total recruitment rate per 1000 deliveries per annum total recruitment rate per eligible women recruitment rates related disease severity acceptability randomisation among potential participants offered trial entry adherence treatment arm completeness outcome data
0,PMC3420230,S114,20056,20220,Parallel audit, All centres undertook audit parallel trial start recruitment 1 April 2010 initial target 90 women recruited
0,PMC3420230,S115,20221,20581,Parallel audit, They identified pregnant women raised bile acid levels collaboration hospital  s chemical pathology laboratory undertook postnatal case note review ascertain whether diagnosis intrahepatic cholestasis pregnancy confirmed treatment given whether participation trial offered
0,PMC3420230,S116,20582,20665,Parallel audit, The number deliveries per centre per month audit period obtained
7a,PMC3420230,S118,20708,20821,Sample size, For planned factorial trial estimated provisional sample size would 1498 women 749 per group
7a,PMC3420230,S119,20822,20959,Sample size, This would give 80 power 0 05 show reduction primary composite endpoint fetal death severe morbidity 6 3
7a,PMC3420230,S120,20960,21123,Sample size, However detailed power calculations possible without accurate estimate event rate clinical spectrum likely recruits trial
7a,PMC3420230,S121,21124,21285,Sample size, The target sample size initial phase determined 90 participants allow reasonably precise estimates variables main trial
7a,PMC3420230,S122,21294,21530,Sample size, After decision analyse initial phase alone unblinding undertook sample size calculation based new primary outcome measure maternal itch score clinically meaningful difference determined
7a,PMC3420230,S123,21531,21745,Sample size, This confirmed study carried 99 9 power detect difference 30 mm standard deviation 26 mm across arms correlation baseline follow up measurements
0,PMC3420230,S125,21797,21977,Statistical analysis, Trial analysis followed intention treat principle women infants analysed according original randomised allocation irrespective adherence crossovers
12a,PMC3420230,S126,21978,22135,Statistical analysis, For repeated measurements time severity itch biochemistry used average arithmetic geometric mean intervention period 19
12a,PMC3420230,S127,22136,22434,Statistical analysis, In analyses regression methods used adjustment made stratification variables gestation recruitment ursodeoxycholic acid trial study centre trials potential confounders baseline bile acid levels others imbalance substantial
0,PMC3420230,S128,22443,22535,Statistical analysis, For analysis perinatal outcomes treated infants singletons twins equally
12a,PMC3420230,S129,22536,22707,Statistical analysis, To allow multiple pregnancy adjusted standard errors clustering mother using Huber White sandwich estimator multiplicity included covariate 20
12a,PMC3420230,S130,22708,22865,Statistical analysis, Mode delivery expressed perinatal outcome owing inclusion twin pregnancies mode delivery may different one twin
0,PMC3420230,S131,22874,23013,Statistical analysis, For continuous outcomes visual analogue scale measurement biochemical results covariates included baseline measurement 21
12a,PMC3420230,S132,23014,23125,Statistical analysis, Because spread distribution values based analysis biochemical markers logged values
12a,PMC3420230,S133,23126,23278,Statistical analysis, The treatment effect presented concentration ratio ratio treatment groups geometric mean concentration post randomisation
12a,PMC3420230,S134,23279,23450,Statistical analysis, We estimated risk ratios risk differences yes outcomes used binary regression log link risk ratios linear link risk differences
12a,PMC3420230,S135,23451,23553,Statistical analysis, Time delivery treated partially censored data analysed using Cox  s proportional hazards
0,PMC3420230,S136,23554,23915,Statistical analysis, For ursodeoxycholic acid comparison censoring delivery 37 weeks pregnancies randomised early term delivery arm trial undergoing induction labour caesarean section owing trial allocation rather maternal fetal compromise request mother obstetrician otherwise 40 weeks
0,PMC3420230,S137,23916,23994,Statistical analysis, For timing delivery comparison censoring 40 weeks cases
0,PMC3420230,S138,24003,24291,Statistical analysis, For subgroup analyses principal subgroup level bile acids baseline continuous three categories normal raised alanine transaminase levels bile acids 14 alanine transaminase 100 U L mild bile acids 15 40 severe bile acids 40
12b,PMC3420230,S139,24292,24541,Statistical analysis, We used interaction tests determine whether apparent differences treatment effect groups could interpreted real due chance hence indentify subgroups might might benefit randomised treatment
12a,PMC3420230,S140,24550,24657,Statistical analysis, Analyses done statistical package Stata version 11 1 later StataCorp College Station TX
0,PMC3420230,S143,24761,24909,Ethical approval, The updated statistical analysis plan uploaded onto trials website unblinding data incorporated revised protocol
0,PMC3420230,S144,24910,25009,Ethical approval, The trial reported accordance consolidated standards reporting trials guidelines
3a,PMC3489506,S33,3907,4052,Study design and oversight, This randomised parallel group double masked multicentre placebo controlled phase III trial undertaken 19 sites England Wales
4b,PMC3489506,S33,3907,4052,Study design and oversight, This randomised parallel group double masked multicentre placebo controlled phase III trial undertaken 19 sites England Wales
0,PMC3489506,S34,4053,4172,Study design and oversight, The trial independently overseen independent data safety monitoring committee trial steering committee
4a,PMC3489506,S36,4220,4732,Study population, Children eligible participate aged 3 years 15 years 8 months registration visit neurodevelopmental disorder scoring 1 5 SD mean adaptive behaviour assessment system ABAS 11 sleep disorder reported parents least past five months characterised failing fall asleep within one hour off  three nights five achieving less six hours continuous sleep three nights five
4a,PMC3489506,S37,4733,4870,Study population, Children required free drugs could cause sleepiness taken melatonin within preceding five months
0,PMC3489506,S38,4871,5010,Study population, At registration parents carers provided booklet advice previously trialled standardised sleep behaviour treatment 12
0,PMC3489506,S39,5011,5222,Study population, This used run ensure children progressed randomisation phase include whose sleep disorder could amenable treatment non pharmacological intervention
4a,PMC3489506,S40,5223,5467,Study population, Sleep monitored registration period using sleep diaries completed parents children randomised continued fulfil eligibility criteria sleep disorder criteria evident sleep diaries
5,PMC3489506,S42,5517,5725,Study intervention, The child  s age appropriate bedtime established start registration period trial drug administered 45 minutes time either orally feeding tube required
5,PMC3489506,S43,5726,5837,Study intervention, If child tube fed capsule opened study treatment suspended appropriate medium 12
5,PMC3489506,S44,5838,5884,Study intervention, At randomisation child given 0 5 mg
5,PMC3489506,S45,5885,6253,Study intervention, At four weekly intervals child  s sleep pattern recorded sleep diary reviewed dose increased next dose increment basis child fulfilled sleep disorder eligibility criteria received least five possible seven doses preceding week experienced serious adverse events
5,PMC3489506,S46,6254,6347,Study intervention, There maximum three dose increments 0 5 mg 2 mg 6 mg maximum 12 mg
5,PMC3489506,S47,6348,6432,Study intervention, Step dose possible adverse effects experienced higher dose
5,PMC3489506,S48,6433,6569,Study intervention, Participants followed 12 weeks randomisation combination home visits telephone calls clinic attendance
8a,PMC3489506,S50,6614,6822,Randomisation, The trial statistician generated randomisation lists Stata release 9 College Station TX 1 1 ratio using block randomisation random variable block lengths two four stratified centre
8b,PMC3489506,S50,6614,6822,Randomisation, The trial statistician generated randomisation lists Stata release 9 College Station TX 1 1 ratio using block randomisation random variable block lengths two four stratified centre
10,PMC3489506,S50,6614,6822,Randomisation, The trial statistician generated randomisation lists Stata release 9 College Station TX 1 1 ratio using block randomisation random variable block lengths two four stratified centre
10,PMC3489506,S51,6823,6909,Randomisation, The statistician access determination analysis population
11b,PMC3489506,S52,6910,6995,Randomisation, The placebo capsules contents identical internal external appearance
9,PMC3489506,S53,6996,7082,Randomisation, Treatment packs numbered sequentially dispensed pharmacy site
9,PMC3489506,S54,7083,7182,Randomisation, Treatment packs held enough drugs 12 week period allowed potential dose escalation
11a,PMC3489506,S55,7183,7272,Randomisation, All trial staff participants blind treatment allocation throughout trial
3a,PMC3489506,S57,7319,7441,Measuring sleep, The trial design included subjective diary objective actigraphy measures sleep recommended Sadeh 13
0,PMC3489506,S58,7442,7767,Measuring sleep, There benefits approach reasons results might concordant4 7 example sleep diaries would detect periods child awake disturbing household particular concern determining sleep onset latency actigraphy could interpret restless sleep awake
0,PMC3489506,S59,7768,7863,Measuring sleep, Between registration study completion parents asked complete weekly sleep diaries
0,PMC3489506,S60,7872,8050,Measuring sleep, The actigraph MicroMini Motionlogger Ambulatory Monitoring New York accelerometer worn wrist movement monitored continuously stored within unit
0,PMC3489506,S61,8051,8190,Measuring sleep, Subsequent analysis frequency pattern movement means validated algorithms permits detection basic sleep wake patterns 13
5,PMC3489506,S62,8191,8309,Measuring sleep, Children wore actigraph continuously registration randomisation 12th week randomisation
6a,PMC3489506,S64,8355,8438,Study outcomes, The primary outcome total sleep time measured diaries completed parents
6a,PMC3489506,S65,8439,8586,Study outcomes, Each night minutes times child went sleep woke next morning calculated minus night time awakenings
6a,PMC3489506,S66,8587,8768,Study outcomes, A minimum five seven nights  data baseline week randomisation final week required weekly average calculated time point
6a,PMC3489506,S67,8777,8997,Study outcomes, Secondary sleep outcomes included total sleep time measured actigraphy sleep onset latency measured diaries actigraphy sleep efficiency proportion time spent bed asleep measured actigraphy
6a,PMC3489506,S68,8998,9225,Study outcomes, Sleep onset latency measured time taken child go sleep down  time recorded sleep diary sleep diary actigraphy measures onset sleep determined respective methods
6a,PMC3489506,S69,9234,9780,Study outcomes, Four questionnaires completed baseline final visit composite sleep disturbance index CSDI based allocating scores according frequency duration sleep problems reported parents questionnaires 14 15 16 aberrant behaviour checklist ABC assess behavioural problems17 18 family impact module paediatric quality life inventory PedsQL assess quality life care giver19 Epworth sleepiness scale ESS assess daytime sleepiness care giver 20
6a,PMC3489506,S70,9781,9871,Study outcomes, We used seven point Likert scale assess parental perception child  s sleep quality
6a,PMC3489506,S71,9880,9993,Study outcomes, We measured salivary melatonin concentrations participant calculate dim light melatonin onset DLMO
0,PMC3489506,S72,9994,10095,Study outcomes, Melatonin hormone produced pineal gland circadian rhythm influenced light levels
0,PMC3489506,S73,10096,10223,Study outcomes, Concentrations usually low day evening approaches start rise sharply peaking around midnight
0,PMC3489506,S74,10224,10306,Study outcomes, The beginning rise known dim light melatonin onset time
6a,PMC3489506,S75,10307,10490,Study outcomes, Salivary samples collected two time points night randomisation clinic visit beginning 11th week two nights trial treatment omitted
6a,PMC3489506,S76,10491,10570,Study outcomes, Saliva samples collected hourly 5 pm child  s usual bedtime
6a,PMC3489506,S77,10571,10724,Study outcomes, A minimum 2 ml saliva obtained asking child spit tube placing saliva sponge buccal cavity child  s mouth
0,PMC3489506,S78,10733,10850,Study outcomes, Saliva samples also taken DNA analysis identify genetic polymorphisms associated sleep outcomes
0,PMC3489506,S79,10851,10876,Study outcomes, DNA analyses ongoing
6a,PMC3489506,S81,10926,11009,Safety assessments, A paediatrician physically examined children screening final visits
6a,PMC3489506,S82,11010,11284,Safety assessments, The frequency severity spontaneously reported adverse events recorded weekly along prompted reports adverse events interest treatment emergent signs symptoms covering somnolence increased excitability mood swings rash hypothermia cough
6a,PMC3489506,S83,11285,11426,Safety assessments, Weekly seizure diaries recording type number seizures completed children pre existing diagnosis epilepsy
6a,PMC3489506,S84,11427,11519,Safety assessments, The Investigator  s Brochure referred assessment causality expectedness
6a,PMC3489506,S86,11571,11847,Exploratory analyses, Interactions treatment autism type sleep disorder categorised delayed sleep onset poor sleep maintenance baseline measurements child  s age weight considered primary outcome sleep onset latency post hoc analyses
6a,PMC3489506,S87,11856,12088,Exploratory analyses, Additional analyses assessed whether change morning wake time number duration night awakenings determine whether observed increase total sleep time explained reduced sleep onset latency
12a,PMC3489506,S89,12146,12258,Statistical considerations, We used treat  principle throughout undertook analyses SAS version 9 1 3 Cary NC
12a,PMC3489506,S90,12259,12311,Statistical considerations, Results presented 95 confidence intervals
12a,PMC3489506,S91,12312,12473,Statistical considerations, Continuous outcomes presented means standard deviations baseline study completion week 12 change baseline group
12a,PMC3489506,S92,12474,12677,Statistical considerations, We used analysis covariance adjust results dependent variables total sleep time sleep onset latency measured baseline exploratory analyses treatment covariate interactions
12b,PMC3489506,S92,12474,12677,Statistical considerations, We used analysis covariance adjust results dependent variables total sleep time sleep onset latency measured baseline exploratory analyses treatment covariate interactions
0,PMC3489506,S93,12686,12842,Statistical considerations, The trial originally designed two primary outcomes total sleep time according sleep diary sleep onset latency measured actigraphy
6b,PMC3489506,S94,12843,13068,Statistical considerations, During trial recruitment observed high rates missing data 66 actigraphy re designated sleep onset latency secondary outcome removed Bonferroni multiplicity adjustment21 protocol amendment
0,PMC3489506,S95,13069,13148,Statistical considerations, The process adopted protecting trial validity suggested Evans 22
7a,PMC3489506,S96,13157,13352,Statistical considerations, Total sleep time powered 80 5 significance level detect change baseline one hour melatonin placebo group common standard deviation 1 7 23 24
7a,PMC3489506,S97,13353,13491,Statistical considerations, Allowing 20 missing data based observed rates time amendment calculated needed 57 participants group
7a,PMC3489506,S98,13500,13847,Statistical considerations, We reassessed estimate common standard deviation used sample size calculation first 20 participants 1 2 95 confidence interval 0 8 1 7 independent data safety monitoring committee recommended trial continue without revision sample size calculation estimated standard deviation used
0,PMC3502035,S36,7287,7529,Methods, The Australian universal health insurance scheme Medicare provides citizens free access public hospitals reimbursed access 70 services co payment widespread network primary care general practice clinics
0,PMC3502035,S37,7530,7826,Methods, A parallel system Pharmaceutical Benefits Scheme provides subsidised drug treatment Australians capped payments chronic illness prescriptions drugs generated general practitioners managing people chronic conditions hypertension
4b,PMC3502035,S39,7863,8064,Participants, Study participants recruited 260 general practitioners 119 general practices distributed throughout every state territory Australia except sparsely populated Northern Territory
4a,PMC3502035,S40,8065,8296,Participants, People routinely managed doctors potentially eligible participate aged 18 diagnosis hypertension requiring active drug treatment according guidelines consented participate
4a,PMC3502035,S41,8297,8672,Participants, We excluded people mean initial systolic blood pressure 180 mm Hg sitting prescribed three antihypertensives moderate severe renal disease clinical diagnosis estimated glomerular filtration rate 60 mL min 1 73m2 contraindications angiotensin receptor blockers calcium channel blockers thiazide diuretics
3a,PMC3502035,S44,8812,8948,Study design, This open label two arm randomised trial comparing intensive blood pressure management strategy usual care control 13
8a,PMC3502035,S45,8949,9141,Study design, Randomisation computer generated group assignment stratified according nominated blood pressure target three strata block randomisation units 12 per general practitioner
8b,PMC3502035,S45,8949,9141,Study design, Randomisation computer generated group assignment stratified according nominated blood pressure target three strata block randomisation units 12 per general practitioner
10,PMC3502035,S46,9142,9275,Study design, An independent data management team Baker IDI coordinated standardised protocol randomising participants telephone
3a,PMC3502035,S47,9276,9543,Study design, Participants assigned groups using prespecified ratio 1 2 usual care versus intervention ratio 1 2 within intervention arm assign participants monotherapy strategy two possible combined treatment strategies
0,PMC3502035,S48,9544,9660,Study design, Quality control sites general practitioners achieved visits randomisation study end
0,PMC3502035,S49,9661,9799,Study design, The study independently monitored routine visits case report forms verified clinical records 20 patients
0,PMC3502035,S50,9800,9874,Study design, We used standardised operating procedures data queries management
0,PMC3502035,S51,9875,9980,Study design, All queries resolved time study dataset locked changes permitted
0,PMC3502035,S52,9981,10049,Study design, Figure 1 provides graphical representation study timelines
3a,PMC3502035,S53,10059,10091,Study design, Fig 1 Summary study timelines
5,PMC3502035,S53,10059,10091,Study design, Fig 1 Summary study timelines
0,PMC3502035,S55,10134,10244,Study entry, Eligible participants underwent baseline assessment including determination absolute cardiovascular risk 5
0,PMC3502035,S56,10245,10470,Study entry, On basis assessment identified target risk factor measures including blood pressure lipid levels exercise levels smoking status body mass index participant according national guidelines 6
0,PMC3502035,S57,10471,10654,Study entry, A computer program developed Baker IDI enabled clinical profiling participants subsequent management intervention patients see appendix I supplementary file
5,PMC3502035,S58,10655,10973,Study entry, Eligible participants began standard 28 day run in period treatment open label oral valsartan 80 mg daily mandatory blood pressure check 14 days start treatment determine need immediate rescue randomisation systolic blood pressure mm Hg clinically indicated
0,PMC3502035,S59,10974,11178,Study entry, We randomised study achieve prespecified blood pressure target within run in period specifically withdrawn lost follow up blinded allocation
0,PMC3502035,S61,11236,11357,Blood pressure measurement, Throughout study used standardised protocol based national guidelines record blood pressure measurements 6
6a,PMC3502035,S62,11358,11668,Blood pressure measurement, After participants rested least five minutes seated obtained three blood pressure measurements separated one minute intervals using appropriate sized cuff calibrated semiautomated oscillometric device approved Therapeutic Goods Administration Australia
6a,PMC3502035,S63,11669,11880,Blood pressure measurement, We defined aberrant measurements lowest reading 10 mm Hg systolic blood pressure 5 mm Hg diastolic blood pressure highest three seated readings
6a,PMC3502035,S64,11881,11971,Blood pressure measurement, If occurred participant rested three minutes procedure repeated
0,PMC3502035,S65,11972,12084,Blood pressure measurement, Given size nature study impractical obtain independent blinded blood pressure levels
6a,PMC3502035,S66,12085,12343,Blood pressure measurement, Nominated study staff site general practitioner practice nurse verified blood pressure measurements independent audit clinical details case records outputs blood pressure monitor computer decision tool
6a,PMC3502035,S68,12385,12810,Usual care, For assigned usual care asked general practitioners follow usual pattern clinic visits treatment strategies restriction prescribed drugs achieve individualised blood pressure target prevention targets identified run in phase mandatory study visits weeks 6 typically brief 10 15 minute consultation 26 final comprehensive evaluation
0,PMC3502035,S69,12811,13111,Usual care, We explicitly acknowledged enhanced form usual care given participants already subject clinical profiling identified blood pressure target doctors potentially knowledge intervention inherent problem contamination
6a,PMC3502035,S71,13161,13493,Study intervention, Those allocated intervention arm followed intensive stepped programme management mandatory visits doctor weeks 6 10 14 18 randomisation review blood pressure adjust treatment needed according prespecified algorithms see appendix II supplementary file
0,PMC3502035,S72,13494,13639,Study intervention, Typically consultations lasted 10 15 minutes 60 minutes total addition time taken clinical profiling baseline
5,PMC3502035,S73,13640,13877,Study intervention, Reflecting contemporary treatment options management hypertension different drug pathways mandated initial monotherapy valsartan 160 mg combined hydrochlorothiazide amlodipine single combined pills
5,PMC3502035,S74,13878,14053,Study intervention, Scheduling visits up titration drug treatment guided computer program developed Baker IDI facilitate initial risk profiling management
6a,PMC3502035,S75,14054,14128,Study intervention, A final clinic visit clinical re evaluation scheduled 26 weeks
6a,PMC3502035,S77,14175,14419,Study endpoints, The primary endpoint percentage participants achieved individualised blood pressure target according national guidelines6 26 weeks follow up using last recorded blood pressure intention treat analyses
6a,PMC3502035,S78,14420,14796,Study endpoints, These stringent blood pressure targets rarely examined feasibility controlled trial mm Hg patient proteinuria mm Hg end organ damage present including form cardiovascular disease diabetes microalbuminuria classic target mm Hg without evidence two criteria
6a,PMC3502035,S79,14805,15017,Study endpoints, Key secondary endpoints included change mean sitting systolic diastolic blood pressure absolute risk cardiovascular disease within five years based Framingham risk score5 applicable
6a,PMC3502035,S80,15018,15315,Study endpoints, Secondary endpoints also included type rate adverse events potentially attributable antihypertensive treatment serious adverse events including cause mortality fatal non fatal cardiovascular events  for example acute myocardial infarction stroke heart failure
0,PMC3502035,S81,15316,15611,Study endpoints, Several secondary endpoints subject future expanded reports including changes quality life depression self care behaviours evidence end organ damage including electrocardiographic evidence left ventricular hypertrophy newly detected proteinuria
0,PMC3502035,S83,15654,15764,Study power, We largely met study targets overall recruitment number participants entering run in phase
7a,PMC3502035,S84,15765,16068,Study power, Based combination strong potential interventional contamination balanced need establish clinically significant differences two groups study initially powered detect minimum absolute difference 7 groups primary endpoint 13
7a,PMC3502035,S85,16069,16526,Study power, As proportionately patients achieved blood pressure control study run in thus number randomised participants reduced recalculated total randomised cohort 1500 participants would still provide sufficient study power detect minimum 8 difference groups 85 study power two sided level 0 05 adjusting 2 1 randomisation study intervention versus usual care 13
0,PMC3502035,S87,16578,16755,Statistical analyses, The study statistician behalf clinical safety efficacy committee independently analysed data according prospectively designed statistical analysis plan
12a,PMC3502035,S88,16756,16921,Statistical analyses, If blood pressure values missing 26 weeks carried forward last recorded blood pressure measurement randomisation primary endpoint analysis
12a,PMC3502035,S89,16922,16998,Statistical analyses, Baseline outcome data analysed using SPSS Windows version 19 0
12a,PMC3502035,S90,16999,17094,Statistical analyses, Continuous data presented means standard deviations medians interquartile ranges
12a,PMC3502035,S91,17095,17141,Statistical analyses, Categorical data presented percentages
0,PMC3502035,S92,17150,17392,Statistical analyses, We carried efficacy analyses intention treat population consisting participants randomised intervention arm usual care arm least one recorded blood pressure measurement randomisation
0,PMC3502035,S93,17393,17476,Statistical analyses, Analyses based treatment group participant randomised
12a,PMC3502035,S94,17477,17684,Statistical analyses, We compared primary endpoint measure blood pressure control week 26 study groups using log binomial generalised linear model stratification status randomisation covariate
12a,PMC3502035,S95,17685,17879,Statistical analyses, Stratification status fit categorical variable three blood pressure target groups mm Hg mm Hg mm Hg based participant  s clinical profile
12a,PMC3502035,S96,17880,18106,Statistical analyses, Change systolic diastolic blood pressure baseline 26 weeks analysed analysis covariance treatment group stratification status factors mean baseline blood pressure covariate
0,PMC3502035,S97,18107,18184,Statistical analyses, We also describe proportion rate adverse events per participant
3a,PMC3551223,S41,5523,5743,Study design, This report covers planned analysis first 24 weeks including primary endpoint on going 2 year double blind placebo controlled parallel group clinical trial NCT00810199 EudraCT 2008 001847 20
11a,PMC3551223,S42,5744,5945,Study design, The treatment allocation individual patients remained blinded patients site personnel data analysis interpretation team except separate subgroup technically preparing data
0,PMC3551223,S43,5954,6126,Study design, The study approved appropriate institutional review boards ethics committees written informed consent obtained patient study participation
0,PMC3551223,S44,6127,6334,Study design, The study conducted full accordance International Conference Harmonisation good clinical practice principles laws regulations countries research conducted
4a,PMC3551223,S46,6374,6809,Patients, Eligible patients confirmed RA according 1987 American College Rheumatology ACR criteria active disease defined disease activity score based 28 joints  erythrocyte sedimentation rate DAS28  ESR greater 4 4 baseline 4 0 screening receiving methotrexate least 12 weeks stable dose least 15 mg week 6 weeks longer starting study treatment
4a,PMC3551223,S47,6810,6997,Patients, For inclusion patients also required bone damage radiographic evidence least one joint definite erosion attributable RA determined central reader
4a,PMC3551223,S48,6998,7355,Patients, Major exclusion criteria included severe comorbidities previous use biological agents well conventional disease modifying antirheumatic drug treatment methotrexate month 3 months leflunomide preceding baseline visit see supplementary data available online full inclusion exclusion criteria
0,PMC3551223,S50,7402,7560,Study treatment, Patients randomly assigned either add on switch strategy group see supplementary data available online study design schematic
8b,PMC3551223,S51,7561,7670,Study treatment, Randomisation stratified study site baseline DAS28  ESR 5 5 using minimisation algorithm
5,PMC3551223,S52,7671,7752,Study treatment, All patients received open label tocilizumab 8 mg kg intravenously every 4 weeks
11b,PMC3551223,S53,7753,8015,Study treatment, Treatment methotrexate placebo double blind patients received identical capsules either placebo switch strategy arm methotrexate 2 5 mg add on strategy arm number capsules study entry consistent prestudy dosage
5,PMC3551223,S53,7753,8015,Study treatment, Treatment methotrexate placebo double blind patients received identical capsules either placebo switch strategy arm methotrexate 2 5 mg add on strategy arm number capsules study entry consistent prestudy dosage
5,PMC3551223,S54,8016,8336,Study treatment, Tocilizumab and or disease modifying antirheumatic drug treatment reduced temporarily interrupted patients alanine aminotransferase aspartate transaminase values greater one three times upper limit normal ULN discontinued persistent increases greater three times ULN
5,PMC3551223,S56,8393,8605,Concomitant RA treatments, Oral corticosteroids mg day prednisone equivalent non steroidal anti inflammatory drugs permitted long doses stable least 25 28 days start study treatment
5,PMC3551223,S57,8606,8745,Concomitant RA treatments, Alterations non steroidal anti inflammatory drug dose recommended study particularly first 24 weeks
5,PMC3551223,S58,8746,8830,Concomitant RA treatments, The corticosteroid dose could changed first 24 weeks study
0,PMC3551223,S60,8900,9005,Collected patient data and assessments, Data collected baseline included demographics disease characteristics RA disease duration
6a,PMC3551223,S61,9006,9277,Collected patient data and assessments, At baseline every 4 weeks thereafter following parameters assessed tender joint count swollen joint count health assessment questionnaire  disability index HAQ  DI patient s global assessment physician s global assessment C reactive protein CRP ESR
6a,PMC3551223,S62,9278,9417,Collected patient data and assessments, Quality life assessed baseline weeks 4 8 12 24 using rheumatoid arthritis quality life questionnaire RAQoL
6a,PMC3551223,S63,9418,9557,Collected patient data and assessments, At visit patients monitored adverse events vital signs laboratory tests eg blood counts transaminases cholesterol
6a,PMC3551223,S64,9558,9637,Collected patient data and assessments, Radiographs hands wrists feet obtained baseline week 24
6a,PMC3551223,S65,9638,9924,Collected patient data and assessments, Each radiograph assessed applying Genant modified Sharp scoring system GSS two independent readers Perceptive Informatics Medical Imaging Services Berlin Germany blinded treatment assignment chronological order radiographs patient s clinical status
6a,PMC3551223,S66,9925,10111,Collected patient data and assessments, The smallest detectable change SDC GSS computed based observed SD difference x ray readers 14 whereas three readers total participated campaign
0,PMC3551223,S67,10112,10232,Collected patient data and assessments, The SDC smallest change attributed something observed variability reader differences
0,PMC3551223,S69,10284,10467,Statistical analysis, The clinical superiority tocilizumab plus methotrexate combination treatment phase II CHARISMA study13 important influence statistical parts design
6a,PMC3551223,S70,10476,10853,Statistical analysis, To assess working hypothesis add on strategy ie initiation tocilizumab plus continuation methotrexate would superior switch strategy ie initiation tocilizumab discontinuation methotrexate primary outcome measure study defined percentage patients remission according DAS28  ESR DAS28 2 6 week 24
12a,PMC3551223,S71,10854,10969,Statistical analysis, A two sided statistical test difference two treatment arms 5 significance level used
12a,PMC3551223,S72,10970,11261,Statistical analysis, Specifically primary endpoint well similar endpoints logistic regression model employed including stratification factors used randomisation site baseline DAS28 5 5 supportive Cochran  Mantel  Haenszel test stratified parameters
12a,PMC3551223,S73,11262,11341,Statistical analysis, Analysis covariance models used compare continuous outcome measures
12a,PMC3551223,S74,11350,11739,Statistical analysis, Efficacy analyses conducted intention to treat population randomly assigned treated patients analysed arm randomly assigned non responder imputation categorical variables eg DAS28 remission ACR response last observation carried forward patient withdrawal missing joint counts additional imputation missing values
7a,PMC3551223,S75,11748,11999,Statistical analysis, The target sample size 235 patients per arm computed provide 80 power detect 12 5 treatment effect difference expected 42 5 DAS28 remission rate week 24 add on strategy arm versus 30 switch strategy arm 12
0,PMC3551223,S76,12000,12143,Statistical analysis, This difference 12 5 deemed clinically relevant study s steering committee see supplementary data available online
0,PMC3551223,S77,12152,12356,Statistical analysis, The following additional endpoints analysed accordance European League Against Rheumatism EULAR ACR collaborative recommendations reporting RA disease activity clinical trials 11
6a,PMC3551223,S78,12389,12745,Statistical analysis, Other outcome measures week 24 included mean changes DAS28  ESR selected variables eg swollen joint count tender joint count ESR CRP HAQ  DI RAQoL percentage patients improved 24 weeks study according ACR20 50 70 90 EULAR response percentage patients DAS28 3 2 low disease activity state
6a,PMC3551223,S79,12746,12925,Statistical analysis, Remission defined 2010 ACR  EULAR criteria Boolean definition 15 simplified disease activity index clinical disease activity index analysed post hoc
6a,PMC3551223,S80,12960,13122,Statistical analysis, To approach concepts onset action sustainability changes time selected variables joint counts CRP pain HAQ  DI evaluated
6a,PMC3551223,S81,13157,13235,Statistical analysis, The domain fatigue evaluated using question 21 RAQoL questionnaire
6a,PMC3551223,S82,13270,13493,Statistical analysis, Radiographic endpoints included changes baseline total GSS erosion joint space narrowing scores proportion patients radiographic progression progression defined change GSS SDC 0
6a,PMC3551223,S83,13522,13819,Statistical analysis, Safety endpoints included incidence adverse events AE serious AE serious infections specific laboratory abnormalities analysed safety population treated patients least one post dose assessment safety analysed according treatment received
0,PMC3551223,S157,25752,25764,Supplementary Material, Web appendix
3a,PMC3590447,S41,6033,6194,Trial design and participants, In randomised controlled trial patients recruited 37 45 renal units acute hospitals throughout UK obtained local ethical approval
4b,PMC3590447,S41,6033,6194,Trial design and participants, In randomised controlled trial patients recruited 37 45 renal units acute hospitals throughout UK obtained local ethical approval
4a,PMC3590447,S42,6195,6859,Trial design and participants, Inclusion criteria age 18  75 years biopsy proven diagnosis membranous nephropathy impose limit time since biopsy regarded idiopathic evidence underlying cause drugs infections tumours serum plasma creatinine concentration less 300 together 20 greater decline excretory renal function measured creatinine clearance estimated Cockcroft Gault calculation later Modification Diet Renal Disease MDRD formula13 based least three measurements period 3 months longer within 2 years study entry
4a,PMC3590447,S43,6868,6998,Trial design and participants, We excluded patients whose membranous nephropathy result secondary causes defined according usual clinical practice
4a,PMC3590447,S44,6999,7479,Trial design and participants, Other exclusion criteria known infection hepatitis B C virus HIV known malignant disease positive antibodies double stranded DNA current treatment gold penicillamine non steroidal anti inflammatory drugs cytotoxic drugs ciclosporin 3 months treatment corticosteroids preceding 2 years pregnancy unreliable contraception previous adverse reaction prednisolone methylprednisolone chlorambucil ciclosporin
0,PMC3590447,S45,7488,7600,Trial design and participants, Ethics approval obtained South West Multicentre Research Ethics Committee reference MREC 97 6 12
0,PMC3590447,S46,7601,7664,Trial design and participants, Each participating centre also obtained local ethical approval
0,PMC3590447,S47,7665,7708,Trial design and participants, All patients gave written informed consent
10,PMC3590447,S49,7753,7934,Randomisation, Eligible patients randomly assigned member staff clinical trials office Glasgow Royal Infirmary Glasgow UK otherwise involved trial
8a,PMC3590447,S50,7935,8166,Randomisation, A random numbers table prepared allocate patients one three groups supportive therapy alone supportive therapy plus 6 months prednisolone chlorambucil supportive therapy plus 12 months ciclosporin
5,PMC3590447,S50,7935,8166,Randomisation, A random numbers table prepared allocate patients one three groups supportive therapy alone supportive therapy plus 6 months prednisolone chlorambucil supportive therapy plus 12 months ciclosporin
8b,PMC3590447,S50,7935,8166,Randomisation, A random numbers table prepared allocate patients one three groups supportive therapy alone supportive therapy plus 6 months prednisolone chlorambucil supportive therapy plus 12 months ciclosporin
10,PMC3590447,S51,8167,8265,Randomisation, Treatment allocation communicated fax clinician entering patient trial
11a,PMC3590447,S52,8266,8319,Randomisation, We attempt mask patients investigators
0,PMC3590447,S54,8361,8523,Procedures, We recorded baseline data supportive treatment alone group randomisation patients effectively continuing existing management
0,PMC3590447,S55,8524,8672,Procedures, In two groups receiving immunosuppressive treatment addition supportive therapy baseline data recorded new treatment began
0,PMC3590447,S56,8673,8821,Procedures, We could always start immunosuppressive treatment immediately randomisation new treatments prescribed delivered
0,PMC3590447,S57,8830,8904,Procedures, The treatment schedules based best available evidence time
5,PMC3590447,S58,8905,9026,Procedures, All patients received supportive therapy including renin angiotensin blockade statins anticoagulants indicated
5,PMC3590447,S59,9027,9265,Procedures, Those assigned supportive therapy plus 6 months prednisolone chorambucil11 received intravenous methyl prednisolone 1 g per day 3 consecutive days oral prednisolone 0  5 mg kg per day 28 days months 1 3 5
5,PMC3590447,S60,9266,9320,Procedures, Intravenous prednisolone administered hospital
5,PMC3590447,S61,9321,9425,Procedures, During months 2 4 6 patients received oral chlorambucil starting dose 0  15 mg kg per day
5,PMC3590447,S62,9426,9659,Procedures, We gave reduced dose parent drug metabolites renally excreted preliminary work14 shown dose 0  2 mg kg per day poorly tolerated patients impaired excretory renal function
5,PMC3590447,S63,9660,9808,Procedures, We reduced dose patient developed leucopenia weekly full blood counts advised interrupted leucopenia severe
5,PMC3590447,S64,9817,10037,Procedures, Those assigned supportive therapy plus 12 months ciclosporin received starting dose 5 mg kg per day 12 adjusted according trough blood concentrations drug achieve concentration 100  200
5,PMC3590447,S65,10038,10082,Procedures, We reduced dose toxicity evident
6a,PMC3590447,S66,10091,10202,Procedures, We followed patients met primary endpoint minimum 3 years
0,PMC3590447,S67,10203,10292,Procedures, The trial formally analysed 3 years patients begun treatment
0,PMC3590447,S68,10293,10374,Procedures, All surviving trial patients remain routine follow up renal units
6a,PMC3590447,S69,10383,10592,Procedures, The primary endpoint 20 decline excretory renal function baseline readings calculated patients Cockcroft Gault equation standard methodology start trial
6a,PMC3590447,S70,10601,10793,Procedures, Secondary endpoints proteinuria measured 24 h urinary collections estimated protein  creatinine ratios multiplying ratio mg mmol 10 severe adverse events
0,PMC3590447,S71,10794,10934,Procedures, The primary investigator PWM identified adverse events serious categorised according affected body system
0,PMC3590447,S72,10935,11374,Procedures, We report serious adverse events defined Medicines Healthcare products Regulatory Agency MHRA guidance15  ie adverse event adverse reaction unexpected adverse reaction results death life threatening results admission hospital extends length existing hospital stay results persistent serious disability incapacity consists congenital anomaly birth defect
0,PMC3590447,S73,11375,11530,Procedures, We also regarded serious important medical events might jeopardised patient needed intervention prevent one outcomes
6a,PMC3590447,S74,11531,11611,Procedures, We recorded information deaths development end stage renal disease
0,PMC3590447,S75,11620,11861,Procedures, In accordance Medical Research Council s guidelines good clinical practice trial steering committee data monitoring committee established receive yearly reports primary endpoints adverse events deaths
7a,PMC3590447,S77,11913,12161,Statistical analysis, To 90 power detect reduction frequency primary endpoint 80 supportive treatment group 40 immunosuppression groups p 0  05 calculated 35 patients would needed group 105 total
7a,PMC3590447,S78,12162,12267,Statistical analysis, After allowing estimated dropout rate 10 concluded needed recruit 116 patients
0,PMC3590447,S79,12276,12429,Statistical analysis, Primary analysis followed principles intention treat secondary analysis assessed patients received least one dose treatment
12a,PMC3590447,S80,12430,12532,Statistical analysis, Unless otherwise stated p values estimates treatment effects based two way comparisons
12a,PMC3590447,S81,12533,12586,Statistical analysis, We make adjustments multiple comparisons
12a,PMC3590447,S82,12587,12742,Statistical analysis, We analysed time 20 decline renal function log rank test calculated hazard ratios HRs Cox proportional hazards regression
12a,PMC3590447,S83,12743,12894,Statistical analysis, We used log rank test survival endpoints repeated measures analysis variance fowr continuous longitudinal data eg proteinuria
12a,PMC3590447,S84,12895,13009,Statistical analysis, We analysed serious adverse event data log rank test basis time first serious adverse event
12a,PMC3590447,S85,13010,13071,Statistical analysis, We statistical analyses using SAS software version 9 2
0,PMC3590447,S86,13080,13333,Statistical analysis, In 2003 trial shown comply requirements EU clinical trials directive 2004 clinical trial authorisation CTA obtained Medicines Healthcare products Regulatory Authority CTA number 18524 0001 001
0,PMC3590447,S87,13334,13496,Statistical analysis, In 2008 trial adopted onto National Institute Health Research portfolio assigned UK Clinical Research Network identification number 2579
0,PMC3590447,S90,13653,13786,Role of the funding source, The sponsors study role study design data collection data analysis data interpretation writing report
0,PMC3590447,S91,13787,13912,Role of the funding source, The corresponding author full access data study final responsibility submit publication
4a,PMC3623038,S30,3600,3835,Patients, Consecutive patients diagnosed according Gibb s criteria9 monitored Lille University Hospital s PD clinic invited participate study CM AD LD DD required number participants obtained
4b,PMC3623038,S30,3600,3835,Patients, Consecutive patients diagnosed according Gibb s criteria9 monitored Lille University Hospital s PD clinic invited participate study CM AD LD DD required number participants obtained
0,PMC3623038,S32,3968,4075,Patients, The research protocol approved local independent ethics committee Protocol ID 2008 008210 38
4a,PMC3623038,S33,4084,4305,Patients, The main inclusion criterion presence severe gait disorder defined score UPDRS part III item 29 abnormal forward leaning stance score item 28 despite optimal L dopa treatment
4a,PMC3623038,S34,4306,4483,Patients, The main exclusion criterion presence axial disorders related insufficient doses L dopa off periods motor fluctuation induced STN stimulation
4a,PMC3623038,S35,4484,4668,Patients, Patients receiving STN stimulation shown improvement least 50 motor symptoms first year treatment without worsening gait posture
4a,PMC3623038,S36,4669,4783,Patients, The appearance axial signs immediately initiation STN stimulation also exclusion criterion
4a,PMC3623038,S37,4784,5081,Patients, Other notable exclusion criteria included inability walk unaided dopaminergic treatment ii dementia diagnosed according DSM IV R criteria Mattis Dementia Rating Scale score 130 iii ongoing administration NMDA antagonist memantine
3a,PMC3623038,S39,5132,5200,Experimental design, We performed 90 day double blind placebo controlled pilot study
5,PMC3623038,S41,5257,5313,Randomisation and masking, Subjects randomly assigned memantine placebo
8a,PMC3623038,S42,5314,5438,Randomisation and masking, The 1    1 assignment sequence based computer random number generator produced Department Biostatistics
10,PMC3623038,S42,5314,5438,Randomisation and masking, The 1    1 assignment sequence based computer random number generator produced Department Biostatistics
11b,PMC3623038,S43,5439,5624,Randomisation and masking, The randomisation list sent independent contract research organisation LC2 Lentilly France preparation distribution identical capsules memantine placebo
10,PMC3623038,S43,5439,5624,Randomisation and masking, The randomisation list sent independent contract research organisation LC2 Lentilly France preparation distribution identical capsules memantine placebo
11a,PMC3623038,S45,5668,5739,Intervention, Patients study staff investigators blinded assignment
5,PMC3623038,S46,5740,5972,Intervention, After 30 day dose titration phase increase 5  mg memantine per week placebo patients received daily dose 7 00 20  mg memantine ie usual recommended dose placebo 60  days
5,PMC3623038,S47,5973,6054,Intervention, All patients undergoing STN stimulation assessed conditions
5,PMC3623038,S48,6055,6206,Intervention, Patients allowed change medication regimen STN stimulation settings 3  months prior study study
6a,PMC3623038,S50,6255,6351,Efficacy criteria, The primary efficacy criterion change stride length conditions
6a,PMC3623038,S51,6352,6500,Efficacy criteria, Stride length assessed optoelectronic analysis 6 camera VICON Video System Oxford Metrics Oxford UK sampling rate 50  Hz
6a,PMC3623038,S52,6501,7319,Efficacy criteria, Secondary efficacy criteria included gait velocity m s cadence steps min ii motor handicap assessed overall UPDRS motor score axial subscore sum items 18 speech 19 facial expression 22 neck rigidity 27 arising chair 28 posture 29 gait 30 postural stability iii LID assessed overall Dyskinesia Rating Scale score axial subscore iv hypertonia axial flexors extensors assessed mean work joules performed 10 passive trunk movements 30  s CON TREX isokinetic dynamometer CMV AG D bendorf Switzerland 10 v trunk flexor extensor strength measured mean work joules performed three repetitions 30  s active flexion extension mode isokinetic dynamometer 10
6a,PMC3623038,S53,7320,7427,Efficacy criteria, All measurements recorded double blind manner hospital s gait laboratory CM AD VT
6a,PMC3623038,S55,7482,7639,Standardised assessment, Efficacy criteria assessed 8 30 morning conditions least 8  h withdrawal dopaminergic medications
6a,PMC3623038,S56,7640,7769,Standardised assessment, After acute administration L dopa 9 00 on  condition assessed 9 30 10 00 morning
6a,PMC3623038,S57,7770,7871,Standardised assessment, All assessments performed 90 day course study medication afterwards
5,PMC3623038,S58,7872,8007,Standardised assessment, The L dopa dose used assessment 150 usual first morning dose taken patients relieve symptoms table 1
6a,PMC3623038,S61,8112,8245,Safety criteria, Adverse events arterial blood pressure values electrocardiogram standard blood biochemistry profile recorded monthly
6a,PMC3623038,S62,8246,8396,Safety criteria, In view possible antagonistic effect memantine nicotinic acetylcholine receptors 5 drowsiness assessed Epworth Sleepiness Scale
0,PMC3623038,S63,8397,8523,Safety criteria, The study s Data Safety Monitoring Board examined adverse event reports periodically blinding code broken
6a,PMC3623038,S64,8524,8764,Safety criteria, In order estimate final plasma concentration memantine blood sample taken patients ie groups maintain blinding morning administration study medication 7 00 last day treatment
0,PMC3623038,S66,8819,9014,Sample size calculation, In previous study 17 patients methylphenidate observed stride length increase relative baseline 0 4  m SD 0 4 stand walk sit test 3  months treatment 11
0,PMC3623038,S67,9015,9180,Sample size calculation, Despite use sensitive optoelectronic analysis present study adopted anticipated stride length difference 0 4  m SD 0 4
7a,PMC3623038,S68,9181,9287,Sample size calculation, With power 80 type I error 5 total sample size found 17 patients per group
7a,PMC3623038,S69,9288,9582,Sample size calculation, Next basis coefficient 0 4 correlation baseline measurement end of study measurement covariance analysis ii low dropout rate iii replacement dropouts calculated required sample size 14 patients per group
12a,PMC3623038,S71,9634,9739,Statistical analysis, Descriptive analyses Shapiro Wilk test used check whether data normally distributed
12a,PMC3623038,S72,9740,9791,Statistical analysis, Non normally distributed data log transformed
12a,PMC3623038,S73,9792,9941,Statistical analysis, The primary criterion tested covariance analysis adjustment baseline patients data recorded final assessment
0,PMC3623038,S74,9942,9976,Statistical analysis, The effect size also computed
12a,PMC3623038,S75,9977,10084,Statistical analysis, Furthermore covariance model s validity checked analysing residuals Cook distances
12b,PMC3623038,S76,10085,10176,Statistical analysis, Numerical safety data randomised patients assessed analysis variance
0,PMC3623038,S77,10177,10251,Statistical analysis, The threshold statistical significance set p 0 05 cases
12a,PMC3623038,S78,10252,10377,Statistical analysis, All statistical tests two tailed performed SAS software V 9 2 SAS Institute Inc Cary North Carolina USA
0,PMC3623038,S114,15215,15229,Supplementary Material, Web supplement
0,PMC3623038,S116,15320,15330,Supplementary Material, Web figure
0,PMC3623038,S118,15421,15430,Supplementary Material, Web table
3a,PMC3641608,S44,7454,7884,Trial design, ARROW open label randomised parallel group trial untreated except ART prevent mother to child transmission children adolescents aged 3 months 17 years HIV met WHO 2006 criteria ART initiation15 three centres Uganda Joint Clinical Research Centre Kampala Baylor Uganda Mulago MRC UVRI Uganda Research Unit AIDS Entebbe one Zimbabwe University Zimbabwe Harare
4a,PMC3641608,S44,7454,7884,Trial design, ARROW open label randomised parallel group trial untreated except ART prevent mother to child transmission children adolescents aged 3 months 17 years HIV met WHO 2006 criteria ART initiation15 three centres Uganda Joint Clinical Research Centre Kampala Baylor Uganda Mulago MRC UVRI Uganda Research Unit AIDS Entebbe one Zimbabwe University Zimbabwe Harare
4b,PMC3641608,S44,7454,7884,Trial design, ARROW open label randomised parallel group trial untreated except ART prevent mother to child transmission children adolescents aged 3 months 17 years HIV met WHO 2006 criteria ART initiation15 three centres Uganda Joint Clinical Research Centre Kampala Baylor Uganda Mulago MRC UVRI Uganda Research Unit AIDS Entebbe one Zimbabwe University Zimbabwe Harare
4a,PMC3641608,S45,7885,8137,Trial design, Children acute infections drugs contraindicated ART unlikely adhere attend regularly laboratory abnormalities contraindicating ART pregnant breastfeeding perinatally exposed ART 6 months old excluded
5,PMC3641608,S46,8138,8326,Trial design, Participants randomly assigned 1 1 clinically driven monitoring versus routine laboratory plus clinical monitoring toxicity haematology biochemistry efficacy CD4
5,PMC3641608,S47,8327,8798,Trial design, Children also randomly assigned 1 1 1 factorial design three approaches first line ART open label lamivudine abacavir plus NNRTI continuously group A control induction maintenance four drug lamivudine abacavir NNRTI plus zidovudine 36 weeks lamivudine abacavir plus NNRTI group B induction maintenance lamivudine abacavir NNRTI plus zidovudine 36 weeks lamivudine abacavir plus zidovudine group C
0,PMC3641608,S48,8799,8824,Trial design, HLA testing done
0,PMC3641608,S49,8825,8885,Trial design, HIV viral loads done retrospectively stored samples
0,PMC3641608,S50,8886,9127,Trial design, The hypothesis clinically driven monitoring would result similar outcomes routine laboratory monitoring non inferiority four drug induction maintenance would greater efficacy would standard three drug ART
5,PMC3641608,S51,9128,9229,Trial design, The NNRTI nevirapine efavirenz chosen clinicians according local availability age
0,PMC3641608,S52,9230,9384,Trial design, Caregivers gave written informed consent older children 8  17 years aware HIV status also gave assent consent following national guidelines
0,PMC3641608,S53,9385,9470,Trial design, The trial approved research ethics committees Uganda Zimbabwe UK
8b,PMC3641608,S55,9527,9613,Randomisation and masking, Both factorial randomisations stratified centre age 7 7  12 years
9,PMC3641608,S56,9614,9975,Randomisation and masking, The computer generated sequentially numbered randomisation list variable block sizes containing allocations pre prepared trial statistician incorporated within secure database trial centre connected located within clinical centre allowing trial managers access next number whole list
8a,PMC3641608,S56,9614,9975,Randomisation and masking, The computer generated sequentially numbered randomisation list variable block sizes containing allocations pre prepared trial statistician incorporated within secure database trial centre connected located within clinical centre allowing trial managers access next number whole list
10,PMC3641608,S57,9976,10051,Randomisation and masking, Randomisation undertaken clinicians phoning local trials centre
11a,PMC3641608,S58,10052,10146,Randomisation and masking, Once randomised allocation open  ie physicians carers aware group assignment
6a,PMC3641608,S60,10188,10516,Procedures, All participants examined doctor routine full blood count white cell differential lymphocyte subsets CD4 CD8 biochemistry tests bilirubin urea creatinine aspartate aminotransferase alanine aminotransferase screening randomisation lymphocytes weeks 4 8 12 every 12 weeks
0,PMC3641608,S61,10517,10567,Procedures, Screening results used assess eligibility
0,PMC3641608,S62,10568,11081,Procedures, All subsequent results participants assigned routine laboratory monitoring returned clinicians whereas results randomisation participants allocated clinically driven monitoring returned requested clinical management authorised centre project leaders haemoglobin results week 8 automatically returned basis early anaemia DART 16 grade 4 laboratory toxicities protocol safety criteria grades defined17 apart neutrophils18
0,PMC3641608,S63,11082,11303,Procedures, Total lymphocytes CD4 tests never returned participants clinically driven monitoring children investigations could requested concomitant drugs prescribed clinically indicated
5,PMC3641608,S64,11312,11406,Procedures, All children received ART syrups tablets dosed according WHO weight band tables 19  21
5,PMC3641608,S65,11407,11492,Procedures, Children reviewed every 4  6 weeks nurse using standard symptom checklist
5,PMC3641608,S66,11493,11582,Procedures, Antiretroviral drugs could substituted preferably within class adverse events
5,PMC3641608,S67,11583,11708,Procedures, During four drug induction drug could dropped toxicity drug interactions antituberculosis treatment
5,PMC3641608,S68,11709,12131,Procedures, Switching second line ART including ritonavir boosted protease inhibitor based clinical criteria participants new recurrent WHO stage 4 event 15 WHO stage 3 event events clinician discretion particularly recurrent persistent laboratory criteria routine laboratory monitoring confirmed on ART CD4 15 age 1  2 years 10 3  4 years 100 cells mL years
0,PMC3641608,S69,12132,12165,Procedures, See appendix details
6a,PMC3641608,S70,12174,12358,Procedures, Co primary endpoints monitoring randomisation progression new WHO stage 4 event death efficacy grade 3 4 adverse events solely related HIV safety
6a,PMC3641608,S71,12359,12536,Procedures, Co primary endpoints ART strategy randomisation change CD4 percentage randomisation 72 144 weeks efficacy grade 3 4 adverse events safety
6a,PMC3641608,S72,12537,13113,Procedures, Secondary endpoints randomisations co primary mortality new new recurrent WHO stage 4 event death new new recurrent WHO stage 3 4 event death grade 3 4 adverse events definitely probably uncertainly ART related serious adverse events22 solely HIV related ART modifying adverse events admissions hospital height weight body mass index age CD4 number class antiretrovirals received switch second line regimen adherence viral load resistance done retrospectively see appendix
6a,PMC3641608,S73,13114,13326,Procedures, All WHO stage 3 4 events deaths serious adverse events reviewed prespecified criteria endpoint review committee independent chair members masked randomised allocations
11a,PMC3641608,S73,13114,13326,Procedures, All WHO stage 3 4 events deaths serious adverse events reviewed prespecified criteria endpoint review committee independent chair members masked randomised allocations
7a,PMC3641608,S75,13378,13916,Statistical analysis, 1200 children followed 3  5  5  0 years less 10 loss follow up provided 90 power establish clinically driven monitoring inferior routine laboratory monitoring primary efficacy outcome defined upper 95 confidence limit difference clinically driven minus routine laboratory monitoring rate first new WHO stage 4 event deaths per 100 child years greater 1  6 per 100 child years assumed rate routine laboratory monitoring 2  5 per 100 child years
7a,PMC3641608,S76,13917,14202,Statistical analysis, For ART strategy randomisation 1200 children provided 80 power detect differences change CD4 percentage 2  5 across three groups F test two sided assuming 20 missing data loss follow up missed visit test standard deviation 10 23
7b,PMC3641608,S77,14203,14344,Statistical analysis, Interim data reviewed annually independent data monitoring committee four meetings using Haybittle Peto criterion p 0  001
12a,PMC3641608,S78,14353,14674,Statistical analysis, Randomised groups compared Kaplan Meier plots log rank tests proportional hazards models stratified randomisation stratification factors including factorial time to event disease progression ART adverse event outcomes censoring earlier trial closure last follow up
12a,PMC3641608,S79,14675,14749,Statistical analysis, Categorical variables compared exact indicated tests
12a,PMC3641608,S80,14750,14868,Statistical analysis, Change CD4 percentage compared normal linear regression adjusted randomisation stratification factors
12a,PMC3641608,S81,14869,15095,Statistical analysis, Laboratory measurements adherence compared across randomised groups time generalised estimating equations independent correlation closest measurement scheduled visit within equally spaced windows
0,PMC3641608,S82,15096,15152,Statistical analysis, All comparisons randomised intention to treat
0,PMC3641608,S83,15153,15365,Statistical analysis, Subgroups specified analysis plan factorial randomisations time ART sex age centre CD4 weight age randomisation year previous ART prevention mother to child transmission
0,PMC3641608,S84,15366,15451,Statistical analysis, Baseline values nearest within 42 days randomisation
12a,PMC3641608,S85,15452,15561,Statistical analysis, Z scores determined British reference covers full age range ARROW children 24
12a,PMC3641608,S86,15562,15601,Statistical analysis, All analyses done Stata 12 1
12a,PMC3641608,S87,15602,15629,Statistical analysis, All p values two sided
0,PMC3641608,S91,16058,16161,Role of the funding sources, The corresponding author full access data responsibility submission publication
3a,PMC3668094,S34,4729,4968,Study design and sites, This prospective multicentre double blinded randomised trial standard dose oseltamivir 75 mg twice day paediatric equivalent versus double dose 150 mg twice day paediatric equivalent treating severe influenza
5,PMC3668094,S34,4729,4968,Study design and sites, This prospective multicentre double blinded randomised trial standard dose oseltamivir 75 mg twice day paediatric equivalent versus double dose 150 mg twice day paediatric equivalent treating severe influenza
4b,PMC3668094,S35,4969,5090,Study design and sites, The study took place April 2007 February 2010 13 hospitals Indonesia Singapore Thailand Vietnam
4a,PMC3668094,S37,5134,5368,Participants, The inclusion criteria age year respiratory illness duration symptoms days laboratory confirmed influenza either evidence severe influenza defined positive result diagnostic test H5N1
4a,PMC3668094,S38,5369,5650,Participants, Severe influenza defined admission hospital one following new infiltrate chest x ray tachypnoea respiratory rate ages ages 6 11 ages 3 5 ages 1 2 dyspnoea hypoxia arterial oxygen saturation room air
4a,PMC3668094,S39,5651,5944,Participants, Exclusion criteria pregnancy positive chorionic gonadotrophin hCG urine women actively breast feeding delay 72 hours treatment oseltamivir severe renal impairment defined creatinine clearance 10 mL min Cockcroft Gault equation
8a,PMC3668094,S41,5986,6135,Treatment, Patients randomised receive double standard dose oseltamivir based computer generated list stratified site age group
8b,PMC3668094,S41,5986,6135,Treatment, Patients randomised receive double standard dose oseltamivir based computer generated list stratified site age group
5,PMC3668094,S41,5986,6135,Treatment, Patients randomised receive double standard dose oseltamivir based computer generated list stratified site age group
8b,PMC3668094,S42,6136,6192,Treatment, Patients H5N1 influenza stratified separately
5,PMC3668094,S43,6201,6327,Treatment, Oseltamivir capsules paediatric oseltamivir suspensions placebo suspensions provided Roche Basel Switzerland
5,PMC3668094,S44,6328,6477,Treatment, Placebo capsules manufactured pharmaceutical development section National Institutes Health Clinical Center Bethesda MD US
5,PMC3668094,S45,6478,6728,Treatment, The doses 75 mg 150 mg twice daily aged weighing 40 kg 60 mg 120 mg twice daily weighing 23 40 kg 45 mg 90 mg twice daily weighing 15 23 kg 30 mg 60 mg twice daily weighing kg
5,PMC3668094,S46,6729,6821,Treatment, These doses halved patients creatinine clearance 30 mL min 17 19 20
0,PMC3668094,S47,6822,6879,Treatment, All drug treatments supervised research team
5,PMC3668094,S48,6888,6935,Treatment, All patients received five days oseltamivir
5,PMC3668094,S49,6936,7144,Treatment, Those persistent tachypnoea dyspnoea hypoxia day five study defined meeting criteria clinical failure continued take randomised dose additional five days
6a,PMC3668094,S51,7193,7397,Study evaluations, Patients severe influenza like illness screened Quickvue rapid test Quidel San Diego CA US and or reverse transcriptase polymerase chain reaction RT PCR throat nose swabs
0,PMC3668094,S52,7398,7496,Study evaluations, Patients positive results influenza virus met inclusion criteria randomised
6a,PMC3668094,S53,7497,7587,Study evaluations, Swabs obtained virus detection nose throat days 0 10 day 14
0,PMC3668094,S54,7588,7687,Study evaluations, Study swabs collected eluted M4 media Remel Lenexa KS US storage
6a,PMC3668094,S56,7727,7943,Virology, Testing combined nasal throat swab specimens day five primary virological study endpoint done blinded conditions SEAICRN reference laboratories Vietnam Indonesia
11a,PMC3668094,S56,7727,7943,Virology, Testing combined nasal throat swab specimens day five primary virological study endpoint done blinded conditions SEAICRN reference laboratories Vietnam Indonesia
6a,PMC3668094,S57,7944,8095,Virology, Qualitative RT PCR detection influenza A B viruses subtyping influenza A viruses done according WHO US CDC protocols 21 22
6a,PMC3668094,S58,8096,8252,Virology, Quantitative RT PCR influenza virus A B lower limit quantification 103 copies cDNA per mL performed described previously 23
6a,PMC3668094,S59,8253,8484,Virology, Virus culture genotypic screening oseltamivir resistance mutations performed described previously day 0 samples enrolled patients day five samples patients positive results RT PCR 24 25
6a,PMC3668094,S62,8560,8719,Data analysis, The primary efficacy endpoint proportion patients detectable viral RNA RT PCR combined nasal throat swab sample day five
6a,PMC3668094,S63,8720,8908,Data analysis, We also examined numerous secondary clinical endpoints mortality mechanical ventilation admission intensive care symptoms resumption activity virological endpoints
6a,PMC3668094,S64,8909,9177,Data analysis, We chose proportion patients viral RNA shedding day five start treatment primary endpoint represents duration one standard course oseltamivir clinical failure generally evaluated five days treatment
0,PMC3668094,S65,9178,9320,Data analysis, This also consistent 2010 position paper Ison colleagues choice efficacy endpoints severe influenza studies 26
7a,PMC3668094,S67,9384,9622,Data analysis, Based previous studies assumed children adults admitted hospital influenza would detectable virus average 6 3 days plus minus 1 5 days 4 days onset treatment respectively 26 27 28
7a,PMC3668094,S68,9623,9912,Data analysis, If assume 30 children 55 adults treated standard dose oseltamivir would test negative virus day five sample size 242 patients would required show 20 absolute improvement cessation viral shedding 85 power two sided 0 05
7a,PMC3668094,S69,9913,9985,Data analysis, To allow study withdrawals target sample size 300 patients
12a,PMC3668094,S71,10045,10114,Data analysis, Data analysed Stata v10 Stata Corporation Washington DC
0,PMC3668094,S74,10358,10480,Data analysis, Patients died day five assumed virus positive day five unless virus cleared death
12a,PMC3668094,S75,10481,10574,Data analysis, For patients missing results day five carried forward last available results
12a,PMC3668094,S76,10585,10840,Data analysis, We used conditional univariate logistic regression calculate compare odds ratios viral clearance categorical data treatment arms stratified study site Mantel Haenszel method numbers patients small
12b,PMC3668094,S77,10841,10932,Data analysis, The Breslow Day test used test heterogeneity results study sites
12b,PMC3668094,S78,10933,11117,Data analysis, Because found heterogeneity used conditional multiple logistic regression investigate independent predictors viral RNA clearance day five stratified study sites
12b,PMC3668094,S79,11118,11395,Data analysis, In regression models quantifiable viral load data used cDNA copies mL data samples positive qualitative RT PCR quantifiable given value 103 cDNA copies c mL lower limit detection quantitative RT PCR
0,PMC3668094,S80,11396,11462,Data analysis, This analysis repeated giving samples value 0
12b,PMC3668094,S81,11473,11697,Data analysis, For multiple regression forced important variables age group sub type virus treatment arm model factors used forward stepwise variable selection procedure 5 significance
12a,PMC3668094,S82,11698,11865,Data analysis, Normally distributed continuous data compared two arms unpaired test Mann Whitney U Kruskal Wallis tests used skewed data
0,PMC3668094,S83,11866,11930,Data analysis, For comparative analyses P 0 05 considered significant
12a,PMC3668094,S84,11931,11959,Data analysis, All P values two tailed
12a,PMC3668094,S85,11960,12056,Data analysis, Confidence intervals proportions differences calculated Wilson  s method
0,PMC3686261,S35,4966,5043,Study design, Data patients enrolled PREMIER trial9 used analyses
3a,PMC3686261,S36,5044,5439,Study design, PREMIER 2 year active controlled double blind study methotrexate naive patients early progressive RA patients randomly assigned following treatment groups combination treatment subcutaneous adalimumab 40  mg every week oral methotrexate titrated 20  mg week week 8 tolerated adalimumab monotherapy methotrexate monotherapy
5,PMC3686261,S36,5044,5439,Study design, PREMIER 2 year active controlled double blind study methotrexate naive patients early progressive RA patients randomly assigned following treatment groups combination treatment subcutaneous adalimumab 40  mg every week oral methotrexate titrated 20  mg week week 8 tolerated adalimumab monotherapy methotrexate monotherapy
0,PMC3686261,S37,5440,5552,Study design, Employment outcomes assessed large subset patients participated DE032 companion study 19
0,PMC3686261,S38,5553,5764,Study design, All patients provided written informed consent study protocols informed consent forms approved local institutional review boards independent ethics committees participating sites
0,PMC3686261,S39,5765,5884,Study design, The studies conducted accordance principles Declaration Helsinki good clinical practice
4a,PMC3686261,S41,5939,6096,Patient characteristics, Adults aged 18  years older RA diagnosis defined 1987 revised American College Rheumatology criteria 20 eligible enrolment
4a,PMC3686261,S42,6097,6481,Patient characteristics, Patients must satisfied following inclusion criteria disease duration less 3  years eight swollen joints 66 assessed 10 tender joints 68 assessed either erythrocyte sedimentation rate greater 28  mm h C reactive protein CRP concentration 1 5  mg dl greater either rheumatoid factor positivity least one JE
4a,PMC3686261,S43,6482,6744,Patient characteristics, Patients excluded received previous treatment methotrexate cyclophosphamide ciclosporin azathioprine two disease modifying antirheumatic drugs prednisone equivalent greater 10  mg day within 30  days screening
6a,PMC3686261,S45,6837,6978,"Clinical, radiographic, functional and employment assessments", The 28 joint disease activity score CRP DAS28 CRP range 0  10 hereafter referred DAS28 used monitor disease activity 21
6a,PMC3686261,S46,6979,7046,"Clinical, radiographic, functional and employment assessments", DAS28 calculated baseline regular intervals week 104
6a,PMC3686261,S47,7047,7210,"Clinical, radiographic, functional and employment assessments", A time averaged DAS28 TA DAS28 calculated order control intergroup differences speed responses longitudinal fluctuations inflammation
6a,PMC3686261,S48,7211,7375,"Clinical, radiographic, functional and employment assessments", To obtain TA DAS28 areas curve determined time intervals available DAS28 values baseline 52 104  weeks individual patients
6a,PMC3686261,S49,7376,7434,"Clinical, radiographic, functional and employment assessments", Values summed divided total time interval
6a,PMC3686261,S50,7435,7544,"Clinical, radiographic, functional and employment assessments", The distribution TA DAS28 values patients divided tertiles assessment point
6a,PMC3686261,S51,7545,7623,"Clinical, radiographic, functional and employment assessments", Radiographs hands feet taken baseline weeks 52 104
6a,PMC3686261,S52,7624,7851,"Clinical, radiographic, functional and employment assessments", Two readers blinded patient sequence scored radiographs individually bone erosion JE range 0  230 JSN range 0  168 using modified form Sharp scoring method modified total Sharp score mTSS 6 22  24
6a,PMC3686261,S53,7852,7937,"Clinical, radiographic, functional and employment assessments", Physical function evaluated using HAQ DI baseline week 52 week 104 25
6a,PMC3686261,S54,7938,8038,"Clinical, radiographic, functional and employment assessments", Employment status either employed unemployed collected baseline weeks 52 104
6a,PMC3686261,S55,8039,8146,"Clinical, radiographic, functional and employment assessments", At time point patient asked change employment status previous visit
0,PMC3686261,S57,8198,8425,Statistical analysis, Descriptive analyses changes disease activity included observed data patients completed 52 104  weeks treatment one post baseline DAS28 underwent radiography baseline weeks 52 104
0,PMC3686261,S58,8426,8607,Statistical analysis, Analyses relationships HAQ DI JE JSN included observed data patients available HAQ DI radiographic data DAS28 baseline week 52 week 104
0,PMC3686261,S59,8608,8812,Statistical analysis, Analysis relationships employment status JE JSN included observed data patients available employment status radiographic data HAQ DI baseline week 52 week 104
0,PMC3686261,S60,8821,8948,Statistical analysis, Overall mean changes baseline DAS28 calculated weeks 52 104 analysis population treatment group
12a,PMC3686261,S61,8949,9279,Statistical analysis, At weeks 52 104 associations TA DAS28 tertiles changes baseline JE JSN compared patients received ADA MTX combination therapy adalimumab monotherapy methotrexate monotherapy within treatment groups using analysis variance van der Waerden normal scores 26
12a,PMC3686261,S62,9288,9434,Statistical analysis, The relationships HAQ DI JE JSN baseline week 52 week 104 evaluated using quantile non parametric regression models
12b,PMC3686261,S63,9435,9637,Statistical analysis, Each model evaluated relationships HAQ DI either concurrent JE JSN independent variables covariate adjustment concurrent DAS28 baseline disease duration age sex
12a,PMC3686261,S64,9646,9877,Statistical analysis, The relationships employment status JE JSN baseline week 52 week 104 evaluated using logistic regression models covariate adjustment concurrent HAQ DI baseline disease duration age sex
12a,PMC3686261,S65,9878,10167,Statistical analysis, The relationship baseline JE JSN baseline employment status evaluated calculating tertiles JE JSN determining percentages patients tertile employed baseline differences across JE JSN tertiles evaluated
0,PMC3756454,S38,5537,5723,Subjects, The study performed approval local research ethics committee accordance Declaration Helsinki written informed consent participants
4a,PMC3756454,S39,5724,5943,Subjects, Inclusion criteria typical history myocardial ischaemia lasting 20  min within 24  h hospitalisation ischaemic electrocardiographic changes elevated troponin I concentration 0 2   g l
4a,PMC3756454,S40,5944,6152,Subjects, Patients excluded event significant comorbidity including active systemic inflammatory disorders insulin dependent diabetes mellitus use anti inflammatory drugs aspirin
4a,PMC3756454,S41,6153,6356,Subjects, Given immunosuppressive effects etanercept exclusion criteria also included history recent recurrent infection tuberculosis opportunistic infection within previous 6  months
3a,PMC3756454,S43,6400,6608,Study design, In randomised double blind parallel group design patients evaluated two occasions 24  h intravenous administration TNF   antagonist etanercept 10  mg saline placebo
5,PMC3756454,S43,6400,6608,Study design, In randomised double blind parallel group design patients evaluated two occasions 24  h intravenous administration TNF   antagonist etanercept 10  mg saline placebo
0,PMC3756454,S44,6609,6764,Study design, A single subcutaneous 25  mg dose etanercept improves endothelium dependent vasodilatation within 6  h administration patients heart failure 12
5,PMC3756454,S45,6765,6953,Study design, In order achieve rapid onset action elected use intravenous route single intravenous doses 10  mg m2 used safely patients heart failure 15
0,PMC3756454,S46,6954,7066,Study design, Subcutaneous etanercept 23 bioavailability achieves peak plasma concentrations 0 43   g ml 66  h 16
0,PMC3756454,S47,7067,7185,Study design, In contrast single intravenous dose 10  mg etanercept achieves maximum concentration 2 32   g ml 50  min 16
5,PMC3756454,S48,7186,7376,Study design, Given plasma half life approximately 70  h 16 judged 24  h would appropriate time point capture potential beneficial cardiovascular effects intravenous etanercept
8a,PMC3756454,S49,7377,7669,Study design, Randomisation performed computer generated sequence ensure concealment treatment allocation following minimisation age sex time randomisation peak troponin serum cholesterol cardiovascular risk factors including diabetes mellitus hypertension smoking 17
9,PMC3756454,S49,7377,7669,Study design, Randomisation performed computer generated sequence ensure concealment treatment allocation following minimisation age sex time randomisation peak troponin serum cholesterol cardiovascular risk factors including diabetes mellitus hypertension smoking 17
8b,PMC3756454,S49,7377,7669,Study design, Randomisation performed computer generated sequence ensure concealment treatment allocation following minimisation age sex time randomisation peak troponin serum cholesterol cardiovascular risk factors including diabetes mellitus hypertension smoking 17
0,PMC3756454,S50,7670,7774,Study design, Study procedures completed prior invasive angiography percutaneous coronary intervention
6a,PMC3756454,S52,7843,7967,Venous sampling and cytokine analysis, Patients abstained food caffeine containing drinks 4  h 24  h ingestion alcohol prior phlebotomy
6a,PMC3756454,S53,7968,8220,Venous sampling and cytokine analysis, Blood samples obtained 17 gauge cannula careful attention ensure smooth extraction blood avoid artefactual platelet activation ex vivo anticoagulated D phenylalanyl L propyl L arginine chloromethyl ketone PPACK
6a,PMC3756454,S54,8221,8508,Venous sampling and cytokine analysis, During vasomotor assessments venous blood withdrawn simultaneously arm collected tubes containing acidified buffered citrate t PA assays trisodium citrate plasminogen activator inhibitor type 1 PAI 1 assays potassium EDTA cytokine assays
6a,PMC3756454,S55,8509,8715,Venous sampling and cytokine analysis, Citrate acidified buffered citrate samples centrifuged 2000  g 30  min 4  C EDTA samples 1000  g 10  min 20  C Platelet free plasma decanted stored 80  C assay
6a,PMC3756454,S56,8716,8988,Venous sampling and cytokine analysis, Plasma TNF   IL 6 concentrations determined described previously18 using ELISA Quantikine human TNF IL 6 immunoassays R D Systems Dako A S respectively fibrinolytic activities using photometric method Coatest t PA PAI 1 Chomogenix AB
6a,PMC3756454,S57,8989,9091,Venous sampling and cytokine analysis, Haematocrit white cell count determined using automated Coulter counter Beckman Coulter
6a,PMC3756454,S59,9143,9259,Vasomotor assessment, Assessment vasomotor function response intra arterial vasodilators performed described previously 19
6a,PMC3756454,S60,9260,9390,Vasomotor assessment, Briefly studies performed quiet temperature controlled environment patient supine position throughout
6a,PMC3756454,S61,9391,9593,Vasomotor assessment, Venous 17 gauge cannulae inserted forearm blood sampling 27 standard wire gauge steel needle placed brachial artery non dominant forearm vasodilator infusions
6a,PMC3756454,S62,9594,9911,Vasomotor assessment, A baseline 30  min intra arterial infusion saline followed intra arterial infusion substance P 2 4 8  pmol min acetylcholine 5 10 20   g min finally sodium nitroprusside 2 4 8   g min infused 10  min dose agonist separated 20  min saline infusion
6a,PMC3756454,S63,9912,10043,Vasomotor assessment, Forearm blood flow measured arms venous occlusion plethysmography use mercury in silastic strain gauges
6a,PMC3756454,S64,10044,10213,Vasomotor assessment, Heart rate blood pressure non infused arm monitored intervals throughout use semiautomated non invasive oscillometric sphygmomanometer
6a,PMC3756454,S66,10278,10359,Immunostaining and flow cytometry, All reagents obtained AbD Serotec Oxford UK unless otherwise stated
6a,PMC3756454,S67,10360,10530,Immunostaining and flow cytometry, The following antibodies used IgG1 FITC CD14 PE CD42a FITC IgG2a PE CD62P PE IgG1 PE eBioscience Ltd UK CD14 RPE IgG1 RPE DakoCytomation Denmark
6a,PMC3756454,S68,10531,10581,Immunostaining and flow cytometry, All antibodies diluted 1 20 flow buffer
6a,PMC3756454,S69,10582,10640,Immunostaining and flow cytometry, FACS Lyse obtained Becton Dickinson Cowley UK
6a,PMC3756454,S70,10641,10805,Immunostaining and flow cytometry, Blood anticoagulated PPACK labelled appropriate antibodies exactly 5  min collection incubated dark 20  min room temperature
6a,PMC3756454,S71,10806,10926,Immunostaining and flow cytometry, Immunolabelling performed whole blood avoid artefactual platelet activation caused purification procedures
6a,PMC3756454,S72,10927,11073,Immunostaining and flow cytometry, Samples fixed run FACSCalibur Becton Dickinson flow cytometer within 2  h fixing using established flow protocol 20
6a,PMC3756454,S73,11074,11163,Immunostaining and flow cytometry, For determination PMA total 3000 events collected CD14 monocyte gate
6a,PMC3756454,S74,11164,11250,Immunostaining and flow cytometry, For platelet expression P selectin 7500 events collected platelet gate
12a,PMC3756454,S76,11311,11405,Data and statistical analysis, Cytometric data analysis performed FlowJo V 7 2 5 Flow Cytometry Analysis Software
12a,PMC3756454,S77,11406,11764,Data and statistical analysis, Plethysmographic data net t PA release determined described previously 19 21 product infused forearm plasma based mean haematocrit infused FBF concentration difference infused t PA inf non infused t PA non inf arms estimated net t PA release FBF  1  Hct   tPA inf  tPA non inf
12a,PMC3756454,S78,11765,11812,Data and statistical analysis, Continuous variables reported means  SEM
12a,PMC3756454,S79,11813,11959,Data and statistical analysis, Analysis variance repeated measures two tailed Student test performed appropriate use GraphPad Prism software
6a,PMC3756454,S80,11960,11996,Data and statistical analysis, The primary outcome measure PMA
7a,PMC3756454,S81,11997,12302,Data and statistical analysis, On basis previous work examining effect clopidogrel PMA22 estimated 5 absolute change PMA would clinical significance least 12 paired samples would provide 80 power detect 10 absolute difference PMA baseline significance level 5
3a,PMC3944682,S33,5231,5469,Summary of study design and trial groups, This study pragmatic open factorial trial delayed antibiotic strategies controlling symptomatic advice regarding analgesia steam parallel observational component patients judged need immediate antibiotics
0,PMC3944682,S34,5479,5635,Summary of study design and trial groups, Health professionals mainly doctors also practice nurses decided negotiation patients whether immediate antibiotics needed
5,PMC3944682,S35,5636,5888,Summary of study design and trial groups, If antibiotics needed patients randomised one four delayed prescribing groups recontact prescription post dated prescription collection prescription patient led patient given prescription
0,PMC3944682,S39,6090,6136,Summary of study design and trial groups, Numbers based general practitioner reports
8b,PMC3944682,S40,6145,6224,Summary of study design and trial groups, Each group randomised 12 subgroups according three factors
8b,PMC3944682,S41,6225,6424,Summary of study design and trial groups, These factors antipyretic regimens ibuprofen paracetamol combined regular antipyretic versus required  dosing steam inhalation advice versus advice inhale steam
0,PMC3944682,S42,6425,6521,Summary of study design and trial groups, The web figure uses example group prescription illustrate randomisation process
3b,PMC3944682,S43,6522,6702,Summary of study design and trial groups, During trial January 2011 strategy antibiotic prescription added randomised comparison bringing total number randomised groups five fig 1
0,PMC3944682,S46,6793,6998,Summary of rationales, We chose factorial design analgesic steam components deal management symptoms antibiotic component particularly deal antibiotic use beliefs antibiotics
0,PMC3944682,S47,6999,7234,Summary of rationales, The factorial design efficient assessing multiple interventions also provides better control symptomatic advice regarding analgesia steam could plausibly affect symptom control antibiotic groups
0,PMC3944682,S48,7245,7383,Summary of rationales, A non randomised immediate prescription group chosen allow patients enter study provide two important opportunities
0,PMC3944682,S49,7384,7577,Summary of rationales, Firstly observe often immediate antibiotics thought necessary clinicians secondly able compare patient outcomes prescribed prescribed antibiotics
3b,PMC3944682,S50,7588,7739,Summary of rationales, During study became clear systematic reviews delayed prescribing might result higher antibiotic use initial prescription 8
3b,PMC3944682,S51,7740,8030,Summary of rationales, We therefore added prescription group facilitate interpretation effect delayed prescription compared alternatives strategies particularly delayed prescription groups current study higher antibiotic use previous studies
8a,PMC3944682,S53,8083,8198,Summary of rationales, A statistician independent study team coordinated randomisation using computer generated random numbers
10,PMC3944682,S53,8083,8198,Summary of rationales, A statistician independent study team coordinated randomisation using computer generated random numbers
10,PMC3944682,S54,8199,8395,Summary of rationales, If doctor thought immediate antibiotics definitely required prescribed antibiotics otherwise patients randomised one four methods delayed antibiotic prescribing
10,PMC3944682,S55,8396,8615,Summary of rationales, We assessed evidence subversion randomisation monitoring order use envelopes evidence selective envelope use baseline table showed groups well balanced
0,PMC3944682,S56,8626,8768,Summary of rationales, A key concern complex pragmatic factorial trials keeping logistics simple avoiding errors point intervention delivery
9,PMC3944682,S57,8769,9041,Summary of rationales, We made simple execute randomisation delivery health professional took next pack shelf contained pre randomised advice sheets requirement  and hence error  in finding using correct advice sheets
0,PMC3944682,S58,9042,9201,Summary of rationales, With careful attention practitioner equipoise method randomisation different advice strategies proved successful previous trials 11 13 14
0,PMC3944682,S59,9202,9328,Summary of rationales, There evidence subversion current study  either selective envelope use bias patient characteristics
4a,PMC3944682,S61,9400,9520,Summary of rationales, The study included patients aged 3 years presenting health professional general practitioner nurse
4a,PMC3944682,S62,9521,9754,Summary of rationales, Patients present general practice setting respiratory tract infection diagnosed health professional acute cold influenza sore throat otitis media sinusitis croup lower respiratory tract infection
0,PMC3944682,S63,9755,9801,Summary of rationales, Patient parental written consent given
4a,PMC3944682,S64,9812,10129,Summary of rationales, Patients excluded asthmatic unless ibuprofen aspirin previously provided problems active previous peptic ulceration hypersensitive analgesics unable complete outcome measures example visually impaired psychosis severely depressed
4a,PMC3944682,S65,10130,10346,Summary of rationales, Exclusion also applied patients required hospital admission example meningitis severe pneumonia epiglottitis Kawasaki disease known immune deficiency pregnant breastfeeding
6a,PMC3944682,S67,10395,10595,Outcomes, The primary outcome symptom severity measured end day days 2 4 two week symptom diary days 2 4 symptoms respiratory infections worst11 14
0,PMC3944682,S68,10596,10741,Outcomes, We chose symptom severity key outcome recent systematic review documented worse symptom control delayed prescription 8
6a,PMC3944682,S69,10742,10826,Outcomes, The diary completed patients children symptoms returned normal
6a,PMC3944682,S70,10827,10929,Outcomes, It used previously validated formats11 15 rating symptoms 0 no problem 6 as bad could
6a,PMC3944682,S71,10930,11131,Outcomes, Symptoms included feeling generally unwell sleep disturbance fever interference normal activities sore throat cough short breath facial sinus pain earache runny blocked nose
6a,PMC3944682,S72,11132,11251,Outcomes, Symptom resolution secondary outcome duration differs according particular respiratory infection 7
6a,PMC3944682,S73,11260,11347,Outcomes, Patients telephoned days 2 3 check problems diary completion
5,PMC3944682,S74,11348,11549,Outcomes, If diary received two weeks one mailed reminder sent phone call made necessary document key outcomes using brief questionnaire  which shown reliable 13
0,PMC3944682,S75,11558,11582,Outcomes, Secondary outcomes
6a,PMC3944682,S76,11615,11721,Outcomes, Any antibiotic use 14 days recruitment documented diary brief questionnaire
6a,PMC3944682,S77,11756,11839,Outcomes, Side effects rash diarrhoea vomiting abdominal pain documented diary
6a,PMC3944682,S78,11874,11978,Outcomes, Mean temperature readings morning evening using tempadot thermometers orally possible
6a,PMC3944682,S79,12013,12064,Outcomes, Duration symptoms rated moderately bad worse
6a,PMC3944682,S80,12099,12328,Outcomes, Return new worsening symptoms complications intervention  that patient returning symptom diagnosis respiratory tract infection recorded using structured proforma member research team
6a,PMC3944682,S81,12329,12513,Outcomes, Complications defined new consultation documented notes within one month otitis media sinusitis pneumonia quinsy cervical adenitis meningitis septicaemia
6a,PMC3944682,S82,12548,12674,Outcomes, Belief effectiveness antibiotics satisfaction measured main diary using previously developed questions13
6a,PMC3944682,S83,12703,12924,Outcomes, General practitioners asked complete non recruitment logs questionnaire end study documenting common reasons non recruitment eligible patients eligible patients declined
7a,PMC3944682,S85,12980,13114,Sample size calculation , We calculated sample size based value 0 05 value 0 2 using NQuery program multiple group sample sizes
7a,PMC3944682,S86,13115,13242,Sample size calculation , There two elements calculation firstly symptom control primary outcome secondly antibiotic use
7a,PMC3944682,S87,13243,13314,Sample size calculation , We assumed standard deviation 1 1 primary outcome 11 13 15
7a,PMC3944682,S88,13315,13585,Sample size calculation , Assuming one analgesic group symptom control 0 5 standard deviations better one groups moderate effect size 228 patients needed allow 12 groups 80 follow up 504 patients 0 33 standard deviations
7a,PMC3944682,S89,13586,13838,Sample size calculation , This effect size equivalent one three people rating symptoms mild rather moderate agreed modest effect size trial steering committee Medical Research Council funded trial prescribing strategies acute cough11
6a,PMC3944682,S90,13848,14060,Sample size calculation , For antibiotic outcome antibiotic strategies key outcome component study compared difference antibiotic use delayed strategies antibiotic prescription
7a,PMC3944682,S91,14061,14215,Sample size calculation , Seventy two patients per group 450 total needed groups prescription delayed prescription allowing 20 loss follow up
7a,PMC3944682,S92,14216,14437,Sample size calculation , These numbers also assumed 15 use antibiotics antibiotic group 20 35 use delayed prescription groups 20 25 35 35 recontact post date collection patient led respectively
7a,PMC3944682,S93,14438,14637,Sample size calculation , We estimated 72 patients per group would provide 80 power detect difference 0 5 standard deviations symptom control delayed prescription groups prescription group
12a,PMC3944682,S95,14677,14801,Analysis, We performed analysis randomised groups secondary analysis included non randomised immediate group
12a,PMC3944682,S96,14802,14984,Analysis, We used analysis covariance factorial study main continuous outcomes controlling stratification analgesic steam strategies confounders appropriate
12b,PMC3944682,S96,14802,14984,Analysis, We used analysis covariance factorial study main continuous outcomes controlling stratification analgesic steam strategies confounders appropriate
12a,PMC3944682,S97,14985,15117,Analysis, Logistic regression used antibiotic use return surgery Cox regression used duration symptoms
12a,PMC3944682,S98,15118,15186,Analysis, Odds ratios converted risk ratios using standard formulas 16
12a,PMC3944682,S99,15187,15291,Analysis, The effect antibiotic strategies interactions assessed using likelihood ratio test
0,PMC3944682,S100,15292,15574,Analysis, The likelihood ratio test particularly useful assessing effect variables multiple levels example delayed prescribing factor five levels provides overall test whether variable makes significant difference statistical model
12a,PMC3944682,S101,15575,15887,Analysis, Analysis intention treat practitioners patients analysed intended randomisation groups whether complied impute missing values interim analysis clinical subgroups antibiotic prescribing strategies specified advance
7b,PMC3944682,S101,15575,15887,Analysis, Analysis intention treat practitioners patients analysed intended randomisation groups whether complied impute missing values interim analysis clinical subgroups antibiotic prescribing strategies specified advance
3a,PMC4066691,S42,6598,6770,Methods, This Phase II randomised double blind placebo controlled crossover study investigate efficacy safety three doses once daily tiotropium Respimat 
4b,PMC4066691,S43,6771,7079,Methods, The study conducted 19 sites three European countries Germany Austria Ukraine ClinicalTrials gov identifier NCT01233284 carried accordance principles Declaration Helsinki International Conference Harmonisation Good Clinical Practice Guidelines
0,PMC4066691,S44,7080,7128,Methods, All patients provided written informed consent
5,PMC4066691,S46,7165,7453,Study design, After initial screening visit 4 week run in period patients randomised one four treatment sequences received four treatments tiotropium 5   g 2 5   g 1 25   g placebo delivered via Respimat  SoftMist  inhaler Figure  1
3a,PMC4066691,S46,7165,7453,Study design, After initial screening visit 4 week run in period patients randomised one four treatment sequences received four treatments tiotropium 5   g 2 5   g 1 25   g placebo delivered via Respimat  SoftMist  inhaler Figure  1
5,PMC4066691,S47,7454,7685,Study design, Each treatment administered 4  weeks washout treatment periods pharmacodynamic steady state tiotropium known achieved 3  weeks chronic obstructive pulmonary disease 13 14
0,PMC4066691,S48,7686,7972,Study design, Seven clinic visits scheduled screening Visit 0 prior 4 week run in Visit 1 randomisation 4 week run in Visit 2 every 4  weeks end treatment period Visits 3  6 21  days following end final treatment period Visit 7
3a,PMC4066691,S49,7982,8004,Study design, Figure 1 Study design
5,PMC4066691,S50,8014,8147,Study design, Tiotropium Respimat  two puffs placebo Respimat  two puffs administered daily evening 18 00 20 00
5,PMC4066691,S51,8148,8331,Study design, All patients required continue maintenance treatment stable medium dose ICS 400  800   g budesonide equivalent least 4  weeks prior Visit 1 Visit 7
5,PMC4066691,S52,8332,8524,Study design, Patients using ICS plus short acting ICS    LABA fixed dose combinations switched dose ICS mono product least 8 24  hours respectively prior Visit 1
5,PMC4066691,S53,8525,8631,Study design, Study medication taken immediately ICS inhalation normal ICS dosing evening
5,PMC4066691,S54,8632,8987,Study design, Concomitant use following permitted maintenance treatment systemic oral depot corticosteroids anticholinergics tiotropium LABAs ICS plus short acting ICS    LABA fixed dose combinations leukotriene modifiers anti immunoglobulin E treatment chromone methylxanthines phosphodiesterase 4 inhibitors
5,PMC4066691,S55,8988,9105,Study design, Salbutamol hydrofluoroalkane metered dose inhaler provided sponsor rescue medication use needed
5,PMC4066691,S56,9106,9303,Study design, Permitted medication treatment acute asthma exacerbations included salbutamol hydrofluoroalkane metered dose inhaler systemic corticosteroids short acting theophylline preparations
5,PMC4066691,S58,9347,9384,Study design, Each patient received treatments
0,PMC4066691,S59,9385,9489,Study design, Eligible patients randomly allocated one four treatment sequences Visit 2 Figure  1
8a,PMC4066691,S60,9490,9680,Study design, The randomisation list generated Boehringer Ingelheim Pharma GmbH  Co KG Biberach der Riss Germany using validated pseudo random number generator supplied seed number
8b,PMC4066691,S61,9681,9783,Study design, A fixed block randomisation block size 4 used ensure balanced equal assignment
4a,PMC4066691,S63,9838,10042,Study patients, Male female patients aged 18  75 years least 3 month history asthma time enrolment initial diagnosis asthma made age 40  years included study
4a,PMC4066691,S64,10043,10286,Study patients, Patients required maintenance treatment stable medium dose ICS 400  800   g budesonide equivalent alone fixed dose combination LABA short acting least 4  weeks prior Visit 1
4a,PMC4066691,S65,10287,10438,Study patients, A diagnosis asthma confirmed Visit 1 required bronchodilator reversibility 15  30 minutes 400   g salbutamol
4a,PMC4066691,S66,10439,10729,Study patients, Patients required seven question Asthma Control Questionnaire ACQ 7 mean score Visits 1 2 pre bronchodilator FEV1 predicted normal FEV1 Visit 1 demonstrate absolute FEV1 variability within 30 Visits 1 2
4a,PMC4066691,S67,10730,10907,Study patients, Patients required never smoked ex smokers stopped smoking least 1  year prior enrolment smoking history less 10 pack years
4a,PMC4066691,S68,10908,11285,Study patients, Patients excluded following reasons diagnosis chronic obstructive pulmonary disease respiratory disease asthma myocardial infarction within last 6  months hospitalisation due cardiac failure unstable cardiac arrhythmia within past year treatment anti immunoglobulin E antibodies within 6  months prior Visit 1
6a,PMC4066691,S70,11333,11542,Study end points, All end points determined end 4 week treatment period Visits 3  6 analysed response defined change study baseline pre treatment value measured Visit 2 evening
6a,PMC4066691,S71,11543,11653,Study end points, The primary efficacy end point peak FEV1 measured within first 3  hours dosing peak FEV1 0 3h
6a,PMC4066691,S72,11654,12095,Study end points, The following secondary efficacy end points investigated trough FEV1 peak forced vital capacity FVC within first 3 hours dosing FVC 0 3h trough FVC FEV1 area curve AUC within first 3  hours dosing FEV1 AUC 0 3h FVC AUC 0 3h pre dose PEFam PEFpm using Asthma Monitor2 device AM2   ERT Philadelphia Pennsylvania USA based mean final week treatment period
6a,PMC4066691,S73,12096,12238,Study end points, Control asthma assessed ACQ 7 self administered end 4 week treatment period additional exploratory end point
6a,PMC4066691,S74,12239,12363,Study end points, Safety tolerability assessed based incidence intensity adverse events changes vital signs
6a,PMC4066691,S76,12412,12496,Study assessments, Spirometric lung function tests conducted in clinic visits Visits 1  6
6a,PMC4066691,S77,12497,12565,Study assessments, Pre dose lung function tests scheduled 18 00 20 00
6a,PMC4066691,S78,12566,12686,Study assessments, At Visits 2  6 lung function tests performed 10  minutes prior 3  hours dosing study treatment
6a,PMC4066691,S79,12687,12758,Study assessments, ACQ 7 self administered Visits 1  6 prior lung function tests
6a,PMC4066691,S80,12759,12960,Study assessments, Measurement PEFam PEFpm performed prior ICS study treatment inhalation approximately time day 06 00 08 00 PEFam 18 00 20 00 PEFpm
6a,PMC4066691,S81,12961,13067,Study assessments, Adverse events concomitant medications recorded electronic case report form visit
6a,PMC4066691,S82,13068,13161,Study assessments, Vital signs measured recorded conjunction lung function tests Visits 2  6
0,PMC4066691,S84,13213,13489,Statistical analyses, Efficacy data reported full analysis set defined randomised patients treated least one dose study medication baseline data least one on treatment efficacy measurement 4  weeks treatment within period
0,PMC4066691,S85,13490,13620,Statistical analyses, Data presented adjusted mean change baseline 4  weeks treatment defined response unless noted otherwise
0,PMC4066691,S86,13629,13787,Statistical analyses, Evaluation safety tolerability performed treated set defined randomised patients received least one dose study medication
0,PMC4066691,S87,13788,13857,Statistical analyses, Analysis adverse events vital signs descriptive nature
12a,PMC4066691,S88,13866,14103,Statistical analyses, To control probability type I error primary efficacy analysis stepwise testing null hypothesis used test efficacy tiotropium Respimat  5   g 2 5   g 1 25   g placebo Respimat 
0,PMC4066691,S89,14104,14207,Statistical analyses, If previous step successful analysis current step considered descriptive
7a,PMC4066691,S90,14208,14390,Statistical analyses, To detect treatment difference 80  mL peak FEV1 0 3h 90 power assuming standard deviation 228  mL calculated 88 completed patients required
12a,PMC4066691,S91,14391,14440,Statistical analyses, Testing performed one sided
12a,PMC4066691,S92,14449,14541,Statistical analyses, The pre specified hypotheses tested using mixed effects model repeated measures
12a,PMC4066691,S93,14542,14648,Statistical analyses, The statistical model included fixed effects random effect
12a,PMC4066691,S94,14649,14759,Statistical analyses, Study baseline defined pre treatment values measured Visit 2 evening included covariate
0,PMC4066691,S166,25065,25092,Supplementary Material, Additional file 1 Table S1
0,PMC4066691,S167,25103,25213,Supplementary Material, Adjusted mean differences lung function ACQ 7 score tiotropium Respimat  placebo Respimat 
0,PMC4066691,S168,25255,25274,Supplementary Material, Click file
4a,PMC4085478,S46,4856,5765,METHODS, Inclusion criteria follows proven mesalazine refractory ulcerative colitis European consensus definition 16 inadequate response mesalazine 6 weeks dose 4 weeks documented intolerance mesalazine documented intolerance required previous doctors letters medical notes stated adverse event possibly related mesalazine led discontinuation therapy active disease blood stool least 6 weeks SCCAI SCCAI subscore stool  baseline visit V2 comedication allowed stable dose 4 weeks e g 5 ASA systemic acting steroids taken weeks start study azathioprine 2  2 5  mg kg 6 mercaptopurine 1  1 5  mg kg taken months negative pregnancy test V1 V2 plus use adequate contraception applicable
4a,PMC4085478,S47,5766,6552,METHODS, Exclusion criteria follows toxic megacolon fulminant courses therapy cyclosporine tacrolimus methotrexate TNF   antagonists within 3 months study entry current treatment opiates loperamide current antibiotic treatment rectal applications aminosalicylates steroids budesonide oral application topically acting steroids ulcerative proctitis disease extent 10  cm inflammatory bleeding disorders gastrointestinal tract UC diseases may cause diarrhea gastrointestinal bleeding condition surgery colon uncontrolled systemic diseases e g cardiac renal pulmonary hepatic severe chronic diseases e g malignancies HIV infection pregnant nursing women
0,PMC4085478,S48,6553,6610,METHODS, 5 ASA 5 aminosalicylic acid AE adverse event Discont
0,PMC4085478,S49,6611,6788,METHODS, Intervent discontinued intervention INR international normalized ratio SCCAI Simple Clinical Colitis Activity Index TNF   tumor necrosis factor   UC ulcerative colitis
7a,PMC4085478,S50,6790,6906,METHODS, We calculated 160 patients mesalazine refractory UC screening phase order randomize 144 patients
7b,PMC4085478,S51,6907,7002,METHODS, A planned interim analysis included possibility increasing sample size necessary
4a,PMC4085478,S52,7003,7394,METHODS, The main inclusion criteria follows active disease Simple Clinical Colitis Activity Index SCCAI subscore stool  baseline history bloody diarrhea least 6 weeks inclusion despite mesalazine treatment dose documented intolerance mesalazine details criteria see legend Figure 1
5,PMC4085478,S53,7395,7507,METHODS, Patients required maintain stable comedication throughout study steroid tapering allowed
0,PMC4085478,S54,7508,7581,METHODS, UC defined accordance European consensus conference 21
4b,PMC4085478,S55,7582,7663,METHODS, Recruitment took place 24 referral centers Germany Lithuania Romania
8a,PMC4085478,S56,7664,7822,METHODS, The Contract Research Organization CRO produced computer generated randomization lists every study center allocation 1 1 1 1 blocks 4
8b,PMC4085478,S56,7664,7822,METHODS, The Contract Research Organization CRO produced computer generated randomization lists every study center allocation 1 1 1 1 blocks 4
10,PMC4085478,S56,7664,7822,METHODS, The Contract Research Organization CRO produced computer generated randomization lists every study center allocation 1 1 1 1 blocks 4
9,PMC4085478,S57,7823,7996,METHODS, The study interventions consisting three different doses LT 02 0 8 1 6 3 2  g tested placebo provided sequentially numbered containers
5,PMC4085478,S57,7823,7996,METHODS, The study interventions consisting three different doses LT 02 0 8 1 6 3 2  g tested placebo provided sequentially numbered containers
0,PMC4085478,S58,7997,8073,METHODS, Doses selected based results previous studies 18 19 20
5,PMC4085478,S59,8074,8162,METHODS, The study medication provided sachets pellets taken orally four times daily
5,PMC4085478,S60,8163,8280,METHODS, The study medication produced packed labeled according Good Manufacturing Practice stored 2  8    C
0,PMC4085478,S61,8287,8442,METHODS, Patients interviewed examined screened eligibility screening visit V1 inclusion exclusion criteria see legend Figure 1
0,PMC4085478,S62,8443,8635,METHODS, Patients included received detailed study information gave written informed consent instructed completing study diary comprising SCCAI interview parameters
0,PMC4085478,S63,8636,8764,METHODS, Stool samples taken exclude infectious enterocolitis including Clostridium difficile Escherichia coli 0157 H7
6a,PMC4085478,S64,8765,8909,METHODS, If patient still eligible 1 week screening V2 baseline safety lab taken sigmoidoscopy colonoscopy performed
7b,PMC4085478,S65,8910,9068,METHODS, At interim visits 2 6 weeks baseline V3 V4 possible disease exacerbation changes medication adverse events AEs assessed
6a,PMC4085478,S66,9069,9233,METHODS, The treatment period ended 12 weeks baseline V5 involved interview physical examination sigmoidoscopy safety lab SCCAI assessment
6a,PMC4085478,S67,9234,9525,METHODS, The maximal duration study 21 weeks per patient 1 week screening period plus 12 weeks treatment period patients reaching partial complete remission SCCAI 5 end treatment underwent additional 8 week follow up without study medication see Appendix Figure A1
0,PMC4085478,S68,9532,9596,METHODS, Patients could discontinue study time without reason
0,PMC4085478,S69,9597,9722,METHODS, The investigator could withdraw patient case AEs disease exacerbation therapeutic intervention required
7b,PMC4085478,S70,9723,9945,METHODS, Discontinuation criteria development complications pseudomembranous colitis SCCAI increase baseline fever 39    C Discontinuation disease exacerbation defined AE
0,PMC4085478,S71,9946,10067,METHODS, Patients discontinued study early qualified discontinuation  resulted final study visit
0,PMC4085478,S72,10068,10095,METHODS, Dropouts replaced
0,PMC4085478,S73,10102,10188,METHODS, Patients compliance monitored returned sachets diary entries interviews
0,PMC4085478,S74,10189,10278,METHODS, The central ethics committees approved study protocol participating countries
0,PMC4085478,S75,10279,10344,METHODS, No changes study methods made study initiation
0,PMC4085478,S77,10393,10523,Precautions against bias, To avoid selection bias patients fulfilled criteria included study predefined randomized order
11b,PMC4085478,S78,10524,10614,Precautions against bias, Pellets sachets containers completely indistinguishable treatment arms
11a,PMC4085478,S79,10615,10747,Precautions against bias, Both patients study personnel remained blinded unaware allocation method throughout study database closure
11a,PMC4085478,S80,10748,10886,Precautions against bias, It possible patients investigators guess next allocated medication order avoid selection allocation biases
12a,PMC4085478,S81,10887,11201,Precautions against bias, To avoid attrition bias handled incomplete data conservative manner patients premature treatment termination included final analyses last available data last observation carried forward LOCF possible LT 02 treatment effect rather reduced increased
0,PMC4085478,S82,11202,11450,Precautions against bias, More placebo patients may stopped treatment owing lack efficacy reasons unlikely results would improved treatment continued carrying forward last value appeared conservative
0,PMC4085478,S84,11515,11666,Precautions against bias, Individuals possible conflict interest neither allowed recruit patients involved conduct analyses study
0,PMC4085478,S85,11667,11755,Precautions against bias, There changes study methods outcome parameters study initiation
0,PMC4085478,S86,11756,11844,Precautions against bias, All authors access study data reviewed approved manuscript
0,PMC4085478,S88,11884,12056,Outcomes, The disease activity assessed using SCCAI 22 validated proven correlate well indices comprising invasive methods 23 24 25 26
6a,PMC4085478,S89,12057,12125,Outcomes, The primary end point changes SCCAI baseline V2 V5
0,PMC4085478,S90,12126,12297,Outcomes, The SCCAI assesses stool frequency day night defecation urgency blood stool general well being abdominal pain extraintestinal manifestations
0,PMC4085478,S91,12298,12387,Outcomes, The score ranges 0 19 points  the lower score lower disease activity
6a,PMC4085478,S92,12396,12942,Outcomes, We assessed following secondary priori defined end points exploratory sense complete remission 3 mean SCCAI 26 stool  subscore 0 see European Crohn s Colitis Organization ECCO definition remission 21 LOCF partial remission SCCAI 5 LOCF clinical response SCCAI decrease 26 mucosal healing endoscopic Mayo Score EMS achievement mucosal healing EMS V5 improvement EMS V2 V5 patients complete remission frequency  subscore 0
6a,PMC4085478,S93,12943,13042,Outcomes, All SCCAI based end points refer patient s mean values 1 week rounded integer numbers
6a,PMC4085478,S94,13043,13152,Outcomes, Time symptom resolution defined first 3 days stools per day without visible blood 21
6a,PMC4085478,S95,13161,13476,Outcomes, The EMS categorized follows 0 inactive 1 mild disease erythema decreased vascular pattern minimal granularity 2 moderate disease marked erythema friability granularity absent vascular pattern bleeding minimal trauma ulcerations 3 severe disease ulceration spontaneous bleeding
6a,PMC4085478,S96,13477,13653,Outcomes, The histologic index Riley ranges 1 representing remission 4 representing severe colitis central pathologist blinded groups assessed score
7a,PMC4085478,S98,13695,13854,Statistics, Data dose finding study 19 showed relative effect size SCCAI could expected 3 2  g dose group compared placebo
7a,PMC4085478,S99,13855,14070,Statistics, Under parametric assumptions t test 30 patients per group needed detect difference relative effect size 0 8 placebo active group power 85 one sided
7a,PMC4085478,S100,14071,14236,Statistics, The sample size increased 30 36 patients per group accommodate nonresponse loss follow up deviations planned study conditions
0,PMC4085478,S101,14237,14404,Statistics, We also included dose groups 0 8 1 6  g LT 02 allow dose finding dose response analyses drug LT 02 new tested studies
0,PMC4085478,S102,14413,14524,Statistics, Primary analysis based full analysis set intention treat included randomized patients
12a,PMC4085478,S103,14525,14630,Statistics, If patient missing value final visit V5 latest available value carried forward
12a,PMC4085478,S104,14631,14823,Statistics, Analysis covariance used model primary end point including following baseline covariates mean SCCAI past 7 days screening period ii disease extent
12a,PMC4085478,S105,14824,14932,Statistics, The model including two covariates treatment group effect considered core model
0,PMC4085478,S106,14933,15142,Statistics, It used compare effects placebo individual dose groups fixed sequence starting highest dose group 3 2  g LT 02 daily followed lower dose groups descending order
12a,PMC4085478,S107,15143,15323,Statistics, The confirmatory testing procedure stopped first nonsignificant result superiority given one sided P value 0 025 equivalent two sided level 0 05
12a,PMC4085478,S108,15332,15470,Statistics, Survival methods used analyze time to event variables log rank test compared time event curves treatment groups
12a,PMC4085478,S109,15471,15620,Statistics, likelihood ratio tests based nominal logistic regression planned compare results qualitative variables treatment groups
12a,PMC4085478,S110,15621,15815,Statistics, The analysis plan specify groups compared order increase statistical power focused comparisons placebo three active groups pooled
0,PMC4085478,S111,15824,15956,Statistics, The statistical power detect treatment effects categorical parameters small sample size far usual 80  90
0,PMC4085478,S112,15957,16218,Statistics, This defined categorical variables rate remission mucosal healing priori secondary exploratory order discover trends treatment effects gather information sample size calculation future phase III studies
12a,PMC4085478,S113,16227,16317,Statistics, Linearity checked important continuous variables compared log transformation
12a,PMC4085478,S114,16318,16406,Statistics, Normality continuous parameters assumed absolute value skewness was 1
12a,PMC4085478,S115,16407,16472,Statistics, In addition Shapiro  Wilk goodness of fit tests applied
7b,PMC4085478,S116,16481,16703,Statistics, A planned interim analysis conducted independent data monitoring committee half patients terminated treatment period adjust sample size stop trial futility indicated
7a,PMC4085478,S117,16712,16873,Statistics, Software sample size estimation included nQuery Advisor V5 0 Statistical Solutions Ltd Cork Ireland StudySize V2 0 CREOSTAT HB V Frolunda Sweden
12a,PMC4085478,S118,16874,16989,Statistics, Statistical analyses performed using SAS JMP V9 SAS JMP V8 higher JMP SAS Institute Inc Cary NC
3a,PMC4145439,S40,4544,4886,Study design, This 12 week Phase IIb dose ranging double blind placebo PBO active controlled multicenter randomised study NCT01242488 conducted November 2010 June 2012 evaluate efficacy safety subcutaneous OKZ patients moderately severely active RA previously failed TNF inhibitor therapy
4a,PMC4145439,S40,4544,4886,Study design, This 12 week Phase IIb dose ranging double blind placebo PBO active controlled multicenter randomised study NCT01242488 conducted November 2010 June 2012 evaluate efficacy safety subcutaneous OKZ patients moderately severely active RA previously failed TNF inhibitor therapy
0,PMC4145439,S41,4887,5069,Study design, The study protocol approved Institutional Review Board Independent Ethics Committee defined local regulations performed according Declaration Helsinki
0,PMC4145439,S42,5070,5108,Study design, All patients provided written consent
6a,PMC4145439,S43,5117,5256,Study design, The primary objective study evaluate efficacy OKZ different doses administration frequencies compared PBO
6a,PMC4145439,S44,5257,5485,Study design, Secondary objectives evaluate safety pharmacokinetics PK pharmacodynamics PD immunogenicity repeated doses OKZ assess dose response exposure response relationship OKZ efficacy
6a,PMC4145439,S45,5486,5565,Study design, An exploratory endpoint compare efficacy safety OKZ TCZ
10,PMC4145439,S47,5674,5755,Study design, Randomisation performed centrally using interactive voice response system
8a,PMC4145439,S47,5674,5755,Study design, Randomisation performed centrally using interactive voice response system
5,PMC4145439,S48,5756,5875,Study design, Patients received either PBO OKZ 60 120 240  mg every 4  weeks Q4W every 2  weeks Q2W 8  mg kg TCZ Q4W
5,PMC4145439,S49,5876,6123,Study design, Doses selected order cover 35  75 maximal anticipated effect DAS28 erythrocyte sedimentation rate ESR 12  weeks 45  85 maximal anticipated effect 24  weeks based PK PD analysis previous study data 19 20
8b,PMC4145439,S51,6172,6273,Study design, Randomisation stratified according number prior failed TNF inhibitors 1 vs 2
0,PMC4145439,S52,6274,6359,Study design, Two safety follow up visits undertaken 6 12  weeks last study dose
11a,PMC4145439,S53,6360,6492,Study design, To maintain blinding treatment patients received intravenous infusion Q4W two 1 2  mL subcutaneous injections Q2W
0,PMC4145439,S54,6493,6624,Study design, TCZ dose approved dose Europe EMA 21 highest dose approved US Food Drug Administration FDA 18
0,PMC4145439,S55,6633,6742,Study design, Patients completed study eligible receive OKZ open label extension study NCT01296711
4a,PMC4145439,S57,6782,6914,Patients, This study population individuals active RA inadequate response MTX least one previous anti TNF therapy
4a,PMC4145439,S58,6915,7185,Patients, Patients old adult onset RA least 6  months duration 1987 American College Rheumatology ACR classification criteria22 score ACR European League Against Rheumatism EULAR Classification Diagnostic Criteria RA 23
4a,PMC4145439,S59,7186,7387,Patients, Eligible patients tender joint count TJC assessment 68 joints swollen joint count SJC assessment 66 joints CRP times upper limit normal ULN ESR 28  mm h
4a,PMC4145439,S60,7388,7483,Patients, Patients required stable dose MTX continued current steroids NSAIDs
4a,PMC4145439,S61,7492,7734,Patients, Major exclusion criteria included diagnoses inflammatory arthritis non inflammatory type arthritis interfered efficacy evaluations functional capacity Steinbrocker Class IV 24 prior exposure IL 6 inhibitors
4a,PMC4145439,S62,7735,7868,Patients, Patients permitted use DMARDs MTX within 12  weeks prior screening unless undertaking appropriate washout
4a,PMC4145439,S63,7869,8121,Patients, Patients known risk severe major infections elevated levels screening creatinine alanine aminotransferase ALT aspartate aminotransferase AST reduced platelets white blood cell count neutrophil count excluded
6a,PMC4145439,S65,8170,8379,Efficacy analyses, Efficacy outcomes assessed Full Analysis Set FAS consisting randomised patients received least one dose study medication least one post baseline efficacy measurement
6a,PMC4145439,S66,8388,8472,Efficacy analyses, The primary efficacy endpoint change baseline DAS28 CRP Week 12
6a,PMC4145439,S67,8473,8557,Efficacy analyses, Secondary efficacy endpoints ACR20 ACR50 ACR70 Week 12 OKZ PBO
6a,PMC4145439,S68,8558,8835,Efficacy analyses, Major exploratory analyses included ACR20 50 70 response rates Weeks 1 2 4 6 8 10 12  patients DAS28 CRP 2 6 Weeks 2 4 8 12 TJC SJC Clinical Disease Activity Index CDAI Health Assessment Questionnaire Disability Index HAQ DI
6a,PMC4145439,S70,8873,9038,Safety, Safety assessments included measurement vital signs laboratory parameters well recording treatment emergent adverse events TEAEs serious TEAEs
0,PMC4145439,S71,9039,9178,Safety, Safety variables analysed using Safety Set SS patients received least 1 dose partial dose study medication
0,PMC4145439,S73,9230,9288,Statistical analyses, Unless specifically stated FAS used analyses
12a,PMC4145439,S74,9289,9370,Statistical analyses, DAS28 CRP analysed using mixed effects model repeated measures MMRM
12b,PMC4145439,S75,9371,9500,Statistical analyses, ACR20 50 70 responder rates estimated using generalised estimating equation GEE methodology Multiple Imputation MI
12b,PMC4145439,S76,9501,9618,Statistical analyses, Missing data SJC TJC HAQ DI CDAI change baseline imputed using last observation carried forward LOCF
12b,PMC4145439,S77,9619,9731,Statistical analyses, Non responder imputation used analysis  patients DAS28 CRP 2 6 control missing values
0,PMC4145439,S78,9732,9842,Statistical analyses, The number prior failed TNF inhibitors included categorical covariate statistical analyses
12a,PMC4145439,S79,9843,9905,Statistical analyses, Unless otherwise stated statistical tests two sided
12b,PMC4145439,S79,9843,9905,Statistical analyses, Unless otherwise stated statistical tests two sided
7a,PMC4145439,S80,9914,10114,Statistical analyses, Power sample size calculations based upon simulations change baseline DAS28 assessed postbaseline visits using MMRM method specified primary efficacy analysis
0,PMC4145439,S82,10186,10317,Pharmacokinetic/pharmacodynamic analyses, Blood samples determination plasma OKZ TCZ anti OKZ antibodies collected baseline subsequent visit
12b,PMC4145439,S83,10318,10394,Pharmacokinetic/pharmacodynamic analyses, Non linear mixed modelling employed analysis OKZ PK data
12b,PMC4145439,S84,10395,10656,Pharmacokinetic/pharmacodynamic analyses, The final population PK model used derive individual concentration exposure measures use PK PD analyses involved describing relationship PK measures multiple efficacy safety endpoints via mixed effects methodology
0,PMC4145439,S196,26827,26841,Supplementary Material, Web supplement
4a,PMC4145444,S40,4812,5117,Subjects, Children active rickets identified using radiographs wrists knees among children presented leg deformities primary care setting Family Medicine Department Jos University Teaching Hospital geographic centre Nigeria 10  north latitude
4b,PMC4145444,S40,4812,5117,Subjects, Children active rickets identified using radiographs wrists knees among children presented leg deformities primary care setting Family Medicine Department Jos University Teaching Hospital geographic centre Nigeria 10  north latitude
4a,PMC4145444,S41,5118,5353,Subjects, Children eligible enrolment radiographic score least 2 5 validated 10 point scoring method assessed severity rickets growth plates distal radius ulna around knee 5
0,PMC4145444,S42,5354,5587,Subjects, Approval study obtained Ethical Committee Jos University Teaching Hospital Institutional Review Board Mayo Clinic written informed consent obtained parent enrolled child
0,PMC4145444,S43,5596,5727,Subjects, Data collected regarding symptoms rickets frequency quantity dairy product intake usual sunlight exposure
0,PMC4145444,S44,5728,5835,Subjects, The percentage unclothed skin enrolment estimated Lund Browder age related burn chart
0,PMC4145444,S45,5836,5897,Subjects, Standing height measured wall mounted stadiometer
0,PMC4145444,S46,5898,6005,Subjects, Two 24 h dietary recalls obtained separate days determine energy phosphorus calcium intake
0,PMC4145444,S47,6006,6100,Subjects, Energy mineral intakes calculated using food composition tables African foods 6  8
0,PMC4145444,S48,6101,6151,Subjects, Weight measured hanging weighing scale
0,PMC4145444,S49,6152,6241,Subjects, Anthropometric z scores calculated Epi Info 3 2 2 CDC Atlanta Georgia USA
0,PMC4145444,S50,6242,6299,Subjects, All children examined clinical signs rickets
6a,PMC4145444,S51,6308,6490,Subjects, Dual energy X ray absorptiometry left distal proximal 1 3 forearm performed single investigator TDT portable densitometer Norland pDEXA Model 476A110
6a,PMC4145444,S52,6491,6694,Subjects, The densitometer short term vivo precision 6 4 areal bone density distal radius ulna 7 2 proximal 1 3 radius ulna long term vitro precision 1 1
5,PMC4145444,S54,6738,6809,Intervention, All children treated calcium carbonate powdered limestone
0,PMC4145444,S55,6810,6893,Intervention, Powdered limestone locally available much lower cost calcium tablets
5,PMC4145444,S56,6894,7057,Intervention, The content elemental calcium 1 0  g limestone 268  mg courtesy Michael Gruzak USDA ARS Children s Nutrition Research Center Houston Texas USA
0,PMC4145444,S57,7058,7123,Intervention, Samples limestone toxic concentrations heavy metals
5,PMC4145444,S58,7124,7271,Intervention, One level teaspoon powdered limestone approximately 3 5  g 938  mg elemental calcium mixed child s food porridge twice daily
8b,PMC4145444,S59,7272,7598,Intervention, Enrolled children randomised coin toss performed TDT receive direct observation either oral vitamin D2 50  000  IU ergocalciferol Pliva Inc East Hanover New Jersey every 4  weeks Ca D group placebo single vitamin B complex tablet every 4  weeks Ca group 24  weeks
10,PMC4145444,S59,7272,7598,Intervention, Enrolled children randomised coin toss performed TDT receive direct observation either oral vitamin D2 50  000  IU ergocalciferol Pliva Inc East Hanover New Jersey every 4  weeks Ca D group placebo single vitamin B complex tablet every 4  weeks Ca group 24  weeks
5,PMC4145444,S60,7607,7694,Intervention, Subjects returned every 4  weeks supplements assessment adverse events
0,PMC4145444,S61,7695,7776,Intervention, The weight limestone remaining visit recorded assess adherence
6a,PMC4145444,S62,7777,7938,Intervention, Height weight venous blood wrist knee radiographs forearm bone density measurements obtained baseline 12 24  weeks enrolment
6a,PMC4145444,S63,7939,8031,Intervention, Serum samples stored transported frozen Mayo Clinic analysis
6a,PMC4145444,S64,8032,8128,Intervention, Serum calcium phosphorus alkaline phosphatase albumin measured standard methods
6a,PMC4145444,S65,8129,8235,Intervention, Serum 25 OH D measured isotope dilution liquid chromatography  tandem mass spectrometry LC MS MS 9
6a,PMC4145444,S66,8236,8381,Intervention, Unless otherwise indicated subscript notation individual metabolites 25 OH D refers total concentrations 25 OH D2 25 OH D3
6a,PMC4145444,S67,8382,8534,Intervention, Concentrations 25 OH D limit detection 5  nmol L 25 OH D3 10  nmol L 25 OH D2 designated zero data analysis
6a,PMC4145444,S69,8586,8739,Statistical analysis, The primary outcome combined attainment radiographic score 1 5 less serum alkaline phosphatase concentration 350  U L less
6a,PMC4145444,S70,8740,8859,Statistical analysis, All radiographs scored independently two authors TDT PRF mean score used analysis
7a,PMC4145444,S71,8860,9238,Statistical analysis, Based primary outcome measures radiographic score serum alkaline phosphatase values SDs based previous studies 1 6 radiographic score 150  U L alkaline phosphatase 40 subjects treatment group would provide 80 power 95 CI detect difference groups 1 0 final radiographic score 100  U L alkaline phosphatase
12a,PMC4145444,S72,9247,9399,Statistical analysis, Data analysis performed Excel 2003 Microsoft Corp Redmond Washington USA JMP V 9 0 1 SAS Institute Inc Cary North Carolina USA
12a,PMC4145444,S73,9400,9567,Statistical analysis, Unless otherwise noted means SDs reported continuous variables normal distributions medians reported non normally distributed variables
12a,PMC4145444,S74,9568,9767,Statistical analysis, A paired t test used compare values continuous normally distributed variables baseline values unpaired t test used compare values continuous variables groups
12a,PMC4145444,S75,9768,9841,Statistical analysis, The Wilcoxon test used compare non normally distributed variables
12a,PMC4145444,S76,9842,10030,Statistical analysis, Logistic regression used assess effect treatment group primary outcome controlling baseline group differences test interactions variables
0,PMC4145444,S77,10031,10083,Statistical analysis, p Values less 0 05 considered significant
3a,PMC4213545,S37,5614,5927,Study design, This phase 3 randomized double blind study patients moderate severe COPD conducted 222 centers throughout North America Australia New Zealand NCT01437397 accordance International Conference Harmonization Good Clinical Practice guidelines Declaration Helsinki
4b,PMC4213545,S37,5614,5927,Study design, This phase 3 randomized double blind study patients moderate severe COPD conducted 222 centers throughout North America Australia New Zealand NCT01437397 accordance International Conference Harmonization Good Clinical Practice guidelines Declaration Helsinki
0,PMC4213545,S38,5928,6102,Study design, The protocol approved Institutional Review Board study center patients gave written informed consent participating study procedures
11a,PMC4213545,S39,6103,6212,Study design, The study comprised 2 3 week run in period prior 24 week double blind treatment period Figure  1
3a,PMC4213545,S39,6103,6212,Study design, The study comprised 2 3 week run in period prior 24 week double blind treatment period Figure  1
5,PMC4213545,S40,6213,6454,Study design, Patients equally randomized twice daily aclidinium formoterol FDC 400 12   g aclidinium formoterol FDC 400 6   g aclidinium 400   g formoterol 12   g placebo administered via multidose dry powder inhaler Genuair  Pressair 
3a,PMC4213545,S42,6554,6576,Study design, Figure 1 Study design
5,PMC4213545,S43,6577,6760,Study design, ACL400 FOR12 FDC fixed dose combination aclidinium 400   g formoterol 12   g ACL400 FOR6 FDC fixed dose combination aclidinium 400   g formoterol 6   g D day Wk week
4a,PMC4213545,S45,6801,7136,Patients, Patients aged eligible current former smokers pack years diagnosed stable moderate severe expiratory airflow obstruction according GOLD guidelines postbronchodilator forced expiratory volume 1  second FEV1 forced vital capacity FVC 70 FEV1    30 80 predicted 1
4a,PMC4213545,S46,7137,7617,Patients, Main exclusion criteria COPD exacerbation respiratory tract infection hospitalized exacerbation screening clinically significant respiratory conditions including asthma clinically significant cardiovascular CV conditions including myocardial infarction MI within previous 6  months unstable angina unstable arrhythmia required changes pharmacological therapy intervention within previous 6  months
5,PMC4213545,S47,7618,7706,Patients, Use long acting bronchodilators investigative treatment permitted
5,PMC4213545,S48,7707,7936,Patients, Other COPD medications theophylline inhaled corticosteroids ICS oral parenteral corticosteroids 20  mg every day prednisone allowed treatment stable prior screening
5,PMC4213545,S49,7937,8000,Patients, Use albuterol salbutamol rescue medication permitted
6a,PMC4213545,S51,8056,8412,Outcomes and assessments, Coprimary efficacy parameters assessed standardized spirometric measurements lung function 14 change baseline week 24 1 hour morning postdose FEV1 FDC versus aclidinium contribution formoterol change baseline week 24 morning predose trough FEV1 FDC versus formoterol contribution aclidinium
6a,PMC4213545,S52,8413,8666,Outcomes and assessments, Secondary efficacy parameters change baseline St George  s Respiratory Questionnaire SGRQ total score week 24 FDC versus placebo improvement Transition Dyspnea Index TDI focal score week 24 FDC versus placebo
6a,PMC4213545,S53,8675,8928,Outcomes and assessments, Additional treatment comparisons coprimary parameter included aclidinium formoterol FDC dose versus monotherapy active treatment versus placebo aclidinium formoterol FDC 400 12   g versus aclidinium formoterol FDC 400 6   g
6a,PMC4213545,S54,8929,9459,Outcomes and assessments, Additional efficacy parameters included change baseline peak FEV1 visits 12 hour spirometry measurements subset intention to treat ITT population based change baseline FEV1 study visits SGRQ Baseline Transition Dyspnea Index BDI TDI study visits except week 24 rescue medication use onset action bronchodilation daily COPD symptoms assessed Exacerbations Chronic Pulmonary Disease Tool EXACT Respiratory Symptoms E RS questionnaire 15
6a,PMC4213545,S55,9460,9723,Outcomes and assessments, A Nighttime Symptoms COPD Instrument NiSCI 16 17 Early Morning Symptoms COPD Instrument EMSCI 18   newly developed patient reported outcome measures undergoing empirical testing  were completed twice daily patients using electronic diary
6a,PMC4213545,S56,9732,9900,Outcomes and assessments, Safety assessed reporting adverse events AEs clinical laboratory tests vital signs electrocardiograms ECGs 24 hour 12 lead Holter monitoring
6a,PMC4213545,S57,9901,10023,Outcomes and assessments, Major adverse cardiovascular events MACE defined composite CV deaths nonfatal MIs nonfatal strokes
6a,PMC4213545,S58,10024,10187,Outcomes and assessments, MACE evaluated classified adjudication committee independent cardiologists participating study blinded treatment
6a,PMC4213545,S59,10188,10410,Outcomes and assessments, To identify MACE list AEs reported randomized patients based standard medical dictionary regulatory activities MedDRA queries cardiac disorders cerebrovascular disorders used
6a,PMC4213545,S60,10419,10550,Outcomes and assessments, Assessments efficacy safety outcomes occurred various timepoints throughout study Additional file 1 Table S1
12a,PMC4213545,S62,10602,10661,Statistical analysis, Statistical analyses performed using SAS  version 9 2
0,PMC4213545,S63,10662,10882,Statistical analysis, All efficacy analyses exception E RS based ITT population defined randomized patients took dose study medication baseline least one postbaseline FEV1 assessment
0,PMC4213545,S64,10883,11066,Statistical analysis, E RS data analyzed ITT Exacerbation Population included patients randomized population took least 1 dose double blind investigational product
12a,PMC4213545,S65,11067,11416,Statistical analysis, Change baseline bronchodilation outcomes analyzed mixed model repeated measures MMRM treatment group sex smoking status visit treatment group by visit interaction fixed effect factors corresponding baseline values age covariates pre postbronchodilator FEV1 covariate FEV1 outcomes
12b,PMC4213545,S65,11067,11416,Statistical analysis, Change baseline bronchodilation outcomes analyzed mixed model repeated measures MMRM treatment group sex smoking status visit treatment group by visit interaction fixed effect factors corresponding baseline values age covariates pre postbronchodilator FEV1 covariate FEV1 outcomes
7a,PMC4213545,S66,11417,11895,Statistical analysis, A sample size 1550 310 per randomized group estimated provide least 90 power detect statistically significant treatment difference 100  mL standard deviation 280  mL FDC dose versus aclidinium monotherapy change baseline 1 hour morning postdose FEV1 week 24 65  mL standard deviation 240  mL FDC dose versus formoterol monotherapy change baseline morning predose trough FEV1 week 24
12a,PMC4213545,S67,11896,12086,Statistical analysis, To control family wise type 1 error rate 2 sided 5 significance level primary secondary efficacy endpoints prespecified multiple comparison strategy conducted
12a,PMC4213545,S68,12095,12467,Statistical analysis, The onset action bronchodilation FEV1 additional endpoint defined 15 increase baseline FEV1 5 minutes 3 hours postdose day 1 evaluated using logistic regression model treatment groups sex smoking status fixed effect factors pre postbronchodilator FEV1 screening age baseline FEV1 covariates
12b,PMC4213545,S68,12095,12467,Statistical analysis, The onset action bronchodilation FEV1 additional endpoint defined 15 increase baseline FEV1 5 minutes 3 hours postdose day 1 evaluated using logistic regression model treatment groups sex smoking status fixed effect factors pre postbronchodilator FEV1 screening age baseline FEV1 covariates
12a,PMC4213545,S69,12468,12535,Statistical analysis, Odds ratios estimated treatment group versus placebo
12a,PMC4213545,S70,12536,12642,Statistical analysis, Change baseline TDI SGRQ analyzed using MMRM described bronchodilation outcomes
12a,PMC4213545,S71,12643,12887,Statistical analysis, A logistic random effect model used analyze number percentage patients achieved clinically meaningful improvement baseline SGRQ total score decrease units 19 TDI focal score increase unit
0,PMC4213545,S72,12888,13054,Statistical analysis, Use rescue medication analyzed using averages daily diary values time periods visits based change baseline values
12a,PMC4213545,S73,13055,13211,Statistical analysis, Daily COPD symptoms analyzed means MMRM adjusted baseline treatment visit sex age smoking status treatment by visit interaction
0,PMC4213545,S74,13212,13363,Statistical analysis, Safety results summarized descriptively based safety population defined randomized patients took dose study medication
4a,PMC4215282,S41,5160,5614,Patients, Eligible patients men women aged 18  55  years RRMS defined revised 2005 MacDonald Criteria15 Expanded Disability Status Scale EDSS score 0  5 5 least one following characteristics documented relapse s within 12  months screening documented relapses within 24  months screening least one T1 weighted gadolinium enhanced Gd lesion detected brain MRI screening
4a,PMC4215282,S42,5623,6065,Patients, Study exclusion criteria use systemic corticosteroids within 30  days randomisation use immunomodulators interferon glatiramer acetate immunosuppressants cyclosporine sirolimus mycophenolic acid within 3  months randomisation use immunosuppressants azathioprine methotrexate natalizumab non lymphocyte depleting biologic agents eg daclizumab within 6  months prior randomisation
4a,PMC4215282,S43,6066,6273,Patients, Patients treated time certain immunosuppressive cyclophosphamide mitoxantrone cladribine lymphocyte depleting biological agents alemtuzumab rituximab excluded study
3a,PMC4215282,S45,6332,6724,Study design and procedures, This prospective multicentre multinational 94 centres 23 countries including Europe Australia Canada USA randomised double blind placebo controlled four arm parallel group dose finding phase IIb study conducted accordance Declaration Helsinki16 adhering International Conference Harmonisation Guidelines Good Clinical Practice 17
4b,PMC4215282,S45,6332,6724,Study design and procedures, This prospective multicentre multinational 94 centres 23 countries including Europe Australia Canada USA randomised double blind placebo controlled four arm parallel group dose finding phase IIb study conducted accordance Declaration Helsinki16 adhering International Conference Harmonisation Guidelines Good Clinical Practice 17
8b,PMC4215282,S46,6725,6880,Study design and procedures, Within investigation site patients randomised 1 1 1 1 ratio once daily treatment placebo ponesimod 10 20 40  mg 24  weeks
5,PMC4215282,S46,6725,6880,Study design and procedures, Within investigation site patients randomised 1 1 1 1 ratio once daily treatment placebo ponesimod 10 20 40  mg 24  weeks
8a,PMC4215282,S47,6889,7087,Study design and procedures, Patients randomised assignment unique randomisation number using interactive voice web response system supplied independent service provider ICON Clinical Research USA
10,PMC4215282,S47,6889,7087,Study design and procedures, Patients randomised assignment unique randomisation number using interactive voice web response system supplied independent service provider ICON Clinical Research USA
8b,PMC4215282,S48,7088,7208,Study design and procedures, Patient randomisation stratified centre using block size four first two blocks eight thereafter
11a,PMC4215282,S49,7209,7408,Study design and procedures, The primary investigator treating neurologist independent evaluating neurologist physician evaluating cardiac safety assessments care providers patients sponsor blinded treatment
11a,PMC4215282,S50,7409,7555,Study design and procedures, The investigators sponsor blinded lymphocyte count results first dose effects ponesimod unless alerted safety reasons
11b,PMC4215282,S51,7556,7645,Study design and procedures, All ponesimod doses matching placebo indistinguishable identically packaged
0,PMC4215282,S52,7654,7724,Study design and procedures, The dose range selected study based phase I data 12 13
0,PMC4215282,S53,7725,7949,Study design and procedures, Ponesimod 10  mg selected lowest dose associated approximate 50 reduction peripheral lymphocyte counts 13 considered minimum reduction required immunomodulatory effect
0,PMC4215282,S54,7950,8241,Study design and procedures, Ponesimod 40  mg selected highest dose associated approximate 70 reduction peripheral lymphocyte counts13 degree reduction previously shown associated significant therapeutic effect patients MS treated fingolimod 18
0,PMC4215282,S55,8242,8513,Study design and procedures, Furthermore phase I studies demonstrated use up titration dosing regimen first dose effects ponesimod 20 40  mg heart rate conductivity reduced safety tolerability higher dose considered acceptable
3a,PMC4215282,S56,8522,8561,Study design and procedures, Study design summarised figure 1
5,PMC4215282,S57,8562,8645,Study design and procedures, All patients randomised ponesimod initially received ponesimod 10  mg days 1  7
5,PMC4215282,S58,8646,8808,Study design and procedures, On day 8 patients randomised receive ponesimod 20 40  mg up titrated 20  mg dose patients randomised 10  mg dose mock up titrated
5,PMC4215282,S59,8809,8970,Study design and procedures, On day 15 patients randomised receive ponesimod 40  mg up titrated 40  mg dose patients randomised ponesimod 10 20  mg mock up titrated
5,PMC4215282,S60,8971,9052,Study design and procedures, Patients randomised placebo mock up titrated days 8 15 figure 1
3a,PMC4215282,S61,9061,9083,Study design and procedures, Figure  1 Study design
5,PMC4215282,S62,9084,9167,Study design and procedures, All patients randomised ponesimod initially received ponesimod 10  mg days 1  7
5,PMC4215282,S63,9168,9330,Study design and procedures, On day 8 patients randomised receive ponesimod 20 40  mg up titrated 20  mg dose patients randomised 10  mg dose mock up titrated
5,PMC4215282,S64,9331,9492,Study design and procedures, On day 15 patients randomised receive ponesimod 40  mg up titrated 40  mg dose patients randomised ponesimod 10 20  mg mock up titrated
5,PMC4215282,S65,9493,9563,Study design and procedures, Patients randomised placebo mock up titrated days 8 15
0,PMC4215282,S66,9564,9615,Study design and procedures, Patient numbers all treated population
0,PMC4215282,S67,9616,9630,Study design and procedures, FU follow up
5,PMC4215282,S68,9639,9852,Study design and procedures, Study visits took place screening baseline day 1 randomisation days 8 15 up titration week 4 every 4  weeks end 24 week treatment period study drug discontinuation
0,PMC4215282,S69,9853,10065,Study design and procedures, Patients completed treatment week 24 offered enrolment ongoing long term dose blinded extension study patients would receive ponesimod ClinicalTrials gov identifier NCT01093326
5,PMC4215282,S70,10066,10315,Study design and procedures, For patients prematurely discontinued study treatment completed 24  weeks treatment chose enter extension study two safety follow up visits performed 7 30  days last dose study drug figure 1
6a,PMC4215282,S71,10324,10506,Study design and procedures, MRI scans performed baseline every 4  weeks week 4 24 end treatment EOT second safety follow up visit patients entering extension study
11a,PMC4215282,S72,10507,10620,Study design and procedures, MRI scans centrally evaluated fully blinded manner Medical Image Analysis Centre Basel Switzerland
6a,PMC4215282,S73,10621,10824,Study design and procedures, EDSS assessments performed screening baseline week 24 follow up visit 2 unscheduled visits case MS relapse independent neurologist otherwise involved patient care
6a,PMC4215282,S74,10825,11032,Study design and procedures, The main pharmacodynamic variable total lymphocyte count centrally analysed screening baseline days 8 15 every 4  weeks thereafter EOT two safety follow up visits
6a,PMC4215282,S75,11041,11157,Study design and procedures, On treatment initiation dose up titration days cardiac monitoring performed independent cardiologist
6a,PMC4215282,S76,11158,11279,Study design and procedures, This included 12 lead ECG blood pressure measurements 6  h Holter ECG monitoring 24  h subset patients
11a,PMC4215282,S77,11280,11352,Study design and procedures, All ECG Holter measurements centrally read blinded manner
6a,PMC4215282,S78,11353,11449,Study design and procedures, Pulmonary function tests PFTs performed study visits except day 1 randomisation
6a,PMC4215282,S79,11450,11564,Study design and procedures, Unscheduled PFTs performed event respiratory symptoms decreased PFT parameters treatment
6a,PMC4215282,S80,11573,11646,Study design and procedures, Adverse events AEs serious AEs SAEs collected visit
6a,PMC4215282,S81,11647,11728,Study design and procedures, Laboratory assessments performed visit except day 1 randomisation
6a,PMC4215282,S82,11729,11846,Study design and procedures, AEs special interest defined basis preclinical previous clinical safety findings ponesimod
6a,PMC4215282,S83,11847,12049,Study design and procedures, They reported treatment follow up periods grouped follows cardiovascular AEs infection related AEs pulmonary AEs hepatobiliary disorders liver toxicity macular oedema
6a,PMC4215282,S85,12096,12237,Study endpoints, The primary efficacy endpoint cumulative number new Gd lesions per patient detected T1 weighted MRI scans weeks 12 24
6a,PMC4215282,S86,12238,12408,Study endpoints, MRI scans weeks 4 8 excluded analysis primary endpoint due delayed anti inflammatory effects evident S1P modulator fingolimod 18
6a,PMC4215282,S87,12409,12574,Study endpoints, In addition primary endpoint aligned another agent dimethyl fumarate delayed onset anti inflammatory effects patients RRMS 19
6a,PMC4215282,S88,12575,12729,Study endpoints, Secondary efficacy endpoints annualised confirmed relapse rate ARR time first confirmed relapse within 24  weeks ponesimod initiation
6a,PMC4215282,S89,12730,12971,Study endpoints, Relapse defined occurrence acute episode one new symptoms worsening existing symptoms MS associated fever infection lasting least 24  h stable period least 30  days
6a,PMC4215282,S90,12972,13269,Study endpoints, A confirmed relapse defined relapse increase points baseline EDSS score increase one point least one functional system score excluding bowel bladder mental functional systems assessed within 7  days onset independent neurologist
6a,PMC4215282,S91,13278,13757,Study endpoints, Exploratory efficacy MRI endpoints included cumulative number new enlarging non enhancing T2 lesions weeks 12 16 20 24 cumulative number combined unique active lesions CUALs sum new T1 Gd lesions new enlarging T2 lesions since previous MRI scan weeks 12 16 20 24 percentage change baseline week 24 brain volume measured MRI using Structural Image Evaluation Using Normalisation Atrophy SIENA program 20
0,PMC4215282,S93,13809,13982,Statistical analyses, The global null hypothesis none three ponesimod groups differed placebo group mean cumulative number new T1 Gd lesions weeks 12 24
0,PMC4215282,S94,13983,14096,Statistical analyses, The alternate hypothesis least one ponesimod treatment groups differed placebo group
12a,PMC4215282,S95,14097,14268,Statistical analyses, The test null hypothesis based negative binomial regression model treatment group four level nominal covariate per protocol analysis set
12a,PMC4215282,S96,14269,14360,Statistical analyses, The null hypothesis tested Wald test two sided significance level 5
12a,PMC4215282,S97,14361,14412,Statistical analyses, No adjustment applied multiple comparisons
0,PMC4215282,S98,14421,14619,Statistical analyses, The per protocol analysis set defined randomised patients received study drug study drug initiation planned EOT valid post baseline MRIs weeks 12  24
12a,PMC4215282,S99,14620,14806,Statistical analyses, The dose  response relationship explored primary endpoint lymphocyte counts means multiple comparison procedures modelling techniques previously described 21
12a,PMC4215282,S100,14807,15086,Statistical analyses, Briefly linear linear log dose emax sigmoid emax logistic exponential models evaluated using multiple comparisons data fitted using model either smallest Akaike Information Criteria normally distributed data maxT count data
12a,PMC4215282,S101,15087,15192,Statistical analyses, To assess precision model fitting bootstrap simulation performed using 1000 iterations
12a,PMC4215282,S102,15201,15448,Statistical analyses, The cumulative number new enlarging non enhancing T2 lesions weeks 12  24 cumulative number CUALs weeks 12 24 analysed using statistical model patient analysis set primary endpoint
12a,PMC4215282,S103,15449,15528,Statistical analyses, The time first confirmed relapse analysed using Kaplan  Meier method
12a,PMC4215282,S104,15529,15644,Statistical analyses, The treatment effect versus placebo described HRs 95 CIs derived proportional hazards model
0,PMC4215282,S105,15645,15932,Statistical analyses, Total lymphocyte counts summarised all treated analysis set randomised patients received least one dose study drug absolute values changes baseline scheduled visits EOT last available value summarised descriptive statistics
0,PMC4215282,S106,15933,16062,Statistical analyses, AEs SAEs reported summarised throughout treatment safety follow up periods all treated analysis set
7a,PMC4215282,S107,16071,16484,Statistical analyses, The underlying assumption sample size calculation 50 decrease mean cumulative number new Gd lesions weeks 12 24 least one ponesimod treatment group compared placebo assuming mean eight lesions placebo anticipated sample size 90 evaluable patients per group 90 power detect significant difference ponesimod groups placebo
0,PMC4392313,S46,6100,6319,Patients, This trial conducted independently pivotal RA trials approved independent ethics committee institutional review board patients gave written informed consent participation trial
4a,PMC4392313,S47,6320,6484,Patients, Adult patients moderately severely active RA diagnosed per American College Rheumatology ACR criteria 6  months  duration recruited
4a,PMC4392313,S48,6485,6749,Patients, Enrolment criteria included inadequate response stable methotrexate MTX therapy exemplified swollen joint count SJC tender joint count TJC together C reactive protein CRP 10  mg L erythrocyte sedimentation rate ESR 28  mm h
4a,PMC4392313,S49,6750,6925,Patients, Patients inadequate response antitumour necrosis factor   aTNF agent 6  months baseline two previous aTNF agents ineligible
5,PMC4392313,S50,6926,6969,Patients, MTX therapy continued study
5,PMC4392313,S51,6970,7167,Patients, Initiation lipid lowering oral antidiabetic antihypertensive medications change dose within 12  weeks baseline prohibited glucocorticoid doses remain stable
8b,PMC4392313,S52,7168,7320,Patients, Patients stratified randomisation age 52 vs mean arterial blood pressure 93 3 vs CRP 1 66 vs
3a,PMC4392313,S54,7362,7554,Procedures, This two arm randomised multicentre double blind placebo controlled parallel group phase III study conducted USA Canada UK figure 1 34 sites MEASURE study
4b,PMC4392313,S54,7362,7554,Procedures, This two arm randomised multicentre double blind placebo controlled parallel group phase III study conducted USA Canada UK figure 1 34 sites MEASURE study
11a,PMC4392313,S55,7555,7842,Procedures, Patients randomly assigned using interactive voice response system blinded patient treating clinical team intravenous treatment TCZ 8  mg kg placebo 1 1 ratio combination oral MTX every 4  weeks 6  months November 2007 June 2008
5,PMC4392313,S55,7555,7842,Procedures, Patients randomly assigned using interactive voice response system blinded patient treating clinical team intravenous treatment TCZ 8  mg kg placebo 1 1 ratio combination oral MTX every 4  weeks 6  months November 2007 June 2008
8a,PMC4392313,S55,7555,7842,Procedures, Patients randomly assigned using interactive voice response system blinded patient treating clinical team intravenous treatment TCZ 8  mg kg placebo 1 1 ratio combination oral MTX every 4  weeks 6  months November 2007 June 2008
5,PMC4392313,S56,7843,8066,Procedures, Patients despite scheduled infusions double blind study medication weeks 8 12 achieve improvement baseline SJC TJC week 16 offered escape therapy open label TCZ 8  mg kg
5,PMC4392313,S57,8067,8198,Procedures, At completion 24 week randomised treatment period patients offered open label treatment TCZ 8  mg kg plus MTX
6a,PMC4392313,S58,8199,8324,Procedures, Assessments part 1 randomised phase study performed day 1 weeks 1 2 4 8 12 16 20 24
6a,PMC4392313,S59,8325,8430,Procedures, Open label assessments performed every 12  weeks week 104 ClinicalTrials gov number NCT00535782
3a,PMC4392313,S61,8573,8595,Procedures, Figure  1 Study design
5,PMC4392313,S61,8573,8595,Procedures, Figure  1 Study design
0,PMC4392313,S62,8596,8632,Procedures, MTX methotrexate TCZ tocilizumab
0,PMC4392313,S63,8633,8800,Procedures, A Patients achieve improvement baseline swollen tender joint counts week 16 offered escape therapy open label TCZ 8  mg kg
0,PMC4392313,S64,8801,8860,Procedures, placebo MTX 65 TCZ MTX patients completed 12  weeks
0,PMC4392313,S65,8861,8920,Procedures, placebo MTX 65 TCZ MTX patients completed 24  weeks
0,PMC4392313,S66,8921,8986,Procedures, B TCZ 8  mg kg every 4  weeks background MTX 7 5  25  mg weekly
0,PMC4392313,S67,8987,9058,Procedures, therapy open label TCZ 8  mg kg every 4  weeks background MTX
0,PMC4392313,S68,9059,9136,Procedures, received least one dose TCZ double blind open label
0,PMC4392313,S70,9194,9432,Lipid and biomarker assays, Commercial assays used measure cholesterol triglycerides apolipoproteins A1 B ApoA1 ApoB CRP high sensitivity assay ESR assays conducted facilitated Covance Laboratories Greenfield Indiana USA
0,PMC4392313,S71,9433,9554,Lipid and biomarker assays, Serum lipid subclasses characterised nuclear magnetic resonance NMR LipoScience Raleigh North Carolina USA
0,PMC4392313,S72,9555,9779,Lipid and biomarker assays, Assays HDL associated SAA serum paraoxonase secretory phospholipase A2 IIA sPLA2 IIA oxidised LDL d dimer fibrinogen Lp a haptoglobin performed Pacific Biomarkers Inc Seattle Washington USA
0,PMC4392313,S73,9780,9843,Lipid and biomarker assays, Specific details provided online supplementary material
6a,PMC4392313,S75,9894,10065,Vascular physiology, Arterial stiffness assessed PWV according manufacturer s instructions using pulse wave analysis apparatus SphygmoCor AtCor San Jose California USA 19
0,PMC4392313,S76,10066,10185,Vascular physiology, Blinded assessors centres underwent training expert assessor certification provided AtCor
0,PMC4392313,S77,10186,10356,Vascular physiology, All PWV scans reviewed AtCor meeting predetermined quality control measures accepted analysis details online supplementary material
6a,PMC4392313,S79,10408,10572,Statistical analysis, The primary objective investigate effect 12  weeks treatment TCZ PWV small LDL particle number assessed NMR compared placebo
6a,PMC4392313,S80,10573,10689,Statistical analysis, The secondary objective investigate effect TCZ compared placebo measurements week 24
0,PMC4392313,S81,10690,10771,Statistical analysis, All analyses including lipid lipoprotein parameters exploratory
7a,PMC4392313,S82,10772,11067,Statistical analysis, A sample size 120 patients 60 per arm calculated based previous results patients RA 5 18 expected provide sufficient power detect difference week 12 PWV small LDL 30 reduction patients treated TCZ compared placebo
12a,PMC4392313,S83,11076,11223,Statistical analysis, The co primary efficacy end points change baseline PWV small LDL particle number analysed parametric analysis covariance
12a,PMC4392313,S84,11224,11446,Statistical analysis, The 12 week 24 week efficacy analyses primary secondary end points performed intent to treat ITT population using last observation carried forward impute missing data analysis time point
0,PMC4392313,S85,11447,11517,Statistical analysis, Only measurements recorded escape therapy carried forward
12b,PMC4392313,S86,11518,11667,Statistical analysis, All exploratory end points summarised ITT population observed cases without imputation missing data excluding escape data
0,PMC4392313,S87,11668,11817,Statistical analysis, All laboratory parameter values converted SI units lipid parameters latest fasted values within time window included
0,PMC4392313,S88,11818,12048,Statistical analysis, Assumptions normality homogeneity variance assessed inspecting normal probability plots plots standardised residual versus predicted values plots standardised residual versus continuous covariates
12a,PMC4392313,S89,12049,12354,Statistical analysis, Primary end points study analysed based normal distribution however baseline values several laboratory assessments study demonstrated non normal distributions values exploratory serum analytes presented medians median percentage changes baseline
12b,PMC4392313,S90,12355,12462,Statistical analysis, Exploratory analyses based observed cases performed using non parametric Kruskal  Wallis test
12b,PMC4392313,S91,12463,12532,Statistical analysis, Hodges  Lehmann estimates location shift 95 CIs presented
0,PMC4392313,S92,12533,12580,Statistical analysis, No adjustments multiplicity performed
0,PMC4392313,S176,25412,25426,Supplementary Material, Web supplement
0,PMC4392313,S177,25478,25487,Supplementary Material, Web table
3a,PMC4431679,S40,5021,5351,Methods, This open label parallel one one randomised controlled trial conducted four acute care hospitals Rabin Medical Center Petah Tikva 192 patients Rambam Health Care Campus 38 patients Holy Family Hospital Nazareth 7 patients Wolfson Medical Center 6 patients Israel July 2007 April 2014
4b,PMC4431679,S40,5021,5351,Methods, This open label parallel one one randomised controlled trial conducted four acute care hospitals Rabin Medical Center Petah Tikva 192 patients Rambam Health Care Campus 38 patients Holy Family Hospital Nazareth 7 patients Wolfson Medical Center 6 patients Israel July 2007 April 2014
0,PMC4431679,S41,5352,5424,Methods, Informed consent obtained patients legal guardian
4a,PMC4431679,S43,5480,5621,Study population and procedures, We included adult inpatients severe infections caused MRSA including bacteraemia patients highly probable MRSA infections
0,PMC4431679,S44,5622,5826,Study population and procedures, We defined bacteraemia isolation MRSA one blood culture bottle isolated single bottle accompanied fever 38  C chills systolic blood pressure 90 mm Hg
0,PMC4431679,S45,5827,6069,Study population and procedures, We defined microbiologically documented MRSA infections using predefined criteria adapted surveillance definitions healthcare associated infections 26 plus isolation MRSA sterile sample source infection
4a,PMC4431679,S46,6070,6210,Study population and procedures, Patients skin soft tissue infections could included fulfilled sepsis inflammatory response syndrome criteria 27
4a,PMC4431679,S47,6211,6396,Study population and procedures, Patients polymicrobial infections could included except involving meticillin susceptible S aureus mandating treatment vancomycin trimethoprim sulfamethoxazole
4a,PMC4431679,S48,6397,6655,Study population and procedures, The highly probable group included patients ventilator associated pneumonia prior antibiotic treatment central catheter related infections surgical site infections presence foreign body without microbiological documentation 28
4a,PMC4431679,S49,6656,7366,Study population and procedures, We excluded patients received trimethoprim sulfamethoxazole vancomycin 48 hours patients MRSA resistant trimethoprim sulfamethoxazole vancomycin highly suspected confirmed left sided endocarditis meningitis patients chronic renal failure creatinine clearance 15 mL min chronic haemodialysis severe acute renal failure including acute haemodialysis could included neutropenic patients acute leukaemia bone marrow transplantation patients known allergy either study drug treatment methotrexate pregnancy lactation previous enrolment study concurrent participation another trial
8a,PMC4431679,S50,7375,7515,Study population and procedures, We used central computer generated random number list randomise patients treatment trimethoprim sulfamethoxazole vancomycin
9,PMC4431679,S51,7516,7645,Study population and procedures, Allocation concealed sealed opaque numbered envelopes opened consecutively informed consent obtained
5,PMC4431679,S52,7646,7876,Study population and procedures, Trimethoprim sulfamethoxazole started intravenously dose 320 mg trimethoprim 1600 mg sulfamethoxazole twice daily could switched oral treatment using dose discretion treating physician
0,PMC4431679,S53,7877,8044,Study population and procedures, Dosing based pharmacokinetic study showing lower dose resulted inhibition killing S aureus dose used previous trial 23 29
5,PMC4431679,S54,8045,8094,Study population and procedures, The vancomycin starting dose 1 g twice daily
5,PMC4431679,S55,8095,8275,Study population and procedures, In arms treatment adjusted renal function vancomycin arm directed serum concentrations obtain drug trough concentrations 10 20 mg dL
5,PMC4431679,S57,8329,8447,Study population and procedures, Treatment administered minimum seven days following duration depended indication
5,PMC4431679,S58,8448,8556,Study population and procedures, Concomitant antibiotics combination vancomycin co trimoxazole could administered
11a,PMC4431679,S59,8557,8657,Study population and procedures, After randomisation blinding performed outcomes adjudicated blinded allocation
6a,PMC4431679,S61,8697,9273,Outcomes, The primary efficacy outcome clinical treatment failure seven days composite death persistence fever 38  C two consecutive days increase 38  resolution required rule persistence persistence hypotension 90 mm Hg systolic need vasopressor support non improving Sequential Organ Failure Assessment SOFA score baseline SOFA decrease least 30 required baseline SOFA 3 stable decreased SOFA score required rule failure persistent bacteraemia day 7
6a,PMC4431679,S62,9274,9455,Outcomes, Blood cultures repeated day 2 patients bacteraemia daily thereafter patients persistent fever persistent bacteraemia signs infection
6a,PMC4431679,S63,9456,9531,Outcomes, We also defined primary safety outcome cause mortality 30 days
6a,PMC4431679,S64,9540,10090,Outcomes, Secondary outcomes included failure modification treatment comprising treatment failure defined antibiotic treatment modification bacteriological failure defined growth MRSA day 7 cultures persistence bacteraemia 48 hours length hospital admission duration fever summing days least one measurement temperature 38  C day 30 development resistance defined acquisition trimethoprim sulfamethoxazole vancomycin resistant S aureus vancomycin resistant Enterococci
6a,PMC4431679,S65,10091,10267,Outcomes, Adverse events included renal failure defined using RIFLE criteria 30 rash leucopoenia diarrhoea Clostridium difficile associated diarrhoea adverse events
7a,PMC4431679,S67,10323,10413,Sample size and analysis, To establish non inferiority allowed difference 15 primary outcome
7a,PMC4431679,S68,10414,10705,Sample size and analysis, Assuming 30 treatment failure rate treatment groups needed sample 128 patients per arm one sided test rule pre specified difference 95 confidence interval difference groups allowing 10 non evaluable patients
7b,PMC4431679,S69,10706,10872,Sample size and analysis, We interim analyses primary safety outcome recruitment one third two thirds patients stopping boundaries two sided level P 0 01
0,PMC4431679,S70,10881,10931,Sample size and analysis, We primary analysis intention treat
12b,PMC4431679,S71,10932,11082,Sample size and analysis, We per protocol analysis patients without exclusion criteria randomisation received allocated treatment minimum seven days
12b,PMC4431679,S72,11083,11143,Sample size and analysis, We subgroup analysis patients MRSA bacteraemia
12a,PMC4431679,S73,11144,11211,Sample size and analysis, We used Fisher  s exact tests compare categorical outcomes
12a,PMC4431679,S74,11212,11361,Sample size and analysis, Continuous outcomes skewed described medians compared using median difference 95 confidence intervals 31
12a,PMC4431679,S75,11362,11481,Sample size and analysis, We multivariable analyses primary efficacy outcome including treatment arm independent variable
12b,PMC4431679,S76,11482,11664,Sample size and analysis, We entered variables significantly associated outcome univariate analysis P 0 05 correlated Spearman correlation 0 5 logistic regression analysis
12a,PMC4431679,S77,11665,11733,Sample size and analysis, We present risk ratios odds ratios 95 confidence intervals
3a,PMC4469977,S41,5243,5408,Trial design and oversight, We carried multicentre parallel group observer blind randomised controlled trial compare efficacy safety ciclosporin prednisolone
0,PMC4469977,S42,5409,5452,Trial design and oversight, Participants gave written informed consent
0,PMC4469977,S43,5453,5572,Trial design and oversight, Oversight trial included trial management group independent trial steering data monitoring committees
0,PMC4469977,S44,5573,5712,Trial design and oversight, Patients suitable topical treatment entered parallel observational study results reported separately
0,PMC4469977,S46,5763,5829,Patient involvement, Patients involved design conduct research
0,PMC4469977,S47,5830,6053,Patient involvement, During feasibility stage priority research question choice outcome measures methods recruitment informed discussions patients focus group session two structured interviews
0,PMC4469977,S48,6054,6130,Patient involvement, During trial patient joined independent trial steering committee
0,PMC4469977,S49,6131,6299,Patient involvement, Members UK Dermatology Clinical Trials Network also identified research priority area clinicians treating patients pyoderma gangrenosum
0,PMC4469977,S50,6300,6534,Patient involvement, Once trial published participants informed results dedicated website www stopgaptrial co uk sent details results study newsletter suitable non specialist audience
4b,PMC4469977,S52,6578,6639,Participants, Recruitment took place 39 hospitals United Kingdom
4a,PMC4469977,S53,6640,6757,Participants, Participants aged 18 years diagnosis pyoderma gangrenosum made recruiting dermatologist
0,PMC4469977,S54,6758,6956,Participants, Histopathology rarely pathognomonic pyoderma gangrenosum many clinicians avoid biopsy risk immunological reaction results ulcer extension biopsy site
0,PMC4469977,S55,6957,7175,Participants, If clinical diagnosis uncertain biopsy performed exclude diagnoses malignancy granulomatous pyoderma gangrenosum arteritis advice sought expert panel necessary
4a,PMC4469977,S56,7184,8095,Participants, We excluded patients pustular granulomatous variants pyoderma gangrenosum may respond differently treatment measurement single ulcer possible patients receiving oral prednisolone ciclosporin intravenous immunoglobulin previous month patients participating another clinical trial women pregnant lactating risk pregnancy patients known hypersensitivity either study treatments patients clinically important renal impairment pretreatment findings would result investigator using either study drugs patients malignant premalignant disease patients concurrent medical condition treatments might interfere ongoing treatment cause harm patients taking rosuvastatin received live vaccine two weeks randomisation
5,PMC4469977,S58,8140,8322,Interventions, Participants received oral prednisolone brand chosen according local practice 0 75 mg kg day single dose ciclosporin Neoral Novartis 4 mg kg day two divided doses
5,PMC4469977,S59,8323,8492,Interventions, As pragmatic trial dose could adjusted according normal practice maximum 1 mg kg day prednisolone 5 mg kg day ciclosporin 7 10
5,PMC4469977,S60,8493,8543,Interventions, Topical treatment prohibited trial
3b,PMC4469977,S61,8544,8723,Interventions, A change protocol made August 2011 82 participants enrolled bowel perforation experienced participant receiving prednisolone 110 mg day
3b,PMC4469977,S62,8724,8826,Interventions, As result implemented ceiling doses 75 mg day prednisolone 400 mg day ciclosporin
8a,PMC4469977,S64,8884,9169,Randomisation and blinding, Participants randomised 1 1 treatment allocation using web based randomisation system hosted Nottingham Clinical Trials Unit using computer generated pseudorandom list permuted blocks randomly varying size two six RALLOC add on12 Stata TX
8b,PMC4469977,S64,8884,9169,Randomisation and blinding, Participants randomised 1 1 treatment allocation using web based randomisation system hosted Nottingham Clinical Trials Unit using computer generated pseudorandom list permuted blocks randomly varying size two six RALLOC add on12 Stata TX
10,PMC4469977,S64,8884,9169,Randomisation and blinding, Participants randomised 1 1 treatment allocation using web based randomisation system hosted Nottingham Clinical Trials Unit using computer generated pseudorandom list permuted blocks randomly varying size two six RALLOC add on12 Stata TX
8b,PMC4469977,S65,9170,9295,Randomisation and blinding, Randomisation stratified target lesion size 20 cm2 cm2 presence absence underlying systemic disease
11a,PMC4469977,S66,9296,9493,Randomisation and blinding, It possible blind clinicians participants treatment allocation owing resource limitations complexities different dosing regimens safety testing two drugs
11a,PMC4469977,S67,9494,9650,Randomisation and blinding, As result clinicians participants informed treatment allocation data irrevocably entered randomisation database
11a,PMC4469977,S68,9651,9872,Randomisation and blinding, Treatment allocation concealed statistician blinded assessors digital images interventions assigned recruitment data collection data cleaning blind analysis complete
6a,PMC4469977,S69,9881,10019,Randomisation and blinding, Assessors blind allocated treatment assessed ulcer size global treatment response digital images target lesion
6a,PMC4469977,S70,10020,10186,Randomisation and blinding, If digital images available assessors used physical measurements lesion taken clinic visits global response treating clinician
6a,PMC4469977,S72,10229,10366,Assessments, Clinic visits took place baseline week 2 week 6 primary outcome ulcer healed maximum six months
6a,PMC4469977,S73,10367,10452,Assessments, Patient reported outcomes collected daily diaries postal questionnaires
6a,PMC4469977,S74,10453,10574,Assessments, For participants whose pyoderma gangrenosum healed assessed recurrence time recurrence medical notes
6a,PMC4469977,S76,10631,10767,Digital image assessments, A template photographed alongside target ulcer calibrate image image analysis software see supplementary figure
6a,PMC4469977,S77,10768,10901,Digital image assessments, Two trained assessors mapped circumference lesion using VERG Videometry VEV MD software Vista Medical Winnipeg Canada
6a,PMC4469977,S78,10902,11148,Digital image assessments, Two dermatologists independently reviewed images ensure lesions consistent diagnosis pyoderma gangrenosum measurements taken trained assessors accurate representation ulcer  s size
6a,PMC4469977,S81,11225,11340,Outcomes, The main outcome measure speed healing six weeks captured single target lesion patient
6a,PMC4469977,S82,11341,11474,Outcomes, If multiple lesions present designated largest lesion could photographed single plane target lesion
6a,PMC4469977,S83,11485,11736,Outcomes, We chose speed healing primary outcome previous studies shown good predictor healing patients leg ulcers 13 14 blinded outcome assessment possible using digital images independent assessors
0,PMC4469977,S84,11737,11914,Outcomes, Assessing primary outcome six weeks also minimised loss follow up impact participants switching alternative treatments primary outcome assessment
6a,PMC4469977,S85,11915,12084,Outcomes, In cases digital images unavailable poor quality used physical measurements ulcer taken non blinded clinicians baseline six weeks
6a,PMC4469977,S87,12143,12309,Secondary outcomes, Time healing  defined time sterile dressings longer required reported patients confirmed clinicians subsequent clinic visits
6a,PMC4469977,S88,12310,12385,Secondary outcomes, We identified outcome important secondary outcomes
6a,PMC4469977,S89,12394,12650,Secondary outcomes, Pyoderma gangrenosum specific global treatment response  to assess treatment response used seven point Likert scale ranging completely clear worse assessed clinicians participants digital images blinded assessment
6a,PMC4469977,S90,12659,12768,Secondary outcomes, Resolution inflammation  this recorded clinicians participants using scale reported Foss 15
6a,PMC4469977,S91,12777,12919,Secondary outcomes, Self reported pain  participants self reported severity pain daily using score 0 4 none mild moderate severe extreme
6a,PMC4469977,S92,12928,13094,Secondary outcomes, Health related quality life  assessed using dermatology life quality index16 European quality life 5 dimensions three levels EQ 5D 3L EQ VAS 17 18
6a,PMC4469977,S93,13103,13240,Secondary outcomes, Time recurrence  defined interval target lesion healing episode pyoderma gangrenosum site
6a,PMC4469977,S94,13241,13357,Secondary outcomes, The period follow up available varied depending time participants randomised trial
6a,PMC4469977,S95,13366,13599,Secondary outcomes, Number treatment failures  defined withdrew randomised treatment treatment intolerance whose pyoderma gangrenosum worsened whose target lesion remained unhealed six months follow up
6a,PMC4469977,S96,13608,13726,Secondary outcomes, Adverse reactions study drugs  adverse events possibly probably definitely related study drug
0,PMC4469977,S98,13769,13845,Sample size, This superiority trial prednisolone control intervention
7a,PMC4469977,S99,13846,14093,Sample size, To provide 80 power 5 level significance detect difference means 0 5 standard deviations primary outcome speed healing six weeks target sample size 140 participants assuming loss follow up 10
7a,PMC4469977,S100,14094,14329,Sample size, We chose difference 0 5 standard deviations clinically meaningful group difference observational data suggested ciclosporin potentially effective higher cost prednisolone 19 20 21
7a,PMC4469977,S101,14330,14442,Sample size, As result felt substantial treatment effect necessary justify change clinical practice
0,PMC4469977,S103,14494,14554,Statistical analysis, We prespecified analyses statistical analysis plan
0,PMC4469977,S104,14555,14753,Statistical analysis, Analysis conducted using intention treat principles defined randomised participants excluding later diagnosis determined something pyoderma gangrenosum
0,PMC4469977,S105,14754,14871,Statistical analysis, We included participants available data baseline six week visit primary analysis
12a,PMC4469977,S106,14872,14938,Statistical analysis, The impact missing values explored sensitivity analysis
12a,PMC4469977,S107,14939,15103,Statistical analysis, A linear regression model used analyse differences treatment groups primary outcome six weeks adjusting stratification variables
12a,PMC4469977,S108,15112,15503,Statistical analysis, Secondary outcomes analysed using Cox regression models time event outcomes linear regression models dermatology life quality index EQ 5D EQ VAS adjusted baseline values self reported pain summarised using area curve proportional odds models ordered categorical outcomes logistic regression models binary outcomes
0,PMC4469977,S109,15504,15564,Statistical analysis, All analyses adjusted stratification variables
12b,PMC4469977,S110,15573,15912,Statistical analysis, Sensitivity analysis primary outcome time healing adjusted additional baseline variables including age sex weight size recruiting centre geographical region missing data participants switched randomised treatments received trial drugs combination period trial
0,PMC4469977,S111,15922,16114,Statistical analysis, We analysed adverse reactions occurred trial according original randomised allocation regardless whether drugs introduced adverse reaction
12a,PMC4469977,S112,16123,16216,Statistical analysis, All statistical analyses conducted using SAS software version 9 2 R version 2 10 1
0,PMC4515982,S40,4975,5066,Patients, The trial coordinated ALS Centre IRCCS Foundation Besta  Milan
4b,PMC4515982,S41,5067,5152,Patients, Consecutive patients screened eligibility 25 Italian ALS centres
4a,PMC4515982,S42,5153,5310,Patients, Patients aged 18  75  years diagnosed probable laboratory supported probable definite ALS according El Escorial revised criteria eligible
4a,PMC4515982,S43,5311,5450,Patients, Inclusion criteria onset weakness months slow vital capacity sVC predicted seated position screening visit
4a,PMC4515982,S44,5451,5987,Patients, Exclusion criteria haematocrit 51 men 49 women haemoglobin value 17  g dL non invasive ventilation NIV 6  h daily known familial ALS first degree relative ALS diagnosis frontotemporal dementia history and or instrumental evidence previous thrombotic vascular event cardiac diseases uncontrolled hypertension systolic diastolic irrespective treatments two consecutive evaluations active solid myeloproliferative malignancy known hypercoagulable disorders
0,PMC4515982,S45,5988,6112,Patients, All patients asked continue riluzole 100  mg daily stable dose least 30  days prior screening
4a,PMC4515982,S46,6113,6296,Patients, Patients take riluzole screening visit considered eligible could randomized case could start riluzole entire study period
0,PMC4515982,S47,6297,6360,Patients, The protocol approved ethics committee site
0,PMC4515982,S48,6361,6443,Patients, All patients provided written informed consent study related procedure
6a,PMC4515982,S50,6489,6634,Trial outcomes, The primary outcome one single composite outcome time randomisation death tracheotomy 23  h NIV daily 14 consecutive days
6a,PMC4515982,S51,6635,6800,Trial outcomes, Secondary outcomes changed baseline ALSFRS R score sVC seated position patients  quality life measured ALSAQ 40 questionnaire
6a,PMC4515982,S52,6801,6878,Trial outcomes, Tolerability evaluated analysing adverse events AEs causing withdrawal
5,PMC4515982,S54,6923,7059,Randomisation, Patients randomly assigned receive either intravenous rhEPO 40  000  IU matching placebo 1 1 ratio fortnightly 12  months
8b,PMC4515982,S55,7060,7214,Randomisation, Randomisation stratified centre disease severity ALSFRS R vs 33 onset spinal bulbar block size four within centre
8a,PMC4515982,S56,7215,7403,Randomisation, The Neuroepidemiology Unit coordinating centre independent study generated computer based randomisation sequence known two staff persons drug dispenser
9,PMC4515982,S56,7215,7403,Randomisation, The Neuroepidemiology Unit coordinating centre independent study generated computer based randomisation sequence known two staff persons drug dispenser
10,PMC4515982,S56,7215,7403,Randomisation, The Neuroepidemiology Unit coordinating centre independent study generated computer based randomisation sequence known two staff persons drug dispenser
10,PMC4515982,S57,7404,7486,Randomisation, Treatment allocated web based randomisation system available 24  h day
0,PMC4515982,S58,7487,7601,Randomisation, The procedure incorporated eligibility checks according protocol performed request centres
0,PMC4515982,S59,7602,7660,Randomisation, The sequence always available emergency unmasking
11b,PMC4515982,S61,7699,8080,Masking, RhEPO Eprex purchased Janssen Cilag SpA Cologno Monzese Italy coordinating centre directly shipped company Pierrel Research IMP srl Cant  Italy charge preparing investigational drug rhEPO 1 cc saline syringes identical appearance sealed sequentially numbered identical containers according allocation sequence
5,PMC4515982,S62,8081,8192,Masking, Shipping performed patient within 1  week randomisation using refrigerated express carrier
5,PMC4515982,S63,8193,8245,Masking, Each centre stored investigational drug
11a,PMC4515982,S64,8254,8465,Masking, Patients neurologists laboratory biologists technicians two centre statistician masked treatment allocation access data related rhEPO haematopoietic activity
0,PMC4515982,S65,8466,8608,Masking, Briefly participating centres generated specific access code blood withdrawals patients ALS enrolled EPOS trial
0,PMC4515982,S66,8609,8759,Masking, At treatment visit local laboratory unit received de identified vial reporting randomisation number treatment administration
0,PMC4515982,S67,8760,8980,Masking, Blood parameters emailed coordinating unit trained person readily alerted treating neurologist decision administer delay treatment based safety protocol parameters see
11a,PMC4515982,S68,8981,9173,Masking, Patients treating neurologists access data blood parameters whereas laboratory personnel access data allowing identification patient
0,PMC4515982,S69,9174,9243,Masking, This procedure elaborated maintain blindness study
0,PMC4515982,S70,9244,9408,Masking, Finally designed study reasoned patients treated rhEPO could higher risk treatment delay defined safety protocol
11a,PMC4515982,S71,9409,9626,Masking, Therefore randomisation centre generated list placebo patients randomly assigned 1  week treatment delay balanced number patients allocated rhEPO treatment needing true delay centre
0,PMC4515982,S72,9627,9696,Masking, This procedure elaborated maintain blindness study
6a,PMC4515982,S74,9738,10049,Procedures, After giving informed written consent eligible patients underwent haematological examinations haemochromocytometry renal liver function serum iron ferritin transferrin reticulocyte count coagulation tests blood pressure body mass index BMI measurement sVC ALSFR R ALSQ40 assessment
0,PMC4515982,S75,10050,10119,Procedures, Randomisation performed within 15  days screening visit
6a,PMC4515982,S76,10120,10368,Procedures, At fortnightly treatment visit safety parameters haematocrit 51 men 49 women haemoglobin value 17  g dL value raised 1  g dL end interval two subsequent doses blood pressure BMI assessed
6a,PMC4515982,S77,10369,10547,Procedures, Symptoms nocturnal hypoventilation nocturnal arousals morning headache excessive daytime sleepiness vivid dreams medications AE actively monitored recorded
6a,PMC4515982,S78,10548,10586,Procedures, ALSFR R sVC assessed monthly
6a,PMC4515982,S79,10587,10722,Procedures, At 6 month study end dropout visit patient also underwent complete haematological examinations ALSAQ 40 assessment
5,PMC4515982,S80,10723,10878,Procedures, At treatment visit treatment administration allowed delayed 1  week trial coordinating office assessment safety parameters
5,PMC4515982,S81,10879,10983,Procedures, If treatment delayed following week safety parameters repeated drug administration
0,PMC4515982,S82,10984,11080,Procedures, The delay treatment administration two times caused dropout patient
6a,PMC4515982,S83,11081,11214,Procedures, After study end month 12 patients underwent monthly follow up visits 6  months record primary outcome events
6a,PMC4515982,S84,11215,11379,Procedures, All centres provided spirometer Spirobank G multifunction Medisan srl Milano Italy disposable tubes sVC assessment trained use
0,PMC4515982,S85,11380,11491,Procedures, All data recorded electronic case record form specifically developed Nubilaria srl Novara Italy
0,PMC4515982,S86,11492,11685,Procedures, Trial monitoring performed independent contract research organisation CROM srl Verona Italy assured consistency measuring outcomes across centres scheduled site visits
0,PMC4515982,S88,11730,11829,Co-treatments, Nutritional status ventilation could affect survival thus primary outcome trial
0,PMC4515982,S89,11830,12045,Co-treatments, During first investigator meeting held Milan 6 June 2010 participating centres agreed approach cotreatments sharing opinion ultimate decision would personal patient
5,PMC4515982,S90,12046,12327,Co-treatments, We agreed percutaneous endoscopic gastrostomy equivalent device proposed patients case score 1 2 item 3 ALSFRS R unintentional loss body weight 10 past 3  months choking food liquids medication ingestion
5,PMC4515982,S91,12328,12518,Co-treatments, NIV proposed patients case score 0 1 item 10 11 ALSFRS R sVC 50 abnormal nocturnal oximetry SaO2 90 4 overnight recorded time
7a,PMC4515982,S93,12572,13134,Sample size estimation, On basis results pilot study ie observed rates 0 56 death 0 33 tracheotomy 18  months placebo group 13 estimated would need sample size 203 patients followed 12  months give 97 power detect significant difference rhEPO placebo corresponding 67 relative reduction risk death 74 power detect 70 relative reduction risk respiratory events tracheotomy 23  h NIV two sided type 1 error 5 given anticipated dropout rate 10
0,PMC4515982,S95,13186,13360,Statistical analysis, The main analysis primary secondary outcomes included randomised patients took least one dose investigational drug original assigned groups
0,PMC4515982,S96,13361,13530,Statistical analysis, All analyses performed entire population subgroups patients ALSFRS R 3314 spinal bulbar onset randomisation
0,PMC4515982,S97,13531,13628,Statistical analysis, A per protocol analysis carried excluding non compliers patients took 80 therapy
0,PMC4515982,S98,13629,13850,Statistical analysis, Demographic characteristics clinical features randomised patients baseline reported treatment arm compared using test student test Wilcoxon rank sum test Fisher  s exact test appropriate
12a,PMC4515982,S99,13851,14121,Statistical analysis, Time randomisation death tracheotomy 23  h NIV daily 14 consecutive days analysed terms annualised rate corresponding 95 CI p value using test one degree freedom rate comparison based Poisson regression
12a,PMC4515982,S100,14122,14218,Statistical analysis, The Kaplan Meier method used obtain survival curves corresponding log rank test
12a,PMC4515982,S101,14219,14375,Statistical analysis, A Cox model applied estimate treatment effect terms HR 95 CI adjusted sex age ALSFRS R score baseline disease duration
12a,PMC4515982,S102,14376,14572,Statistical analysis, The number patients experiencing AE causing withdrawal reported compared two groups Kaplan Meier curves time withdrawal corresponding log rank test
12a,PMC4515982,S103,14573,14659,Statistical analysis, Change baseline sVC ALSFRS R ALSAQ 40 assayed mixed effect models
12a,PMC4515982,S104,14660,14746,Statistical analysis, All data analysed using SAS V 9 3 SAS Institute INC Cary North Carolina USA
4b,PMC4621368,S39,5394,5546,Trial population, Between June 2011 September 2013 consecutive patients referred elective CABG surgery recruited two clinics Edinburgh Heart Centre
4a,PMC4621368,S40,5547,5653,Trial population, Patients 18  years older referred isolated CABG surgery requiring two grafts
4a,PMC4621368,S41,5654,6178,Trial population, Exclusion criteria included patients recent myocardial infarction within 1  month surgery emergency concomitant valve surgery significant renal impairment estimated glomerular filtration rate 40  mL min severe respiratory disease maintenance corticosteroid therapy forced expiratory volume 1  s 50 predicted severe LV impairment EF 40 contraindication magnetic resonance scanning treatment chronic inflammatory disease women childbearing potential inability provide consent
5,PMC4621368,S43,6238,6396,Study drug and randomisation, Intravenous recombinant human elafin Proteo Biotech AG Germany 200  mg saline placebo prepared infused aqueous solution 250  mL 0 9 saline
8b,PMC4621368,S44,6397,6532,Study drug and randomisation, Patients randomised 1 1 receive elafin matched placebo Edinburgh Clinical Trials Unit ensure allocation concealment
10,PMC4621368,S44,6397,6532,Study drug and randomisation, Patients randomised 1 1 receive elafin matched placebo Edinburgh Clinical Trials Unit ensure allocation concealment
9,PMC4621368,S44,6397,6532,Study drug and randomisation, Patients randomised 1 1 receive elafin matched placebo Edinburgh Clinical Trials Unit ensure allocation concealment
11a,PMC4621368,S45,6533,6829,Study drug and randomisation, Randomisation incorporated minimisation age presence diabetes mellitus extent coronary artery disease renal function surgeon A B To ensure blinding study drugs prepared staff independent study investigators clinical team responsible patient  s care
8b,PMC4621368,S45,6533,6829,Study drug and randomisation, Randomisation incorporated minimisation age presence diabetes mellitus extent coronary artery disease renal function surgeon A B To ensure blinding study drugs prepared staff independent study investigators clinical team responsible patient  s care
0,PMC4621368,S46,6838,6955,Study drug and randomisation, Intravenous elafin 200  mg causes complete inhibition plasma elastase activity 2  h 50 inhibition 6  h
5,PMC4621368,S47,6956,7152,Study drug and randomisation, This dosage regimen selected cover increased elastase release following CABG surgery peaks time weaning cardiopulmonary bypass returned baseline 6  7  h
5,PMC4621368,S48,7153,7388,Study drug and randomisation, The study drug administered patient central venous cannula period 30 min The intravenous infusion started first skin incision completed least 20 min cardiopulmonary bypass commenced
0,PMC4621368,S50,7466,7553,Anaesthesia and coronary artery bypass surgery, General anaesthesia maintained isoflurane propofol infusion bypass
0,PMC4621368,S51,7554,7720,Anaesthesia and coronary artery bypass surgery, Surgical approach via median sternotomy cardiopulmonary bypass started heparin administration non pulsatile flow membrane oxygenator
0,PMC4621368,S52,7721,7911,Anaesthesia and coronary artery bypass surgery, Cardioprotection provided cold blood cardioplegia 1 4 administered antegradely cross clamping aorta coronary arteries cross clamp fibrillation
6a,PMC4621368,S54,7956,8058,Blood samples, Blood samples taken baseline time 0 skin incision 2 6 24 48  h postoperatively
6a,PMC4621368,S55,8059,8295,Blood samples, Plasma cardiac troponin I cTnI concentrations measured ARCHITECTSTAT troponin I assay ARCHITECTSTAT high sensitive troponin I assay Abbott Laboratories Abbott Park Illinois USA validated institution 16 17
6a,PMC4621368,S56,8296,8487,Blood samples, Plasma concentrations high sensitive C reactive protein IL 6 IL 8 myeloperoxidase elastase quantified using ELISAs R D Systems UK Elastase ELISA Cambridge Biosciences UK
6a,PMC4621368,S57,8488,8621,Blood samples, Plasma elastase activity serum elafin concentrations measured Department Dermatology University Kiel Germany
6a,PMC4621368,S59,8677,8779,Cardiac MRI and analysis, Each patient underwent cardiac MRI twice within 6  weeks surgery 5  days surgery
6a,PMC4621368,S60,8780,8881,Cardiac MRI and analysis, Patients scanned using research dedicated 3T Siemens Verio scanner Siemens Medical Germany
6a,PMC4621368,S61,8882,9086,Cardiac MRI and analysis, Quantification LV mass EF late gadolinium enhancement infarct size determined using established protocols dedicated cardiac analysis software two trained independent blinded observers
6a,PMC4621368,S63,9138,9237,Statistical analysis, The primary outcome variable 48 h area curve AUC plasma cTnI concentration
12a,PMC4621368,S64,9238,9392,Statistical analysis, It analysed using generalised linear model including terms treatment allocation variables randomisation minimised
12a,PMC4621368,S65,9393,9519,Statistical analysis, Log transformations applied data skewed results unlogged presented geometric means
6a,PMC4621368,S66,9520,9691,Statistical analysis, Secondary outcome measures involving AUC hs CRP IL 6 IL 8 myeloperoxidase elastase analysed similarly taking log transformation data skewed
12a,PMC4621368,S67,9692,9790,Statistical analysis, LVEF mass analysed using QMass software Medis Medical Imaging Systems Netherlands
12a,PMC4621368,S68,9791,10012,Statistical analysis, The change volume infarction preoperative first postoperative magnetic resonance scans categorised increased change reduced according detection threshold based interobserver variability
12a,PMC4621368,S69,10013,10077,Statistical analysis, Post hoc analyses individual time points used Wilcoxon tests
0,PMC4621368,S70,10086,10251,Statistical analysis, The primary analysis included randomised patients intention to treat basis regardless compliance allocated treatment post randomisation events
6a,PMC4621368,S71,10252,10523,Statistical analysis, A secondary pre specified exploratory analysis AUC cTnI release excluded patients myocardial infarction cardiac arrest resulting loss cardiac output 1 min Type V myocardial infarction defined according third universal definition 18
6a,PMC4621368,S72,10524,10628,Statistical analysis, Finally post hoc examined treatment effect time point using high sensitive cTnI assay
7a,PMC4621368,S73,10637,10780,Statistical analysis, Power calculations based recent study patients undergoing remote ischaemic preconditioning coronary artery bypass surgery 5
7a,PMC4621368,S74,10781,10932,Statistical analysis, Mean cardiac troponin T release quantified AUC 36 12   g L SD 26 08 20 58   g L SD 9 58 control treated patients respectively
7a,PMC4621368,S75,10933,11091,Statistical analysis, No contemporary AUC data available cTnI release patient group measurements equivalent terms quantifying myocardial injury
7a,PMC4621368,S76,11092,11300,Statistical analysis, With sample size 80 patients 90 power detect 40 difference AUC cTnI significance level 5 using test unequal variances allowing four dropouts arm
0,PMC4770816,S36,4870,4939,Participants, The methods used PAST BP reported detail elsewhere 14
3a,PMC4770816,S37,4940,5174,Participants, PAST BP individually randomised trial participants allocated either intensive blood pressure target 130 mm Hg 10 mm Hg reduction baseline pressure 140 mm Hg standard target 140 mm Hg
4b,PMC4770816,S38,5175,5299,Participants, Patients recruited 106 general practices 99 contributed least one patient England 2009 11
4a,PMC4770816,S39,5300,5390,Participants, Patients considered inclusion practice  s TIA stroke register
4a,PMC4770816,S40,5391,5838,Participants, They excluded baseline systolic blood pressure less 125 mm Hg already taking three antihypertensive agents greater 20 mm Hg postural change systolic blood pressure standing already treated 130 mm Hg systolic blood pressure target unable provide informed consent insufficient corroborative evidence stroke TIA
0,PMC4770816,S41,5839,5955,Participants, Potentially eligible participants identified using search general practice  s clinical computer system
0,PMC4770816,S42,5956,6069,Participants, A general practitioner reviewed list exclude patients study invitation would inappropriate
0,PMC4770816,S43,6070,6250,Participants, The remainder sent letter inviting attend study clinic appointment held general practice research nurse written informed consent obtained
10,PMC4770816,S45,6307,6515,Randomisation and masking, The central study team University Birmingham randomised patients minimisation based age sex diabetes mellitus atrial fibrillation baseline systolic blood pressure general practice
8b,PMC4770816,S45,6307,6515,Randomisation and masking, The central study team University Birmingham randomised patients minimisation based age sex diabetes mellitus atrial fibrillation baseline systolic blood pressure general practice
10,PMC4770816,S46,6516,6598,Randomisation and masking, The research nurse ascertained treatment allocation either telephone online
11a,PMC4770816,S47,6607,6680,Randomisation and masking, Neither participants clinicians blinded treatment allocation
6a,PMC4770816,S48,6681,6844,Randomisation and masking, A research nurse otherwise involved patient  s care obtained primary outcome measure blood pressure using automated sphygmomanometer
5,PMC4770816,S50,6886,7087,Procedures, Patients randomised intensive arm given target systolic blood pressure 130 mm Hg target reduction 10 mm Hg baseline blood pressure 125 140 mm Hg
5,PMC4770816,S51,7088,7184,Procedures, The target standard arm less 140 mm Hg irrespective baseline blood pressure
5,PMC4770816,S52,7185,7443,Procedures, Apart different blood pressure targets management blood pressure groups carried practice nurse monitor blood pressure general practitioner responsible modifying blood pressure treatment
5,PMC4770816,S53,7444,7695,Procedures, Patients whose systolic blood pressure baseline target everyone intensive arm patients standard arm whose blood pressure mm Hg antihypertensive treatment reviewed general practitioner
5,PMC4770816,S54,7696,7971,Procedures, A practice nurse would see patients three month intervals blood pressure target previously measured one month previous blood pressure target refer general practitioner blood pressure target
5,PMC4770816,S55,7972,8201,Procedures, The protocol required formal down titration treatment blood pressure target general practitioners discretion change reduce treatment light symptoms attributable blood pressure drugs
5,PMC4770816,S56,8202,8368,Procedures, We provided general practitioners treatment protocols reflected national guidelines blood pressure lowering operation time trial 15
5,PMC4770816,S57,8369,8540,Procedures, In arms trial general practitioners access computer based algorithm actively suggested drugs dosage participant target
7b,PMC4770816,S58,8541,8610,Procedures, Follow up ceased participant major cardiovascular event
6a,PMC4770816,S59,8619,8707,Procedures, The primary outcome change systolic blood pressure baseline one year
6a,PMC4770816,S60,8708,8872,Procedures, Participants blood pressure measured research nurse separate practice nurse  s measurements described baseline six 12 months
6a,PMC4770816,S61,8873,9016,Procedures, Blood pressure measured using British Hypertension Society validated automated electronic monitor supplied validated study 16
6a,PMC4770816,S62,9017,9165,Procedures, Blood pressure measured standardised way patient seated five minutes six measurements taken one minute intervals
6a,PMC4770816,S63,9166,9239,Procedures, The primary outcome average second third measurements
6a,PMC4770816,S64,9248,9441,Procedures, Secondary measures blood pressure included diastolic blood pressure six 12 months systolic blood pressure six months proportion achieving target blood pressures 12 months
6a,PMC4770816,S65,9442,9622,Procedures, For systolic blood pressure also calculated means readings 2 6 5 6 look differential effects regard habituation blood pressure measurement
0,PMC4770816,S66,9631,9720,Procedures, We identified clinical events review general practice record 12 months
0,PMC4770816,S67,9721,9934,Procedures, These comprised major cardiovascular events composite fatal non fatal stroke myocardial infarction fatal coronary heart disease cardiovascular death emergency hospital admissions deaths
0,PMC4770816,S68,9935,10003,Procedures, Participants flagged mortality NHS Central Register
0,PMC4770816,S69,10004,10076,Procedures, Side effects assessed use standard questionnaires 14
7a,PMC4770816,S71,10128,10426,Statistical analysis, We estimated sample size 305 patients group would detect 5 mm Hg difference systolic blood pressure groups 90 power significance level 5 assuming standard deviation 17 5 mm Hg 10 loss follow up 5 mortality 10 major vascular events 5 7
12a,PMC4770816,S72,10427,10626,Statistical analysis, We used mixed models primary analysis adjusting baseline blood pressure age group 80 years years sex diabetes mellitus atrial fibrillation practice random effect
12a,PMC4770816,S73,10627,10679,Statistical analysis, The principal analysis complete case analysis
12a,PMC4770816,S74,10680,10827,Statistical analysis, We also explored potential effects missing values use three approaches multiple imputation group mean last available value
12b,PMC4770816,S75,10828,10923,Statistical analysis, Subgroup analyses pre specified diabetes mellitus atrial fibrillation age group
12b,PMC4770816,S76,10924,11025,Statistical analysis, In addition subgroup analysis baseline systolic blood pressure 140 mm Hg mm Hg
12b,PMC4770816,S77,11026,11200,Statistical analysis, We compared number consultations treatment changes side effects using generalised mixed modelling adjusting variables primary outcome
12b,PMC4770816,S78,11201,11385,Statistical analysis, For clinical events calculated hazard ratios 95 confidence intervals using Cox proportional hazards modelling adjusting covariates mentioned previously
12b,PMC4770816,S79,11386,11535,Statistical analysis, We checked proportional hazard assumption Schoenfeld residual plots including interaction terms model term time
0,PMC4770816,S80,11536,11647,Statistical analysis, For clinical event analyses censored patients time first event relevant analysis
0,PMC4770816,S81,11648,11751,Statistical analysis, Thus patient one emergency hospital admission first one would counted
12a,PMC4770816,S82,11752,11794,Statistical analysis, We used SAS 9 2 Stata 12 analyses
0,PMC4770816,S84,11845,12008,Patient involvement, The study discussed stroke survivor group agreed important research question blood pressure important outcome
0,PMC4770816,S85,12009,12147,Patient involvement, Patients involved developing plans recruitment design study representation Trial Steering Committee
0,PMC4770816,S86,12148,12228,Patient involvement, No patients asked advise interpretation writing results
0,PMC4770816,S87,12229,12367,Patient involvement, We plan disseminate results research relevant patient community local nationally organised stroke groups
0,PMC4797126,S44,5960,5967,Methods, Methods
0,PMC4797126,S45,5983,5995,Trial design, Trial design
3a,PMC4797126,S46,6004,6347,Trial design, The COSTA trial quilizumab Phase II randomized double blind placebo controlled study including recruiting sites 14 countries Argentina Belgium Bulgaria Canada Germany Hungary Mexico New Zealand Peru Poland Romania Russia Ukraine United States enrolled 578 adults uncontrolled allergic asthma
4b,PMC4797126,S46,6004,6347,Trial design, The COSTA trial quilizumab Phase II randomized double blind placebo controlled study including recruiting sites 14 countries Argentina Belgium Bulgaria Canada Germany Hungary Mexico New Zealand Peru Poland Romania Russia Ukraine United States enrolled 578 adults uncontrolled allergic asthma
4a,PMC4797126,S46,6004,6347,Trial design, The COSTA trial quilizumab Phase II randomized double blind placebo controlled study including recruiting sites 14 countries Argentina Belgium Bulgaria Canada Germany Hungary Mexico New Zealand Peru Poland Romania Russia Ukraine United States enrolled 578 adults uncontrolled allergic asthma
3a,PMC4797126,S47,6356,6496,Trial design, Patients randomly assigned 1 1 1 1 one three dosing regimens quilizumab placebo using interactive web response system
8a,PMC4797126,S47,6356,6496,Trial design, Patients randomly assigned 1 1 1 1 one three dosing regimens quilizumab placebo using interactive web response system
5,PMC4797126,S47,6356,6496,Trial design, Patients randomly assigned 1 1 1 1 one three dosing regimens quilizumab placebo using interactive web response system
8b,PMC4797126,S48,6497,6763,Trial design, Randomization stratified based serum periostin level 50  ng mL exacerbation history number exacerbations 1 1 requiring use systemic corticosteroids prior 18  months IgE level 75  200  IU mL 200  IU mL country
11a,PMC4797126,S49,6764,6905,Trial design, Patients study site personnel blinded treatment assignments follow up data Week 84 collected verified
5,PMC4797126,S50,6914,7144,Trial design, Quilizumab Genentech Inc South San Francisco CA delivered subcutaneously nine monthly intervals 300  mg per dose 300  mg  M three quarterly intervals Week 4 150 450  mg per dose 150 450  mg Q
5,PMC4797126,S51,7145,7331,Trial design, The treatment period ended 36  weeks randomization followed 48 week period assess sustained efficacy safety quilizumab see Additional file 1 Figure S1
0,PMC4797126,S52,7351,7383,Trial design, Ethics consent permissions
0,PMC4797126,S53,7394,7642,Trial design, Quorum Review based Seattle WA primary central IRB used sites North America however multiple site specific institutional review boards global sites approved protocol patients gave written informed consent
0,PMC4797126,S54,7643,7914,Trial design, The trial conducted full conformance International Conference Harmonisation E6 guidelines Declaration Helsinki laws regulations country research conducted whichever afforded greater protection individual
0,PMC4797126,S55,7946,7958,Participants, Participants
0,PMC4797126,S56,7978,7996,Participants, Inclusion criteria
4a,PMC4797126,S57,8007,8978,Participants, Adult asthma patients aged 18  75 years required bronchodilator reversibility either reversibility using 4 puffs short acting SABA PC20 FEV1 methacholine provocative concentration methacholine producing 20  fall FEV1 forced expiratory volume 1  s 8  mg mL less within last 2  years pre bronchodilator FEV1 screening 40  80  predicted daily use ICS total daily dose fluticasone propionate equivalent second controller minimum 3 consecutive months inadequately controlled asthma documented 5 item Asthma Control Questionnaire ACQ 5 21 score screening randomization despite compliance asthma controller therapy least one positive aeroallergen specific IgE kU A L total serum IgE history least one protocol defined asthma exacerbation 18  months prior screening
6a,PMC4797126,S58,8979,9239,Participants, Asthma exacerbations defined new increased asthma symptoms wheezing cough chest tightness shortness breath nighttime awakening due symptoms led treatment systemic corticosteroids least 3  days hospitalization
0,PMC4797126,S59,9268,9286,Participants, Exclusion criteria
4a,PMC4797126,S60,9297,9700,Participants, Patients excluded study asthma exacerbation requiring systemic steroids 30  days prior screening screening randomization 20  relative change FEV1 screening randomization pre existing active lung disease asthma infections elevated IgE levels reasons allergy former current smokers
0,PMC4797126,S61,9732,9748,Outcome measures, Outcome measures
6a,PMC4797126,S62,9757,9876,Outcome measures, The primary efficacy outcome annualized rate protocol defined asthma exacerbations baseline Week 36
6a,PMC4797126,S63,9885,10180,Outcome measures, Secondary efficacy outcomes included assessments lung function using relative change pre bronchodilator FEV1 baseline Weeks 12 36 change asthma symptoms baseline Week 36 using total daytime symptom severity scores derived daily patient diary
6a,PMC4797126,S64,10181,10386,Outcome measures, The diary also used determine proportion patients nighttime awakenings due asthma symptoms proportion patients fewer 2  days SABA use per week Week 36
6a,PMC4797126,S65,10395,10513,Outcome measures, Exploratory outcome measures included change asthma control baseline Week 36 measured ACQ 5
6a,PMC4797126,S66,10514,10843,Outcome measures, To assess change allergy related quality of life measures baseline Week 36 Standardized Asthma Quality Life Questionnaire AQLQ S 22 Standardized Rhinoconjunctivitis Quality Life Questionnaire RQLQ S 23 administered patient visits throughout treatment follow up periods
6a,PMC4797126,S67,10844,10987,Outcome measures, We also evaluated ability biomarkers serum periostin blood eosinophils exhaled NO serum IgE predict benefit quilizumab
6a,PMC4797126,S68,10996,11089,Outcome measures, Safety outcomes assessed throughout 36 week treatment 48 week follow up periods
0,PMC4797126,S69,11112,11123,Assessments, Assessments
6a,PMC4797126,S70,11132,11486,Assessments, The patient daily diary included two sections addition peak flow measurements 1 morning section capturing awakenings rescue medication use night symptoms awakening 2 evening section capturing daytime symptom severity rescue medication use preventive inhaler use activity impairment day nasal symptoms
6a,PMC4797126,S71,11487,11758,Assessments, The modified total asthma symptom score mTASS generated subset diary questions adapted previous questionnaire 24 scoring nighttime awakenings 0  3 symptoms awakening 0  1 daytime symptom severity 0  4 total score range 0  8
6a,PMC4797126,S72,11759,11932,Assessments, For analyses symptom scores rescue medication use nighttime awakenings daily scores averaged previous 7  days prior time point interest
6a,PMC4797126,S73,11933,12061,Assessments, Baseline values derived minimum 10  days patient diary entries 14  days prior first treatment
0,PMC4797126,S74,12084,12119,Pharmacokinetics and immunogenicity, Pharmacokinetics immunogenicity
6a,PMC4797126,S75,12128,12303,Pharmacokinetics and immunogenicity, Serum levels quilizumab pharmacokinetic assessments measured using validated enzyme linked immunosorbent assay ELISA Genentech Inc South San Francisco CA
6a,PMC4797126,S76,12304,12605,Pharmacokinetics and immunogenicity, The pharmacokinetic outcomes included serum concentrations prior dosing Weeks 0 4 12 24 32 serum concentrations Week 5 Week 25 maximum observed serum concentrations Cmax obs time maximum observed serum concentration Tmax obs terminal elimination half life t1 2
6a,PMC4797126,S77,12606,12790,Pharmacokinetics and immunogenicity, Serum anti therapeutic antibodies ATAs assessed samples Weeks 0 4 12 24 36 48 60 84 using validated bridging ELISA Genentech Inc South San Francisco CA
0,PMC4797126,S78,12813,12823,Biomarkers, Biomarkers
0,PMC4797126,S79,12832,12902,Biomarkers, Samples biomarker assessments collected throughout study
6a,PMC4797126,S80,12903,13042,Biomarkers, Allergen specific total IgE measured serum ImmunoCAP  Specific IgE blood tests ViraCor IBT Laboratories Lee  s Summit MO
6a,PMC4797126,S81,13043,13279,Biomarkers, Specific IgE measured following allergens cat house dust mite HDM Dermatophagoides farinae HDM Dermatophagoides pteronyssinus ragweed aspergillus timothy grass bermuda grass oak birch plantain orchard grass
6a,PMC4797126,S82,13280,13402,Biomarkers, The maximum specific IgE defined specific IgE highest titer specific IgEs pre dose patient
0,PMC4797126,S83,13403,13503,Biomarkers, Only observed values IgE levels analyzed imputation performed missing IgE data
6a,PMC4797126,S84,13504,13589,Biomarkers, Peripheral blood eosinophil counts obtained standard complete blood counts
6a,PMC4797126,S85,13590,13715,Biomarkers, Serum periostin measured immunoassay using Roche Elecsys platform Roche Diagnostics Ltd Rotkreuz Switzerland
6a,PMC4797126,S86,13716,13928,Biomarkers, Fractional exhaled nitric oxide FeNO measured using hand held portable device NIOX MINO  Niox Morrisville NC according American Thoracic Society European Respiratory Society 2009 guidelines 25
0,PMC4797126,S87,13951,13970,Statistical methods, Statistical methods
0,PMC4797126,S88,13979,14124,Statistical methods, All patients received least one dose study drug intention to treat ITT population included safety efficacy analyses
0,PMC4797126,S89,14125,14211,Statistical methods, Demographic baseline characteristics summarized using descriptive statistics
6a,PMC4797126,S90,14212,14566,Statistical methods, The primary endpoint annualized exacerbation rate calculated total number protocol defined exacerbations observed group treatment period divided total patient weeks risk number weeks first study drug administration earliest Week 36 study discontinuation group multiplied 52
0,PMC4797126,S91,14567,14672,Statistical methods, For patients discontinued study prematurely imputation additional exacerbations
12a,PMC4797126,S92,14673,14923,Statistical methods, The rates asthma exacerbations compared study groups using Poisson regression overdispersion model including terms periostin status 50 number prior exacerbations 1 1 IgE level 200
12b,PMC4797126,S92,14673,14923,Statistical methods, The rates asthma exacerbations compared study groups using Poisson regression overdispersion model including terms periostin status 50 number prior exacerbations 1 1 IgE level 200
12b,PMC4797126,S93,14924,15010,Statistical methods, For biomarker subgroup analyses unadjusted asthma exacerbation rates calculated
12a,PMC4797126,S94,15011,15093,Statistical methods, Corresponding two sided p values 90  confidence intervals CI reported
12a,PMC4797126,S95,15102,15274,Statistical methods, The relative change pre bronchodilator FEV1 baseline calculated absolute change FEV1 volume liters baseline divided FEV1 baseline
12a,PMC4797126,S96,15275,15445,Statistical methods, For secondary exploratory end points means standard deviations values relative change calculated according study group Weeks 12 36
12a,PMC4797126,S97,15446,15620,Statistical methods, The mean relative changes baseline compared study groups using differences means group associated two sided 90  CIs
12a,PMC4797126,S98,15621,15758,Statistical methods, Missing values imputed using last observation carried forward LOCF approach prespecified statistical analysis plan
12a,PMC4797126,S99,15759,15991,Statistical methods, An analysis covariance ANCOVA model factors baseline level periostin status 50  ng mL number prior exacerbations 1 1 IgE level 200  IU mL fit assess treatment effect
12b,PMC4797126,S99,15759,15991,Statistical methods, An analysis covariance ANCOVA model factors baseline level periostin status 50  ng mL number prior exacerbations 1 1 IgE level 200  IU mL fit assess treatment effect
0,PMC4797126,S100,16011,16036,Statistical methods, Sample size determination
3a,PMC4797126,S101,16047,16183,Statistical methods, We planned randomize 560 patients one three dose regimens quilizumab placebo 1 1 1 1 ratio 140 patients per group
7a,PMC4797126,S101,16047,16183,Statistical methods, We planned randomize 560 patients one three dose regimens quilizumab placebo 1 1 1 1 ratio 140 patients per group
7a,PMC4797126,S102,16184,16442,Statistical methods, This sample size provided approximately 84  power detect 50  reduction average exacerbation rates due quilizumab assuming 0 63 exacerbations per patient placebo group 36 week treatment period significance level
7a,PMC4797126,S103,16443,16780,Statistical methods, This sample size also provided approximately 70  power detect 50  reduction average exacerbation rates subgroup periostin high patients assuming 0 69 exacerbations per patient placebo group 36 week period significance level 0 15 50  patients treatment arm periostin high
3a,PMC4893154,S27,3411,3575,Study population, VINDICATE randomized placebo controlled double blind trial vitamin D supplementation vitamin D  deficient chronic HF patients optimal medical therapy
4a,PMC4893154,S28,3576,3849,Study population, Patients were  eligible stable 3 months New York  Heart Association functional class II III symptoms left ventricular ejection fraction LVEF maximally tolerated medical therapy 3  months 25 OH vitamin D level 50  nmol l 20 ng ml
4a,PMC4893154,S29,3858,4466,Study population, Patients ineligible taking taken calcium vitamin supplements last 3 months chronic HF due untreated valvular heart disease anemia thyrotoxicosis existing indications vitamin D supplementation e g previous osteoporotic fracture symptoms osteomalacia history primary hyperparathyroidism sarcoidosis tuberculosis lymphoma cholecalciferol concentration time screening 50 nmol l 20 ng ml significant renal dysfunction estimated glomerular filtration rate  30 ml min
8b,PMC4893154,S31,4525,4820,Allocation and intervention, Patients enrolled VINDICATE allocated blocks 20 using minimization balancing etiology chronic HF ischemic non ischemic diabetes mellitus sex chronic obstructive pulmonary disease requiring use  of regular bronchodilators ethnic origin Caucasian non Caucasian
8a,PMC4893154,S31,4525,4820,Allocation and intervention, Patients enrolled VINDICATE allocated blocks 20 using minimization balancing etiology chronic HF ischemic non ischemic diabetes mellitus sex chronic obstructive pulmonary disease requiring use  of regular bronchodilators ethnic origin Caucasian non Caucasian
5,PMC4893154,S32,4821,4999,Allocation and intervention, Each participant asked take 2 tablets per day providing either total 100 cholecalciferol 4 000 IU daily placebo Cultech Port Talbot Wales United Kingdom
5,PMC4893154,S33,5008,5112,Allocation and intervention, The supplement dose chosen based upon guidelines studies vitamin D supplementation 17
0,PMC4893154,S34,5113,5521,Allocation and intervention, These guidelines suggest studies 1   aim replace physiological requirements supplementing 75 250 2 last least 9 months 3 supplement vitamin D3 D2 4   assay supplements potency 5 include regular serum measurement 25 OH D3 levels 6   aim achieve serum levels patients active therapy 100 160 nmol l 40 ng ml 64  ng ml
5,PMC4893154,S35,5522,5701,Allocation and intervention, Also basis recent data demonstrating adverse effect hyperparathyroidism chronic HF 18 chose dose likely suppress parathyroid hormone PTH release
0,PMC4893154,S36,5702,6072,Allocation and intervention, Our proof concept study using inclusion exclusion criteria protocol VINDICATE previously demonstrated efficacy 4 000 IU daily achieve positive remodeling significant reductions left ventricular end diastolic volume LVEDV left ventricular end systolic volume LVESV left ventricular end diastolic dimension LVEDD
0,PMC4893154,S37,6073,6209,Allocation and intervention, The consort diagram results study presented online supplementary datasets Online Figure  1 Online Tables  1 2
0,PMC4893154,S38,6210,6460,Allocation and intervention, A simple linear model based trend test study demonstrated significant decrease PTH year p  0 0095 allocated vitamin D trend patients allocated placebo arm p  0 977 Online Figure  2 19
6a,PMC4893154,S40,6509,6666,Outcome variables, The pre specified primary endpoint VINDICATE difference change 6 min walk test distance 6MWT baseline 12 months 2 groups
6a,PMC4893154,S41,6667,6950,Outcome variables, Key pre specified secondary endpoints included cardiac structure function safety endpoints serum calcium concentration renal function vitamin D levels   Hypervitaminosis D defined 25 OH D3 200  nmol l 80  ng ml hypercalcemia 2 6 nmol l 10 4  mg dl
6a,PMC4893154,S43,6998,7076,Study procedures, At baseline patient performed 6MWT according standard criteria 20
6a,PMC4893154,S44,7077,7204,Study procedures, Each patient also underwent echocardiography blood sampling serum calcium serum creatinine vitamin D PTH levels
6a,PMC4893154,S45,7205,7306,Study procedures, Patients also invited undergo cardiac magnetic resonance CMR imaging measure LV volumes
6a,PMC4893154,S46,7307,7422,Study procedures, Subsequent visits took place 3 6 9 12 months blood draws repeated visit safety data
6a,PMC4893154,S48,7472,7542,Serum biochemistry, Serum 25 OH D2 25 OH D3 analyzed tandem mass spectrometry
6a,PMC4893154,S49,7543,7641,Serum biochemistry, Samples  were prepared using protein precipitation reagent containing deuterated cholecalciferol
6a,PMC4893154,S50,7642,7782,Serum biochemistry, The supernatant analyzed API5000 LC MS MS AB SCIEX Warrington United Kingdom atmospheric pressure chemical ionization mode
6a,PMC4893154,S51,7783,7920,Serum biochemistry, The inter assay coefficient variability 10 concentrations ranging 12  nmol l 159 nmol l 4 8 ng ml 63 7 ng ml
6a,PMC4893154,S52,7921,8154,Serum biochemistry, Ergocalciferol cholecalciferol concentrations summed reported total 25 OH D We defined deficiency and  insufficiency vitamin D concentrations as  50  nmol l 20 ng ml 75  nmol l 30  ng ml respectively 21 22
6a,PMC4893154,S53,8155,8294,Serum biochemistry, We also  measured serum calcium creatinine PTH Siemens Advia Centaur Siemens Healthcare Diagnostics Camberley United Kingdom
6a,PMC4893154,S54,8295,8450,Serum biochemistry, To confirm effective conversion supplement also measured 1 25 OH D3 radioimmunoassay IDS Boldon United Kingdom baseline 12 months
6a,PMC4893154,S56,8498,8694,Echocardiography, Echocardiography performed patients baseline LV function assessed according European Society Cardiology criteria using Simpson  s biplane measure determine LVEF 23
6a,PMC4893154,S57,8695,8738,Echocardiography, Echocardiography repeated 12 months
6a,PMC4893154,S58,8739,8881,Echocardiography, Echocardiograms time points analyzed offline end study 2 senior echocardiographers blinded patient treatment
6a,PMC4893154,S60,8924,9033,CMR imaging, CMR studies performed dedicated 1 5 T 3 T CMR systems Philips Healthcare Best Netherlands
6a,PMC4893154,S61,9034,9132,CMR imaging, The system used baseline follow up studies 12 months individual patients
6a,PMC4893154,S62,9133,9481,CMR imaging, A multislice multiphase data  set covering entire left ventricle 10 12  short axis slices acquired using validated 2 dimensional balanced steady state free precession pulse sequence TR 2 8 ms TE 1 4 ms flip angle 55  spatial resolution 2 0 mm    2 0 mm    10 mm interslice gap 30 phases cardiac cycle 1 slice per breath hold
6a,PMC4893154,S63,9482,9676,CMR imaging, Offline analysis experienced CMR observer using QMASS V7 0 software Medis Leiden Netherlands blinded study allocation derived end diastolic end systolic LV volumes LVEF
7a,PMC4893154,S65,9719,9804,Sample size, VINDICATE powered provide information patient oriented outcome 6MWT
7a,PMC4893154,S66,9805,9969,Sample size, A trial iron supplementation similar patient group demonstrated improvements 30 40 could expected type intervention 24
7a,PMC4893154,S67,9970,10110,Sample size, We assumed based upon preliminary data pilot study 19 would change 2 groups 12 months 30  m
7a,PMC4893154,S68,10111,10341,Sample size, The SD change 6MWT estimated data upper limit 80 confidence interval CI estimated using bootstrapping used calculations allow small sample size proof concept
7a,PMC4893154,S69,10342,10494,Sample size, This determined 210  patients required 90 power show difference change 6MWT 28 5 significance SD  62
7a,PMC4893154,S70,10495,10570,Sample size, We aimed recruit 230 patients 115 per group allow dropout
12a,PMC4893154,S72,10622,10770,Statistical analysis, Differences baseline variables allocations tested using Student tests continuous data chi square test categorical data
12a,PMC4893154,S73,10771,11034,Statistical analysis, The analysis primacy main efficacy endpoints based analysis covariance linear models relating differences final walk distance imaging variables treatment allocation adjusting baselines values reported 95 CIs 25
12a,PMC4893154,S74,11035,11110,Statistical analysis, All significance tests 2 sided called significant 5 level
12a,PMC4893154,S75,11111,11197,Statistical analysis, All analyses conducted Stata version 14 StataCorp College Station Texas
11a,PMC4893154,S77,11262,11421,Ethical and safety considerations, A single unblinded observer involvement patients  care study follow up J H B reviewed vitamin D result time point safety
11a,PMC4893154,S78,11422,11634,Ethical and safety considerations, An  agreed operating procedure subject who  developed serum vitamin D concentration 200 nmol l 80 ng ml involved reducing dose of  treatment 2 1 tablets per day maintain patient blinding
3a,PMC4902320,S39,5061,5100,METHODS, This randomized controlled trial
5,PMC4902320,S41,5284,5415,METHODS, We randomly allocated participants 1 1 either perioperative intravenous IV iron administration intervention usual care
8a,PMC4902320,S42,5416,5518,METHODS, Randomization followed computer generated number sequence allocation conducted telephone
11a,PMC4902320,S43,5519,5645,METHODS, The surgeon performing operation informed patient participation study group allocation revealed
4a,PMC4902320,S44,5652,5771,METHODS, We screened 626 patients scheduled abdominal surgery presence IDA August 2011 November 2014
4a,PMC4902320,S45,5772,6020,METHODS, After informed written consent patients eligible inclusion 18 yrs IDA ferritin 300  mcg L transferrin saturation 25 Hb 12 0  g dL women Hb 13 0  g dL men randomized 4 21 days surgery 2 groups
0,PMC4902320,S46,6021,6246,METHODS, Owing wide range preoperative period patients standard approach used assess transfusion events preoperative period including transfusion administered 21 days surgery
5,PMC4902320,S47,6247,6451,METHODS, Patients intervention group received IV ferric carboxymaltose given single dose 15 minutes surgery simplified dosing protocol 15  mg kg bodyweight maximum dose 1000  mg
5,PMC4902320,S48,6452,6635,METHODS, Postoperatively within 2 days surgery intervention group participants received 0 5  mg ferric carboxymaltose per recorded 1 mL blood loss blood loss least 100  mL
5,PMC4902320,S49,6636,6768,METHODS, Blood loss measured accurately possible recording suction bottle volume weighing packs end operation
5,PMC4902320,S50,6769,6921,METHODS, Patients usual care group received perioperative care including anemia management provided primary care physician surgical home team
5,PMC4902320,S51,6922,7024,METHODS, Usual care provided included treatment continued observations oral iron recommendations ABT
0,PMC4902320,S52,7025,7164,METHODS, At time initiation study IV iron considered usual care however prescription administration disallowed
5,PMC4902320,S53,7171,7286,METHODS, In institution prescription administration intervention facilitated anesthetic team
0,PMC4902320,S54,7287,7374,METHODS, Baseline testing Short Form Health Survey SF36 conducted study entry 28
0,PMC4902320,S56,7448,7505,METHODS, The SF36 screening bloods repeated time
5,PMC4902320,S57,7506,7665,METHODS, Patients found noteworthy ID IDA follow up irrespective group allocation referred General Practitioner ongoing management
0,PMC4902320,S59,7715,7818,Quality Control Procedure, A trial information session given departmental members involved commencing study
0,PMC4902320,S60,7819,7896,Quality Control Procedure, Regular refreshers scheduled assure protocol knowledge adherence
0,PMC4902320,S61,7897,7977,Quality Control Procedure, The multidisciplinary composition research team facilitated process
0,PMC4902320,S62,7978,8152,Quality Control Procedure, Follow up data entry meticulously conducted research assistant primary care physician follow up care initiated necessary assure patient safety
6a,PMC4902320,S64,8192,8234,Outcomes, The primary endpoint incidence ABT
6a,PMC4902320,S65,8235,8624,Outcomes, Secondary endpoints included hemoglobin Hb admission Hb difference randomization admission ICU admission perioperative morbidity defined new onset infection respiratory failure renal impairment deep venous thrombosis discharge Hb length stay Hb follow up Hb difference discharge follow up iron status 30 day mortality quality life QoL
6a,PMC4902320,S66,8625,8709,Outcomes, QoL score scaled 36 160 lower scores reflecting poorer well being
7a,PMC4902320,S68,8761,8885,Statistical Analysis, The sample size study calculated primary outcome parameter perioperative allogeneic transfusion event
7a,PMC4902320,S69,8886,9131,Statistical Analysis, To reduce risk perioperative allogeneic transfusion event 30 15 50 risk reduction power  0 8 significance level  0 05 determined total 121 patients group would needed
7a,PMC4902320,S70,9132,9212,Statistical Analysis, To account possible dropouts intended include 134 patients per group
7a,PMC4902320,S71,9213,9318,Statistical Analysis, The power calculation performed using nQuery Advisor Version 7 0 Statistical Solutions Saugus MA
12a,PMC4902320,S72,9319,9464,Statistical Analysis, Parametric data tested one way ANOVA presented mean standard error mean mean 95 confidence intervals
12a,PMC4902320,S73,9465,9605,Statistical Analysis, Nonparametric data tested Mann Whitney U tests reported either median IQR median minimum  maximum indicated
12a,PMC4902320,S74,9606,9733,Statistical Analysis, Categorical data analyzed 2 tailed Pearson test presented accordingly number percent total
12a,PMC4902320,S75,9734,9826,Statistical Analysis, Statistical analysis performed using SPSS software version 17 0 SPSS Inc Chicago IL
0,PMC4902320,S160,21143,21171,Supplementary Material, Supplemental Digital Content
4a,PMC5009486,S44,6270,6472,Patients, Male female patients 40  80 years age diagnosis COPD defined American Thoracic Society ATS 11 smoking history least 10 pack years included study
4a,PMC5009486,S45,6473,6954,Patients, Key lung function criteria inclusion pre post short acting bronchodilator ipratropium bromide Atrovent  HFA forced expiratory volume 1  s FEV1 forced vital capacity FVC ratio 0 7 post bronchodilator FEV1    30  80  predicted value screening Visit 1 pre bronchodilator FEV1  80  randomization Visit 2 calculated using Third National Health Nutrition Examination Survey NHANES III reference equations 12
4a,PMC5009486,S46,6955,7064,Patients, Key exclusion criteria diagnosis asthma deficiency respiratory disease
4a,PMC5009486,S47,7065,7262,Patients, Poorly controlled COPD required hospitalization treatment systemic corticosteroids within 3  months antibiotics within 6  weeks prior screening Visit 1 also led exclusion
4a,PMC5009486,S48,7263,7482,Patients, In addition patients clinically significant abnormal electrocardiogram ECG results pregnant lactating women patients could meet ATS criteria acceptable spirometry results excluded 13
5,PMC5009486,S49,7491,7797,Patients, Patients using oral inhaled LABAs LABA ICS combination inhalers phosphodiesterase inhibitors mast cell stabilizers leukotriene antagonists tiotropium discontinued duration trial instead received open label ipratropium four times daily run in period
5,PMC5009486,S50,7798,8063,Patients, Patients using ICS LABA FDC inhalers received stable dose least 4  weeks prior screening switched corresponding dose single ICS agent fluticasone mometasone budesonide administered BID remainder study
5,PMC5009486,S51,8064,8266,Patients, Patients receiving maintenance dose ICS administered FDC permitted continue provided maintained stable dose least 4  weeks prior screening
5,PMC5009486,S52,8275,8444,Patients, Other prohibited medications included non selective antagonists tricyclic antidepressants monoamine oxidase inhibitors anticonvulsants phenothiazines
3a,PMC5009486,S54,8502,8697,Study design and treatment, This randomized incomplete block crossover placebo blinded active open label control study NCT01566773 conducted 10 sites USA 11 April 2012 10 August 2012
4b,PMC5009486,S54,8502,8697,Study design and treatment, This randomized incomplete block crossover placebo blinded active open label control study NCT01566773 conducted 10 sites USA 11 April 2012 10 August 2012
5,PMC5009486,S55,8698,8798,Study design and treatment, Six doses GP MDI 18 9 4 6 2 4 1 2 0 6   g administered BID 14  days assessed
11b,PMC5009486,S56,8799,8906,Study design and treatment, Investigators patients blinded GP MDI placebo MDI treatment using non distinguishable MDIs
11a,PMC5009486,S56,8799,8906,Study design and treatment, Investigators patients blinded GP MDI placebo MDI treatment using non distinguishable MDIs
5,PMC5009486,S57,8907,9026,Study design and treatment, Open label tiotropium 18   g Spiriva  HandiHaler  DPI administered daily QD included active control
5,PMC5009486,S58,9035,9198,Study design and treatment, In study GP expressed salt glycopyrrolate glycopyrronium bromide dose 18   g equivalent 14 4   g glycopyrronium active moiety
8a,PMC5009486,S59,9207,9394,Study design and treatment, Following screening patients randomized using interactive web response system one 120 pre defined treatment sequences comprising four eight possible treatments
5,PMC5009486,S60,9395,9482,Study design and treatment, Each treatment period 14  days separated 7 21 day washout period Fig   1
3a,PMC5009486,S60,9395,9482,Study design and treatment, Each treatment period 14  days separated 7 21 day washout period Fig   1
3a,PMC5009486,S61,9483,9513,Study design and treatment, Fig 1 Study design schematic
0,PMC5009486,S62,9514,9575,Study design and treatment, Rand Randomization PFT Pulmonary Function Test Rx Treatment
0,PMC5009486,S63,9585,9825,Study design and treatment, At study visit prior performing study procedures patients confirm withheld COPD medication least 6  h visit rescheduled soon practical within specified visit windows
5,PMC5009486,S64,9826,9941,Study design and treatment, During study albuterol sulfate salbutamol HFA Ventolin  MDI permitted needed relief symptoms
5,PMC5009486,S65,9942,10074,Study design and treatment, During screening washouts treatment periods ipratropium bromide Atrovent  HFA MDI used maintenance medication
0,PMC5009486,S66,10083,10254,Study design and treatment, This study conducted accordance International Conference Harmonization guidelines Declaration Helsinki 14 US Code Federal Regulations
6a,PMC5009486,S68,10297,10439,Assessments, Patients attended scheduled clinic visits screening Visit 1 randomization Visit 2 Days 1 7 14 treatment period
6a,PMC5009486,S69,10448,10610,Assessments, All pulmonary function tests including FEV1 FVC inspiratory capacity IC defined ATS guidelines performed accordance ATS criteria 13
6a,PMC5009486,S70,10611,10699,Assessments, Spirometry performed assess lung function pre post dose study visit
6a,PMC5009486,S71,10700,10832,Assessments, The assessed time points Days 1 7 treatment period 60 30  min pre dose 15 30 60 120  min post dose
6a,PMC5009486,S72,10833,10901,Assessments, On Day 14 post dose time points assessed 12  h post dose
6a,PMC5009486,S73,10910,11018,Assessments, Safety evaluations included heart rate diastolic blood pressure ECGs conducted every clinic visit
6a,PMC5009486,S74,11019,11180,Assessments, Blood samples taken pre post dose Days 1 14 treatment period perform laboratory assessments including hematology blood chemistry
6a,PMC5009486,S75,11181,11329,Assessments, Adverse events AEs serious AEs documented investigators paradoxical bronchospasm dry mouth classified events interest
6a,PMC5009486,S77,11370,11463,Endpoints, The primary objective study assess efficacy relative placebo MDI GP MDI
6a,PMC5009486,S78,11464,11668,Endpoints, To end dose GP MDI compared placebo MDI primary efficacy endpoint FEV1 area curve 0 12 h AUC0  12 relative baseline Day 14 treatment period
6a,PMC5009486,S79,11669,11786,Endpoints, FEV1 AUC0  12 values normalized dividing length time obtained typically 12  h
6a,PMC5009486,S80,11787,12289,Endpoints, The key secondary endpoints time onset action improvement baseline FEV1 Day 1 peak change baseline FEV1 Days 1 7 14 change baseline morning pre dose trough FEV1 Days 7 14 change baseline 12 h post dose trough FEV1 Day 14 peak change baseline IC Days 1 7 14 mean change baseline morning pre dose trough IC Days 7 14 proportion patients achieving improvement FEV1 Day 1
7a,PMC5009486,S82,12341,12476,Statistical analysis, The planned sample size 120 patients designed provide approximately 93  power detect differences 100  mL FEV1 AUC0  12
7a,PMC5009486,S83,12477,12655,Statistical analysis, The 100 mL difference selected grounds minimum clinically important difference defined change FEV1 perceived patient 15
7a,PMC5009486,S84,12656,12897,Statistical analysis, The principal population primary efficacy analyses modified intent to treat mITT population comprising patients completed least two treatment periods least 2  h post dose data Day 14 periods
6a,PMC5009486,S85,12898,13154,Statistical analysis, For primary efficacy analysis assessing dose  response curve family wise Type I error controlled multiplicity beyond specifying primary endpoint six key comparisons namely dose GP MDI compared placebo MDI
12a,PMC5009486,S86,13155,13389,Statistical analysis, To compare dose GP MDI placebo MDI linear mixed effects model used FEV1 AUC0  12 dependent variable baseline trough FEV1 bronchodilator reversibility period sequence treatment covariates
12a,PMC5009486,S87,13390,13518,Statistical analysis, Baseline defined mean pre dose values obtained first day treatment cycle averaged across periods
6a,PMC5009486,S88,13527,13715,Statistical analysis, Secondary efficacy analysis primary efficacy endpoint assessed non inferiority treatment group open label tiotropium using margin clinical relevance 100  mL
6a,PMC5009486,S89,13716,13911,Statistical analysis, Other secondary efficacy analyses involved superiority comparisons secondary endpoints treatment group versus placebo MDI non inferiority comparisons versus open label tiotropium
6a,PMC5009486,S90,13912,14164,Statistical analysis, Non inferiority determined treatment group lower bound 95  confidence interval CI difference higher dose levels statistically significantly non inferior open label tiotropium
12b,PMC5009486,S91,14165,14309,Statistical analysis, Non inferiority testing performed time onset action Day 1 cumulative incidence Kaplan  Meier curves plotted
12b,PMC5009486,S92,14310,14459,Statistical analysis, The proportion patients achieving improvement baseline Day 1 tabulated logistic regression used compare treatments
0,PMC5009486,S93,14468,14675,Statistical analysis, For safety analyses safety population used defined patients randomized received least one dose study treatment post baseline safety assessment treatment
0,PMC5009486,S94,14676,14952,Statistical analysis, Safety tolerability data including laboratory parameters vital signs ECG results summarized descriptively AEs tabulated according severity relationship study drug Medical Dictionary Regulatory Activities system level preferred term
3a,PMC5033259,S31,5062,5249,Research Design and Methods, Forty eight men women provided written informed consent participate randomized placebo controlled double blind study full details available Supplementary Fig 1
4b,PMC5033259,S32,5250,5435,Research Design and Methods, Participants first screening visit Beth Israel Deaconess Medical Center Clinical Research Center ensure met inclusion exclusion criteria study
7a,PMC5033259,S33,5436,5532,Research Design and Methods, No prior studies lorcaserin human brain existed base power calculations
7a,PMC5033259,S34,5533,5664,Research Design and Methods, We thus enrolled 48 subjects priori plan replace 8 subjects would drop assuming 20 attrition
7a,PMC5033259,S35,5665,5801,Research Design and Methods, Sample size selected similar prior randomized trials pharmaceuticals studied using similar neuroimaging protocols
7a,PMC5033259,S36,5802,5950,Research Design and Methods, With 80 power 2 groups 20 participants estimated would able detect effect size difference 0 9  0 05 level
11b,PMC5033259,S37,5957,6125,Research Design and Methods, After screening visit participants randomized 1 1 receive oral lorcaserin 10 mg twice daily placebo identical appearance lorcaserin
5,PMC5033259,S37,5957,6125,Research Design and Methods, After screening visit participants randomized 1 1 receive oral lorcaserin 10 mg twice daily placebo identical appearance lorcaserin
8a,PMC5033259,S38,6126,6331,Research Design and Methods, Randomization tables produced Harvard Catalyst biostatisticians SAS using blocks four delivered directly Research Pharmacy use study staff would remain blinded
8b,PMC5033259,S38,6126,6331,Research Design and Methods, Randomization tables produced Harvard Catalyst biostatisticians SAS using blocks four delivered directly Research Pharmacy use study staff would remain blinded
11a,PMC5033259,S38,6126,6331,Research Design and Methods, Randomization tables produced Harvard Catalyst biostatisticians SAS using blocks four delivered directly Research Pharmacy use study staff would remain blinded
10,PMC5033259,S38,6126,6331,Research Design and Methods, Randomization tables produced Harvard Catalyst biostatisticians SAS using blocks four delivered directly Research Pharmacy use study staff would remain blinded
4b,PMC5033259,S39,6332,6441,Research Design and Methods, The study took place 4 weeks participants visited Clinical Research Center weeks 0 1 2 4
6a,PMC5033259,S40,6442,6807,Research Design and Methods, The first study visit baseline overnight visit consisted least 12 h fast followed blood draw vital signs physical examination anthropometry waist hip measurements resting metabolic rate measured SensorMedics Vmax Spectra two fMRI scans one fasting state another fed state neurocognitive testing
5,PMC5033259,S41,6808,7079,Research Design and Methods, In addition visit participants given standard care obesity met registered dietitian counseled weight loss recommendation decreasing caloric intake 500 kcal day exercising 30 min 3 days week
6a,PMC5033259,S42,7080,7334,Research Design and Methods, Patients also given Modified Scale Suicidal Ideation MSSI physician visit ensure develop suicidal thoughts manipulating serotonin levels could potentially lead changes mood suicidal ideation
6a,PMC5033259,S43,7335,7399,Research Design and Methods, They returned 1 4 weeks overnight visits
6a,PMC5033259,S44,7406,7532,Research Design and Methods, Participants also attended outpatient follow up visit 2 weeks consisted physical examination blood draw
5,PMC5033259,S45,7533,7726,Research Design and Methods, In visits patients continued take medication home kept detailed food diary discussed patients visit analyzed registered dietitians
6a,PMC5033259,S46,7727,7789,Research Design and Methods, Fasting blood drawn venipuncture registered nurse
6a,PMC5033259,S47,7790,7890,Research Design and Methods, Samples analyzed LabCorp Clinical Laboratory Improvement Amendments  certified laboratory
12a,PMC5033259,S49,7928,8019,Data Analysis, Data analyzed using SPSS 19 software first summarized descriptive statistics
0,PMC5033259,S50,8020,8095,Data Analysis, Data categorical variables presented numbers and or percentages
12a,PMC5033259,S51,8096,8222,Data Analysis, Kolmogorov Smirnov test frequency histograms used check normality distribution continuous variables
12a,PMC5033259,S52,8223,8337,Data Analysis, Repeated measures ANOVA performed across time points lorcaserin placebo between subjects factor
0,PMC5033259,S53,8338,8422,Data Analysis, On treatment analysis performed variables results reported Table 1
12b,PMC5033259,S54,8423,8609,Data Analysis, Intention to treat analysis done anthropometric data confirm on treatment analysis using last observation carried forward method results reported Table 2
6a,PMC5033259,S58,8923,9159,fMRI Protocol and Analysis, Participants viewed food nonfood items within 3 Tesla GE MRI scanner MRI center Beth Israel Deaconess Medical Center fasting fed states InVivo Therapeutics 8 channel high definition receiver head coil
6a,PMC5033259,S59,9160,9237,fMRI Protocol and Analysis, Scanning done using protocol similar previously described 18
6a,PMC5033259,S60,9238,9364,fMRI Protocol and Analysis, First scanning sessions T1 weighted magnetization prepared rapid gradient echo structural MRI acquired
6a,PMC5033259,S61,9365,9723,fMRI Protocol and Analysis, Next five 7 min gradient echo T2 weighted echo planar images depicting blood oxygenation level  dependent BOLD contrast acquired noncontiguous near axial planes repetition time  3 5 echo time  25 ms in plane resolution  2 5 2 5 mm matrix size  96 96 field view  24 24 cm voxel bandwidth  83 33 kHz slice thickness  3 mm
6a,PMC5033259,S62,9724,9774,fMRI Protocol and Analysis, E Prime software controlled stimulus presentation
6a,PMC5033259,S63,9775,9913,fMRI Protocol and Analysis, Images presented blocks block presented counterbalanced order interspersed periods visual fixation
6a,PMC5033259,S64,9922,10406,fMRI Protocol and Analysis, The fMRI protocol consisted five runs subjects viewed blocks highly desirable high calorie high fat images cakes onion rings similar foods less desirable low calorie low fat images vegetables fruits nonfood images examples included flowers rocks trees provided responses well could imagine visualize image using response box held right hand previously described 19 20
6a,PMC5033259,S65,10407,10512,fMRI Protocol and Analysis, Approximately 150 images used randomized order presented fasting fed states
6a,PMC5033259,S66,10513,10706,fMRI Protocol and Analysis, Blocks consisted 5 images image shown 3 15 total block 10 fixation rest blocks 16 blocks shown 5 runs
6a,PMC5033259,S67,10715,10853,fMRI Protocol and Analysis, BOLD data preprocessed using SPM8 software Statistical Parametric Mapping The Wellcome Trust Centre Neuroimaging London U K
6a,PMC5033259,S68,10854,11079,fMRI Protocol and Analysis, Briefly images individual subject flipped realigned motion corrected normalized EPI template affine registration followed nonlinear transformation smoothed Gaussian kernel 6 mm
12a,PMC5033259,S69,11080,11236,fMRI Protocol and Analysis, A general linear model constructed subject using onsets food nonfood image blocks realignment parameters six dimensions
6a,PMC5033259,S70,11237,11308,fMRI Protocol and Analysis, The data high pass filtered remove low frequency signal drifts
6a,PMC5033259,S71,11309,11508,fMRI Protocol and Analysis, The contrast images highly desirable  less desirable food images food highly less desirable  nonfood images first level analysis used second level group statistics
12a,PMC5033259,S72,11509,11618,fMRI Protocol and Analysis, Flexible factorials used compare two groups weeks 1 4 controlling baselines week 0
12a,PMC5033259,S73,11619,11761,fMRI Protocol and Analysis, Whole brain regressions used examine brain activations baseline week 0 related changes weight BMI caloric intake
6a,PMC5033259,S74,11762,11967,fMRI Protocol and Analysis, Given multiple areas studied activations passed corrected threshold P  0 05 family wise error FWE corrected multiple comparisons cluster and or peak activation reported
6a,PMC5033259,S75,11976,12263,fMRI Protocol and Analysis, On basis priori hypothesis hypothalamus owing findings rodents lorcaserin  s weight reducing efficacy mediated hypothalamus performed region interest analysis hypothalamus using 10 mm radius sphere defined previously 19
6a,PMC5033259,S76,12264,12472,fMRI Protocol and Analysis, Effect size data hypothalamus activations significantly different week 1  week 0 week 1  week 4 contrasts extracted using MarsBaR http marsbar sourceforge net
6a,PMC5033259,S77,12473,12550,fMRI Protocol and Analysis, Effect sizes examined groups time hypothalamus
12b,PMC5033259,S78,12551,12661,fMRI Protocol and Analysis, Effect sizes contrasts correlated changes BMI caloric intake using Pearson correlations
3a,PMC5064025,S44,6282,6576,Methods, Novartis Pharmaceuticals Cambridge Massachusetts initiated Phase II double blind randomized placebo controlled trial final study protocol designed collaboration investigators R P C J C T Z A F based previously published methods 19 23 24
4b,PMC5064025,S45,6577,6802,Methods, The study undertaken 9 centers Canada United Kingdom the  United States Germany Israel compliance principles Declaration Helsinki and  according Good Clinical Practice guidelines
0,PMC5064025,S46,6803,6908,Methods, The  protocol reviewed approved institutional review board equivalent center
0,PMC5064025,S47,6909,7000,Methods, All participants provided written informed consent undertaking study procedures
4a,PMC5064025,S49,7033,7366,Patients, Patients ages 18 74 years eligible inclusion clinically evident atherosclerotic vascular disease previous myocardial infarction history angina carotid stenosis 30 peripheral vascular disease ankle  brachial index 0 9 endarterectomy 3 months previously transient ischemic attack stroke
4a,PMC5064025,S50,7367,7625,Patients, In addition patients must also either T2DM for    14 years glycosylated hemoglobin HbA1c levels 6 10 IGT defined peak 2 h glucose reading    140 mg dl but  200 mg dl oral glucose tolerance test screening
4a,PMC5064025,S51,7626,7770,Patients, Patients stable statin therapy period of    6 weeks screening physician documented statin intolerance
5,PMC5064025,S52,7779,7914,Patients, After consent eligible patients randomized 1 1 receive canakinumab 150 mg placebo subcutaneously monthly 12 months
4a,PMC5064025,S53,7915,8218,Patients, Exclusion criteria included pregnancy systemic steroid use baseline high sensitivity C reactive protein hs CRP levels 30 mg l history significant multiple drug allergies history evidence chronic infection including tuberculosis liver disease standard contraindication MRI
8a,PMC5064025,S55,8283,8440,Patients, Patient groups assigned centrally according validated computer generated randomization code stratified according glycemic status T2DM IGT
8b,PMC5064025,S55,8283,8440,Patients, Patient groups assigned centrally according validated computer generated randomization code stratified according glycemic status T2DM IGT
10,PMC5064025,S55,8283,8440,Patients, Patient groups assigned centrally according validated computer generated randomization code stratified according glycemic status T2DM IGT
6a,PMC5064025,S57,8490,8582,Imaging procedures, An integrated vascular MRI performed baseline 3 12 months treatment
0,PMC5064025,S58,8583,8683,Imaging procedures, If imaging data meet evaluable standard time point patient rescanned
0,PMC5064025,S59,8684,8734,Imaging procedures, Randomization required evaluable baseline scan
6a,PMC5064025,S60,8735,8857,Imaging procedures, The imaging procedure comprised measures aortic wall area distensibility well carotid wall area bilaterally
0,PMC5064025,S61,8858,9031,Imaging procedures, The imaging protocol adapted Lee et  al 19 staff imaging site underwent individualized training ensure consistency method data acquisition
6a,PMC5064025,S62,9032,9240,Imaging procedures, All trial sites used 3 0 T whole body MRI scanner including Trio TIM Trio Verio Siemens Medical Solutions USA Inc Malvern Pennsylvania Achieva Philips Amsterdam Netherlands platforms
6a,PMC5064025,S63,9241,9506,Imaging procedures, For carotid imaging bilateral 4 channel carotid array Machnet B V Roden Netherlands used Siemens scanners equivalent multi channel 4 8 phased array carotid coil Shanghai Medical Shanghai China used Philips scanners
0,PMC5064025,S64,9515,9613,Imaging procedures, Detailed information regarding imaging protocols analysis available Online Appendix
0,PMC5064025,S65,9622,9711,Imaging procedures, The velocity arterial pulse propagates termed pulsed wave velocity PWV
0,PMC5064025,S66,9712,9815,Imaging procedures, A measure arterial stiffness independent predictor mortality T2DM IGT 26
6a,PMC5064025,S67,9816,9859,Imaging procedures, The Sphygmocor platform AtCor Medical Pty
6a,PMC5064025,S68,9860,10067,Imaging procedures, Ltd West Ryde Australia applied immediately MRI scanning acquire aortic central pulse pressure radial artery applanation tonometry PWV carotid femoral pulse waves
6a,PMC5064025,S70,10117,10314,Safety assessments, Monitoring vital signs electrocardiogram standard hematology biochemistry including measurement lipoproteins liver function creatine kinase conducted throughout study
0,PMC5064025,S71,10315,10386,Safety assessments, A data monitoring committee oversaw subject safety ongoing basis
6a,PMC5064025,S72,10387,10533,Safety assessments, In addition 3 adjudication committees made blinded assessments adverse events relation cardiac malignant infection related events
11a,PMC5064025,S72,10387,10533,Safety assessments, In addition 3 adjudication committees made blinded assessments adverse events relation cardiac malignant infection related events
6a,PMC5064025,S74,10574,10814,Endpoints, The primary efficacy objectives effects drug aortic distensibility total plaque burden aorta carotid arteries primary safety objective safety tolerability canakinumab population
6a,PMC5064025,S75,10815,11023,Endpoints, Secondary objectives included effects canakinumab on  aortic PWV hs CRP HbA1c homeostasis model assessment HOMA   insulin resistance peak blood glucose level 2 h oral glucose challenge
6a,PMC5064025,S76,11024,11165,Endpoints, Exploratory analyses peripheral biomarkers inflammation including IL 6 serum amyloid A plasma lipoproteins also performed
0,PMC5064025,S78,11217,11278,Statistical analyses, Sample size calculated study Lee et  al 19
7a,PMC5064025,S79,11279,11468,Statistical analyses, To detect 35 change aortic distensibility 11 change plaque burden 12 months achieve power 0 8 nominal p  0 05 2 sided 60 patients per group required
7a,PMC5064025,S80,11469,11563,Statistical analyses, To ensure 120 datasets 12 month follow up data planned randomize 190 patients
12a,PMC5064025,S81,11564,11675,Statistical analyses, Given exploratory nature study corrections made multiplicity statistical tests
0,PMC5064025,S82,11676,11939,Statistical analyses, As defined protocol patients included 3 month data analysis missing doses 3 months 12 month analysis participants required missing doses 3 months 1 missing doses 3 12 months
12b,PMC5064025,S83,11948,12140,Statistical analyses, To compare treatment placebo conducted analysis covariance change baseline including glycemic status factor baseline covariate 3 12 months
12a,PMC5064025,S84,12141,12213,Statistical analyses, All data checked normality log transformed appropriate
12b,PMC5064025,S85,12214,12490,Statistical analyses, When log transformation change baseline possible negative values analysis covariance conducted log transformed 3 12 month data including glycemic index status factor log transformed baseline covariate
0,PMC5064025,S86,12491,12536,Statistical analyses, We considered p value  0 05 significant
0,PMC5064025,S87,12537,12594,Statistical analyses, Results reported as  means 95 confidence limits
7b,PMC5064025,S88,12595,12846,Statistical analyses, Two interim analyses pre specified n  60 patients completed 3 months treatment respectively intention halting study adverse measures identified futility interim positive efficacy
7b,PMC5064025,S89,12847,12957,Statistical analyses, The interim analyses performed independent personnel directly associated study  s conduct
0,PMC5064025,S91,13167,13315,Statistical analyses, The trial design endpoints statistical analyses largely derived academic investigators  previously published studies 19 23 24
0,PMC5064025,S92,13316,13452,Statistical analyses, Following final database lock patient data analyzed independently Centre Statistics Medicine Oxford J B
0,PMC5064025,S93,13453,13688,Statistical analyses, The manuscript drafted the  academic investigators R P C J S B J C T Z A F accordance written agreement Novartis academic institutions and  reviewed revised writing committee
0,PMC5064025,S94,13689,13788,Statistical analyses, All authors full access data study assume responsibility publication
12a,PMC5064025,S95,13797,13894,Statistical analyses, All statistical analyses performed using Stata 14 StataCorp LP College Station Texas
4a,PMC5099201,S38,5264,5565,Study design and participants, n randomised controlled study patients RA diagnosed according 1987 American College Rheumatology ACR criteria less 10  years aged 20 75  years moderate high disease activity baseline visits enrolled November 2009 March 2012
3a,PMC5099201,S38,5264,5565,Study design and participants, n randomised controlled study patients RA diagnosed according 1987 American College Rheumatology ACR criteria less 10  years aged 20 75  years moderate high disease activity baseline visits enrolled November 2009 March 2012
4a,PMC5099201,S39,5566,5735,Study design and participants, Moderate high disease activity defined disease activity score 28 joints DAS28 basis erythrocyte sedimentation rate ESR 3 2
4a,PMC5099201,S40,5736,5869,Study design and participants, Participants receiving stable doses MTX treatment RA least 8  weeks enrolment 9
4a,PMC5099201,S41,5870,6092,Study design and participants, Patients excluded previously taken taking biologic treatment leflunomide within 12  weeks baseline tacrolimus within 4  weeks conventional DMARDs MTX within 8  weeks
4a,PMC5099201,S42,6093,6185,Study design and participants, Patients taking prednisolone equivalent dose 10  mg day excluded
0,PMC5099201,S44,6302,6424,Study design and participants, This study approved ethics committee site conducted accordance Declaration Helsinki
0,PMC5099201,S45,6425,6479,Study design and participants, All participants gave written informed consent
3a,PMC5099201,S47,6526,6712,Study treatment, Patients randomly assigned centralised system 1 1 ratio one two open label treatment groups TCZ added MTX ADD ON group TCZ switched MTX SWITCH group
5,PMC5099201,S47,6526,6712,Study treatment, Patients randomly assigned centralised system 1 1 ratio one two open label treatment groups TCZ added MTX ADD ON group TCZ switched MTX SWITCH group
8a,PMC5099201,S47,6526,6712,Study treatment, Patients randomly assigned centralised system 1 1 ratio one two open label treatment groups TCZ added MTX ADD ON group TCZ switched MTX SWITCH group
5,PMC5099201,S48,6713,6897,Study treatment, TCZ administered dose 8  mg kg intravenously every 4  weeks MTX maintained dose baseline unless clinically relevant adverse event AE occurred
0,PMC5099201,S50,6967,7044,Collected patient data and assessments, Data collected baseline included demographics disease characteristics
6a,PMC5099201,S51,7045,7384,Collected patient data and assessments, The following parameters assessed baseline weeks 4 12 24 52 tender joint count swollen joint count health assessment questionnaire disability index patient global assessment using visual analogue scale VAS evaluator global assessment using VAS C reactive protein CRP ESR matrix metalloproteinase 3
6a,PMC5099201,S52,7385,7460,Collected patient data and assessments, Radiographs hands feet obtained baseline week 52
6a,PMC5099201,S53,7461,7663,Collected patient data and assessments, Each radiograph assessed applying van der Heijde modified total Sharp scoring system mTSS two independent readers blinded treatment assignment patient s clinical status
11a,PMC5099201,S53,7461,7663,Collected patient data and assessments, Each radiograph assessed applying van der Heijde modified total Sharp scoring system mTSS two independent readers blinded treatment assignment patient s clinical status
0,PMC5099201,S54,7664,7749,Collected patient data and assessments, At visit patients monitored physical signs laboratory tests AEs
6a,PMC5099201,S56,7801,7928,Statistical analysis, The primary outcome study defined percentage patients remission according DAS28 ESR week 24
7a,PMC5099201,S57,7929,8256,Statistical analysis, With assumption DAS28 ESR remission would achieved 50 patients ADD ON group 45 SWITCH group 133 patients per treatment group calculated necessary 80 power prove null hypothesis difference treatment arms non inferiority margin 10
12a,PMC5099201,S58,8257,8341,Statistical analysis, A two sided statistical test difference 5 significance level used
6a,PMC5099201,S59,8342,8561,Statistical analysis, As sensitivity analysis percentage patients remission according simplified disease activity index SDAI clinical disease activity index CDAI substitution DAS28 analysed
12a,PMC5099201,S60,8570,8684,Statistical analysis, Efficacy analyses conducted full analysis population last observation carried forward method
6a,PMC5099201,S61,8685,8835,Statistical analysis, Safety endpoints including incidence AEs serious AEs infections specific laboratory abnormalities analysed treated patients
12a,PMC5099201,S62,8844,8991,Statistical analysis, All analyses proportions analysed treatment differences test continuous variables compared Student s test
0,PMC5099201,S147,21870,21884,Supplementary Material, Web supplement
4a,PMC5264229,S39,4309,4665,Patients, Patients 18  75 years old RA classified 1987 American College Rheumatology ACR classification criteria RA enrolled patients RA least 6  months least six tender joints six swollen joints erythrocyte sedimentation rate ESR C reactive protein required
4a,PMC5264229,S40,4666,4789,Patients, Patients take MTX least 6  months stable dose least 4  weeks randomisation
4a,PMC5264229,S41,4790,4876,Patients, For details inclusion exclusion criteria see online supplementary appendix S1
3a,PMC5264229,S43,4920,5059,Study design, This study phase III randomised double blind multinational multicentre parallel group study NCT01936181 EudraCT 2012 005733 37
3a,PMC5264229,S44,5060,5340,Study design, The study consists 54 week main study additional 24 week transition switching study report results 54 week main study week 30 graphical presentation see online supplementary appendix S2 1 includes primary outcome
5,PMC5264229,S45,5341,5435,Study design, Patients randomised 1 1 ratio receive either SB2 INF 3  mg kg intravenously
10,PMC5264229,S46,5436,5590,Study design, Randomisation treatment allocation implemented interactive web responsive system Cenduit LLC see online supplementary appendix S3 1
8a,PMC5264229,S46,5436,5590,Study design, Randomisation treatment allocation implemented interactive web responsive system Cenduit LLC see online supplementary appendix S3 1
5,PMC5264229,S47,5591,5737,Study design, Infusion SB2 INF done 2  h dosing done visit week 0 week 2 week 6 week 14 week 22 week 30 week 38 week 46
5,PMC5264229,S48,5738,5829,Study design, Dose increases could occur week 30 1 5 mg kg per visit total 7 5  mg kg
0,PMC5264229,S49,5830,5885,Study design, The final visit main study occurred week 54
5,PMC5264229,S50,5886,6043,Study design, To prevent infusion related reactions IRRs premedications corticosteroids antihistamines paracetamol allowed per investigator discretion
5,PMC5264229,S51,6044,6144,Study design, MTX given oral parenteral weekly dose 10  25  mg week folic acid 5  10  mg week
5,PMC5264229,S52,6145,6298,Study design, Non steroidal anti inflammatory drugs corticosteroids prednisolone allowed taken stable dose 4  weeks randomisation
5,PMC5264229,S53,6299,6391,Study design, Other disease modifying antirheumatic drugs except MTX prohibited study
0,PMC5264229,S54,6392,6583,Study design, All patients screened tuberculosis TB medical history chest X ray QuantiFERON TB Gold In Tube tests Qiagen QuantiFERON tests done screening week 22 week 54
4a,PMC5264229,S55,6584,6788,Study design, Patients active TB ineligible study found latent TB undergo prophylaxis according country specific guidelines enrol continue study
4b,PMC5264229,S56,6789,6864,Study design, The study conducted 73 centres 11 countries Europe Asia
0,PMC5264229,S57,6865,7012,Study design, The study conducted according Declaration Helsinki Good Clinical Practice issued International Committee Harmonisation
0,PMC5264229,S58,7013,7097,Study design, All patients gave formal written informed consent participating study
6a,PMC5264229,S60,7140,7256,Assessments, Efficacy safety immunogenicity assessments patients done visit SB2 INF infusion
6a,PMC5264229,S61,7265,7374,Assessments, The primary end point study ACR 20 ACR20 response week 30 per protocol set PPS
6a,PMC5264229,S62,7375,7581,Assessments, Other secondary efficacy end points included ACR50 ACR70 disease activity score measured 28 joints erythrocyte sedimentation rate DAS28 ESR European League Rheumatism EULAR response
6a,PMC5264229,S63,7582,7791,Assessments, A post hoc analysis simplified disease activity index SDAI clinical disease activity index CDAI done measure proportion patients achieving low disease activity LDA remission 15 16
6a,PMC5264229,S64,7792,7981,Assessments, Efficacy components tender swollen joint counts visual analogue scales scores health assessment questionnaire disability index scores assessed infusion
6a,PMC5264229,S65,7990,8126,Assessments, Safety assessments included monitoring vital signs physical examination laboratory assessments reports adverse events AEs
6a,PMC5264229,S66,8127,8211,Assessments, AEs collected particular serious AEs serious infections TB IRRs
6a,PMC5264229,S67,8220,8347,Assessments, Immunogenicity assessments done measuring serum antidrug antibodies ADAs infliximab visit infusion
6a,PMC5264229,S68,8348,8439,Assessments, ADA positivity defined least one positive ADA result week 30
0,PMC5264229,S69,8440,8563,Assessments, This prespecified outcome according recommendations American Association Pharmaceutical Scientists 17
0,PMC5264229,S70,8564,8675,Assessments, It accommodates measures ADA incidence individual time point may subject variation
6a,PMC5264229,S71,8676,8759,Assessments, Those ADA positive additionally assessed neutralising antibodies
6a,PMC5264229,S72,8760,8833,Assessments, A single assay approach SB2 tag used assess immunogenicity
6a,PMC5264229,S73,8834,9069,Assessments, ADAs measured using validated electrochemiluminescence immunoassays neutralising antibodies measured using competitive ligand binding assay MesoScale Discovery platform Meso Scale Discovery Rockville Maryland USA
6a,PMC5264229,S74,9078,9193,Assessments, PK assessments done measuring serum trough concentrations Ctrough infliximab infusion
6a,PMC5264229,S75,9194,9266,Assessments, Serum infliximab concentrations determined using validated ELISA
6a,PMC5264229,S77,9334,9407,Sample size and statistical analysis, The primary objective demonstrate equivalence ACR20 week 30
7a,PMC5264229,S78,9408,9551,Sample size and statistical analysis, To determine equivalence SB2 INF 95 CI ACR20 rate difference within prespecified margin 15
7a,PMC5264229,S79,9552,9664,Sample size and statistical analysis, The equivalence margin determined using data several INF studies4 18 19 regulatory guidelines 20 21
7a,PMC5264229,S80,9665,9779,Sample size and statistical analysis, Sample size calculated assuming equivalence margin effect size 57 20 dropout rate
7a,PMC5264229,S81,9780,9971,Sample size and statistical analysis, With significance level 5 power 80 sample size least 292 randomised patients per treatment group required order reach required subject size PPS
0,PMC5264229,S82,9980,10070,Sample size and statistical analysis, The primary efficacy outcome analysed using PPS full analysis set FAS 22
0,PMC5264229,S83,10071,10221,Sample size and statistical analysis, FAS follows principles intention to treat analysis FAS included randomised patients received least one dose SB2 INF
12a,PMC5264229,S84,10222,10322,Sample size and statistical analysis, In addition missing data occurred patients assumed ACR20 non responders FAS
12a,PMC5264229,S85,10323,10487,Sample size and statistical analysis, For analysis ACR20 rate difference adjusted baseline C reactive protein geographical region using non parametrical analysis covariance 23  25
0,PMC5264229,S86,10488,10673,Sample size and statistical analysis, Analysis ACR50 ACR70 also done PPS FAS DAS28 SDAI CDAI EULAR response done FAS available DAS28 SDAI CDAI analysed case
12b,PMC5264229,S87,10674,10817,Sample size and statistical analysis, Subgroup analysis ACR20 done comparing ACR20 response rates within ADA subgroup positive negative prespecified manner
12a,PMC5264229,S88,10818,10979,Sample size and statistical analysis, To formally test differential influence ADA SB2 INF analysis covariance done including ADA by treatment interaction term model
12a,PMC5264229,S89,10988,11184,Sample size and statistical analysis, A prespecified exponential time response model using non linear mixed models26 fitted compare ACR20 response SB2 INF time see also online supplementary appendix S3 2
12a,PMC5264229,S90,11185,11390,Sample size and statistical analysis, The squared differences across time points two curves 2 norm measured upper limit 95 CI 2 norm less 61 80 two curves considered equivalent
12b,PMC5264229,S91,11399,11580,Sample size and statistical analysis, Safety results presented number patients percentage particular AE safety analysis set SAF received least one dose SB2 INF
12b,PMC5264229,S92,11581,11709,Sample size and statistical analysis, Immunogenicity results presented number patients percentages incident ADA week 30 SAF
0,PMC5264229,S93,11710,11831,Sample size and statistical analysis, PK assessment done PK population approximately first enrolled 50 study population week 30
12b,PMC5264229,S94,11832,11929,Sample size and statistical analysis, PK results shown mean Ctrough SD coefficient variation PK population
12a,PMC5264229,S95,11938,12025,Sample size and statistical analysis, General statistical analysis done using SAS V 9 2 SAS Cary North Carolina USA
12b,PMC5264229,S96,12026,12147,Sample size and statistical analysis, PK parameters calculated non compartmental analyses WinNonlin V 5 2 Pharsight Mountain View California USA
0,PMC5264229,S97,12148,12217,Sample size and statistical analysis, Graphical figures made using R 3 0 1 http www r project org
0,PMC5264229,S188,23997,24011,Supplementary Material, Web supplement
3a,PMC5418559,S39,5583,5818,Study design, This multicenter phase 2 randomized double blind placebo controlled study conducted 79 sites USA ClinicalTrials gov identifier NCT01923428 August 2013 October 2014 last patient last visit July 2014
4b,PMC5418559,S39,5583,5818,Study design, This multicenter phase 2 randomized double blind placebo controlled study conducted 79 sites USA ClinicalTrials gov identifier NCT01923428 August 2013 October 2014 last patient last visit July 2014
4b,PMC5418559,S40,5819,5993,Study design, The sites conducting study gastroenterology practices n 26 primary care research practices n 53 specializing internal medicine and or gastroenterology
5,PMC5418559,S41,5994,6349,Study design, After 2 week screening period eligible patients randomly assigned 1 1 1 1 ratio one four treatment groups tenapanor 5  mg 20  mg 50  mg twice daily b i d dosed hydrochloride salt placebo b i d Patients received tenapanor placebo 12 consecutive weeks followed additional 4 weeks
0,PMC5418559,S42,6350,6602,Study design, Patients visited study site seven times study 2 week screening period week five times active treatment period weeks 0 2 4 8 12 end 4 week follow up period week 16
0,PMC5418559,S43,6603,6725,Study design, The study conducted accordance Declaration Helsinki patients provided written informed consent
4a,PMC5418559,S45,6765,6876,Patients, Men women aged 18  75 years met Rome III criteria IBS C 20 eligible study enrollment
4a,PMC5418559,S46,6877,7278,Patients, In addition patients colonoscopy within past 10 years 50 years age presence unexplained warning symptoms e g lower gastrointestinal bleeding iron deficiency anemia clinically significant weight loss systemic signs infection colitis agree use appropriate methods contraception surgically sterile post menopausal
4a,PMC5418559,S47,7279,8243,Patients, The main exclusion criteria functional diarrhea IBS diarrhea mixed IBS un subtyped IBS defined Rome III criteria clinically symptomatic biochemical structural abnormality active disease gastrointestinal tract within 6 months screening use medications known affect stool consistency except described hepatic dysfunction defined alanine aminotransaminase serum glutamic pyruvic transaminase aspartate aminotransaminase serum glutamic oxaloacetic transaminase 2 5 upper limit normal renal impairment serum creatinine 2  mg dl surgery stomach small intestine colon excluding appendectomy major psychiatric disorder requiring hospitalization last 3 years history attempted suicide uncontrolled bipolar disorder clinical evidence significant disease may interfere patient successfully completing trial
4a,PMC5418559,S48,8244,8291,Patients, Pregnant lactating women also excluded
4a,PMC5418559,S49,8300,9135,Patients, After 2 week screening period order patients randomly assigned study treatment needed complete symptom assessments via touch tone telephone diary least 11 14 days ensure diary compliant meet following study entry criteria average weekly stool frequency five fewer spontaneous bowel movements SBMs defined non aided bowel movements two fewer complete spontaneous bowel movements CSBMs defined bowel movement accompanied sensation complete evacuation average weekly stool consistency score 3 less using Bristol Stool Form Scale BSFS 21 average weekly abdominal pain score least 3 0  10 point scale liquid stools SBM mushy stools one SBM according BSFS
5,PMC5418559,S50,9144,9316,Patients, Rescue medication bisacodyl 5  mg tablet 10  mg suppository allowed maximum 2 days screening period 48  h randomization
5,PMC5418559,S51,9317,9484,Patients, During study rescue medication allowed relieve severe constipation defined least 72  h without bowel movement symptoms became intolerable
5,PMC5418559,S52,9485,9605,Patients, Bowel movements considered SBMs CSBMs reported 24  h use rescue medication
5,PMC5418559,S53,9614,9913,Patients, Patients stable continuous regimen fiber bulk laxatives stool softeners and or probiotics 30 days screening visit included study provided maintained treatment dose throughout trial included analysis
6a,PMC5418559,S55,9963,10035,Efficacy variables, The CSBM responder rate primary efficacy variable study
6a,PMC5418559,S56,10036,10305,Efficacy variables, Secondary efficacy variables included composite CSBM responder rate abdominal pain responder rate responder rates individual abdominal symptoms including abdominal discomfort abdominal bloating abdominal fullness abdominal cramping
6a,PMC5418559,S57,10306,10473,Efficacy variables, Additional secondary efficacy variables weekly averages stool frequency stool consistency straining abdominal pain constipation severity IBS severity
6a,PMC5418559,S58,10474,10594,Efficacy variables, Degree relief IBS symptoms treatment satisfaction 12 weeks additional secondary efficacy variables
6a,PMC5418559,S60,10645,10740,Efficacy variables, Data efficacy variables recorded patients using touch tone telephone diary
6a,PMC5418559,S61,10741,11047,Efficacy variables, Variables recorded daily included stool frequency CSBMs SBMs stool consistency BSFS abdominal symptom scores pain bloating cramping discomfort fullness 0  10 point scale 0 absent 10 very severe straining score 1  5 point scale 1 not 5 an extreme amount
6a,PMC5418559,S62,11048,11372,Efficacy variables, Variables scored weekly patients included constipation severity IBS severity 1  5 point scale 1 none 5 very severe degree relief IBS symptoms 1  7 point scale 1 completely relieved 7 as bad I imagine treatment satisfaction 1  5 point scale 1 not satisfied 5 very satisfied
6a,PMC5418559,S64,11427,11600,Efficacy variables, The CSBM responder rate defined proportion patients increase least one CSBM week compared baseline least 6 12 treatment weeks
6a,PMC5418559,S65,11601,11735,Efficacy variables, The baseline value defined average number CSBMs per week 2 week screening period i e weeks
6a,PMC5418559,S66,11746,12026,Efficacy variables, Responder rates individual abdominal symptoms abdominal pain bloating cramping discomfort fullness defined proportion patients decrease least 30 baseline average weekly severity score least 6 12 treatment weeks
6a,PMC5418559,S67,12027,12345,Efficacy variables, A composite responder rate 22 calculated proportion patients increase least one CSBM week baseline primary efficacy variable decrease least 30 baseline average weekly abdominal pain severity score week least 6 12 treatment weeks
0,PMC5418559,S69,12402,12459,Safety variables, Adverse events AEs monitored throughout trial
0,PMC5418559,S70,12460,12587,Safety variables, They reported patient spontaneously and or response open question study personnel site visit
6a,PMC5418559,S71,12588,12950,Safety variables, Safety assessments included vital signs visit systolic diastolic blood pressure heart rate respiratory rate body temperature weight clinical laboratory tests serum electrolytes hematology urinalysis weeks 4 12 physical examinations weeks 12 16 12 lead electrocardiogram monitoring weeks 12
6a,PMC5418559,S72,12951,13144,Safety variables, Blood samples pharmacokinetic assessments tenapanor collected site visits weeks 8 12 1  4  h morning dosing subsets 30 randomly selected patients per group
8a,PMC5418559,S74,13195,13346,Statistical methods, A computer generated randomization scheme made available clinical centers participating study via interactive web response system
10,PMC5418559,S74,13195,13346,Statistical methods, A computer generated randomization scheme made available clinical centers participating study via interactive web response system
9,PMC5418559,S75,13347,13460,Statistical methods, The packaging labeling study drug kits based separate drug packaging randomization schedule
8b,PMC5418559,S76,13461,13695,Statistical methods, The interactive web response system determined drug package center administer patient based randomization schedule treatment allocated using block size four within study site
8a,PMC5418559,S76,13461,13695,Statistical methods, The interactive web response system determined drug package center administer patient based randomization schedule treatment allocated using block size four within study site
10,PMC5418559,S76,13461,13695,Statistical methods, The interactive web response system determined drug package center administer patient based randomization schedule treatment allocated using block size four within study site
0,PMC5418559,S77,13696,13821,Statistical methods, This ensured whole partial block sizes allocated facilitating even distribution patients amongst dose group
6a,PMC5418559,S78,13822,14064,Statistical methods, Data collected touch tone telephone diary system throughout study automatically entered database abnormal values automatically flagged relevant site could follow up patient clarification
0,PMC5418559,S79,14065,14175,Statistical methods, Compliance study treatment determined based amount unused study drug returned study sites
0,PMC5418559,S80,14184,14379,Statistical methods, The intention to treat analysis set included patients received least one dose study drug placebo least one valid week efficacy assessment data collected
6a,PMC5418559,S81,14380,14433,Statistical methods, A valid week required least four non missing days
6a,PMC5418559,S82,14434,14580,Statistical methods, Scores stool frequency standardized 7 days missing days week imputed average non missing days
12a,PMC5418559,S82,14434,14580,Statistical methods, Scores stool frequency standardized 7 days missing days week imputed average non missing days
6a,PMC5418559,S83,14581,14718,Statistical methods, The average weekly scores efficacy variables calculated observed number responses without standardization
7a,PMC5418559,S85,14830,15051,Statistical methods, A sample size 90 patients treatment group expected provide 80 power detect difference 20 CSBM responder rate placebo group least one tenapanor treatment groups
7a,PMC5418559,S86,15052,15335,Statistical methods, An assumed responder rate 20 patients treated placebo based historical data similar trial patients IBS C 23 assumed responder rate 40 patients treated tenapanor considered clinically meaningful patient population
12a,PMC5418559,S87,15344,15516,Statistical methods, The primary efficacy variable CSBM responder rate analyzed using Cochran  Mantel  Haenszel CMH test pooled investigator sites stratification variable
12a,PMC5418559,S88,15517,15631,Statistical methods, A closed testing procedure used control experiment wise type I error rate 5 significance level
12a,PMC5418559,S89,15632,15866,Statistical methods, A CMH screening test conducted first primary efficacy variable look association treatment responder rate across placebo tenapanor 20  mg b i d tenapanor 50  mg b i d treatment groups
12a,PMC5418559,S90,15867,16089,Statistical methods, If result test found statistically significant 5 level tenapanor 20  mg b i d 50  mg b i d treatment groups compared placebo group using 5 significance level
12a,PMC5418559,S91,16090,16311,Statistical methods, If either comparisons found significant result either treatment groups considered individually simultaneously significantly different placebo group
12a,PMC5418559,S92,16312,16552,Statistical methods, If tenapanor 20  mg b i d tenapanor 50  mg b i d treatment groups significantly different placebo group tenapanor 5  mg b i d treatment group compared placebo group using 5 significance level
12a,PMC5418559,S93,16561,16823,Statistical methods, CMH pairwise comparison tests tenapanor doses vs placebo used evaluate abdominal pain responder rate composite responder rate responder rates abdominal symptoms abdominal bloating cramping discomfort fullness
12a,PMC5418559,S94,16824,17089,Statistical methods, Continuous efficacy variables assessed using analysis covariance model pooled investigator sites treatment group terms baseline covariate analysis variance model pooled investigator sites treatment terms
4a,PMC5529963,S36,3881,4216,Study population and protocol, We studied 18 patients early erosive RA required diagnosis RA according American College Rheumatology 1987 criteria ii symptoms 6  months  3  years iii minimum two swollen metacarpophalangeal MCP joints despite treatment MTX iv seropositivity IgM rheumatoid factor
4a,PMC5529963,S37,4217,4737,Study population and protocol, In addition eligible patients required either erosion MCP joint demonstrated plain radiography cortical break irregular margins contour greyscale ultrasound longitudinal transverse scanning planes ii erosions MCP joints cortical breaks irregular margins contour greyscale ultrasound either transverse longitudinal plane associated strong vascular signal power Doppler mode site cortical break 7
5,PMC5529963,S38,4748,4900,Study population and protocol, All patients received oral MTX greater equal least 8  weeks minimum stable dosage 12 5  mg week exceeding 17 5  mg week
5,PMC5529963,S39,4901,5032,Study population and protocol, Patients treated oral corticosteroids must receiving stable dosage 10  mg prednisolone per day 4  weeks
0,PMC5529963,S41,5099,5198,Study population and protocol, Vascular properties HDL 18 patients RA compared 18 healthy control subjects
0,PMC5529963,S42,5199,5350,Study population and protocol, Healthy controls CV risk factors history clinical examination laboratory tests matched patients RA age gender
11a,PMC5529963,S44,5464,5591,Study population and protocol, All physicians patients nurses non clinical members study team blinded first year study
10,PMC5529963,S45,5592,5730,Study population and protocol, Eighteen patients RA randomised one two treatment groups pharmacist participate screening visit
5,PMC5529963,S46,5731,5904,Study population and protocol, Eleven patients received infusions infliximab 5  mg kg seven received placebo normal saline infusions weeks 0 2 6 every 8  weeks week 46
0,PMC5529963,S47,5905,6006,Study population and protocol, At end first year patients maintained single blinded study year
5,PMC5529963,S48,6007,6139,Study population and protocol, Patients methotrexate infliximab M I  group received infliximab infusions weeks 54 56 62 thereafter every 8  weeks
5,PMC5529963,S49,6140,6364,Study population and protocol, Those M I group received placebo infusion week 56 order maintain blinding received infliximab infusions every 8  weeks end study 110  weeks see online supplementary appendix figure 1
0,PMC5529963,S50,6365,6465,Study population and protocol, As result patients received minimum 1  year infliximab two phases study
0,PMC5529963,S51,6489,6523,Study population and protocol, 10 1136 heartjnl 2015 308953 supp1
0,PMC5529963,S52,6536,6560,Study population and protocol, supplementary appendix 1
5,PMC5529963,S53,6609,6706,Study population and protocol, Baseline dosages MTX corticosteroid maintained first 18  weeks study
5,PMC5529963,S54,6707,7097,Study population and protocol, After week 18 patient failed achieve 50 reduction baseline number swollen hand wrist joints weekly dose MTX increased 2 5  mg every 4  weeks 50 reduction baseline number swollen hand wrist joints achieved dosage oral MTX reached 25  mg week dose escalation limited toxicity
5,PMC5529963,S55,7098,7239,Study population and protocol, Thereafter irrespective response status patients continued receive maximum tolerated MTX dosage end study
0,PMC5529963,S56,7240,7346,Study population and protocol, The study approved Riverside Research Ethics Committee patients provided informed consent
0,PMC5529963,S57,7347,7447,Study population and protocol, Clinical monitoring study performed independently Centocor Malvern Pennsylvania USA
6a,PMC5529963,S60,7570,7680,Laboratory assays, Anthropometric measurements made body mass index BMI kg m2 calculated weight height
6a,PMC5529963,S61,7681,7790,Laboratory assays, Blood pressure measured triplicate HEM 705CP Omron average readings calculated
6a,PMC5529963,S62,7791,7920,Laboratory assays, Blood drawn processed overnight fast serum plasma samples stored subsequent analysis
6a,PMC5529963,S63,7921,8190,Laboratory assays, Full blood count lipid glucose level measurements made standard biochemistry assays C reactive protein CRP measured immunoturbidimetric high sensitivity assay Tina quant assay performed Cobas Integra analyzer Roche Diagnostics
6a,PMC5529963,S65,8246,8348,Laboratory assays, Measurements HDL function carried baseline 54  weeks 110  weeks patients RA
0,PMC5529963,S66,8349,8418,Laboratory assays, Baseline measurements compared healthy controls
6a,PMC5529963,S68,8468,8593,Laboratory assays, HDL isolated sequential ultracentrifugation d 1 063  1 21  g mL using solid potassium bromide density adjustment 8
6a,PMC5529963,S69,8594,8709,Laboratory assays, All functional assays HDL carried within two  weeks isolation blinded investigator duplicate
6a,PMC5529963,S71,8797,9005,Laboratory assays, The effect HDL 50   g mL 60  min 37  C endothelial nitric oxide NO bioavailability bovine aortic endothelial cells BAECs passage 4  7 Lonza Bioscience measured using fluorescent indicator
6a,PMC5529963,S72,9006,9188,Laboratory assays, BAECs incubated 4 5 diaminofluorescein diacetate DAF 2 1Um Cayman Chemical triazolofluorescein fluorescence measured using excitation wavelength 485  nm 9
6a,PMC5529963,S74,9269,9526,Laboratory assays, The effect HDL endothelial cell superoxide production SO measured unstimulated tumour necrosis factor   TNF   stimulated 5  ng mL R D Systems human aortic endothelial cells HAECs erythrocyte sedimentation rate ESR spectroscopy
6a,PMC5529963,S75,9527,9810,Laboratory assays, HAECs incubated HDL patients controls 50   g mL 60  min 37  C without TNF   resuspended Krebs Hepes buffer pH 7 4 Noxygen containing diethyldithiocarbamic acid sodium salt 5   M Noxygen deferoxamine methanesulfonate salt 25   M Noxygen
6a,PMC5529963,S76,9811,10024,Laboratory assays, ESR spectra recorded addition spin probe 1 hydroxy 3 methoxycarbonyl 2 2 5 5 tetramethylpyrrolidine CMH Noxygen final concentration 200   M using Bruker e scan spectrometer Bruker Biospin
6a,PMC5529963,S77,10025,10296,Laboratory assays, The ESR instrumental settings centre field B0 3495  G field sweep width 10  G microwave frequency 9 75  GHz microwave power 19 91  mW magnetic field modulation frequency 86 00  kHz modulation amplitude 2 60  G conversion time 10 24  ms number x scans 1020 9
6a,PMC5529963,S79,10371,10454,Laboratory assays, HDL measurements efflux capacity extracted serum ApoB depletion
6a,PMC5529963,S80,10455,10606,Laboratory assays, Whole serum incubated 20  min 20 polyethylene glycol PEG solution 20 PEG 8000 sigma P2139 200  mM glycine sigma G8898 pH 10
6a,PMC5529963,S81,10607,10695,Laboratory assays, Samples centrifuged 1900 g supernatant collected stored 4  C
6a,PMC5529963,S82,10696,10802,Laboratory assays, J774 cells radiolabeled 24  hours medium containing 2 3H cholesterol per microlitre
6a,PMC5529963,S83,10803,10900,Laboratory assays, Addition 0 3  mM 8 4 chlorophenylthio cyclic AMP 6  hours upregulated expression ABCA1
6a,PMC5529963,S84,10901,11009,Laboratory assays, An efflux medium containing 2 8 apolipoprotein B depleted serum individual added 4  hours
6a,PMC5529963,S85,11010,11193,Laboratory assays, To prevent cholesterol esterification labelling equilibration flux 2   g mL CP113 818 acyl coenzyme A cholesterol acyltransferase inhibitor added mediums
6a,PMC5529963,S86,11194,11341,Laboratory assays, Efflux capacity quantified using liquid scintillation measure radioactive cholesterol effluxed cells medium intracellular lipids
6a,PMC5529963,S87,11342,11494,Laboratory assays, All assays performed duplicate final average value normalised baseline control statistical analyses time points 10
6a,PMC5529963,S89,11564,11722,Laboratory assays, Serum paraoxonase activities measured ultraviolet spectrophotometry 96 well plate format using paraoxon Sigma Aldrich St Louis Missouri USA
6a,PMC5529963,S90,11723,11871,Laboratory assays, Briefly 50   g mL HDL diluted reaction mixture containing 10  mM Tris hydrochloride pH 8 0 1  M sodium chloride 2  mM calcium chloride
6a,PMC5529963,S91,11872,12114,Laboratory assays, At 24  C 1 5  mM paraoxon added initiate reaction increase absorbance 405 nm recorded 30  min An extinction coefficient 405  nm 17 000 M  1 cm  1 used calculate units paraoxonase 1 PON 1 11
7a,PMC5529963,S93,12176,12379,Statistics, HDL studies powered 1 1 randomised controlled trial basis NO bioavailability using paired assessments 35 healthy controls mean 0 98 SD 0 13 intraclass correlation 0 91 12
7a,PMC5529963,S94,12380,12551,Statistics, From power calculation total seven patients per group required power 80 detect 5 difference primary outcome NO bioavailability
0,PMC5529963,S95,12552,12613,Statistics, Normal distribution assessed using Shapiro Wilk test
0,PMC5529963,S96,12614,12704,Statistics, All measures reported mean SD median IQR normally distributed
12a,PMC5529963,S97,12705,12829,Statistics, Baseline comparisons performed using independent t test Mann Whitney U test data non normally distributed
12a,PMC5529963,S98,12838,13058,Statistics, Post hoc multivariate analysis variance ANOVA modelling performed evaluate effects treatment infliximab vs placebo duration treatment HDL function CV clinical markers 54  weeks
12a,PMC5529963,S99,13059,13284,Statistics, A repeated measures ANOVA time point comparisons using Bonferroni corrected t tests performed determine differences HDL function CV clinical markers patients received 2  years infliximab treatment
12a,PMC5529963,S100,13285,13406,Statistics, The Greenhouse Geisser correction F test used adjust degrees freedom deviation sphericity
12a,PMC5529963,S101,13407,13469,Statistics, Analysis performed using GraphPad Prism analysis software
0,PMC5529963,S102,13470,13551,Statistics, A two sided p value 0 05 considered indicate statistical significance
12a,PMC5529963,S103,13552,13686,Statistics, An additional multilevel logistic regression analysis conducted R confirm results see online supplementary appendix 2
12a,PMC5529963,S104,13687,13898,Statistics, We fit multilevel logistic regression models measure HDL function using lme4 package http cran r project org web packages lme4 index html R statistical language http www r project org
0,PMC5529963,S105,13899,13945,Statistics, All coefficients taken random effects
0,PMC5529963,S106,13965,13999,Statistics, 10 1136 heartjnl 2015 308953 supp2
0,PMC5529963,S107,14010,14034,Statistics, supplementary appendix 2
